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Summary
Malaria can be regarded as one of the world's worst health problems and its incidence 
is rising inexorably. It already accounts for the deaths of approximately three children 
every minute. This situation is exacerbated by the increased frequency of parasite 
resistance to current antimalarial agents and necessitates the development of new 
drugs to combat this disease
P. falciparum possesses a plastid-like organelle, termed the apicoplast, which contains 
a small, highly reduced 35kb genome encoding tRNA, DNA polymerases and 
ribosomal proteins. Nuclear proteins are targeted to the apicoplast using clearly 
defined N-terminal signal and target peptide sequences. This led to the discovery that 
the apicoplast may be the site of at least two anabolic pathways; isoprenoid synthesis 
and Type II fatty acid synthesis (FAS). This system is also present in bacteria and 
plants and differs significantly from the Type I FAS system found in humans. This 
makes the pathway an attractive target for novel antimalarials. Furthermore, the 
antibiotic thiolactomycin, inhibits the growth of bacteria via inhibition of Type II 
FAS.
This project describes the characterisation of pfFabF and pfFabH, the P-ketoacyl-ACP 
synthase enzymes in the Type II FAS pathway of P. falciparum. One of these 
proteins, pfFabF, was shown to be the target of thiolactomycin inhibition. This 
enzyme was also capable of catalysing the final step of the unsaturated FAS pathway.
Thiolactomycin derivatives synthesised in this project were tested against cultures of 
the parasite and both the condensing enzymes of P. falciparum. Significant 
improvements in the inhibitory activity against parasite cultures and one of the 
condensing enzymes were achieved compared to thiolactomycin. Although the 
inhibitory effects of these compounds was only in the micromolar range, this study 
demonstrates that thiolactomycin derivatives may provide lead compounds for the 
inhibition of P. falciparum by targeting either of the J3 -ketoacyl-ACP synthase 
proteins.
Contents
Summary
Abbreviations
Chapter 1 Introduction
1.1 The Malaria Problem 1
1.2 Parasite lifecycle and Anopheles mosquito 5
1.2.1 Pre-erythrocytic phase 5
1.2.2 Erythrocytic cycles 6
1.2.3 Sexual stages of the parasite 9
1.3 Clinical manifestations of malaria 10
1.3.1 General Symptoms 10
1.3.2 Symptoms specific to Plasmodium falciparum malaria 11
1.3.3 Cerebral malaria 13
1.3.4 Plasmodium falciparum  malaria in pregnancy 14
1.4 Anopheles control 15
1.5 The Apicomplexa 16
1.6 The apicoplast 19
1.6.1 Discovery of the apicoplast 19
1.6.2 Identifying the location of a 35kb genetic fragment 20
1.6.3 Genetic analysis of the apicoplast origin and function 22
1.7 Apicoplast function 25
1.8 Fatty Acid Synthesis 28
1.8.1 Determination of chain length 33
1.8.2 Synthesis of unsaturated fatty acids 34
1.8.2.1 Bacterial UFA synthesis 34
1.8.2.2 The FabB/FabA system 34
1.8.2.3 FabM isomerase 37
1.8.2.4 Desaturation of existing fatty acids 38
1.8.3 Eukaryotic unsaturated fatty acid synthesis 38
1.9 Apicomplexan fatty acid synthesis 39
1.9.1 Initial discovery of FAS in Apicomplexans 40
1.9.2 Individual enzymes of the Type II FAS pathway 42
1.9.2.1 The initial reactions of Type D FAS 42
1.9.2.2 The ketoacyl-ACP reductase 44
1.9.2.3 The dehydratase 44
1.9.2.4 Enoyl reductases of Apicomplexans 45
1.9.3 The function of Type II FAS in apicomplexan parasites 46
1.10 Type II FAS condensing enzymes 48
1.10.1 Condensing enzyme nomenclature 48
1.10.2 Classification of KAS enzymes 49
1.10.3 Substrate specificity of KAS enzymes 50
1.10.4 Structural and active site motifs 51
1.10.5 Active site differences 52
1.10.6 Differences in the substrate-binding pocket 55
1.11 Inhibition of Type D Fatty Acid Synthesis 56
1.11.1 Thiolactomycin 56
1.11.1.1 Enzyme targets of thiolactomycin 59
1.11.1.2 Mechanism of thiolactomycin inhibition 61
1.11.1.3 Structure of a FabB-TLM complex 62
1.11.1.4 Significance for the development of TLM as an antibiotic 64
1.11.1.5 Resistance to thiolactomycin 65
1.11.2 Other inhibitors of FAS as potential antibiotics 66
1.11.2.1 Cerulenin 67
1.11.2.2 Triclosan 70
1.11.2.3 Aryloxyphenoxypropionate herbicides 72
1.11.2.4 C 18 Fatty acids 73
1.12 Aims of this project 73
Chapter 2 - Materials and Methods
2.1 Materials 75
2.1.1 Cloning and expression Vectors 75
2.1.2 Escherichia coli host strains 75
2.1.3 Media 76
2.1.4 Molecular weight standards 77
2.1.5 Other materials 7 8
2.2 Methods
2.2.1 DNA amplification by the polymerase chain reaction 79
2.2.2 Ligation of DNA into plasmid vectors 79
2.2.3 Creation of blunt ended DNA fragments with Klenow enzyme 80
2.2.4 Shrimp Alkaline phosphatase (SAP) 80
2.2.5 Isolation of plasmid DNA 81
2.2.6 DNA modifying enzymes and Agarose gel electrophoresis 81
2.2.7 Purification of DNA fragments from agarose gel 81
2.2.8 Double stranded DNA sequencing 82
2.2.9 Preparation of Competent E. coli cells 82
2.2.10 Transformation of E. coli cells by plasmid DNA 83
2.2.11 Sodium dodecyl sulphate - polyacrylamide gel electrophoresis 83
2.2.12 Analytical scale expression of recombinant proteins 84
2.2.13 Analytical production of soluble and insoluble fractions 85
2.2.14 Preparation of cell pellets and culture media for SDS-PAGE 85
2.2.15 Immunological detection of proteins by Western blotting 86
2.2.16 Refolding of insoluble recombinant protein 87
2.2.17 Screening by hybridisation 88
2.2.18 Single-stranded RNA synthesis 90
2.2.19 Double-stranded RNA production 92
2.2.20 Design of siRNA oligomers 92
2.2.21 Preparation of cell extracts for radioactive assays 93
2.2.22 Fatty acid synthase activity assays in E. coli extracts 94
2.2.23 Conformationally sensitive gels 95
2.2.24 Assay of FabB/F condensing enzymes and inhibitor studies 96
2.2.25 Assay of FabH enzyme activity and inhibitor studies 97
2.2.26 The overexpression and purification of E. coli FabD 98
2.2.27 Preparation of acyl-ACP synthetase 99
2.2.28 Extraction of lipids and productions of FAMEs from E. coli 100
2.2.29 Determination of minimum inhibitory concentrations 102
Chapter 3 The cloning and expression of P. falciparum  FabF
3.1 Introduction 103
3.2 Identification of a P. falciparum condensing enzyme 104
3.2.1 Phylogenetic analysis of the P. falciparum enzyme 107
3.3 Cloning of the truncated pffabF gene 108
3.4 Adoption of a new cloning strategy 112
3.5 Assembly of a truncated form of the pffabF gene 115
3.6 Identification of a 5' extension of the pffabF gene 118
3.7 Cloning of a 5' extension of the pffabF gene 121
3.8 Assembly of a Gene encoding the mature pfFabF protein 122
3.9 Recombinant Expression of pfFabF 125
3.9.1 Cloning of the pffabF gene into the pET15b vector 125
3.9.2 Expression of the pfFabF protein in pLysS cells 126
3.10 Expression of pfFabF in Codon Plus cells 130
3.11 Cloning of the pffabF gene into the pMAL vector system 132
3.12 Expression of an MBP-pfFabF fusion protein 135
3.13 Purification of the MBP-pfFabF protein 138
3.14 Attempted cleavage of the MBP-pfFabF protein 139
3.15 Discussion 145
Chapter 4 Substrate specificity and characterisation of MBP-pfFabF
4.1 Initial studies of MBP-pfFabF activity 152
4.2 Refining the conditions of the MBP-pfFabF assay 156
4.3 Acyl-ACP substrate specificity of MBP-pfFabF 158
4.4 Sensitivity of MBP-pfFabF to thiolactomycin 160
4.4.1 A general investigation of MBP-pfFabF sensitivity to TLM 160
4.4.2 Determination of the lC5o of TLM against pfFabF 161
4.5 Complementation of an E. coli fa b f  knockout with MBP-pfFabF 163
4.6 Discussion 172
Chapter 5 The cloning and Expression of Plasmodium falciparum  FabH
5.1 Overview 1 7 8
5.2 Cloning of the P. falciparum fabH  gene 179
5.3 Adoption of a new cloning strategy 183
5.4 Screening for pffabH  by colony hybridisation 185
5.5. Engineering of pffabH  to include E. coli preferred codons 187
5.6 Cloning of a truncated version of pffabH 196
5.7 Cloning of the pffabH  gene into the pMAL vector system 199
5.8 Expression of an MBP-pfFabH fusion protein 200
5.9 Purification of MBP-pfFabH in a soluble form 202
5.10 Attempted cleavage of the MBP-pfFabH fusion 205
5.11 Initial studies of MBP-pfFabH activity 208
5.12 Refining the conditions of the MBP-pfFabH assay 212
5.13 An investigation of MBP-pfFabH sensitivity to TLM and cerulenin 213
5.14 The determination of the IC50 of TLM against pfFabH 217
5.1.5 Discussion 219
Chapter 6 Inhibition of P. falciparum  fatty acid synthesis by thiolactomycin and 
its derivatives
6.1 Introduction 222
6.2 Synthesis of TLM derivatives and determination of LD50 226
6.3 TLM and derivatives of the C5 (R 1) position 226
6.4 Substitutions of the methyl group at the C3 (R2) position 229
6.4.1 Ethyl substitutions at the C3 position 229
6.4.2 Longer hydrocarbon chains at the C3 position 234
6.4.3 C3 Hexadecyl substitutions 237
6.5 Substitutions of the methyl group at the C5 (R3) position 239
6.6. Replacement of the sulphur heteroatom 241
6.6.1 Tetronic acids 241
6.6.2 Replacement of the sulphur heteroatom with a nitrogen 243
6.7 Addressing problems in solubility 244
6.8 Extending from the 4-hydroxyl group 246
6.9 Saturated ring structures (dicarbonyl compounds) 250
6.10 Activity of TLM derivatives against MBP-pfFabF 253
6.11 Activity of TLM derivatives against MBP-pfFabH 257
6.12 Investigation of compound 781 structure 262
6.12.1 The effect of storage in ethanol on compound 781 264
6.13 Discussion
6.13.1 Alterations of the C5 (R 1) side chain 266
6.13.2 Alterations of the C3 (R2) side chain 271
6.13.3 A comparison of TLM derivatives in biological and
enzyme assays 272
Chapter 7 General Discussion
7.1 Studies of the P. falciparum  FabF protein 274
7.1.2 Inhibition of pfFabF activity by TLM 276
7.2 The potential of TLM as a novel antimalarial drug 277
7.2.1 The inhibitory activity of TLM against malaria parasites 278
7.2.2 Synthesis of TLM or derivatives as potential antimalarial drugs 280
7.2.3 Alternative targets of TLM inhibition in the human host 281
7.2.4 Elucidating the target of TLM derivatives 283
7.2.5 Activity of TLM and its derivatives against other parasites 283
Bibliography 286-312
Appendices Supplementary pages
Abbreviations used in this report
A Angstrom
ACCase acetyl-CoA carboxylase
ACP acyl carrier protein
APS ammonium persulphate
ATP adenosine triphosphate
p-mercaptoethanol 2-hydroxyethyl mercaptan
bp base pair
cDNA complementary DNA
CDS coding sequence
CER cerulenin
CoA coenzyme A
CPM counts per minute
CTP cytidine triphosphate
D attenuance
DDT dichlorodiphenyltrichloroethane
DEPC di-ethylene polychloride
DMSO dimethyl-sulphoxide
DNase deoxyribonuclease
dNTPs deoxyribonucleotide triphosphates
DTT dithiothreitol
ecACP Escherichia coli ACP
ecFabD Escherichia coli FabD
EDTA diaminoethanetetra-acetic acid disodium salt
Fab fatty acid biosynthesis
FAME fatty acid methyl ester
FAS Fatty Acid Synthase
GPI glycosyl-phosphatidylinositol
GTP guanosine triphosphate
HPLC high performance liquid chromatography
IPTG isopropyl P-D-thiogalactopyranoside
KAS P-ketoacyl-(ACP) synthase
kDa kilodaltons
kPa kilopascals
LB Luria Bertani
MBP maltose binding protein
MIC minimum inhibitory concentration
MUFA monounsaturated fatty acid
NADH nicotinamide adenine dinucleotide (reduced form)
NADPH nicotinamide adenine dinucleotide phosphate
(reduced form)
NEAT proteins Nuclear-encoded apicoplast-targeted proteins
Ni-AP nickel-alkaline phosphatase conjugate
PDHC pyruvate dehydrogenase complex
PUFAs poly-unsaturated fatty acids
rbc uninfected red blood cells
SAP shrimp alkaline phosphatase
SDM site directed mutagenesis
SDS-PAGE sodium dodecyl sulphate
polyacrylamide gel electrophoresis 
SSC saline sodium citrate
siRNA short interfering RNA
ssRNA single stranded RNA
TBS Tris buffered saline
TCA trichloroacetic acid
TE Tris buffer containing EDTA
TEMED N,N,N',N'-tetramethylethylenediamine
THF tetrahydrofuran
TNFa tumour necrosis factor alpha
TLM thiolactomycin
tRNA transfer RNA
UFA unsaturated fatty acid
UTP uridine triphosphate
WHO World Health Organisation
Chapter 1
1.1 The Malaria Problem
Malaria poses an enormous burden on public health throughout the world, causing 
between 1-3 million deaths every year (World Health Organisation (WHO), 2002). In 
perspective, this mortality rate is second only to tuberculosis for any communicable 
disease, including AIDS. Malaria remains the most widespread parasitic disease, 
affecting 40% of the world's population, with more than 2.4 billion people living in 
areas with moderate or high incidence of malaria (WHO, 2002).
The causative agents of malaria; Plasmodium falciparum, P. vivax, P. ovale and 
P. malariae are amongst the most serious of human pathogens. These single cell 
protozoa infect both human and mosquito hosts. P. vivax is the most abundant species 
in terms of human parasite infections and has the widest geographic distribution. 
However, P. falciparum is responsible for a much greater number of deaths and is, 
therefore, the most clinically important (WHO, 2002). Other species of Plasmodium 
infect mammals, birds and reptiles with serious consequences to the host population. 
Of particular interest is Plasmodium berghei, which infects both mice and rats and can 
be used as a model for human infection. Human malaria parasites are transmitted by 
Anopheles mosquitoes, of which there are more than 30 species.
Although present in more than 100 countries worldwide, over 90% of malaria cases 
are distributed in sub-Saharan Africa. The highest mortality rate in these regions 
occurs in children under 5 years old and may be responsible for up to 25% of total 
infant deaths (Greenwood et al., 1987). It is estimated that every minute, three 
children die from malaria or malaria-related complications. The disease is widespread 
across the tropics in; Central and South America, South East Asia, the Indian
l
sub-continent and even some areas of the Western Mediterranean (Figure 1.1). The 
distribution is largely restricted by the habitats of the vector Anopheles gambiae, 
which feeds preferentially on humans.
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Figure 1.1 Changes in the global distribution of malaria
Malaria has been eradicated from the areas shown in yellow and orange in the last 60 
years. These areas are mostly at risk from the resurgence of malaria and anopheles 
mosquito due to climate change. Reproduced from Sachs and Malaney (2002).
The social and economic implications in malaria endemic regions are staggering. The 
morbidity associated with malaria is responsible for a significant percentage of 
absenteeism from schools and work and has also been linked to impaired learning 
ability (Sachs and Malaney, 2002). P. falciparum  also causes cerebral malaria, which, 
in 5-20% of surviving patients, can cause behavioural disorders and the impairment of 
initiating and planning tasks in later life. This affects the capabilities of the work force
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and a study of income in malarious and non-malarious countries in 1995 showed that 
the average GDP in malarious countries in 1995 was US$1,526 compared to 
US$8,268 in non-malarious countries (Sachs and Malaney, 2002). The presence of 
malaria in tropical and sub-tropical regions correlates extensively with poverty in 
these areas. However, this correlation cannot solely be attributed to malaria, as 
poverty itself is partially responsible for some of the highest malaria transmission 
rates when funding for prevention methods such as bednets and insecticides is 
unavailable.
In recent years the incidence of malaria has seen a resurgence. Vector mosquitoes 
have become increasingly resistant to insecticides. Furthermore, the environmental 
impact of the most effective insecticides means that chemical interventions are 
frequently considered too toxic to use. In parallel, the emergence of drug resistant 
parasites has rendered many antimalarial compounds of moderate effectiveness 
(Olliaro, 2001). Resistance to chloroquine, the mainstay of malaria prophylaxis since 
the 1940s, was first reported in 1961, in highly endemic regions of South America 
(Columbia) and South East Asia (Thailand) (White, 1992). Subsequently, chloroquine 
resistance has spread to other endemic regions reaching West Africa in 1987 
(Figure 1.2) (Reid et al., 1998).
New drugs offer higher levels of protection as chemoprophylaxis but evidence 
suggests that they can have serious side effects at therapeutic doses e.g. neurological 
disturbances associated with mefloquine (Bern et al., 1992; Hoebe et al., 1997; 
Winstanley, 1996).
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Figure 1.2 Drug resistance in m alaria endemic regions
Resistance to the two most historically important antimalarial compounds is 
widespread. Resistance to chloroquine, a 4-amino quinoline, appeared approximately 
50 years after it was first used. The anti-folate combination of 
sulphadoxine-pyrimethamine is the most widely used malaria drug (Newton and 
White, 1999), however, resistance occurs rapidly if this treatment is used excessively. 
Reproduced from Ridley, 2002.
Global climate changes are predicted to increase human population exposure to 
malaria. Simulations have shown that an increase of several degrees in the global 
climate would increase the mosquito population up to 100-fold in temperate regions 
(Martens et al., 1995). Furthermore, conflicts and civil wars, industrialisation, 
increases in leisure travel to endemic areas and increases in the human population in 
endemic countries have resulted in a large, mobile reservoir of malaria. These factors
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combined mean that there is a real risk that malaria could become an even greater 
problem in the tropics and spread further to areas of Australia, Southern USA and 
Southern Europe (Martens et al.y 1995), where it had been eradicated over the last 
century (Figure 1.1). Overall there is an urgent need for new, safe, inexpensive and 
effective antimalarial drugs.
1«2 Parasite lifecycle and the Anopheles mosquito
The malaria parasite has a complicated, multistage lifecycle split between the 
mosquito and human hosts (Figure 1.3). For overviews see Knell, 1991 and Phillips, 
1983.
1.2.1 Pre-erythrocytic phase
Malaria parasites are introduced to the human host when an infected female mosquito 
takes a blood meal (to provide nutrients for maturation of her eggs). The bite from the 
mosquito releases an average of 2-3 infective cells termed sporozoites (Beier et al., 
1991), into the capillary bed of the skin, from where they migrate to invade the liver, 
being cleared from circulation in less than 30 minutes.
The sporozoites associate with the phagocytic Kupffer cell in the liver en route to the 
hepatocytes (Pradel and Frevert, 2001). In the hepatic parenchymal cells, the 
sporozoites mature into merozoites, which, in turn, mature into schizonts. The 
schizonts undergo several rounds of division, termed asexual schizogony, to form a 
large number of merozoites. In P. falciparum  the hepatic phase lasts 6-12 days and 
ends as merozoites emerge from the liver. P. ovale and P. vivax have an extra
5
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Figure 1.3 The lifecycle of human Plasmodium parasites
The diagram above represents the complete lifecycle of the four human malaria 
parasites. The latent hypnozoite stage in the liver is present only in two of the species 
as indicated above. Human cells are shown in pink, mosquito cells in orange and 
separate parasites in black. Adapted from Vickerman and Cox, (1967).
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lifecycle stage in the liver. A proportion of the merozoites of these species become 
hypnozoites, laying dormant in liver cells and developing months or years later. It is 
these stages that are responsible for the characteristic relapses seen in both P. vivax 
and P. ovale. Hie hypnozoite stage is absent from the other two species of human 
malaria.
l i i  Erythrocytic cycles
The rupture of infected liver cells releases infective merozoites that are capable of 
invading erythrocytes in the bloodstream. Following invasion through the red blood 
cell (rbc) membrane, a single merozoite (Figure 1.4A), or in some P. falciparum 
infections, multiple merozoites (Figure 1.4B), develop into early and late ring stages; 
so-called because a distinctive open ring can clearly be seen after Giemsa staining. 
During this period, the ring parasites begin to synthesise proteinases that degrade host 
cell haemoglobin, in order to scavenge from this rich source of amino acids. Late 
rings mature into trophozoites (Figure 1.4C), which characteristically contain a single 
nucleus. During this trophozoite phase there is near-complete degradation of the 
erythrocyte's haemoglobin, providing the parasite with the nutrients needed to grow 
and divide into further merozoites.
Within 15-18h the trophozoite is fully developed and undergoes asexual schizogony 
to yield between 8-24 merozoites (Figure 1.4D). During this phase, the successful 
partitioning of organelles such as mitochondria, into each daughter cell is achieved 
(Waller et al.% 2000 and Striepen et al., 2000). The rupture of the erythrocyte 
membrane releases these daughter merozoites (Figure 1.4E), causing wide distribution
7
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Figure 1.4 Erythrocytic stages of P. falciparum  malaria
A = rbc infected with a single malaria parasite; B = a doubly infected ring adjacent to 
uninfected rbcs; C = trophozoites; D = late schizonts; E = rupture of irbc containing 
schizont; F = daughter merozoites invade uninfected rbc. Blood samples were taken 
from patients suffering from P. falciparum  malaria at the Wellcome-Trust Centre, 
Kilifi, Kenya. Samples were smeared onto glass slides and stained with Giemsa. 
Photographs were captured using the Olympus BX41 microscope, with thanks to Prof. 
Alan Clarke (Cardiff University, UK).
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of the merozoites and allowing them to invade other individual erythrocytes 
(Figure 1.4F). The asexual red blood cell cycle takes approximately 48h (tertian 
cycle) in P. vivax and P. ovale and 72h (quartan cycle) in P. malariae, whereas 
P. falciparum presents itself as an irregular tertian cycle (Knell, 1991).
1.2.3 Sexual stages of the parasite
Within infected rbc, some merozoites form male and female gametocytes, which 
develop no further in the human host but circulate until they die or a female mosquito 
ingests them as she feeds. The female gametocytes (or macrogametocytes) and male 
gametocytes (or microgametocytes) move through the mosquito digestive system until 
they reach the mid-gut.
Once in the mid-gut, the erythrocyte membrane is lost and gametogenesis occurs.
Here the microgametocyte divides mitotically and develops until 16 individual 
microgametes, each possessing a nucleus and flagellum, detach themselves from each 
other. Thereafter, these male nuclei swim towards the fertile macrogametocyte, 
causing fertilisation several minutes after they became mobile. The resulting zygote 
matures into an ookinete within 12-18h and passes through the mid-gut cell wall 24h 
later. In the basal lamina of the cell wall, the ookinete divides repeatedly to form the 
oocyst; during the first 7 days, meiotic division occurs to produce an individual 
daughter sporozoite, this is followed by many rounds of mitosis producing several 
thousand sporozoites. Subsequently, the oocyst ruptures leading to the release of 
sporozoites into the haemocoel of the mosquito.
9
The sporozoites reach and penetrate the lumen of the salivary glands where they can 
remain indefinitely, until release during feeding infects a human host once more. The 
length of the parasite cycle in the vector mosquito is dependent on temperature and 
humidity, for instance, studies in P. vivax have shown that at 20°C the cycle takes 16 
days but just 9 days at 24-25°C (Phillips, 1983).
13 Clinical manifestations of malaria
13.1 General Symptoms
No symptoms of malaria are observed in the pre-erythrocytic hepatic stage of 
infection, with all of the severe symptoms attributed to the asexual blood stages 
(Newton et al., 2000). For this reason, the most useful antimalarials in severe 
infections are blood schizonticides.
Malaria is a complex disease, and the pathogenesis is still not completely understood. 
However, the most clinically recognisable symptom is the cyclic fever that may occur 
at regular intervals. Febrile episodes, which last for 2-3h, occur at 48h for 
P. falciparum, P. vivax and P. ovale but 72h for P. malariae (Knell, 1991). The initial 
symptoms of infection are similar to those of influenza or a hangover, including 
headaches, fever and general body pain. The similarity to these other conditions can 
cause the patient to delay seeking proper medical attention, leading to further 
complications. Cyclic fever is a result of the mass rupture of infected rbc, a process 
that becomes synchronised in the initial stages of infection and can lead to chronic 
anaemia in the patient.
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The rupture of merozoites from infected erythrocytes, releases a malarial toxin 
(Mendis and Carter, 1995) that stimulates the release of cytokines, particularly tumour 
necrosis factor alpha (TNF-ot) from T-cells and macrophages into the bloodstream 
(Karunaweera et al., 1992). In turn, TNF-a induces the increase in serum levels of an 
endogenous pyrogen, interleukin-1, responsible for the characteristic malaria fever 
(Wahlgren et al., 1995). In reality, fevers do not always follow a strong pattern 
because, frequently, the patient may have been bitten by more than one infected 
mosquito, complicating the infection and subsequent treatment.
13.2 Symptoms specific to Plasmodium falciparum  malaria
P. falciparum causes more deaths per infection than any other human malaria species. 
The parasite displays several properties that cause more severe physiological effects 
in the host (WHO, 2002).
1) Hepatic Phase
Compared to other human Plasmodium species, P. falciparum produces a larger 
number of merozoites in the liver, resulting in a higher initial parasitaemia in the 
bloodstream (Despommier and Kerapelou, 1987).
2) Increased cyto-adherence
As P. falciparum reaches the late trophozoite stage, infected rbc become more 
adhesive to each other (agglutination), to uninfected erythrocytes (resetting) and to 
the endothelial lining of capillaries (Udeinya et al.y 1981) (Figure 1.5). Increased 
cyto-adherence can cause congestion of the small blood vessels of the brain, lungs,
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liver and kidneys that often causes serious organ damage and can lead to death. 
Agglutination is believed to provide protection to a proportion of the parasites 
because they are less likely to be removed from circulation by macrophages in the 
spleen or be attacked by circulating macrophages (Cranston et al., 1984; Ramasamy, 
1998). This helps to ensure the longevity of the parasite in the host.
Figure 1.5 Agglutination and rosetting in P. falciparum infections
a) The cytoadherence of infected red blood cells to an endothelial membrane. The 
membrane structure can be observed at the bottom right of the image, b) The 
concomitant binding of uninfected red blood cells (rosetting) significantly contribute 
to the pathology of P. falciparum malaria. Scale bars = 20pm. Photos taken from 
Wahlgren et a l 1994.
Cyto-adherence is caused by P. falciparum  Erythrocytic Membrane Protein 1 
(PfEMP-1). This is a family of 200-300kDa proteins encoded by a large number 
(50-150) of var genes (Baruch et al., 1995; Smith et al., 1995; Su et al., 1995). Only
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one of the var genes is expressed at any one time and expression is switched at regular 
periods to avoid destruction by the host immune response. The large number and 
variability of surface antigens make vaccine development difficult. These proteins, 
along with others, bind to endothelial surface receptors including the glycoprotein 
thrombospondin, intracellular adhesion molecule 1 (ICAM1) (Berendt et al., 1989) 
and CD36 (Barnwell et al., 1989; Doolan and Hoffman, 2001).
Infected cells may also bind to several uninfected red blood cells, a process termed 
rosetting (Wahlgren et al., 1994). This process may provide merozoite progeny with a 
localised source for new infections, allowing for faster, more efficient proliferation of 
the parasite. Small (22-28kDa) proteins termed rosettins are produced by the parasite 
and displayed on the erythrocyte membrane, where they may interact with CD36 and 
A and B blood group components on uninfected blood cell membranes, resulting in 
adhesion (Wahlgren et al., 1994 and 1995). It has also been suggested that PjEMP1 
could cause rosetting by binding to C R 1 on uninfected cells (Doolan and Hoffman, 
2001).
1 3 J  Cerebral Malaria
The two traits described in Section 1.3.2 lead to an increase in cerebral malaria, 
defined as a deep level of unconsciousness in the presence of a P. falciparum asexual 
parasitaemia (Newton et al., 2000; Warrell and Molyneux 1990) and its associated 
complications include haemorrhages of surrounding blocked blood vessels and fitting. 
Cerebral malaria affects 575,000 African children every year and the mortality rate is 
10-40%. Of those who survive, 5-20% exhibit long-lasting neurological disorders and
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impaired intellectual functioning. Other chronic symptoms associated with increased 
cyto-adherence include liver failure, circulatory collapse, hypoglycaemia, anaemia, 
acute pulmonary oedema and kidney failure (Ramasamy, 1998).
13.4 Plasmodium falciparum  malaria in pregnancy
Plasmodium falciparum malaria also causes complications to non-immune pregnant 
women (Nathwani et al., 1992), mainly because the placenta is another common site 
of infected erythrocyte sequestration (Fried and Duffy, 1996). Occasionally, malaria 
parasites are able to pass through the placenta, infecting the foetus and causing severe 
complications. However, the foetus is generally well protected by maternal 
antibodies. Malaria infection in the mother or foetus can lead to maternal death and/or 
intrauterine death and if the foetus survives, low birth weight, which in turn may 
decrease the infant's chance of survival after birth (Warrell and Molyneux, 1990). In 
parallel, pregnant women have a higher incidence of malaria infection compared to 
other groups and this may be due to suppression of the immune system related to a 
decreased cellular immunity, especially within the third trimester (Sholapurkar et al., 
1990; Vleugels et al., 1987). Ultimately, in order to decrease child and maternal 
mortality, new antimalarials must be safe and effective for administration to pregnant 
women.
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1.4 Anopheles control
High rates of malaria transmission are attributed to large numbers of mosquitoes that 
efficiently transmit the malaria parasites. Therefore, controlling the Anopheles 
mosquito population should cause a decrease in the number of malaria cases.
Several strategies have been implemented with different levels of success throughout 
the world. The first programmes were aimed at the annihilation of the Anopheles 
mosquito population by destruction of their natural habitat and the use of insecticides. 
However, the World Health Organisation abandoned the mass spraying of houses and 
marshes with the most promising insecticide, DDT (dichlorodiphenyltrichloroethane), 
in 1969, although DDT is still a valuable tool in some malaria situations. Increasing 
evidence of harmful human (Schefczik and Buff, 1984) and environmental effects of 
DDT and an increase in mosquito resistance were reasons for this change in policy. 
Furthermore, resistance to DDT had arisen by the adaptation of the mosquito 
glutathione S-transferase system. Other insecticides have been tested but with little 
success, as resistance to second generation, organophosphorus insecticides has been 
linked to elevated levels of esterase in Anopheles (Hemingway, 1999).
Programmes to reduce the transmission rates of malaria have been more successful. 
The use of pyrethoid soaked nets and insect repellents have had significant impact on 
lowering human mortality and morbidity (WHO, 2002). Educational programmes, 
teaching people the best ways to avoid being bitten by mosquitoes, have also lowered 
rates of transmission. However, sustained effort and financial backing for these 
programmes have not been forthcoming, because they become expensive and difficult
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to co-ordinate in developing countries that lack the infrastructure to support them. 
Therefore, many of these programmes have been dropped (WHO, 2002).
The production of transgenic mosquitoes that are unable to transmit the malaria 
parasite is an ambitious but achievable target. Mosquitoes that express antibodies to 
the malaria sporozoite have been generated in the laboratory and, when infected with 
P. berghei, such mosquitoes produce a much lower rate of transmission to mice (Ito et 
al.y 2002). However, the fitness of mosquito populations that have been reared in the 
laboratory and the retention of the antibody-encoding transgene in successive 
generations will have to be investigated fully.
1.5 The Apicomplexa
Apicomplexa are members of the eukaryotic Alveolata family, a group that also 
includes the ciliates and the dinoflagellates. The phylum Apicomplexa is composed of 
a diverse group of protozoan parasites that cause millions of human and animal deaths 
every year. The Apicomplexa includes the causative agents of malaria 
(Plasmodium spp.), toxoplasmosis (Toxoplasma gondii), coccidiosis of chickens 
(Eimeria spp.), babesiosis and East Coast cattle fever in cattle (Babesia spp. and 
Theileria spp., respectively) and cryptosporidiosis (Cryptosporidium parvum). A 
summary of the genera and the complications they cause are shown in Table 1.1. 
Unlike malaria, other apicomplexan parasites are not confined to the area surrounding 
the tropics, with the emergence of Toxoplasma and Cryptosporidium as opportunistic 
infections in HIV patients and the huge economic impact of drug-resistant Eimeria 
strains, also focusing attention on the identification of new drug targets.
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Family Genera and Species Comments
Haemosporidae
Plasmodium falciparum 
P. malariae 
P. ovale 
P. vivax
Malaria causes 5 x 108 cases/year and 
9 x 106 child deaths a year
Eimeriidae
Cryptosporidium spp. 
Cyclospora spp. 
Eimeria spp.
Sarcocystis spp. 
Toxoplasma gondii
Diarrhoea, causing problems in AIDS 
sufferers
Traveller’s diarrhoea, causing problems 
in AIDS sufferers
Poultry disease: UK spent £8.4M/year 
on control but still loses an estimated 
£20M/year (Williams, 1999)
Dog/Horse disease like toxoplasmosis
Cat disease, also a problem during 
human pregnancy or for AIDS sufferers. 
50% of Americans exposed in their 
lifetime
Babesiidae Babesia spp. Cattle disease
Theileriidae
Theileria spp. 
Cytauxzoon spp.
Cattle disease, occasionally infects 
humans
Fatal cat disease with no cure
Table 1.1 Members of the Apicomplexa phylum
This Table describes some genera and species of the Apicomplexan phylum. 
However, it is not a comprehensive list.
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Despite the diverse range of primary and secondary hosts that these parasites infect, 
and the complicated lifecycles observed within this phylum, apicomplexan parasites 
share common subcellular and biochemical properties that are unique to the phylum. 
Of particular interest is the distinct organisation of organelles at the anterior region of 
the invading cell. This apical complex, from which the name of this group of 
organisms is derived, contains three secretory organelles that aid the invasion of the 
parasite into the host cell (Figure 1.6).
Figure 1.6 An electron micrograph of a T. gondii tachyzoite
A = apicoplast, C = conoid, D = dense granules, G =golgi body, Mi = micronemes, 
M = mitochondria, R = rhoptries. Adapted from Mar&hal and Cesbron-Delauw, 
(2001).
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1.6 The apicoplast
The diverse group of over 5000 organisms that compose the Apicomplexa share a 
very similar cellular morphology. As well as the usual eukaryotic organelles; a single 
nucleus, mitochondrion, rough endoplasmic reticulum and the golgi body, the 
parasites also harbour a number of unusual structures. These include the rhoptries, 
micronemes and the conoid (a cytoskeletal structure), which are organised at the 
apical region of each parasite cell prior to the invasion of the host cell (Figure 1.6 ). 
The recently discovered plastid-like organelle (apicoplast) in P. falciparum and other 
parasites is perhaps the most unexpected subcellular structure observed in these 
protozoa (Wilson et al., 1996, Kohler et al.y 1997, Cai et al., 2003).
1.6.1 Discovery of the apicoplast
The first suggestion of the organelle now known as the apicoplast, was the discovery 
of an extrachromosomal genetic element, first observed in electron micrographs of the 
avian malarial parasite Plasmodium lophurae (Kilejian et al., 1975). This DNA was 
identified as a 35kb circular fragment that was also present in Toxoplasma gondii and 
P. falciparum. Originally the DNA was thought to be of mitochondrial origin. 
However, the mitochondrial genome was subsequently identified as a smaller 6 kb 
fragment (Feagin, 1992). The identification of a separate mitochondrial genome 
suggested that, like in plants, the 35kb second extrachromosomal DNA fragment 
belonged to a plastid genome.
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1.6.2 Identifying the location of a 35kb genetic fragment in the Apicomplexa
In early electron microscope studies of Apicomplexan parasites, the apicoplast did not 
go undetected. However, because the presence of a plastid was not expected the 
organelle was given several names including ‘the golgi adjunct* and the 
‘Hohlzylinder' or hollow cylinder (Sidall, 1992). The first evidence that this structure 
was also the location of the 35kb plastid genome was in T. gondii tachyzoites, when 
sequencing of a 35kb organellar genome allowed the design and in situ hybridisation 
of DNA probes to plastid DNA. These studies showed that, in each cell, there is a 
single, small (0.15- 1.5pm) plastid that is closely associated with the golgi body. A 
recent study using apicoplast-targeted GFP and MitoTracker® dye, showed that the 
apicoplast and the mitochondrion were very closely associated in blood stages of 
P. falciparum (Waller et al., 1999) (Figure 1.7).
Initial studies, utilising electron microscopy, showed that the apicoplast was 
surrounded by at least two membranes (McFadden et al., 1996); with three, four and 
five membranes sometimes observed, results that were replicated in several other 
studies (McFadden et al., 1997; Siddall, 1992). However, the debate surrounding the 
number of membranes was finally settled when four were consistently visualised 
surrounding the organelle, in electron micrographs (Kohler et al.> 1997) (Figure 1.8; 
Page 22). The four membranes surrounding the apicoplast indicate that the plastid 
may have been acquired by secondary symbiosis (Figure 1.9). This would have 
occurred when an Apicomplexan ancestor engulfed a eukaryotic photosynthetic 
organism. There is evidence that the photosynthetic eukaryote that was engulfed by 
the apicomplexan ancestor, was perhaps a red (rhodophyte) or green alga
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(chlorophyte) and this issue is still being actively debated (Funes et a l , 2002 and 
2003; Waller et a l 2003b; for a review see Funes et al., 2004).
Figure 1.7 The closely associated apicoplast and mitochondria in P. falciparum
A) The close association of apicoplasts (green) and mitochondria (red) in two 
erythrocytic stages of P. falciparum  (adapted from Waller et al., 2000). GFP was 
targeted to the apicoplast by using an ACF icader-GFP construct, which was then 
transfected and expressed in parasites. MitoTracker® Dye was used to define the 
mitochondria. The rbc on the left hand side is infected with a single ring stage 
parasite, whilst the rbc on the right is infected by more than one parasite.
B) Ultrastructure of the apicoplast and mitochondria of Plasmodium falciparum 
(M arshal and Cesbron-Delauw, 2001). Labels are M = mitochondria, P = plastid 
(apicoplast). The white arrow shows the outermost membrane and the black arrow 
highlights the inner envelopes.
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Figure 1.8 Electron microscope studies showing the apicoplast membranes
Ultrathin sections of T. gondii tachyzoites (A) and P. falciparum gametocyte (B) 
clearly show the four membranes (stained black with uranyl acetate) surrounding the 
apicoplast. These electron micrographs were taken from McFadden and Roos, (1999).
1.63 (ienetic analysis of the apicoplast origin and function
The first genes sequenced from the circular DNA, encoded for subunits of RNA 
polymerase, rpoB and rpoC (McFadden et al., 1991). These genes encode RNA 
polymerases similar to those observed in bacteria and chloroplast genomes and are 
distinct from nuclear and mitochondrial encoded RNA polymerases. The complete 
sequence of the 35kb DNA circle was elucidated in 1996 and described a ‘stripped 
down’ plastid DNA genome like that observed in non-photosynthetic plants (Wilson 
et al., 1996). The complete lack of genes dedicated to photosynthesis suggests that the 
loss of the photosynthetic ability of the Apicomplexa occurred early in the evolution 
of the phylum. As well as genes encoding RNA polymerase, the circular DNA
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Primary endosymbiosis
Eukaryotic cell engulfs 
cyanobacterium
Secondary endosymbiosis
Apicomplexan ancestor 
engulfs photosynthetic 
eukaryote
a
a
Figure 1.9 A possible origin of the apicoplast by secondary endosymbiosis
Dotted arrows indicate gene transfer from the nucleus of the engulfed organism to the 
nucleus of the new host.
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contains a large number of ‘housekeeping’ genes encoding for a complete set of 
tRNAs, small- and large-ribosomal RNA subunits (arranged in plastid-like inverted 
repeats), ribosomal proteins and the elongating factor tufA (Wilson et al., 1996) 
(Figure 1.10). This suggests that the apicoplast retains the ability to synthesise 
proteins.
RNA
Figure 1.10 Organisation of the apicoplast genome
Taken from Mardchal and Cesbron-Delauw, (2001).
Only two proteins not involved in DNA replication, transcription and translation have 
been identified on the apicoplast genome (Ellis et al., 2001; Wilson et al., 1996); a 
protein related to SufB, which is involved in the production of Fe-S clusters in E. coli 
and ClpC, a chaperone/protease involved in the processing of nuclear-encoded
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proteins targeted to plastids. The presence of these proteins suggested that, in 
Apicomplexa, nuclear-encoded proteins may be targeted to the apicoplast and that this 
organelle may be the location of at least one essential metabolic pathway.
1.7 Apicoplast function
Antibiotic drugs that disrupt genome replication, transcription and translation within 
the plastid trigger a ‘delayed-death’ phenotype in Apicomplexa parasites (Pfefferkom 
and Borotz, 1994; Fichera et al., 1995; Fichera and Roos, 1997). This phrase denotes 
that initially parasite cultures appear unaffected by exposure to the antibiotic and 
continue to grow at the expected rate. However, daughter merozoites arrest and die 
within new host cells, possibly due to an incorrectly formed parasitophorous vacuole. 
Furthermore, interruption of apicoplast protein synthesis by thiostrepton (Sullivan et 
al., 2000), showed that, when mosquitoes fed on mice infected with P. berghei at 6% 
parasitaemia, thiostrepton reduced the development of oocysts in the mosquitoes to 
10% of controls. This suggests that the apicoplast is also essential for development of 
the parasite during the sexual stage within the mosquito. Collectively, these studies 
highlight that, whatever the ultimate functions of the plastid, the apicoplast is essential 
for the maintenance of parasite infections.
Initial hypotheses of apicoplast function were based on the metabolic pathways 
observed in non-photosynthetic plastids present in some plants. These included the 
production of haem required for respiration, fatty acid biosynthesis, starch storage and 
the synthesis of aromatic amino acids. However, preliminary data obtained from the 
Plasmodium falciparum genome project, provided the first hard evidence of
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apicoplast function. The research groups of Beck and McFadden utilised the genetic 
information to identify several nuclear-encoded proteins that contained a plastid target 
peptide motif, which was sufficient for transport to the apicoplast (Waller et al.t 2000; 
Jomaa et al., 1999). These proteins belonged to two anabolic pathways, fatty acid 
biosynthesis and non-mevalonate isopentenyl diphosphate synthesis, found in 
bacteria, algae and plants. All of these nuclear-encoded apicoplast-targeted (NEAT) 
proteins contained a bipartite leader sequence at their N-terminus, consisting of a 
hydrophobic signal peptide (16-34 amino acids) terminating in a classical ‘von 
Heijne’ cleavage site followed by a typical plastidial transit peptide (30-44 amino 
acids) with a net positive charge (Waller et al., 2000) (Figure 1.11). This distinct 
arrangement of amino acids is essential for the correct targeting and transport of 
proteins bound for the apicoplast (Waller et al., 2000). Two programs have been 
developed that use known apicoplast targeted leader sequences to predict the 
likelihood of any individual Plasmodium protein being targeted to the apicoplast 
(Zuegge et al., 2001; Foth et al., 2003). In conjunction with the sequencing of the 
P. falciparum genome, this has allowed the identification of approximately 550 
candidate apicoplast proteins (Ralph et al., 2004).
Bioinformatics and the prevalence of pathways previously characterised in E. coli and 
plants have accelerated advances in the identification of whole and partial metabolic 
pathways within the apicoplast. In P. falciparum , proteins that constitute complete 
pathways for the synthesis of fatty acids, non-mevalonate isopentenyl diphosphate 
synthesis and a partial pathway for the synthesis of haem (Sato et al., 2000; Sato and 
Wilson, 2002), are targeted to the apicoplast. The other enzymes in the haem
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Figure 1.11 The bipartite signal sequence required for apicoplast targeting
An example of a nuclear-encoded apicoplast-targeted (NEAT) protein and its bipartite 
signal sequence that is both essential and sufficient for targeting to the apicoplast 
(Waller et al., 1998, 2000). SP = signal peptide, necessary for entry of the protein into 
the secretory pathway (Waller et al., 2000). Signal peptides are usually hydrophobic 
domains that end in a signal peptide cleavage site. TP = transit peptide, is required for 
subsequent targeting to the plastid and to avoid secretion into the parasitophorous 
vacuole (Waller et al., 2000). Transit peptides of apicoplasts proteins have a net 
positive charge and are rich in asparagine and lysine and depleted in glutamate and 
aspartate (Foth et al., 2003).
synthesis pathway are found in the cytosol and the mitochondria (Bonday et al., 2000; 
Varadharajan et al., 2002), which is closely-associated to the apicoplast during some 
stages of the parasite lifecycle (Figures 1.7 and 1.8). This may allow for the efficient 
exchange of substrates between the two organelles and the cytosol. All of these 
pathways include steps that differ significantly from those found in the human host 
and provide many potential targets for the development of specific inhibitors. The 
inhibition of these novel targets with existing antibacterial and herbicide compounds
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has already provided one drug, fosmidomycin, an inhibitor of IspC, an enzyme in the 
non-mevalonate isopentenyl diphosphate pathway that has progressed to human trials 
(Lell et a/., 2003).
1.8 Fatty Acid Synthesis
Whilst most species derive some fatty acids from their diet, in many species de novo 
fatty acid synthesis (FAS) is essential. The end products of these pathways are 
integral components of cellular membranes with both structural and signalling 
functions and fatty acyl lipids are also important energy storage molecules. The 
reaction mechanisms of fatty acid biosynthesis are very similar in all organisms, 
taking place in either the cytosol of animals, yeast and bacteria or the plastids of 
plants and alga.
There are two types of FAS and these are distinguished by their structural 
organisation and catalytic mechanisms. Type I FAS of animals and yeast is catalysed 
by multifunctional proteins termed fatty acid synthase. In animals FAS consists of 
two identical, 272kDa polypeptides, with only the homodimer exhibiting activity. 
Each chain contains six catalytic and an acyl carrier protein (ACP) domain, arranged 
in the order; P-ketoacyl-ACP synthase, malonyl/acetyl transacylase, dehydratase, 
enoyl reductase, P-ketoacyl reductase, ACP and thioesterase. In contrast, the Type II 
FAS system present in plants, algae and bacteria contains many of the catalytic 
domains of Type I FAS as discrete enzymes that probably form a multi-enzyme 
complex. Some inhibitors of FAS are either Type I or Type II specific and can be 
exploited as antibiotics.
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The first committed step in the Type D fatty acid synthesis pathway is the conversion 
of acetyl-CoA (a two carbon unit) to malonyl-CoA (a three carbon unit) catalysed by 
acetyl-CoA carboxylase (ACCase) (Figure 1.12). The malonyl group is then 
transferred between the phosphopantathiene prosthetic groups of coenzyme A and 
acyl carrier protein (ACP) by the malonyl-CoA:ACP transacylase (FabD - Fatty Acid 
Biosynthesis) to form malonyl-ACP. Acyl carrier protein is a small (~8 kDa), acidic 
protein that remains bound to all of the intermediates of the FAS pathway and 
distinguishes such compounds from the intermediates of fatty acid oxidation, which 
remain bound to coenzyme A.
Binding sites of ACP are present in at least two of the fatty acid synthesis enzymes in 
E. coli (Zhang et al., 2001& 2003). These sites are found on the surface of the protein 
and contain a number of highly conserved positively charged residues (Zhang et al.y 
2001 & 2003). Disruption of the ACP recognition patch on these enzymes, by 
replacement of positive residues with negatively charged amino acids, caused a large 
decrease in the enzyme activity (Zhang et al., 2003). This suggested that the docking 
of ACP in FAS enzymes is essential for the correct functioning of the pathway.
The initiating step of the FAS cycle is the condensation of malonyl-ACP with 
acetyl-CoA to form a four carbon p-ketoacyl-ACP group (acetoacetyl-ACP) catalysed 
by FabH -  a P-ketoacyl-ACP synthase (Figure 1.12). The subsequent removal of the 
keto group to form a saturated hydrocarbon chain is achieved by a common 
mechanism found in nature. Firstly, the keto group is reduced by a P-ketoacyl-ACP 
reductase, then water is removed by a dehydratase and the resulting double bond of 
the enoyl group is reduced by an enoyl-ACP reductase (Figure 1.13). The product of
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Figure 1.12 The Type II Fatty Acid Synthesis pathway
ACCase = Acetyl-CoA carboxylase. Inhibitors are shown in red and enzymes shown 
in bold. FabH catalyses the first condensation step between acetyl-CoA and malonyl- 
ACP. The FAS pathway carries out several cycles of condensation, reduction, 
dehydration and a second reduction to produce acyl-ACPs.
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Figure 1.13 The individual enzymatic reactions of the Type II FAS system
Enzymes are shown in red, substrates and products shown in blue. The pathway 
proceeds through cycles of condensation, reduction, dehydration and a 2nd reduction. 
Fabl/K/L are individual enoyl reductases that are all capable of catalysing the 
reduction step. They appear to be mutually exclusive as no organism has yet been 
found to contain more than one of the enoyl reductases.
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the first cycle, butyryl-ACP, becomes the substrate for the subsequent rounds of 
condensation, reduction, dehydration and reduction, as the acyl chain is extended by 
two carbons per cycle (Figure 1.12). The final products of the fatty acid synthesis 
differ between organisms (Table 1.2), although saturated or monounsaturated C16 and 
C18 acyl chains are generally the major products.
Organism 
(tissue in brackets)
Type Subunit size 
(kDa)
Major Products
Mammalian or avian (liver) I 220-270 16:0 free acid
Mammalian (mammary 
gland)
I 220-270 4:0-16:0 free acids
Mycobacterium I 290 Bimodal distribution 
16:0-18:0-CoA and 
24:0-26:0CoA
C. parvum I 900 Elongates 16:0-ACP to 
18:0-22:-ACP*
S. cerevisiae I 180 16:0-18:0-CoA
Higher plant chloroplasts n - 16:0-18:0- ACP
Cup he a hookeriana seeds ii - 10:0-14:0-ACP
E. coli n - 16:0, 16:1 and 18:1-ACP
Mycobacterium n Elongates 16:0 and longer 
precursors to form mycolic 
acids b
Plant and mammalian 
mitochondria
n Possible bimodal 
distribution. C8:0 and 
C 14:0-C 16:0-ACP°
Table 1.2 The distribution of different types of FAS and their major products
Adapted, in part, from Lipid Biochemistry, 5th Edition, 2002, Blackwell Science.
* Zhu et a l , 2004. b Kremer et a l , 2000.c Yasuno et a l , 2004.
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1.8.1 Determination of chain length
In Type I FAS, the growing acyl chain is attached to the flexible ACP domain, which 
allows it to interact with catalytic domains between and within each polypeptide 
subunit. In this system, the chain-length specificity of the thioesterase domain 
contributes significantly to the length of the final product. For example, in animals 
there is a twenty-fold decrease in thioesterase activity towards C14 compared to C16 
(Naggert et al.f 1991) and this ensures that, despite the broad range of chain lengths 
accepted by most of the active domains, the main product of the pathway is palmitate. 
In contrast, the final products of Type II FAS appear to be more tightly controlled at 
the entry point of the cycle, by the P-ketoacyl-ACP synthase enzymes and can lead to 
the synthesis of branched chain fatty acids.
In bacteria and plants a second important regulator of fatty acid length is glycerol 
3-phosphate acyltransferase (PlsB), an important enzyme in the synthesis of 
phospholipids. When E. coli plsB mutants are starved of glycerol, unusually long 
(2 0 -2 2 ) carbon acyl chains accumulate, suggesting that under these conditions the 
condensing enzymes are capable of elongating further than C l8 . Therefore, the 
competition between PlsB and elongating condensing enzymes is important to the 
chain length of the acyl product.
The chain length of the products of Type II FAS in plants can be affected by 
thioesterase and acyl-CoA synthases, as well as glycerol 3-phosphate transacylase. As 
an example, a medium chain-length specific acyl-ACP thioesterase is responsible for 
the high proportion (>80%) of C l0:0 (decanoate) and C l2:0 (laurate) present in the 
triacylglycerol energy stores in Cuphea lanceolata seeds (Dormann et al., 1993).
33
Acyl-Co A transferases can activate free fatty acids, presumably following thioesterase 
activity, for essential reactions, such as the introduction of double bonds in eukaryotic 
systems by acyl-CoA desaturases.
1.8.2 Synthesis of unsaturated fatty acids
1.8.2.1 Bacterial
The ability to synthesise unsaturated fatty acids (UFA) in bacteria has been 
extensively studied in the model bacterium E. coli and the findings are discussed in 
detail in this section. Alternative bacterial UFA pathways are also described.
1.8.2.2 The FabB/FabA system
The gamma Proteobacteria (i.e. E. coli and its relatives) are capable of synthesising 
monounsaturated fatty acids (MUFAs) and possess two proteins that are not present in 
other bacteria families. These MUFA synthesising bacteria, contain a P-ketoacyl-ACP 
synthase (FabB) and a dehydratase (FabA) with isomerase activity that are essential 
for the incorporation of a double bond into the growing acyl chain (Figure 1.14).
The first step of UFA synthesis is performed by FabA, which like FabZ, is capable of 
catalysing the dehydration of p-hydroxyacyl-ACPs to produce the double bond 
containing enoyl-ACP. However, at the 10 carbon stage, FabA also catalyses the 
isomerisation of the trans-2 double bond to cis-3 (Heath and Rock, 1996a). In the 
saturated pathway, the natural route of the product following the dehydratase step, is 
the removal of the double bond by FabI, the enoyl-ACP reductase. However, in UFA 
synthesis, FabB shows a high specificity for the cis-3 decenoyl-ACP product and
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FabA
FabZ NAD(P)H
FabM NAD(P)
C12:0-ACP (lauroyl-ACP)
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Figure 1.14 Unsaturated fatty acid synthesis in bacteria
Insertion of the double bond in unsaturated fatty synthesis is depicted on the left-hand 
scheme and the saturated pathway represented by the right-hand scheme. Enzymes are 
shown in red text; substrates/products are shown in blue text. 
/?-hydroxydecanoyl-ACP is shown at a branch point where it can continue along the 
saturated fatty acid synthesis pathway or if acted on by either isomerase 
(FabA/FabM) becomes a substrate for the unsaturated fatty acid synthesis pathway.
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competes with FabI, which can only reduce trans double bonds. FabB is the only 
ketoacyl-ACP synthase that catalyses the condensation of the cis-3 decenoyl-ACP 
compound with malonyl-ACP to form cis-5 dodecanoyl-ACP. This compound then 
re-enters the “generic” fatty acid synthesis cycle and continues through two more 
rounds of condensation, reduction, dehydration and reduction to produce 
cis-9 hexadeeenoyl-ACP (palmitoleic acid). This C16 monounsaturated fatty acid 
(MUFA) is a major component of the fatty acyl chains found in the E. coli membrane 
and is incorporated into bacterial lipids and membranes via the same route as 
saturated fatty acids.
The discovery that the second elongating KAS enzyme of E. coli, FabF, is essential 
for the synthesis of cis- 11 octadecenoic acid (c/s-vaccenic acid) provides a twist in the 
tail of bacterial UFA synthesis. Bacteria incorporate c/s-vaccenic acid into the acyl 
groups of their membrane lipids in order to increase the fluidity of the membrane in 
response to a decrease in temperature. Therefore, whilst the intrinsically 
temperature-sensitive FabF is not essential for the production of UFAs, it is involved 
in the unsaturated pathway in a temperature mediated response. However, the 
production of vaccenic acid is not essential for the survival of the bacterium and fabF  
knockouts show no phenotype. In E. coli, a second method of regulating membrane 
fluidity acts by controlling the level of expression of the fabAJfabB operon, which is 
mediated by the transcriptional activator FadR and transcriptional repressor FabR 
(Hoang and Schweizer, 1997; Campbell et al.y 2001a; Zhang et al.y 2002).
A second dehydratase, called FabZ, cannot catalyse isomerisation of the CIO 
intermediate but is able to catalyse the dehydration of all other intermediates in
36
Type II FAS. Therefore, in E. coli and related bacteria, the combination of Fab A and 
FabB activities is essential for the synthesis of UFAs and organisms containing a 
FabB homologue also contain a FabA enzyme.
1.8.23 FabM isomerase
The FabA/FabB system for the production of UFA is not widely distributed in 
bacteria (Campbell and Cronan, 2001b). Nevertheless, some gram-positive bacteria 
such as streptococci, do not contain FabA and FabB, yet synthesise UFA. In 
Streptococcus pneumoniae, the FabZ enzyme performs all of the dehydration steps of 
FAS. An enzyme unique to this family of bacteria, FabM, diverts fatty acids into the 
UFA pathway by isomerising trans-2 decenoyl-ACP to cis-3 decenoyl-ACP 
(Marrakchi et al., 2002). Within this system FabF catalyses the elongation of the cis-3 
decenoyl-ACP and all other unsaturated and saturated acyl-ACPs.
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1.8.2.4 Desaturation of existing Fatty Acids
Aerobic desaturation of existing fatty acids on membrane phospholipids provides an 
alternative route to UFA synthesis in bacilli and cyanobacteria (Cronan and Campbell, 
2001). These enzymes function outside of the Type II FAS pathway and in this way 
share similarities to UFA synthesis observed in eukaryotic organisms. The 
de Mendoza laboratory has shown that, Bacillus subtilis, contains a A5 desaturase 
(Altabe et al.y 2003). This enzyme can be induced following a sharp decrease in 
temperature and is thought to allow the bacterium to remodel its membrane lipids 
rapidly in a response to abrupt alterations in temperature (Cybulski et al., 2002).
1.8.3 Eukaryotic UFA
So far, in this Section on UFA synthesis, focus has been directed towards bacterial 
UFA synthesis, which mainly occurs via an anaerobic pathway that is harboured only 
by a small group/s of bacteria. The most common mechanism of UFA synthesis is the 
aerobic pathway (see Section 1.8.2.4), which utilises molecular oxygen as an essential 
cofactor. This is by far the most widespread pathway and is present in bacilli (Altabe 
et al.y 2003), cyanobacteria, yeast, algae, higher plants, protozoa and animals. The 
aerobic and anaerobic systems appear to be mutually exclusive as no organism has 
been found to have both.
The desaturase enzymes that catalyse the insertion of double bonds are invariably 
membrane bound, and hence, characterisation of the process was initially slow. 
However, it is known that most of the double bonds are inserted at the A9 position, 
with some exceptions being A7 bonds in algae and the A5-desaturase in
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Bacillus subtilis. Bloch and co-workers also found that molecular oxygen and NADH 
or NADPH were essential cofactors, which suggested a mechanism similar to many 
oxygenases. Most A9-desaturases readily accept saturated substrates from C14-C18 
and are not entirely specific for stearate (C18:0) as first thought (Gibson et al.y 1993).
The animal A9-desaturase is found in the endoplasmic reticulum (ER), with the 
desaturase mainly enveloped within the membrane and only its active site exposed to 
the ER lumen. Two other membrane bound proteins, cytochrome bs and a 
NADH/cytochrome 65 reductase, contribute to the reaction by generating the reducing 
potential required for the reaction. In contrast, the plant stearoyl desaturase is a 
soluble protein, present in the chloroplast stroma (the location of Type II FAS) and 
utilises an ACP bound substrate. These enzymes provide a mechanism for the 
production of monounsaturated fatty acids that are essential to all organisms. They 
also provide a stepping stone for the synthesis of polyunsaturated fatty acids 
(PUFAs), the production of which requires many subsequent enzyme catalysed 
reactions and varies considerably between different species (for a Review see Lipid 
Biochemistiy, 2002, Ed. Gurr, Harwood and Frayn, Blackwell Science).
1.9 Apicomplexan Fatty Acid Synthesis
Until recently, it was suggested that Plasmodium spp. lacked the ability to carry out 
de novo fatty acid synthesis (FAS) (Vial and Ancelin, 1992). This was supported in 
studies with radiolabelled fatty acids and fatty acid precursors, which appeared to 
show that the parasite obtained its fatty acids by scavenging fatty acids from the host 
(Rock, 1971). However, plants and algae both perform de novo fatty acid synthesis in
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their plastids, utilising dissociated enzymes grouped together in a multi-enzyme 
complex, termed Type II FAS.
Type D FAS is widespread in prokaryotes but in eukaryotes is limited to plastid 
containing organisms. Therefore, the discovery of Type II FAS-like proteins in the 
apicoplast and the ability of P. falciparum to incorporate acetate into fatty acids 
(Surolia and Surolia, 2001) suggested that Apicomplexa may contain a previously 
over-looked plastid-based FAS pathway. The presence of the apicoplast as the 
apparent site of Type II FAS highlights a novel target against the Apicomplexa 
phylum including Plasmodium spp., T. gondii and E. tenella (Gleeson, 2000).
1.9.1 Initial discovery of FAS in Apicomplexans
Three genes that encoded proteins involved in Type II FAS were discovered 6  years 
ago in P. falciparum and T. gondii genomes (Waller et al., 1998). These fatty acid 
biosynthesis proteins were homologous to proteins of the Type II FAS enzymes, acyl 
carrier protein (ACP), P-ketoacyl-ACP synthase HI (FabH) and P-hydroxyacyl-ACP 
dehydratase (FabZ) and these enzymes are targeted to the apicoplast (Waller, 2000). 
The completion of the P. falciparum genome has facilitated the bioinformatic 
identification of all the proteins needed to reconstitute a complete Type II FAS 
pathway in apicomplexan parasites (Figure 1.15) (For a recent review see Ralph, et 
al., 2004).
During the course of this project, the characterisation of most of the P. falciparum 
Type II FAS proteins was achieved by several research groups (Waters et al,. 2002;
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Figure 1.15 The apicoplast FAS pathway and contributing reactions
Enzyme names are shown in red, substrates and products are shown in blue. ACCase, acetyl-CoA carboxylase; acetyl CoA, acetyl coenzyme A; ACP, acyl carrier protein; 
ACS, acyl CoA synthetase; ACT1, glycerol-3-phosphate acyltransferase; ACT2, 1-acyl-glycerol-3-phosphate acyltransferase; ADP. adenosine diphosphate; ATP, adenosine 
triphosphate; FabB/F, p-ketoacyl-ACP synthase I/II; FabD, malonyl-CoA transacylase; FabH, fJ-ketoacyl-ACP synthase III; FabI enoyl-ACP reductase; FabZ, 
P-hydroxyacyl-ACP dehydratase; FatA. Acyl-ACP thioesterase; GpdA, glycerol-3-phospahte dehydrogenase; LipA, lipoic acid synthase; LipB, lipoate protein ligase; LPA, 
lysophosphatidic acid; NAD+/NADH, nicotinamide adenosine; PA. phosphatidic acid; PDH, pyruvate dehydrogenase; PDH (E2), pyruvate dehydrogenase complex E2 
subunit; PEP, phosphoenol pyruvate; Pi, inorganic phosphate; PP, pyrophosphate; PPT, phosphoenolpyruvate/phosphate translocator; PYK, pyruvate kinase; SAD, 
stearoyl-ACP desaturase; TPT. triose phosphate transporter. Adapted from Ralph et al., 2004.
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Prigge et al., 2003; Pillai et al., 2003; Surolia and Surolia 2001; Suguna et al., 2003; 
Sharma et al., 2003). To date, the only enzyme that has not been characterised is the 
FabB/F elongating condensing enzyme (p-ketoacyl-ACP synthase) and this provides a 
focus for the work described in Chapters 3  and 4 .
1.93, Individual enzymes of the Type II FAS pathway
1.9.2.1 The initial reactions of Type II FAS
The first committed step of the Type II FAS pathway is the production of 
malonyl-CoA from acetyl-CoA by the large acetyl-CoA carboxylase (ACCase) 
protein (Figure 1.12). A nuclear-encoded apicoplast-targeted (NEAT) ACCase has 
been identified in both P. falciparum and T. gondii (Gardner et al., 2002; Zuther et al., 
1999). However, the production of malonyl-CoA depends on the availability of 
acetyl-CoA as well as the presence of the catalytic enzyme. This begs the question: 
does the apicoplast have the ability to synthesise or import sufficient acetyl-CoA for 
the synthesis of fatty acids?
In plants, the main source of acetyl-CoA for plastidial FAS is pyruvate (Ke et al., 
2000; Bao, et al., 2000), which is transported across the chloroplast membranes as 
phosphoenolpyruvate and converted to pyruvate within the plastid or formed by 
glycolysis in situ. Bioinformatic analyses performed within this project and by other 
groups, identified a putative phosphoenolpyruvate translocator and pyruvate kinase, 
which are predicted to be targeted to the apicoplast (J.Urch unpublished observation; 
Ralph et al., 2004). These two proteins would provide a source of pyruvate to the 
plastid and, additionally, the kinase reaction would generate ATP. In plant plastids the
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conversion of pyruvate to acetyl-CoA is catalysed by the multi-subunit pyruvate 
dehydrogenase enzyme. Genes encoding each of the subunit domains are present in 
the genomes of P. falciparum and T. gondii and the proteins they encode are located 
in the plastid (Ralph et al., 2004). Therefore, the apicoplast appears to possess all of 
the substrates and enzymes required for the synthesis of acetyl-CoA and 
malonyl-CoA, the starting materials required for FAS.
ACP and the initiating condensing enzyme FabH were the first to be identified in 
apicomplexans because the acpP and fabH  genes are located on Chromosome 2, the 
first P. falciparum chromosome to be sequenced in its entirety (Gardner et al., 1998; 
Waller et al., 1998). Both proteins were also identified due to their significant 
sequence homology to bacterial and plant proteins (for ACP 49% identity with E. coli 
ACP and 35% identity with Spinacea oleracea plastidial ACP; for FabH 38% identity 
with E. coli FabH and 43% identity with Spinacea oleracea FabH). ACP and FabH 
are both essential for the first condensation reaction of Type II FAS. However, prior 
to elongation, malonyl-CoA must first be transferred to ACP by the 
malonyl-CoA:ACP transacylase (FabD). The Prigge laboratory, recently identified, 
cloned and expressed P. falciparum FabD in a recombinant form 
(Waters et al., 2002). In the aforementioned study, pfFabD was able to transfer 
efficiently the malonyl moiety from malonyl-CoA to either ecACP (E. coli ACP) or 
pfACP (P. falciparum ACP), to generate malonyl-ACP for the FabH reaction.
The pfFabH enzyme produced acetoacetyl-ACP from acetyl-CoA and malonyl-ACP 
and showed a slight preference for malonyl-pfACP compared to malonyl-ecACP 
(Prigge et al., 2003). The low specificity towards ecACP or pfACP was not surprising
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because the two proteins show 49% sequence identity. Furthermore, 6 of the 7 
residues in helix a2 that are thought to be involved in the docking of ACP to enzymes 
involved in FAS (Zhang et al., 2001), are conserved between the bacterial and 
malarial proteins.
1.9.22 The ketoacyl-ACP reductase
The next step of the FAS pathway is catalysed by a P-ketoacyl-ACP reductase, the 
only Type II FAS enzyme for which only a single homologue (FabG) has been 
detected. The p-ketoacyl-ACP reductase of P. falciparum was identified by its high 
sequence identity to both bacterial and plant FabG proteins (47% sequence identity to 
E. coli FabG and 48% to Brassica napus FabG) (Pillai et al., 2003). This enzyme 
contains a long N-terminal extension of approximately 57 amino acids that is 
predicted to target the enzyme to the apicoplast. pfFabG also possesses the Ser, Tyr 
Lys residues involved in the catalytic triad of short chain alcohol dehydrogenases.
Like all previously characterised FabG proteins, the P. falciparum is NADPH 
dependent and is unable to utilise NADH unlike the enoyl-ACP reductase (FabI -  
discussed later in this section). However, the structure and fold of the FabG and FabI 
reductases are similar, as observed previously in Brassica napus, both containing a 
typical NAD(P)-binding Rossman fold.
1.9.23 The dehydratase of Apicomplexan Type II FAS
The discovery of the enzyme responsible for the dehydration step was first reported in 
2003 (Sharma et a l , 2003). This protein showed significant sequence homology to
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bacterial and especially plant FabZ enzymes (41% identity to E. coli FabZ and 46% 
identity with Arabadopsis thalania FabZ) but less so with the E. coli FabA 
dehydratase/decenoyl isomerase (21% identity). On the basis of this phylogenetic 
analysis, the dehydratase was defined as pfFabZ. The dehydratase identified in 
T. gondii also shows significant sequence identity to FabZ, rather than FabA enzymes, 
suggesting that apicomplexan parasites may not contain the FabA/FabB system for the 
synthesis of unsaturated fatty acids. No FabM homologue has been identified within 
the complete P. falciparum genome. Nevertheless, the possibility that the 
P. falciparum FabZ can catalyse the isomerisation of the trans-2 enoyl product of the 
dehydration reaction cannot be eliminated because the kinetic characterisation was 
performed with four carbon, not 10 carbon, intermediates (Sharma et al., 2003). In 
fact, although no conversion of the trans product to the cis product was observed, 
pfFabZ showed favourable kinetics towards the use of the enoyl product compared to 
the p-hydroxyacyl substrate, suggesting that the enoyl group could be a natural 
substrate for this enzyme.
1.9.2.4 Enoyl reductases of Apicomplexans
The final reaction of the Type II FAS pathway is catalysed by an 
enoyl-ACP reductase, of which several homologous proteins have been identified. 
FabI, enoyl-ACP reductase I, is the most widely distributed of these proteins and is 
present in plants and most bacteria. FabK, enoyl-ACP reductase n, is restricted to the 
Gram-positive bacteria and was first discovered in Streptococcus pneumoniae due to 
its lack of sensitivity to triclosan, an irreversible inhibitor of the FabI enzyme 
(Marrakchi et al., 2001). A third homologue, FabL, was identified in Bacillus subtilis
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(Heath and Rock, 2000) and this enzyme exhibits some sequence homology to FabI 
but not enough for it to be characterised as a FabI protein. FabL enzymes are not 
widely distributed in the bacteria.
A search of the P. falciparum genome with sequences of each of the three enoyl-ACP 
reductases identified a FabI homologue but no homologues of FabK or FabL (Surolia 
and Surolia, 2001). P. falciparum FabI is a 35kDa protein that contains a 77 amino 
acid N-terminal bipartite apicoplast targeting domain, reinforcing the idea that Type II 
FAS takes place in the apicoplast. Like the FabI proteins from plants and bacteria, 
pfFabl is sensitive to triclosan, a chlorinated &/s-phenol regularly used as a 
bactericidal agent in toothpaste and detergents (Suguna et al., 2001; Bhargava and 
Leonard, 1996). Triclosan was the first compound to demonstrate definitively that the 
inhibition of Type II FAS in Plasmodium was sufficient to clear blood stage malaria 
parasites from mice (Surolia and Surolia, 2001). The basis of triclosan inhibition of 
FabI is subsequently discussed in further detail in Section 1.11.2.b.
1.93 The function of Type II FAS in apicomplexan parasites
The fate of acyl-ACPs produced from the Type II FAS pathway is unknown.
However, there is a high possibility that some octanoyl-ACP is converted to lipoic 
acid, an essential cofactor of the pyruvate dehydrogenase complex (PDHC) that aids 
in the transfer of an acetyl group to coenzyme A. The synthesis of lipoic acid from 
octanoyl-ACP occurs in both the mitochondria and plastids of plants (Yasuno and 
Wada, 2002). Firstly, octanoyl-ACP is converted to lipoyl-ACP by lipoic acid 
synthase (LipA) and then lipoic acid protein-ligase (LipB) catalyses the formation of a
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covalent bond to a serine residue of PDHC. NEAT homologues of Lip A and LipB 
proteins have been predicted in P. falciparum and T. gondii (Wrenger and Muller, 
2004; Thomsen-Zieger et al., 2003). In summary, a cyclic pathway incorporating 
Typell FAS and lipoic acid synthesis may exist. Lipoic acid is an essential cofactor 
for the production of acetyl-CoA; one of the starting substrates required for the 
synthesis of acyl-ACPs and these acyl-ACPs may be utilised in the synthesis of lipoic 
acid in the apicoplast.
Fatty acids are also incorporated into phospholipids by esterification of glycerol 
hydroxyl groups. Phospholipids can be exported and assimilated into other cellular 
membranes or in this case may be important in maintaining the apicoplast membranes. 
Two genes encoding glycerol 3-phosphate acyl transferases have been identified in 
the P. falciparum genome. The products of these genes are predicted to be targeted to 
the apicoplast, suggesting that phosphatidic acid is synthesised in the plastid-like 
organelle. However, genes encoding the enzymes involved in the latter stages of 
phospholipid synthesis, for example those involved in phosphatidylcholine synthesis, 
are present in P. falciparum but appear to be targeted to the endoplasmic reticulum 
(Ancelin et al., 2003). Several isoforms of a membrane protein, acyl-CoA synthetase, 
an enzyme that combines free fatty acids with coenzyme A and exports them to 
closely-associated organelles or the cytosol are predicted to be NEAT proteins. This 
would allow acyl chains produced by Type II FAS in the apicoplast to be utilised 
throughout the malaria parasite cell.
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Finally, a NEAT protein that shows significant sequence identity to stearoyl-CoA 
desaturase, may be capable of utilising the products of Type II FAS to synthesise 
monounsaturated fatty acids such as palmitoleic acid (16:1) or oleic acid (18:1). This 
would mimic the eukaryotic method for the production of MUFA and, in the absence 
of UFA synthesis within the Type D pathway, could provide the only alternative route 
for the de novo synthesis of UFA in Plasmodium.
1.10 Type II FAS Condensing Enzymes
p-Ketoacyl-ACP synthases (KAS) enzymes (Edwards et al., 1997; Magnuson et al., 
1995; Jackowski and Rock, 1987) are responsible for the condensation reaction of 
FAS in plant chloroplasts, algae and bacteria (Lu et al., 2004;Beeson et al.t 2001; 
Rock and Cronan, 1985). They perform the systematic addition of two carbon units to 
an existing carbon chain. New carbon-carbon bonds are created by carrying out 
Claisen condensations (Dewar and Dieter, 1988).
1.10.1 Condensing enzyme nomenclature
The nomenclature of Type II KAS enzymes can be somewhat confusing to the 
uninitiated. In E. coli, the model bacterial system, FabB is also designated KAS I, 
FabF as KAS II and FabH as KAS ID. To avoid confusion, the Fab system has been 
adopted throughout the bacterial kingdom except in Mycobacterium species, which 
possess three KAS enzymes, mtFabH, KasA and KasB. As its name suggests mtFabH 
is a homologue of other bacterial and plant FabH enzymes and contains the Cys, His, 
Asn, catalytic triad observed in this family of enzymes. KasA and KasB exhibit 
greater homology to FabF than FabB enzymes. These enzymes accept long chain 
(C16-C28) acyl-ACP substrates and the products are used to synthesise mycolic acids,
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essential components of the protective cell wall in mycobacteria (Schaeffer et al., 
2 0 0 1 ; Kremer et al., 2 0 0 2 ).
In plants, the genes that encode condensing enzymes were historically designated 
KAS I, KAS D and KAS ID and, therefore, are seldom referred to using the Fab 
nomenclature. Plant KAS ID enzymes show significant homology to bacterial FabH 
enzymes and both carry out the same the initial condensation reaction of the Type II 
FAS cycle (Clough et al., 1992; Jackowski et al., 1989; Tsay et al., 1992; Khandekar 
et al.y 2001). Plant KAS I and KAS II enzymes catalyse the chain elongation steps. 
KAS D appears to be essential for the production of stearate (C l8:0) from C l6 -ACP, 
whereas KAS I will condense chains up to C l4:0 with malonyl-ACP (Harwood, 
1996). The Type II FAS pathway in plant plastids does not appear to be capable of 
synthesising unsaturated fatty acids and, accordingly, both KAS I and KAS II appear 
to show greater homology to bacterial FabF proteins than to FabB. Plants synthesise 
UFA downstream of the Type II FAS pathway, using the aerobic system for 
desaturation (Section 1.8.3).
1.10.2 Classification of KAS enzymes
Enzymes that catalyse the Claisen-condensation include KAS enzymes, alfalfa 
chalcone synthase and yeast thiolases. Comparison of the amino acid sequences of 
these enzymes identified a small number of conserved residues and led to the 
discovery of the active site cysteine (Moche et al., 2001).
Recent analysis revealed that these enzymes can be divided into three structural and 
functional classes, based on the catalytic mechanism and residues of the active site,
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substrate specificity and variations in the acyl carrier group (either CoA or ACP) 
(Moche et al., 2001). Group 3 consists of the biosynthetic and degradative thiolases. 
FabB and FabF were placed in group 2. In E. coli these two enzymes share 38% 
identity with each other and limited identity with FabH (14.8% with FabB and 13.2% 
with FabF), which is placed in Group 1 with its distant relative alfalfa chalcone 
synthase (Moche et al., 2001).
1.103 Substrate specificity of KAS enzymes
FabB, FabF and FabH-like proteins have overlapping substrate specificities. However, 
FabH catalyses the first condensation reaction between acetyl-CoA and malonyl-ACP, 
whereas FabB and FabF-like proteins perform the subsequent addition of two carbon 
units using acyl carrier protein activated substrates (Choi et al., 2000; Harwood, 1996; 
Heath and Rock, 1996a and 1996b). In plastids, KAS I extends from C4 U) C 16 in six 
rounds of elongation whereas KAS D performs extensions on longer fatty acid chains, 
carrying out an additional step to form C l8:0 (Magnuson et al., 1993). In vitro studies 
showed that FabB has the ability to perform the first condensation reaction, elongating 
from C2 to C4, suggesting that FabB is the only essential condensing enzyme in E. coli 
(Alberts et al., 1972; Tsay et al., 1992a). This hypothesis is supported by evidence 
that attempts to produce fabB  knockouts in E. coli have been unsuccessful, whilst 
knockout fabF  mutants can be produced (Rock and Cronan, 1996; Allen and Bartlett, 
2000; Kutchma, et al., 1999). Furthermore, Cronan’s laboratory recently reported the 
first discovery of a fabH  mutant lacking FabH activity (Lai and Cronan, 2003). The 
results showed that this mutant retained approximately 1 0 % of the wildtype fatty acid
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synthetic ability, suggesting that another enzyme is able to perform the C2-C4 
condensation step in vivo.
1.10.4 Structural and active site motifs
X-ray crystallography studies of all three p-ketoacyl-ACP synthases from E. coli and 
many other species suggest that the proteins share a similar fold and display some 
differences surrounding the active site (Olsen et al., 1999; Huang et al., 1998; Qiu et 
al., 1999; Olsen et al., 2001; Price et al., 2001; Moche et al., 1999; Moche et al.,
2001; Val et al., 2000; Davies et al., 2000; Qiu et al., 2001; Scarsdale et al., 2001). 
The quaternary structure of all KAS enzymes is a homodimer, the subunits associating 
by a 2-fold crystallographic axis. An extensive subunit interface region is formed and 
buried on dimerisation, resulting in a strong interaction between P-strands in the 
N-terminal regions that run antiparallel to each other, forming one continuous sheet 
(Price et al., 2001; Moche et al., 2001).
KAS enzymes exhibit overall similarities with the degrading enzyme, thiolase 1 from 
yeast and chalcone synthase (Moche et al., 2001). Half of the subunit chain shows 
structural similarity, including the central p-sheets and the surrounding a-helixes, so 
that characteristic a-P -a-p-a layers are present. Outside of the conserved central 
region, the proteins show considerable differences in loop regions positioned at the 
bottom of the enzymes. These loop regions protect the active site from the external 
surroundings and may also result in the appropriate binding pockets for different 
hydrophobic substrates (Moche et al., 2001).
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The active site cysteine residue resides at the carboxyl-terminus of an alpha helix 
dipole, resulting in an increase in the reducing capacity of the sulphydryl group. This 
interaction is essential for the activation of the sulphydryl group and the transfer of 
the acyl primer substrate from either coenzyme A or ACP. New carbon-carbon bonds 
are created by carrying out Claisen condensations (Dewar and Dieter, 1988). The 
reactions comprise three separate steps depicted in Figure 1.16. Briefly, the individual 
reactions are; the transfer of an acyl group from an acyl-ACP primer; the 
decarboxylation of malonyl-ACP the donor substrate and the condensation of the 
resulting carbanion with the enzyme bound acyl group.
1.10.5 Active site differences
Alignments of FabB and FabF-like KAS enzymes highlighted several highly 
conserved residues and allowed the identification of the catalytic triad consisting of a 
cysteine and two histidines (Figure 1.17). There are, however, significant differences 
between the residues that constitute the active site of these enzymes and FabH 
enzymes. A catalytic triad of Cysl 12/His244/Asn274 (E. coli FabH numbering) 
comprise the active site of FabH enzymes, whereas FabB/FabF enzymes possess 
Cys 163/His298/His333 (E. coli FabB numbering) motifs and an additional lysine that 
is essential for their correct positioning (Moche et al., 2001; Olsen et a/., 2001; Price 
et al., 2001; Siggaard-Anderson et al., 1998).
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Figure 1.16 Claisen condensation reactions as catalysed by KAS enzymes
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Figure 1.17 Alignment of condensing enzymes shows regions of similarity.
Asterisks denote active site residues of either FabB /FabF or FabH enzymes. Conserved residues across 
all the enzyme types are shown against a black background. Residues of the same type (acidic D/E, 
basic R/K/H, hydroxyl containing S/T, small A/G, small hydrophobic L/I/V/M etc) are shown against a 
dark grey background. Regions that differ significantly between FabB /FabF are highlighted in cyan.
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Hydrogen bonding to the His-His motif or the His-Asn motif stabilises the 
intermediate carbanion, prior to nucleophilic attack in condensation (Olsen et al., 
2001; Price et al., 2001). Theoretically, histidine would be capable of performing the 
same role as the asparagine residue in FabH and reasons for the difference in active 
site residues between the two groups are yet to be determined.
1.10.6 Differences in the substrate-binding pocket
Structural differences are also observed outside the active site, most notably in the 
substrate binding pocket. In all KAS enzymes, the majority of the pocket is within one 
subunit, close to the dimer interface, with the second subunit making a small 
contribution to the binding cavity through several residues at conserved positions 
(Moche et al., 2001). However, the substrate-binding pockets of FabB/FabF and FabH 
enzymes extend in different directions relative to the active site (Moche et al., 1999). 
This probably results from the use of different acyl cofactors (CoA and ACP) and 
may explain the differences in sensitivity of KAS enzymes to the FAS inhibitor 
cerulenin (Olsen et al., 1999).
Recently, Rock’s laboratory has shown that surface interactions between Type II FAS 
enzymes and ACP contribute to the activity of this pathway (Zhang et al., 2001 and 
2003). E. coli FabH and FabG both contain a positively charged/hydrophobic patch of 
arginine and lysine residues adjacent to the substrate binding tunnel. These interact 
with highly-conserved, negatively charged residues present in helix 2 of ACP. The 
physical surface of these two regions associate temporarily to form a coherent 
interface that contributes significantly to successful interaction.
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1.11 Inhibition of Type II Fatty Acid Synthesis
The differences observed between the structure and organisation of Type I and 
Type II FAS, provide selective targets for inhibition of the Type II pathway present in 
pathogenic bacteria and parasites. These inhibitors were initially discovered due to 
their antibacterial properties and the large amount of research in this area is 
summarised below. Recent investigations of the anti-parasitic nature of these 
compounds is also included in this section.
1.11.1 Thiolactomycin
Thiolactomycin (TLM) (Figure 1.18) is a thiolactone that is a specific inhibitor of 
Type II P-ketoacyl-ACP synthases and was originally isolated from the soil bacteria 
Nocardia species 2-200 (Hayashi et al., 1983; Miyakawa et al., 1982; Noto et al., 
1982; Oishi et al., 1982). The compound contains a single stereo centre at the C5 
position and the bacteria synthesises only the (5R) enantiomer (Figure 1.18) (Sasaki et 
al., 1982; Nishida et al., 1986).
HO c h 3
Figure 1.18 Structure of the natural antibiotic thiolactomycin
The numbers shown in blue are how each of the atoms of the thiolactone ring will be 
referred to within the rest of this report.
56
TLM is a selective inhibitor of Type II FAS. It has been shown to inhibit E. coli 
condensing enzymes FabB and FabF and to a lesser extent FabH and the equivalent 
enzymes from spinach and pea chloroplasts (Clough et al., 1992; Jaworski et al., 
1989; Jones et al., 1995; Jones et al., 2000). In contrast, it has no effect on Type I 
FAS systems in Saccharomyces cerevisiae or rat liver (Hayashi et al., 1983). This 
antibiotic is not toxic to mice at therapeutic doses and provides significant protection 
against urinary tract and intra-peritoneal bacterial infections (Miyakawa et al., 1982). 
The potency of TLM in infected mice is achieved by rapid absorption and distribution 
to infective sites (Miyakawa et al., 1982), this suggests favourable pharmacokinetics 
and suitability for drug administration. Thiolactomycin has been shown to inhibit the 
growth of several species in situ including the parasites Plasmodium falciparum and 
Toxoplasma gondii (Table 1.3).
Organism ICsoof TLM (pM)
P. falciparum 50 a
T. gondii 200 b
Trypanosoma brucei 150c
Mycobacterium tuberculosis 280 d
Pisum sativum (pea) 20 '
Spinacia oleasuceae U> 00 ■
*>
Table 13  Inhibition of growth observed with thiolactomycin
a Waller et al., 1998 and 2003. b McFadden et al., 1999.0 Morita et a l, 2000.d Kremer 
et al., 2000.c Jones et al., 1995 and 2000.f Clough et al., 1992.
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Disruption of apicoplast function was first reported in Toxoplasma gondii using the 
prokaryotic gyrase inhibitor, ciprofloxacin and clindamycin, a prokaryotic 
transpeptidase inhibitor (Pfefferkom et al., 1992; Fichera et al., 1995; Fichera and 
Roos, 1997). These compounds, directly or indirectly, inhibit the replication of the 
plastid genome and reduce its copy number compared to genomic DNA (Fichera and 
Roos, 1997). The inhibition of T. gondii parasites in situ exhibited distinct kinetics. 
There was no effect on tachyzoites growing within the first host cell. However, 
parasites within the second cycle failed to grow in newly infected cells, suggesting 
that disruption of apicoplast division and function decreases the viability of daughter 
merozoites.
An investigation of the action of thiolactomycin in blood stage cultures of 
Plasmodium falciparum was performed recently by McFadden’s laboratory (Waller et 
al.t 2003). These studies showed that TLM did not display a delayed-death phenotype 
but inhibited growth of the parasite most effectively in early rings. Inhibition of 
growth during trophozoite stages was greatly reduced and TLM appeared to have little 
or no effect against schizonts. Similar results were observed with the enoyl reductase 
inhibitor, triclosan and this compound is also capable of clearing malaria infections in 
mice. These results suggest that de novo FAS is most important for the development 
of merozoites following the early erythrocytic stages.
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1.11.1.1 Enzyme targets of thiolactomycin
In vitro, thiolactomycin inhibits all of the E. coli condensing enzymes (FabB, FabF 
and FabH), to various extents (Table 1.4).
Enzyme IC50
E. coli FabB a 6pM
E. coli FabF * 25 pM
E. coli FabH a 110|±M
Staphylococcus aureus 
FabF b
^80pM
Table 1.4 The inhibition of bacterial condensing enzyme activity by 
thiolactomycin
‘ Price et a l, 2001.b Jackowski et al., 2001.
As well as direct in vitro inhibition studies, E. coli strains that overexpress FabB 
exhibit some resistance to thiolactomycin (Tsay et al., 1992b). In contrast, 
overexpression of FabH conferred no resistance to TLM (Tsay et a l , 1992b). A 
selection process used to identify TLM resistant E. coli, isolated only mutants with 
alterations in the fabB  gene. No fabF or fabH  mutants were observed. These 
combined data suggest that despite that in vitro the FabB enzyme exhibits lower 
sensitivity to TLM than FabF, FabB is the physiologically relevant target of TLM in 
this bacterium.
In M. tuberculosis, overexpression of KAS A and KAS B, respectively conferred 
resistance to TLM (Kremer et al., 2000; Slayden et a l , 1996). The relative sensitivity 
of the KAS enzymes to TLM differs between organisms. However, FabH (KAS HI) is
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always reported as the least sensitive (Harwood, 1996; Jones et al., 1995; Jones et al., 
2000; Price et al., 2001). A general observation is that in higher plants sensitivity to 
TLM is greater in KAS II than KAS I but in bacteria FabB (KAS I) has greater 
sensitivity (Jones et al., 1995; Jones et al., 2000; Kremer et al., 2000; Price et al., 
2001).
Compared to TLM, some thiolactomycin derivatives have shown greater inhibition of 
Type D FAS in higher plant chloroplasts (Jones et al., 2000), M. tuberculosis (Kremer 
et al., 2000) and P. falciparum cultures in vitro (Waller et al., 2003). Generally, there 
is greater sensitivity towards derivatives with extended hydrocarbon chains (from 
8-12 carbons in length) and the derivatives with the lowest IC50 against P. falciparum 
and M. tuberculosis in vitro, are unsaturated and contain some methyl side groups 
(Kremer et al., 2000; Waller et al., 2003). The link between increased side-chain 
length and increased efficacy is consistent with occupation of a large hydrophobic 
pocket, present in FabB and FabF proteins but absent in FabH. This pocket does not 
incorporate the growing acyl chain and its function is unknown. However, its absence 
in FabH may be the reason for the lack of this enzyme’s sensitivity to TLM.
Compounds with more double bonds show an increased inhibitory activity compared 
to saturated chains of the same length, indicating that increased desaturation and/or 
rigidity of the side-chain might contribute to inhibition of the target enzymes 
(Harwood, 1996; Kremer et al., 2000; Waller et al., 2003). The results with 
thiolactomycin in Mycobacterium and pea, suggest that the hydrophobic crevice that 
may interact with the extending fatty acid chain of TLM derivatives is a common
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feature to both FabB and FabF. These results provide information that contribute to 
the rational design of thiolactomycin based antibiotics.
1.11.1.2 Mechanism of thiolactomycin inhibition
Kinetic studies of E. coli FabB, elucidated the mechanism of thiolactomycin 
inhibition (Price et al., 2001). Originally, it was thought that the sulphur group of 
TLM would form a covalent bond with the active site cysteine via a thioester 
exchange reaction. Incubation of TLM (20pM) with FabB 30min prior to the addition 
of the other assay components showed no decrease in enzyme activity compared to 
assays when TLM was added at the start point of the assay. To verify whether TLM 
inhibition is reversible or irreversible, a dilution experiment was performed. FabB was 
incubated with lOOpM TLM, causing 95% inhibition. The TLM concentration was 
then diluted to 1 pM and the activity of FabB was recovered to the level observed 
when continuously incubated with lpM TLM. The decrease in inhibition indicated 
that TLM binding is reversible and results in no permanent interactions. This 
contrasted with the covalent inhibitor cerulenin, where a marked reduction in the 
activity of the pre-incubated FabB was observed (Price et al., 2001). These data 
showed that TLM is a reversible inhibitor of the FabB enzyme, reinforcing results 
previously seen in cell extracts (Hayashi et al., 1983).
The study in Rock’s laboratory also calculated the affinity of TLM for each of the 
E. coli KAS enzymes (Price et al., 2001). FabB exhibited the highest affinity (26pM), 
FabF showed intermediate affinity (60pM) and FabH had the lowest affinity (158pM) 
(Price et al., 2001). This was consistent with IC5o values and results of other kinetic 
experiments, generated in the same study.
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1.11.1.3 The structure of a FabB-TLM complex
The structure of TLM complexed to E. coli KAS I (FabB) was the first, and so far 
only, structure of a condensing enzyme with thiolactomycin bound to the active site 
(Figure 1.19).
Figure 1.19 TLM bound in the active site of E. coli FabB
The inhibitor and key residues of E. coli FabB are shown. Hydrogen bonds are shown 
as green dashed lines. Water molecules are shown in orange. The lFJ4.pdb file (Price 
et al., 2001) was downloaded from the Brookhaven database and manipulated using 
SwissPDB viewer (Guex and Peitsch, 1997).
Val 270
Pro 272
T L M
H is 298
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The structure shows that TLM makes a number of specific but non-covalent 
interactions with FabB. The isoprenoid group is sandwiched between two peptide 
bonds and an interaction between these three delocalised systems appears important to 
specificity. The C3 and C5 methyl side groups of TLM are sequestered within two 
hydrophobic pockets consisting of Phe229 & Phe392 and Pro272 & Phe290. Both the 
carbonyl and hydroxyl oxygens of TLM are involved with hydrogen bonding to the 
protein. The carbonyl oxygen forms hydrogen bonds to the two active site histidines 
(298 and 333, respectively), whilst the hydroxyl oxygen bonds via a lattice of water 
molecules to the carbonyl oxygen of valine 390 and the amide nitrogen of glycine 305 
(Figure 1.19). Interestingly, the thiolactone sulphur does not make any specific 
interactions but lies adjacent to the sulphur of the active site Cysl63 (Price et al., 
2001).
Differences in hydrogen-bonding probably contribute to the lower sensitivity of 
E. coli FabH to TLM, where the active site His333 is replaced with an asparagine 
(Davies et al., 2000; Qiu et al., 1999). The importance of the histidine in FabB was 
studied in a FabB[H333N] mutant that retained significant condensation activity but 
sensitivity to thiolactomycin was reduced by an order of magnitude. This establishes 
the importance of a His-His hydrogen bonding to the carbonyl oxygen of TLM for 
high affinity TLM binding (Price et al., 2001). However, the specificity for two 
histidines is not completely understood because the asparagine could also donate a 
hydrogen bond to the carbonyl group of TLM. E. coli FabF (Huang et al., 1998;
Moche et al., 2001), also shares the His-His active site motif with FabB. However, the 
reason for its lowered affinity for TLM is unknown.
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The high affinity of TLM for FabB can be further explained by the minimal distortion 
caused by TLM in the active site. Local changes in FabB structure are observed but 
do not extend beyond the immediate vicinity of the active site, notably, the side chain 
of Cysl63 moves 2.1A to accommodate the TLM sulphur and His298 moves by 2A to 
improve hydrogen bonding to the carbonyl group of TLM. Finally, the relocation of 
His-298 causes knock-on effects in the loop comprising residues 388-394, due to 
hydrogen bonding between the Ne-2 nitrogen of His298 and the main chain carbonyl 
of residue Phe390 (Price et al., 2001).
1.11.1.4 Significance for the development of thiolactomycin as an antibiotic
The crystal structure of E. coli FabB-TLM shows that the isoprenoid moiety fits 
within a hydrophobic pocket of the enzyme, which has indiscernible function during 
fatty acid synthesis (Olsen et al.y 2001; Price et al.y 2001). Previously, it was 
suggested that the isoprenoid group might extend further along the active site (Jones 
et al., 2000; Kremer et al., 2000) but this is not the case. Furthermore, the structures 
of both FabB and FabF (Huang et al.y 1998) appear to contain a similar hydrophobic 
pocket that extends deeper into the enzyme, which may explain the higher sensitivity 
of these enzymes to longer chain TLM derivatives, as observed in Mycobacterium and 
pea (Jones et al.y 2000; Kohler et al.y 1997). An understanding of structural aspects of 
the KAS enzymes and their interactions with inhibitors, such as thiolactomycin 
derivatives, are clearly very important for developing thiolactomycin derivatives with 
increased antimicrobial activity.
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1-11.1-5 Resistance to thiolactomycin
Selection for E. coli mutants that were resistant to TLM showed that a single base 
mutation in the fabB gene was responsible for increasing the resistance to TLM by an 
order of magnitude (Jackowski et al., 2002). In these selection screens, no other fabB 
mutations or mutations of other genes were observed, suggesting that FabB is the 
physiologically relevant target of TLM in this organism. This mutation altered a 
highly conserved phenylalanine residue to a valine (F390V), without affecting the 
specific activity of the enzyme. Bacillus subtilis FabF contains a leucine at position 
390 (Schujman et al., 2001) and is naturally resistant to TLM. This suggested that 
both F390V and F390L substitutions may be responsible for TLM resistance. 
Structural models suggested that a steric clash between a side-chain methyl group of 
V390 and the branched ethene group of the TLM isoprenoid side chain. However, in 
the F390L model no steric clash was observed and the mode of TLM binding was 
similar to the wildtype. Furthermore, no E. coli FabB F390L mutants (generation of 
which would require only a single base mutation) were selected in TLM resistant 
screens and Staphylococcus aureus contains a F390L FabF that is highly sensitive to 
TLM. These data suggest that the FabF F390L alteration in Bacillus subtilis is not 
responsible (at least entirely) for the enzyme’s resistance to TLM.
TLM resistance has also been linked to a mutation in the emrR gene, which causes 
upregulation of the emrAB efflux pump, a membrane transporter that confers 
resistance to structurally unrelated but moderately hydrophobic compounds 
(Furukawa et al., 1993; Lomovskaya et al., 1995). Abrogation of the emrAB efflux 
pump activity in E. coli knockouts lowered the MIC of TLM from 150pM to 25pM 
(Furukawa et al., 1993). However, knockouts of all of the to/C-dependent efflux
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pump family gave an MIC of 3pM (Jackowski et al., 2002; Buchanan, 2001), 
suggesting that other unidentified efflux pumps may be involved in TLM resistance. 
Alterations in the TLM molecule that would give it less affinity for efflux pumps 
would be advantageous in treatment against gram-negative bacteria.
1.11.2 Other Inhibitors of FAS as potential antibiotics
Thiolactomycin is not the only known inhibitor of FAS (see following section) and 
the potential of TLM as an antibiotic increases the relevance of other Type II FAS 
inhibitors. Antibiotics that block different steps of the FAS pathway could be 
combined, providing a ‘multi-block’ strategy and increasing their efficacy (White and 
Ollario, 1996). Used judiciously, combination therapy or the rotation of Type II FAS 
inhibitors through the global population could also lower the probability of resistance 
emerging to any individual drug.
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1.11.2.1 Cerulenin
Cerulenin (CER) (Figure 1.20) is an irreversible inhibitor of FabB and FabF that 
forms a covalently bound complex with the active site cysteine of these enzymes 
(Price et al., 2001). In a situation similar to TLM, FabH enzymes are generally 
insensitive to CER. even at high concentrations.
3
O
O
Figure 1.20 Structure of the natural antibiotic cerulenin
Carbon atoms are numbered in blue text and oxygen atoms in red text.
Cerulenin is not a selective antibiotic because it is also a potent inhibitor of the 
condensing reactions in Type I FAS (Funabashi et al., 1989; Flarwood, 1996). 
Furthermore, cerulenin has also been shown to affect feeding behaviour in mice, 
resulting in reduced food intake and body weight. Whilst cerulenin-based compounds 
are, therefore, excellent candidates in the fight against obesity and heart disease in the 
western World, these complications are undesirable for an antimalarial drug that may 
be used on a high proportion of malnourished patients (Loftus et a l 2000). Structural 
studies, described below, with Type II condensing enzymes (Moche et al., 1999; Price 
et al., 2001) are central to improving selectivity of cerulenin.
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Both FabB and FabF E. coli enzymes are inhibited by cerulenin, FabB being the most 
sensitive (Moche et al., 1999; Price et al., 2001). FabH is not effectively inhibited by 
cerulenin and was discovered because of this insensitivity (Harwood, 1996). The 
crystal structures of the E. coli FabB-CER and E. coli FabF-CER complexes show 
that cerulenin primarily occupies a different area to thiolactomycin (Moche et al.y 
1999; Price etal., 2001) (Figures 1.21 and 1.22).
Phe 392
Pro 272C eru len in
His 333C v s  163
His 298
Figure 1.21 Cerulenin bound in the active site of E. coli FabB 
Hydrogen bonds are shown as green dashed lines. Water molecules are shown in 
orange. The lFJ8.pdb file (Price et al., 2001) was manipulated using SwissPDB 
viewer (Guex and Peitsch, 1997).
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Its extended acyl chain is located within a deep hydrophobic pocket at the dimer 
interface that is believed to harbour the hydrocarbon chain of the acyl intermediate 
during fatty acid synthesis (Olsen et al., 2001). This hydrophobic pocket in FabH is 
shallower, suggesting a possible reason for its insensitivity to cerulenin (Qiu et al., 
1999).
Val 270
P ro  272
P hc  201
His 333
His 298
Figure 1.22 Thiolactomycin and cerulenin bound in the active site of E. coli FabB 
Hydrogen bonds are shown as green dashed lines. Water molecules are shown in 
orange. Cerulenin is shown in cyan and TLM in magenta. The lFJ4.pdb and lFJ8 .pdb 
files (Price et al., 2001) were downloaded from the Brookhaven database and were 
then manipulated using SwissPDB viewer (Guex and Peitsch, 1997).
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The covalent bond is formed between the central C2 of cerulenin and the active site 
Cysl63 sulphur atom (E. coli numbering). The 02  atom of CER is positioned in the 
same position as the carbonyl atom of TLM and, as expected, forms hydrogen bonds 
with the Ne-2s from His298 and His333. Further hydrogen bonding occurs between 
the 03  atom of cerulenin and the main chain amide groups of Cysl63 and Phe392 
(Moche et al.y 1999; Price et al.y 2001).
Like TLM, cerulenin occupies the active site with minimal distortion of the FabB or 
FabF structures and the slight movements that do occur are similar to those observed 
in the TLM complex, described in Section 1.10.1.3 (Moche et al.y 1999; Price et al., 
2001). Interestingly, Del08, a residue of the hydrophobic binding pocket, has to rotate 
to incorporate cerulenin in FabF but not FabB (Moche et al.y 1999 ; Price et al.t 2001). 
This suggests a possible reason for the lower sensitivity of FabF to cerulenin. Further 
demonstration of the importance of Del08 was observed in a FabF [Del08Phe] mutant 
that shows decreased activity with acyl-ACP substrates over 8 carbons in length. In 
the presence of 50pM cerulenin this mutant retains 90% of its activity (the wild-type 
enzyme showed no activity at this concentration) (Val et al.y 2000), suggesting that a 
single amino acid substitution may confer resistance to cerulenin.
1.11.2.2 Triclosan
Triclosan (Figure 1.23) is a broad-range antimicrobial used in many domestic 
products, such as toothpaste and detergents, due to its favourable safety profile 
(Bhargava and Leonard, 1996).
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Figure 1.23 Structure of the antibiotic and antimalarial compound triclosan
Unfortunately, due to hydrophobic nature it is poorly absorbed when taken orally but 
can be effective when administered through an intravenous or intraperitoneal route. 
Recently the Type II FAS reducing enzyme, enoyl-ACP reductase (FabI in E. coli), 
was elucidated as the target of its antimicrobial activity (Heath et a l , 1999; Heath and 
Rock, 2000; McMurry et al., 1998). This enzyme is responsible for the last step of the 
FAS cycle and is, therefore, an important site for chemical control (Heath and Rock, 
1995). Triclosan inhibits FabI by promoting the binding of its oxidised cofactor, 
NAD+, to the active site, forming a robust ternary complex of FabI-NAD+-triclosan, 
effectively removing FabI from the FAS pathway (Heath et al., 1999; Saguna et a l, 
2001; Kapoor et a l, 2001).
Triclosan appears to be selective for Type II FAS enzymes and is able to inhibit 
significantly the growth of T. gondii, in vitro and P. falciparum, in vitro and in vivo 
(McLeod et a l, 2001; Surolia and Surolia, 2001). Furthermore, an enoyl-ACP 
reductase containing an apicoplast targeting sequence that was identified and purified 
from P. falciparum, is triclosan-sensitive (McLeod et a l, 2001; Surolia and Surolia,
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2001). The IC50 against P. falciparum in culture is 0.7pM, much lower than that of 
thiolactomycin (50pM) and cerulenin (20pM) (Price et al., 2001). Triclosan was also 
the first inhibitor of Type D FAS that was shown to clear P. berghei parasites from 
mice (Surolia and Surolia, 2001). The pfFabl was the first Apicomplexan fatty acid 
synthesis enzyme for which a 3D structure was solved (Perozzo et al., 2002) and the 
co-ordinates have since been refined (Muench et al., 2003). Complexes with triclosan 
and active derivatives have also been reported (Suguna et al., 2001; Perozzo et al., 
2002; Kapoor et al., 2004a, b, c) and these studies will contribute to the understanding 
or triclosan inhibition and may lead to the first anti-parasite drug that targets fatty acid 
synthesis.
During 30 years of use in many products, resistance to triclosan is uncommon but may 
be conferred by overexpression of FabI or a single mutation in the FabI gene (Heath 
and Rock, 2000; Kapoor et a l y 2004c). This suggests that, used judiciously, triclosan 
would be an effective addition to our arsenal of antimalarial Type II FAS inhibitors.
1.11.23 Aryloxyphenoxypropionate Herbicides
Aryloxyphenoxypropionate herbicides target acetyl CoA carboxylase (ACCase) 
localised in the chloroplasts of Graminaceae (Harwood, 1996). The ACCases of man, 
rat and yeast (and other plants) are insensitive to treatment by these compounds, 
allowing them to be used commercially as selective herbicides and implying a 
selectivity for particular ACCase structures (Harwood, 1996; Zuther et al., 1999).
They have been shown to inhibit the growth of the apicomplexan T. gondii, in vitro by 
targeting of its ACCase, via an unknown mechanism. The most promising of these
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compounds showed 70% inhibition of growth of T. gondii cultures at IOjiM 
concentrations (no IC50 data available) (Zuther et al., 1999).
1.11.2.4 C|8 Fatty Acids
Several fatty acids (oleic, elaidic, linoleic and linolenic) inhibit P. falciparum growth 
in vitro and also lower parasitaemia in murine models (Krugliak et al., 1995). Nucleic 
acid and protein synthesis was inhibited after 30 minutes in both ring-stage and 
trophozoite infected cells and was irreversible (shown by pre-incubation with 
200pg/ml oleic acid). However, despite rigorous tests, the mechanism of action is so 
far unknown (Krugliak et al., 1995).
1.12 Aims of this Project
As outlined in this Chapter, p-ketoacyl ACP synthases from Apicomplexa are 
potentially very important targets for the development of new antibiotics (McFadden 
and Roos, 1999). In other organisms, most notably E. coli, these enzymes have been 
expressed and purified to allow characterisation and X-ray crystallography to 
investigate inhibitor binding (Edwards et al., 1997; Jackowski and Rock, 1987). At 
the outset of this project only the gene for FabH {pffabH) had been identified 
(Gardner et al., 1998; Waller et al., 1998) in P. falciparum. The pfFabH protein had 
yet to be produced in a recombinant system and, therefore, had not been characterised. 
Furthermore, homologues of FabB and/or FabF, more promising targets for
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thiolactomycin inhibition had not been identified. The aims of the project were to
study P. falciparum FabB, FabF and FabH and their inhibition as follows -
• To clone, express in recombinant form and purify P. falciparum FabFI.
• To identify the gene/s encoding FabB and/or FabF enzymes from P. falciparum^ 
to successfully express and purify these protein/s in recombinant form.
• To perform studies on the substrate specificity and kinetic parameters of all the 
P. falciparum KAS enzymes.
• To perform inhibition studies of P. falciparum KAS enzymes with thiolactomycin 
and its derivatives and compare these to inhibition of the parasites in vitro.
• To carry out structural studies of thiolactomycin and/or the most promising TLM 
derivative complexed to the condensing enzymes, which would provide further 
information on interactions between the two molecules. This would facilitate 
further, rational, design of an effective antimalarial.
• To identify a new lead compound that targets P. falciparum fatty acid synthesis, 
which may be developed further as a potential drug for the treatment of malaria.
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Chapter 2
2.1 Materials
2.1.1 Cloning and Expression Vectors
The pGEM-T vector was purchased from Promega Ltd. (Southampton, UK), the 
pET-22b vector was purchased from Novagen (AMS Biotechnology, Milton Keynes, 
UK), pGEX-4T-2 from Qiagen (West Sussex, UK) and pMALc2x from New England 
Biolabs (Beverly, MA, USA). A pMALc2x plasmid containing the full length 
sequence of P. falciparum ketoacyl-ACP synthase ID was kindly donated by Dr. Sean 
Prigge (Johns Hopkins School of Public Health, Baltimore, USA). The 
pDS-His6-FabD plasmid was a kind gift from Dr. Roland Lange (Morphochem AG, 
Basel, Switzerland). The MG 1655 wildtype and FabF knockout strains were kindly 
provided by the Blattner research group (Wisconsin, USA). The LCH68 strain that 
overexpresses acyl-ACP synthase was kindly provided by Dr. Charles Rock (St. Jude 
Children’s Research Hospital, Memphis, USA).
2.1.2 Escherichia coli Host Strains
All genetic manipulations were carried out in the E. coli strain DH5a (Pharmacia 
Biotechnology Ltd., Milton Keynes, UK). E. coli expression studies were performed 
in the strains, BL21(DE3) pLysS, (purchased from AMS Biotechnology, Milton 
Keynes, UK) or BL21(DE3) Codon Plus-RIL (purchased from Stratagene,
Amsterdam, The Netherlands). The genotype of each of the bacterial strains is 
detailed in Table 2.1.
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Strain Genotype Reference
DH5ct EndAl hsdR17 glnV44 thi-1 recAl 
gyrA relAl A(lacIZYA-argF)U169 
deoR (phi80dlacd(lacZOM 15)
Hanahan, D. (1983)
BL21 (DE3) pLysS E. coliB dcm Ion ompT hsdS(tB-mB-) 
gal lambda (DE3) 
laclQ/placUV5 - T7gene 1
Studier, F.W. and 
Moffat, B.A. (1986)
BL21 (DE3) Codon 
Plus - RIL
E. coli B F - ompT hsdS{re- me-) 
dcm+ Tef gal X (DE3) endA Hte 
[argU ileY leuW Camr]
Studier, F.W. and 
Moffat, B.A. (1986)
Table 2.1. The genotypes of E. coli strains used for recombinant expression in 
this study
2.1.3 Media
Luria Bertani (LB) nutrient medium was prepared as described by the manufacturer’s 
instructions (Sigma Chemicals Ltd., Poole, Dorset, UK). M9 minimal media was 
prepared as described in Sambrook et al., 1989. Antibiotics, when present in 1.2% 
agar plates or media, were used at the following concentrations; ampicillin 
(lOOpg/ml), chloramphenicol (34pg/ml), kanamycin (25pg/ml). All media and 
constituents were sterilised either by autoclaving at 121 °C (975kPa) for 20min or by 
filtration through 0.22pm nitrocellulose filters (Gelman Science, Ann Arbor, MI., 
USA).
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2.1.4 Molecular Weight Standards
Pre-stained high range molecular weight protein standards were purchased from 
BIORAD Laboratories, Hertfordshire, UK. The X HindUl and 0X174 HaeUl DNA 
markers were purchased from Promega Ltd., Southampton, UK (Figure 2.1).
High range molecular weight protein markers (kDa)
Figure 2.1 DNA markers visualised on agarose and acrylamide gels by UV light
Photos taken from the Promega Ltd. (Southampton, UK) webpage 
http://www.promega.com/techserv/apps/cloning/cloning4.htm on the 13/09/2004.
Myosin (H chain) 
Phosphorylase B 
Bovine serum albumin 
Ovalbumin 
Carbonic Anhydrase 
P-Lactoglobulin 
Lysozyme
43.0
31.0
97.4
68.0
200.0
18.4
14.3
Lambda DNA///md III Markers PhiX174 DNAIHae III Markers
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2.1.5 Other Materials
Routine laboratory chemicals were purchased from Sigma Chemicals Ltd., (Poole, 
Dorset, UK) and BDH Chemicals Ltd., (Poole, Dorset, UK). The suppliers of more 
specialised chemicals and equipment are listed below (Table 2.2). All radioactive 
compounds including [y-32P]-ATP, [1-14C] acetyl-CoA, [2-14C] malonyl-CoA were 
purchased from Amersham Pharmacia, Little Chalfont, UK.
Materials and Equipment Companies and Addresses
Thiolactomycin (racemic mixture) Sigma Chemicals Ltd., Poole, Dorset, UK
PCR Oligonucleotides MWG Biotech, Ebersburg, Germany 
and Qiagen Ltd., West Sussex, UK
Restriction Endonucleases and DNA 
modifying enzymes
Promega Ltd., Southampton, UK 
and
New England BioLabs, Beverly, MA, 
USA
Wizard Minipreps DNA Purification 
System
Promega Ltd., Southampton, UK
Acrylamide /Bisacrylamide (SDS-PAGE) National Diagnostics, Manville, NJ, USA
HiTrap® SP 1ml ion exchange columns Pharmacia LKB, Biotechnology, St 
Albans, Herts, UK
Table 2.2 Suppliers of other materials and equipment
The ring stage P. falciparum cDNA library was kindly provided by Prof. Steve Walsh 
of the Liverpool School of Tropical Medicine.
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2.2 Methods
2.2.1 DNA Amplification by the Polymerase Chain Reaction (PCR)
PCRs were performed as first described in Mullis (1986) (Mullis et al.t 1986). 
Reaction mixtures were set-up with the final concentrations described below; 
containing 0.2mM dNTPs, PCR buffer (50mM KC1, lOmM Tris-HCl, pH9.0 at 25°C, 
0.1% Tween20, 3mM MgCb) and lOpmoles of the appropriate primers were made up 
to a final volume of 20 or 50pl with nuclease-free water (Sigma Chemical Company, 
Poole, Dorset, UK). Either Taq polymerase (Promega Ltd., Southampton, UK), or Pfu 
polymerase (Stratagene, Amsterdam, The Netherlands), was added to a concentration 
of 2.5 units per 50pl reaction mixture. The tubes were spun briefly in a microfuge 
before the addition of a thin layer of mineral oil (Sigma Chemical Company, Dorset, 
UK), which served to minimise evaporation during thermocycling. The thermocycling 
steps were performed using a TRIO-Thermoblock thermal cycler (Biometra, 
Goettingen, Germany) or a Flexigene thermal cycler (Techne, Cambridge, UK). 
Denaturation, annealing, extension conditions and cycle numbers are described in the 
appropriate section of text. PCR products were analysed by submarine agarose gel 
electrophoresis (Section 2.2.6).
2.2.2 Ligation of DNA into Plasmid Vectors
DNA inserts and plasmid vectors were digested with the appropriate restriction 
endonucleases. Each restricted product was gel purified prior to ligation. In a typical 
ligation reaction, a vector to insert ratio of 1:4 (on the basis of molarity) was 
maintained in a final reaction volume of lOpl. DNA ligase and the appropriate buffer
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(Promega Ltd., Southampton, UK) were added and the mixture was incubated for 16h 
at 16°C or for 3h at 4°C.
2.23 Creation of Blunt-Ended DNA Fragments with Klenow Enzyme
Reactions were made up to a minimal volume in nuclease-free water as follows;
DNA sample
1 Unit Klenow per pg DNA 
33pM dNTPs
1 x Reaction buffer (Promega or New England Biolabs)
The samples were incubated at 25°C for 15min and the Klenow enzyme deactivated at 
75°C for 20min.
2.2.4 Shrimp Alkaline Phosphatase (SAP)
Reactions were made up to the following conditions in a minimal volume of 
nuclease-free water;
DNA sample
1 unit of SAP (Roche, Basel, Switzerland) per picomole of DNA 
1 x SAP buffer (from 10 x stock)
The reaction mixture was incubated at 37°C for 3h and the phosphatase inactivated at 
75°C for 15min.
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2.2.5 Isolation of Plasmid DNA
Isolation of plasmid DNA was performed in accordance with the instructions supplied 
with the Wizard ™ Miniprep Kit or Wizard ™ Maxiprep kits (Promega Ltd., 
Southampton, UK). This procedure is a modification of the Bimboim and Doly 
(Bimboim and Doly, 1979) alkaline lysis method and uses a resin purification step to 
yield high quality DNA.
2.2.6 DNA Modifying Enzymes and Submarine Agarose Gel Electrophoresis
DNA modifying enzymes were used according to the manufacturer’s instructions. 
Restriction digests were analysed by submarine electrophoresis in 0.5% - 2% agarose 
gels containing ethidium bromide (1.3pM). Sizes of digested fragments were 
estimated from their migration relative to DNA markers of known lengths 
(Section 2.1.4.).
2.2.7 Purification of DNA Fragments from Agarose Gel
Following resolution in an agarose gel, the section of gel containing the DNA 
fragment of interest was excised and the agarose melted, by heating at 70°C. 
Extraction of the DNA was performed in accordance with the Qiagen DNA 
Purification System for DNA Fragments (Qiagen Ltd., West Sussex, UK).
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2.2.8 Double Stranded DNA Sequencing
Double stranded DNA templates were sequenced by the dideoxy-chain termination 
method originally described by Sanger et al. (Sanger et al., 1977). Automated 
sequencing of plasmid DNA was performed in the research support unit in the Cardiff 
School of Biosciences, Cardiff University. The ABI PRISM™ Dye Terminator Cycle 
Sequencing Ready BIG-DYE Reaction Kit (Perkin Elmer) was used to carry out the 
sequencing reactions. Briefly, the Terminator Ready Reaction solution (4pl) was 
mixed with lOng of the appropriate primer and approximately 500ng of plasmid DNA 
in a final volume of 10pl. Thermal cycling (25 cycles of 96°C for 10s, 50°C for 5s, 
60°C for 4min) was performed in an MWG Biotech Primus thermocycler (MWG 
Biotech, D-85560 Ebersberg, Germany), the extension products were then 
precipitated using sodium acetate and ethanol and the pellets resuspended in 50%
(v/v) formamide. The whole of this sample was loaded onto a PE Biosystems ABI 
PRISM 3100 capillary DNA sequencer. Chromatograms produced by this machine 
were analysed using the BioEdit® computer program (Tom Hall, Department of 
Microbiology, North Carolina State University, USA).
2.2.9 Preparation of Competent E. coli Cells
Cells were grown for 16h in LB medium at 37°C with shaking and harvested by 
centrifugation (2,000 x g, 5min). The cells were resuspended in half of the original 
culture volume of lOOmM CaCl2/15% (v/v) glycerol and incubated on ice for 30min. 
The cells were harvested in a centrifuge as before and resuspended in l/lO1*1 of the 
original volume of the CaCh/glycerol mixture. The cell suspension was divided into
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50pl or lOOpl aliquots, snap frozen by dropping into liquid nitrogen and stored at 
-80°C.
2.2.10 Transformation of E. coli Cells by Plasmid DNA
Prior to transformation, an aliquot of competent cells (50pl) was thawed on ice. After 
thawing, 2pg of DNA was added to the competent cells. The cells were incubated on 
ice for 20min, subjected to heat shock at 42°C for 2min and placed on ice for a further 
20min before the addition of 1ml of LB medium (containing no antibiotics). The tubes 
were then placed in shaking incubator at 37°C for lh and subsequently harvested in a 
microcentrifuge at 8,000rpm for lmin. The resulting cell pellet was resuspended in 
lOOpl of LB medium (containing no antibiotic) and spread onto LB agar plates 
containing the appropriate antibiotic for selection of colonies containing the plasmid. 
The plates were allowed to stand for 2min and incubated overnight at 37°C in an 
inverted position.
2.2.11 Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis
Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) was 
performed according to Laemmli (Laemmli, 1970). The separating gel was formed 
from 10-15% (w/v) acrylamide solution (acrylamide and N-N’ methylene 
bisacrylamide in a ratio of 37:1 (w/w)). The gels also contained 375mM Tris-HCl 
buffer, pH8.8,0.1% (w/v) SDS, 0.225% (w/v) ammonium persulphate, 13.2mM 
TEMED and water so that the final volume was 10ml. The stacking gel contained 5% 
(w/v) aciylamide, 0.14% (w/v) N-N’ methylene bisacrylamide, 0.1% (w/v) SDS in
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125mM Tris-HCl buffer, pH6.8, 0.45% (w/v) ammonium persulphate, 13.2mM 
TEMED and was made to a total volume of 5ml. The electrolyte running buffer 
contained 25mM Tris-HCl, pH8.3, 0.1% (w/v) SDS and 192mM glycine.
The 5x protein sample buffer consisted of 0.2% SDS, 8% glycerol, 0.003% (w/v) 
Bromophenol Blue and freshly added 2-hydroxyethylmercaptan (p-mercaptoethanol) 
(10% v/v) in 80mM Tris-HCl buffer, pH6.8. Gels were run at 200V and stained using 
Coomassie Blue solution (0.03% w/v in 50% v/v methanol and 10% v/v acetic acid) 
for l-2h and destained in a wash solution containing methanol (25% v/v) and acetic 
acid (7% v/v). Pre-stained protein markers were subjected to simultaneous 
electrophoresis with the samples in order to determine molecular weights of samples.
2.2.12 Analytical Scale Expression in E. coli and Sample Preparation of 
Recombinant Protein
Cultures (10ml) of E. coli cells harbouring plasmids for expression were established 
by inoculation with a single colony picked from an overnight plate. The cultures were 
incubated at 37°C overnight, in LB medium containing antibiotics for the selection of 
the plasmid. An aliquot (0.5ml) from each culture was added to fresh medium (10ml). 
The cultures were incubated at 37°C or 42°C (200rpm) until a D6oo of 0.4 was 
attained. Upon reaching the required D6oo, protein expression was induced by the 
addition of isopropyl (3-D-thiogalactopyranoside (IPTG), to a final concentration of 
either 0.2mM, 0.4mM or ImM. Samples (1ml) were removed at appropriate time 
intervals (up to 3h) and their D6oo was measured. The samples were collected in a 
microcentrifuge at 14,000 x g for 3min and the cell pellet was resuspended in sterile
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TE (lOmM Tris-HCl pH8.0, ImM EDTA) buffer to give a constant D600 of 10- 
Samples were subsequently stored at -20°C, prior to analysis by SDS-PAGE and 
Western blotting (Sections 2.2.11 and 2.2.15).
22.13 Analytical Scale Production of Soluble and Insoluble Fractions
Samples (1 ml) of each E. coli culture to be analysed were collected in a 
microcentrifuge (10,000 x g, 3min) and the supernatant was discarded. Each cell 
pellet was resuspended in TE buffer (lOmM Tris-HCl pH8.0, ImM EDTA) to give an 
D600 of 10. A lOOpl sample from each cell resuspension solution was repeatedly 
freeze-thawed (3X) and sonicated with a microtip on ice for 3 x 10s (Soniprobe, 
Output=7, Duty cycle=70%, Lucas Dawe Ultrasonics Ltd., London, UK). After 
sonication, insoluble material was collected in a microcentrifuge (14000 x g) for 
3min. The pellets were resuspended in lOOpl of lx SDS sample buffer (containing 2% 
(v/v) P-mercaptoethanol). The supernatant was retained and l/5th volume of 5x SDS 
sample buffer (containing 10% (v/v) p-mercaptoethanol) was added, this was the 
soluble fraction. Soluble and insoluble fractions were then boiled before examination 
by SDS-PAGE.
2.2.14 Preparation of Cell Pellets and Culture Media for SDS-PAGE Analysis
Cell pellets were thawed on ice and resuspended in lx SDS sample buffer to achieve a 
D6ooof 10. All samples were analysed using SDS-PAGE and Western blotting 
(Sections 2.2.11 and 2.2.15). Culture media (20pl) was mixed with 5x SDS protein 
sample buffer (4pl), containing 10% (v/v) P-mercaptoethanol.
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2.2.15 Immunological Detection of Recombinant Proteins by Western Blotting
Following SDS polyacrylamide gel electrophoresis, the resolved proteins were 
transferred to a moistened nitrocellulose membrane measuring 60mm x 80mm 
(Amersham International pic, Bucks, UK). Prior to blotting, five rectangular pieces of 
3MM filter paper (Whatman International Ltd., Maidstone, UK), measuring 60mm x 
80mm were cut. Two pieces were soaked in Anode Solution 1 (300mM Tris-HCl, 
pH 10.4, 20% methanol) and placed on to the anode of the semi-dry blotter (Sartorius 
Ltd., Epsom, Surrey, UK); a third was soaked in Anode Solution 2 (25mM Tris-HCl, 
pH 10.4, 20% methanol) and placed on to the first two pieces of filter paper; the 
nitrocellulose membrane was placed upon these three pieces on the anode, followed 
by the SDS-PAGE gel; and the remaining two pieces of filter paper that had been 
soaked in Cathode Solution (25mM Tris-HCl, 20% methanol, 40mM Caproic Acid) 
were placed on top of the gel, before putting the cathode in place.
Resolved proteins were transferred to the nitrocellulose membrane by passing a 
current of 145mA through the semi-dry blotter for 45min. On completion of transfer, 
the membrane was washed for lOmin in 10ml TBS (20mM Tris-HCl, pH80, 50mM 
NaCl), this was repeated three times. The membrane was blocked for lh at room 
temperature using TBS containing 3% (w/v) bovine serum albumin. All subsequent 
steps were performed in TBS Tween Buffer (TBS with 0.05% (v/v) Tween20). The 
membrane was washed 3 x 5min before being shaken for lh at room temperature in 
10ml of TBS Tween containing the first antibody. The membrane was washed three 
times for 5min and agitated for lh with TBS Tween containing the secondary 
antibody - an alkaline phosphatase conjugate (Sigma Chemical Company, Poole, UK) 
applied at a dilution of 1/5000. As before, the membrane was washed 3 x 5min in
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TBS Tween before being stained with Nitro blue tetrazolium and 
5-Bromo-4-chloro-3-indolyl phosphate (Bio-Rad Laboratories, Watford, Herts, UK) 
with continuous shaking until a colour reaction developed (usually within 5min). 
Immersing the developed membrane in distilled water stopped the staining reaction 
and the membrane was allowed to air-dry.
In expressed proteins that contained a His-tag a Nickel-alkaline phosphatase 
conjugate was added to the solution instead of the first antibody. Therefore, the 
addition of a secondary antibody was unnecessary and the blot was washed in 
TBS/Tween before being developed as described above.
2.2.16 Refolding of insoluble recombinant protein
Insoluble material containing the recombinant protein was collected by centrifugation 
at 16,000 x g for 40min. The pellet was resuspended in 200ml of buffer A (0.1M 
Tris-HCl, pH 11.0, 50mM p-mercaptoethanol) and stirred at 4°C for 4h. Insoluble 
material was washed in this buffer and recollected by centrifugation. The washed 
pellet was resuspended in 10ml of buffer B (6M urea, 0.1M Tris-HCl, pH8.0, ImM 
glycine, ImM EDTA, 50mM p-mercaptoethanol) and stirred overnight in an attempt 
to resolubilise any recombinant material. Residual insoluble material was removed by 
centrifugation at 28,000 x g for 2h. The supernatant containing recombinant protein 
was placed in dialysis tubing and placed in 41 of buffer C (4M urea, 0.1M Tris-HCl, 
pH8.0, ImM glycine, ImM EDTA, 50mM p-mercaptoethanol) at 4°C for 4h with 
stirring. This was transferred to 41 of buffer D (2M urea, 0.1M Tris-HCl, pH8.0, ImM 
glycine, ImM EDTA, 50mM P-mercaptoethanol) at 4°C for 4h with stirring. Finally,
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the remaining solution was placed in fresh dialysis tubing and transferred to 41 of 
lOmM Tris-HCl, pH8.5).
2.2.17 Screening by Hybridisation with Radioactive-labelled Probes
A colony blotting method was used to screen a plasmid library for colonies containing 
genes of interest.
A cDNA library (1 .Opl) was transformed into DH5a cells (200pl), plated out on 8 
LB-ampicillin plates and incubated overnight to give a good distribution of distinct 
colonies. Hybond-C nitrocellulose was carefully lowered onto each plate and was left 
for 3min. The orientation of the nitrocellulose to the plate was marked by piercing 
through the nitrocellulose into the agar, with a syringe needle filled with Indian ink. 
Some of each colony should stick to the nitrocellulose, which was carefully lifted 
from the plate and placed (colony side up) on a series of 3MM (Whatman 
International Ltd., Maidstone, UK) filter papers, soaked in the following solutions;
• Blotting solution: - 10% SDS for 3min.
• Denaturing solution: - 1.5M NaCl, 0.5M NaOH for 5min.
• Neutralising Solution: - 1.5M NaCl, 1.0M Tris-HCl, pH7.4 for 5min.
• 2x SSC for 5min.
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The nitrocellulose blots were then dried for at least 30min on 3MM filter paper. 
Subsequently, blots were covered with dry filter paper, wrapped in tin foil and baked 
at 80°C for 2h. Blots were stored overnight at 4°C.
Dry nitrocellulose blots were moistened on filter paper covered with 2x SSC for 
lOmin, before being transferred to pre-wash solution (5x SSC, 0.5% SDS, ImM 
EDTA) for lOmin. They were then wrapped in gauze and fitted into a hybridisation 
tube, before 25ml of pre-hybridisation solution (6x SSC, 5x Denhardt’s solution 
(0.1% Ficoll, 0.1% polyvinylpyrilidone and 0.1% bovine serum albumin), 10% SDS, 
20ng/ml of yeast tRNA) was added. The tube was left to rotate slowly at 55 °C for 2h.
Gene specific oligonucleotides (see above) were labelled with 32P in the following 
reaction;
2pl (50pg) of each single-stranded oligonucleotide 
5pl of [y-32P]-ATP (Amersham)
2pi lOx Polynucleotide Kinase Buffer 
lpl Polynucleotide Kinase 
4pl nuclease-free H2O
The reaction was mixed by pipetting and incubated at 37°C for 45min. Primers were 
then precipitated with ethanol and collected by centrifugation. The supernatant was 
discarded and the oligonucleotides were resuspended in 50pl of nuclease-free H2O 
before addition to the hybridisation tubes containing the nitrocellulose blots and 
pre-hybridising solution. Hybridisation was left to proceed overnight at 55°C.
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Nitrocellulose blots were carefully removed from the hybridisation tubes and washed 
with Washing solution (2x SSC, 0.1% SDS). Radiation levels on the blots were 
monitored using a Geiger counter. After three washes, the blots had radiation levels 
just above background, suggesting that most of the non-specifically bound probe had 
been washed away. Blots were air dried, wrapped in Saran wrap and placed in an 
AutoRad cassette (Genetic Research Instrumentation Ltd., Dunmow, UK), containing 
radiographic film (Kodak Ready pack, Kodak, New York, USA). The cassettes were 
stored overnight at -80°C to increase the sensitivity of the radiographic film. The film 
was removed from the cassette in the dark room and developed using a Gevamatic 60 
automatic developer (AGFA-Gevaert, Brentford, UK).
Spots on the film were marked on the nitrocellulose blot by piercing with a syringe 
needle. The blot was then aligned with the original agar plate and colonies in the 
proximity were chosen for culturing, plasmid DNA purification and sequencing.
2.2.18 Single-stranded RNA synthesis
Template for single-stranded RNA (ssRNA) synthesis was prepared from pGEM-T 
plasmids containing pfFabF or LmKASl/2 genes, within the multiple cloning site. 
These plasmids were transformed into E. coli DH5a cells (Section 2.2.10), plated onto 
fresh LB agar plates containing ampicillin and incubated at 37°C overnight. Single 
colonies were picked from these plates and used to inoculate 10ml of LB broth 
containing ampicillin. These cultures were grown overnight at 37°C in a shaking 
incubator (250rpm). Overnight cultures (4ml) were used to inoculate 400ml of LB 
broth containing ampicillin, which was grown at 37°C in a shaking incubator until a
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D600 of 0.8. Microgram quantities of plasmid DNA were collected from these cultures 
using the DNA Purification Maxiprep Kit (Promega), according to the manufacturer’s 
instructions.
Plasmid preparations were digested using the restriction enzyme Pvu II according to 
the manufacturer’s instructions (New England Biolabs). This enzyme cuts 
approximately 100 bases upstream of both the T7 and SP6 promoter regions of the 
pGEM-T plasmid and has no cognate sites within the inserted genes. The digested 
plasmid was separated in a 1% agarose gel and visualised using ethidium bromide. 
DNA bands containing the pfFabF or LmKASl/2 flanked by the T7 and SP6 
promoter regions were excised from the gel and purified using the QiaQuick Gel 
Extraction Kit (Qiagen Ltd., West Sussex, UK). The concentration of these DNA 
fragments was analysed using a GenequantPro spectrophotometer (Pharmacia).
Single-strand RNA was synthesised from these fragments derived from the pGEM-T 
plasmid clones. In separate reactions, T7 and SP6 RNA polymerases (Ambion) were 
used to synthesise RNA from the respective promoter regions.
The reaction mixture is shown below;
Plasmid fragment (200ng/pl) 5pl
lOmM NTPs (ATP, CTP, GTP, UTP) 8pl
RNA Polymerase Buffer (1 Ox) 2pl
T7 or SP6 RNA Polymerase (Ambion) 1 (0.1
DEPC treated H2O 4|xl
Total 20pl
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The reaction was incubated at 37°C for 60min after which template DNA was 
digested by the addition of 1 unit of DNase I (Ambion) at 37°C for a further 15min. 
Production of ssRNA and template DNA degradation was analysed by running 
samples in a 1 % agarose/ethidium bromide gel, visualised under UV light. The 
concentrations of RNA in these ssRNA products were analysed using a GenequantPro 
spectrophotometer (Novagen).
2.2.19 Double-stranded RNA production
Equal amounts of T7 and SP6 ssRNA were annealed by heating to 80°C and cooling 
slowly to 20°C over 4h. The concentration of ssRNA products was analysed (see 
above) and added in equimolar amounts to a 0.25ml eppendorf tube. In an attempt to 
optimise the annealing reaction, ssRNA products were purified using the RNAeasy 
Kit (Qiagen Ltd., West Sussex, UK) and resuspended in DEPC treated H2O or lx 
RNA polymerase buffer.
2.2.20 Design of short interfering RNA (siRNA) Oligomers
Short interfering RNA oligomers were designed using the protocol previously 
described by Elbashir. Briefly, only the coding sequence of each gene was used in the 
design process. The first 100 nucleotides downstream of the start codon were ignored 
and the remaining coding sequence was searched for regions containing 
5’-AA(Ni9)UU-3’, where N is any nucleotide. The G/C content of these potential 
siRNA sequences was calculated, those with a G/C content of 50% were chosen as 
prime candidates. Finally, these siRNA sequences were used in Blast searches against
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both parasite and human genomes, to try to ensure that only a single gene is targeted. 
Lyophilised HPP grade siRNA oligos (40nmole) were ordered from Xeragon Inc. 
(www.xeragon.com) and stored at -20°C.
2.2.21 Preparation of Cell Extracts for Radioactive Assays 
BL21 pLysS cells were grown in LB broth containing chloramphenicol. When the 
culture reached late exponential phase, cells were harvested by centrifugation at 
9,000g, 4°C for lOmin in the Beckman JLA 16.250 rotor. Cells were washed three 
times by resuspending the pellet in 10ml of lysis buffer (lOOmM Sodium phosphate, 
pH7.0, 5mM P-mercaptoethanol, ImM EDTA) followed by centrifugation at 9,000g, 
4°C for 5min in the Beckman JA-20 rotor. Following the third washing step, the cell 
pellet was resuspended in twice its wet weight of lysis buffer. The cell resuspension 
was sonicated with a MaxiTip probe on ice for 4 x 10s (Soniprobe, Output=7, Duty 
cycle=40%, Lucas Dawe Ultrasonics Ltd., London, UK). The cell lysate was cleared 
by centrifugation at 20,000g, 4°C, for 60min in the Beckman JA-20 rotor. The 
supernatant was then adjusted to 80% saturation with (NH^SO^ left to stand for 
5min and the precipitate collected by centrifugation at 20,000g at 4°C for 20min. The 
resultant supernatant was discarded and the pellet resuspended in 2ml of lysis buffer.
The protein concentration of this suspension was calculated using a Bradford Assay 
with bovine serum albumin standards ranging from 0.2-1.4mg/ml. Samples were 
diluted with H2O until the absorbance lay between absorbance values corresponding 
to 0.2-0.8mg/ml standards.
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2.2.22 Fatty Acid Synthase Activity Assays in E. coli Extracts 
The assay was based on the method described previously Tsay et al., 1992. The final 
concentrations of components of the assay were ImM NADH, ImM NADPH, 40pM 
acetyl-CoA, 25pM [2-,4C]malonyl-CoA (specific activity, 50.9pCi/pmol), 15pM 
E. coli acyl carrier protein (ACP), ImM P-mercaptoethanol, O.lmM Sodium 
Phosphate buffer pH7.0 and 25 pg of E. coli cell extract, in a final assay of volume of 
40pl. The acetyl-CoA and [2-14C]malonyl-CoA components were mixed together and 
added to the tubes last to initiate the reaction. Reactions were performed in triplicate 
at 37°C for 30min and stopped by the addition of 8 pi 5M KOH. In negative controls, 
KOH was added to tubes prior to the addition of [2-14C]malonyl-CoA and 
acetyl-CoA, with subsequent incubation.
Reaction tubes were then heated to 65 °C for 30min, cooled on ice and condensation 
collected in a microcentrifuge. Following acidification using 12pl of 20% (v/v) H2SO4 
the resulting 14C-labeled fatty acids were extracted with three 1ml volumes of 
petroleum ether. The organic extracts were pooled into glass vials, dried under N2 
(BOC gases, Surrey, UK) and resuspended in 1ml petroleum ether. Fractions of the 
resuspension were then added to scintillation vials, dried once more and 10ml of 
Opti-fluor scintillant (Packard, Groningen, Holland) was added. The incorporation of 
radiolabel into fatty acid chains was determined by using a Beckman 1209 Rackbeta 
Liquid Scintillation Counter (EG&G Wallac, Milton Keynes, UK). Samples were 
counted for 1 min and corrected for quenching by the sample channels ratio method.
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2.2.23 Confonnationally Sensitive Gels
Prepared as shown below (Table 2.3)
Component
Separating Gel
0.5M urea, 13% 
acrylamide
2.5M urea, 15% acrylamide
40% acrylamide 4.9ml 5.6ml
Milli-Q H20 8.9ml 4.6ml
Trizma pre set pH9.0 1.4g 1.4g
8M urea 950pl 4.7ml
0.25M EDTA 60pl 60pl
TEMED 25pl 25 pi
Ammonium 
Persulphate (lOOuM) 
(APS)
45pl 45 pi
Table 2 3  Components of confonnationally sensitive gels
All of the components of the separate gels, except the APS, were added to three 
conical flasks and the solutions degassed for 5min. The APS was then added and the 
gel poured and set.
Short chain acyl-ACPs were separated in 13% polyacrylamide gels containing 0.5M 
urea. Longer chain acyl-ACPs were separated in 15% polyacrylamide gels containing 
2.5M urea. Temperature can have a significant effect on migration positions and care 
was taken to run these urea PAGE gels at 25°C.
2.2.24 Assay of FabB and FabF Condensing Enzymes and Inhibitor Studies
Elongating condensing enzymes from E. coli and P. falciparum were assayed for 
activity using a standard toluene extraction procedure (Garwin et al., 1980; Price 
et al., 2001.). To ensure complete reduction of ACP it was incubated with the DTT 
and Potassium phosphate buffer at 37°C for 20min. The remaining components, 
except the condensing enzyme, were then added to the reduced ACP mix and 16pl 
aliquoted into reaction tubes. Inhibitors were dissolved in 20% DMSO and 2pl added 
to the reaction tubes. Control reactions contained 2% DMSO. This solvent was chosen 
because, unlike ethanol, it had limited effect on the assay.
The reaction was started by the addition of 2pl of the condensing enzyme followed by 
incubation at 37°C for 20min. In assays where a lower concentration of the 
condensing enzyme was used, all dilutions were made in lOOmM Sodium phosphate 
buffer, pH6.8. The final assay contained lOOmM Potassium phosphate buffer, pH6.8, 
100nM ACP, 300|iM DTT, lugecFabD, 50jiM [2 -l4C] malonyl-CoA, 50|xM 
acyl-ACP in a 20pl volume. Addition of 400pl of reducing solution (see below) 
stopped the reaction. This was then vortexed vigorously for 10s and placed at 37°C 
for 40min. Reduced acyl chains were extracted into 400jil toluene with vigorous 
mixing. The upper phase was extracted and placed in scintillation vials containing 
3ml of scintillation cocktail (Fisher). The decays per minute were measured using the 
Beckman 1209 Rackbeta Liquid Scintillation Counter (EG&G Wallac, Milton 
Keynes, UK).
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Reducing Solution contained lOOpM Potassium phosphate buffer, pH6.8,400pM 
KC1, 30% tetrahydrofuran and 5mg/ml NaBH4 . Reducing solution was made in a 
fume cupboard, stirred and stored on ice prior to use.
2.2.25 Assay of FabH Enzyme Activity and Inhibitor Studies
The enzyme FabH condensing enzymes from E. coli and P. falciparum were assayed 
using a filter disc assay (Tsay et al., 1992; Price et al., 2001). The final assay 
contained lOOmM Sodium phosphate buffer, pH6.6, 25pM ACP, ImM 
P-mercaptoethanol, lpg ecFabD, 65 pM malonyl-CoA, 45 pM [1-14C] acetyl-CoA in a 
40pl volume. To ensure complete reduction of ACP it was incubated with 
P-mercaptoethanol and Sodium phosphate buffer at 37°C for 30min. The remaining 
components were then added to the reduced ACP mix and 36pl pipetted into each 
reaction tube. Inhibitors were dissolved in 20% DMSO and 2pl added to the reaction 
tubes. Control reactions contained 2% DMSO.
The reaction was started by the addition of 2pl of FabH, followed by incubation at 
37°C for 15min. To stop the reaction 35pl of the assay was spotted onto a Whatman 
21mm filter disc. Filter discs were washed with gentle shaking in successive solutions 
of 10% trichloroacetic acid (TCA), 5% TCA and 1% TCA at 4°C for 20min, 20ml of 
wash solution per disc. To establish the total number of counts added to each tube, a 
control reaction was spotted onto a filter disc but was not washed in TCA. Filter discs 
were dried and placed in scintillation vials containing 3ml of scintillation cocktail 
(Fisher). The decays per minute were measured using the Beckman 1209 Rackbeta 
Liquid Scintillation Counter (EG&G Wallac, Milton Keynes, UK).
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2.2.26 The overexpression and purification of Escherichia coli FabD
The pDS-His6-FabD plasmid was kindly provided by Dr. Roland Lange 
(Morphochem AG, Basel, Switzerland). The plasmid was transformed (Section 2.2.9) 
into competent E. coli M15 pREP4 cells prepared as described in Section 2.2.10 and 
plated on to LB agar plates containing ampicillin and kanamycin. A single colony was 
used to inoculate 10ml of LB media containing the aforementioned antibiotics and the 
culture was placed in a shaking incubator at 37°C for 16h. The overnight cultures 
(10ml) were used to inoculate 1 litre of freshly prepared LB containing the appropriate 
antibiotics, in 2 x 1 litre conical flasks. Cultures were placed in a shaking incubator at 
30°C, 240rpm. When the cultures reached an = 0.6, expression of E. coli FabD 
was induced by the addition of DPTG to a final concentration of ImM. Cells were 
harvested at 24h post-induction, using a Beckman J series centrifuge (8,000 x g, 4°C, 
15min). The resultant cell pellet was resuspended in 40ml of Lysis Buffer (50mM 
Sodium phosphate, pH7.5, 300mM NaCl, lOmM imidazole) per litre of culture. The 
cells were lysed by sonication, 60% amplitude for 3 x 30s bursts and the lysate 
centrifuged at 20,000 x g, 4°C for 15min. The supernatant was mixed with 5ml of 
Ni-NTA resin (Qiagen Ltd., West Sussex, UK), which had been equilibriated in Lysis 
Buffer and stirred slowly at 4°C for lh. The resin solution was poured into a glass 
chromatography column and the resin was allowed to settle.
The column was washed with 20 column volumes of Lysis buffer and then with Wash 
Buffer (50mM Sodium phosphate, pH7.5, 300mM NaCl, 20mM imidazole) until the 
OD280 was less than 0.02. The His6-FabD protein was eluted across 20 x 1ml fractions 
using Elution Buffer (50mM Sodium phosphate, pH7.5, 300mM NaCl, 250mM 
imidazole). All fractions contained a single band of the expected size for E. coli FabD
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and fractions 4-10 had an OD280 corresponding to that greater than 1 mg/ml. These 
fractions were diluted in 50% of sterile glycerol and stored at -20°C until further use.
2.2.27 Preparation of Acyl-ACP Synthetase
An overnight culture of E. coli strain LCH68 was used to inoculate 1 litre of fresh LB 
broth containing ampicillin that was grown to late log phase. All subsequent steps 
were performed at 4°C or on ice. Cells were collected by centrifugation at 8,000 x g 
for 20min and cell pellets resuspended in 2 x wet weight of 50mM Tris-HCl, pH8.0 
containing 30pg/ml DNase I. Resuspended cells were ruptured in a French Press at 
16,000psi and the homogenate collected in JA-20 centrifuge tubes. Cell debris and 
insoluble material was removed by spinning at 1 l,000rpm for 20min. The supernatant 
was adjusted to lOmM MgCh and the membrane fraction collected at 80,000 x g for 
90min.
The pellet was washed in a volume of 50mM Tris-HCl, pH8.0, 0.5M NaCl, lOmM 
MgCl2 equal to the wet weight of the original cell pellet and the membrane fraction 
collected in an ultracentrifuge under the conditions described above. To help 
solubilise membrane proteins the pellet was resuspended in two thirds the volume 
used in the previous step of 50mM Tris-HCl, pH8.0, 2% Triton X-100, lOmM MgCl2. 
The solution was spun in the ultracentrifuge for a final time and the supernatant 
retained for the purification of Acyl-ACP Synthetase.
A column packed with Blue Sepharose CL-6B was equilibrated with two column 
volumes of 50mM Tris-HCl, pH8.0, 2% Triton X-100. The supernatant was applied to
99
the column and the elutant collected. The column was then washed with 15ml 50mM 
Tris-HCl, pH8.0, 2% Triton X-100, 0.6M NaCl. Then the AAS protein was eluted 
using 50mM Tris-HCl, pH8.0, 2% Triton X-100, 0.5M KCSN and 1ml fractions 
collected for the analysis of activity. Each fraction was immediately dialysed against 
2-41itres of 50mM Tris-HCl, pH8.0, 2% Triton X-100 to remove the potassium 
thiocyanate for a minimum of 4h. Each fraction was transferred to an eppendorf tube 
where ATP and MgCh were added to final concentrations of 5mM.
The protein concentration of each fraction was determined using a Bradford Assay 
and fractions containing significant amounts of protein were assayed for AAS 
activity.
2.2.28 Extraction of Lipids and Production of Fatty Acid Methyl Esters (FAMEs) 
from E. coli
Cells were harvested by centrifugation at 8,000 x g for lOmin at 4°C. The cell pellet 
was resuspended in 500jil of distilled water and transferred to glass test tubes. 
Chloroform/methanol (1:2), 2.5ml, was added to the cell resuspension, which was 
vortexed and left at room temperature for 15min. Then 1.25ml of chloroform and 
1.25ml of Garbus reagent (2M KC1, 0.5M Sodium phosphate buffer, pH7.4) were 
added to the solution, which was vortexed. To ensure complete separation of the 
phases the test tubes were centrifuged for 5min at l,500rpm (Baird Taitlock 
centrifuge). The upper aqueous phase was discarded and the lower phase was 
transferred to a clean test tube, where it was evaporated to dryness under N2. The 
resulting precipitate was resuspended in 200pl of chloroform and lOOpl of this was
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removed to a glass capped vial and stored at -20°C for future studies. The remaining 
lOOpl was placed in a methylating tube and evaporated to dryness under N2. To 
produce fatty acid methyl esters 1ml of toluene and 2ml H2SO4 in dry methanol were 
added to the methylating tubes. The tightly capped methylating tubes were placed in a 
70°C waterbath for 2h to ensure complete methylation of fatty acids. To stop the 
methylating reaction 4ml of 5% (w/v) NaCl was added to the methylating tubes. To 
extract the FAMEs 4ml of petroleum ether was added to the methylating tube, which 
was then vortexed and the upper phase removed to a clean test tube. The extraction 
was repeated and the upper phases pooled. To neutralise any remaining sulphuric 
acid, 4ml of 2% KHCO3 was added to each tube and the upper phase removed to a 
clean test tube. HPLC grade sodium sulphate (0.5g) was added to absorb any water 
present in the sample and the solution was transferred to clean test tube. The solution 
was then evaporated to dryness under N2 and resuspended in 25jjJ of HPLC grade 
hexane.
Gas chromatography of FAMEs were performed using an Agilent model 6890N series 
gas chromatograph equipped with splitless injector, autosampler and flame ionisation 
detector. A capillary column of fused silica coated with VF-23ms™ (0.25mm x 30m 
in length, 0.25pm film thickness; Varian) was used and run isothermally at 170°C. 
Helium was the carrier gas at an initial flow rate of 1.6ml/min. In all analyses, the 
detector was set at 300°C and the injector at 230°C.
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2.2.29 Determination of minimum inhibitory concentrations (MIC)
The MICs of the TLM analogs against E. coli was determined by a broth 
microdilution method. ANSI {tolC::TnlO, metBl, relAl, spoTl, X,R, X~, gyrA216, F~) 
is an E. coli strain that is defective in TolC-dependent type I secretion and efflux 
pumps (Buchanan, 2001). Strain ANSI was grown to mid-log phase in 1% tryptone 
broth and then diluted 30,000 fold in the same medium. A 10|il aliquot of the diluted 
cell suspension (3,000 to 5,000 colony forming units) was used to inoculate each well 
of the 96 well plate (U-bottom with low evaporation lid) containing lOOpl of tryptone 
broth with the indicated concentration of inhibitors. The plate was incubated at 37°C 
for 20 hours before being read by Fusion™ Universal Microplate Analyzer (Packard, 
Canada) at 600nm. The absorbance in wells treated with DMSO solvent control was 
considered as 100%.
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Chapter 3
The Cloning and Expression of P. falciparum  FabF
3.1 Introduction
In studies described in this chapter, a candidate gene that encodes a condensing 
enzyme from Plasmodium falciparum was identified by its sequence homology to 
plant and bacterial FabB and FabF protein sequences. Phylogenetic analysis of the 
translated protein suggested that it was more closely related to FabF enzymes than 
FabB enzymes and the protein was assigned as pfFabF. The pfFabF protein is 
encoded by a 1257 base pair gene, assigned as pjfabF, on chromosome 6 of the 
P. falciparum genome. When translated, this gene encodes a protein of 418 amino 
acids that corresponds to the mature part of the enzyme. Our studies failed to locate 
the initiator ATG codon for the gene and any N-terminal signal sequence of this 
protein. Isolation of naturally occurring pfFabF protein was not considered a feasible 
method of yielding a sufficient quantity of protein for kinetic characterisation or 
structural analysis. Therefore, production of pfFabF was attempted using a 
recombinant system. In this study, the region corresponding to the mature pfFabF has 
successfully been produced in a recombinant form in E. coli. Initial protein expression 
studies showed pfFabF was contained solely within the insoluble fraction of lysed 
E. coli preparations. In an attempt to solubilise the protein, an N-terminal fusion to 
E. coli maltose binding protein was expressed. There was a limited but significant 
increase in the amount of soluble pfFabF protein and this was sufficient to yield 
enough active enzyme for initial characterisation of the enzyme and to allow assays 
with thiolactomycin and its derivatives.
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3.2 Identification of a P. falciparum  Elongating Condensing Enzyme
At the beginning of this project, genes encoding P. falciparum FabB and/or FabF 
proteins had yet to be identified. The tBlastN program (Altschul et al., 1997) was 
used to search databases of P. falciparum contiguous DNA sequences with plant and 
bacterial FabB and FabF protein sequences. Within a 1662bp contiguous sequence 
located on chromosome 6 of the P. falciparum genome, initial studies identified a 
single candidate gene of 1152bp that included a stop codon at the 3’ terminus. The 
deduced gene sequence encoded a protein of 383 amino acids that shared significant 
sequence identity with an assortment of plant and bacterial FabB and FabF enzymes 
(Figure 3.1 -  shown as black text). However, the predicted protein sequence of this 
candidate gene was shorter at the N-terminus than mature proteins of the family and 
there was no obvious initiator ATG codon (Figure 3.1). In addition, for a protein 
believed to be targeted in the apicoplast, an N-terminal bipartite sequence would be 
expected for targeting it to the organelle.
Within the contiguous sequence, all three reading frames were searched upstream of 
the identified gene for an N-terminal exon encoding either an initiator methionine or a 
signal peptide. A 105bp extension encoding 35 amino acids that showed high 
sequence homology to bacterial FabB and FabF proteins was observed in a separate 
reading frame (Figure 3.1 -  shown as red text). This indicated that a frameshift 
mutation may have been introduced during sequencing of the contiguous fragment at 
the Sanger Institute (responsible for sequencing P. falciparum Chromosome 6). This 
region also lacked an obvious initiator ATG codon and did not encode any signal and 
target sequences for transport of the mature protein to the apicoplast. Due to problems
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DNL EQAQGM 
DEL PEVADL
DFVP-HEARQ
RFM P-LTTSK
DYVP-DEARR
NYTPNKYIHA
N IV T --E T T D
N I I T - -E T T Q
P IL R --E T R E
VSGMEYTLCK 3 9 6  
KMLVRTAMSN 4 4  5 
Q E-LNYV LSN 3 9 5  
K E N ID ISfcN T  4 0 0  
-RELTTVMSN 3 8 8  
-R E p T T V ^ S N  3 8 9  
NAKLDTVMSN 3 8 7
E.coli F a b F
A.thalania  K A S II
B .subtilis  F a b F  
P.fal KAS 
E.coli F a b B  
Y.pestis F a b B
P.aeruginosa  F ab B
F K K I - -  4 1 2  
F A S I - -  4 6 1  
jIFKKYQS 4 1 3  
FKKIVK 4 1 8  
RKLKD 4 0 6  
RKYQK 4 0 7  
LKRWQG 4 0 5
Figure 3.1 An alignment of bacterial, plant and P. falciparum condensing enzymes
The region of the mature pfFabF protein that was identified and cloned in Sections 3.4-3.5 is 
shown as black text. The N-terminal extension of 35 amino acids, cloned and assembled in 
Section 3.6-3.7 is shown as red text. The R114S mutation from the published sequence of 
pfFabF (PlasmoDB MAL6P1.165) as a result of a polymorphism is highlighted against a 
blue background. The L390 residue that may be involved in TLM resistance in B. subtilis is 
highlighted against a background of red. Residues of the catalytic triad are highlighted using 
*. The species names in full and the GenBank accession numbers of the sequences are: 
Arabadopsis thalania KAS IJ (NP_178533.2); Bacillus subtilis FabF (CAB 12975); 
Escherichia coli FabB (PI4926); Escherichia coli FabF (P39435); Pseudomonas aeruginosa 
FabB (AAC45620); Yersinia pestis FabB (CAC92996); Plasmodium falciparum KAS -  this 
work and (NP_703921.1; PlasmoDB # MAL6P1.165). This alignment was produced using 
the ClustalW program (Thompson et al., 1994), which is available at www.ebi.ac.uk and 
formatted using the Chroma program (Goodstadt and Ponting, 2001).
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in amplifying the pffabF gene (Sections 3.3 and 3.4) it was decided not to clone this 
region (Section 3.6) until the rest of the gene was assembled (Section 3.5).
Homology searches with FabB and FabF proteins were performed to determine 
whether the candidate P. falciparum gene encoded a FabB or FabF enzyme. Due to 
the high sequence identity that usually exists between FabB and FabF proteins (37% 
between the two E. coli enzymes), it was difficult to come to an accurate conclusion 
as to which the P. falciparum protein resembled. Traditionally, FabB and FabF 
proteins have been characterised not by their sequence homology alone, but by their 
catalytic activity towards acyl-ACP substrates.
Like most plants and bacteria, P. falciparum contains a FabZ homologue but lacks a 
FabA homologue. The lack of a FabA dehydratase/isomerase within P. falciparum 
suggests that the condensing enzyme that was provisionally identified here, may 
belong to the FabF family (Section 1.8.2). E. coli FabF controls 
temperature-dependent regulation of fatty acid composition by elongating palmitoleic 
acid (C l6:1) to c/s-vaccenic acid (C l8:1). FabF proteins are found in Type II FAS 
systems throughout the plant and bacterial kingdoms, whilst FabB proteins are limited 
to the Gram-negative bacteria.
3.2.1 Phylogenetic Analysis of the P, falciparum Condensing Enzyme
The amino acid sequence of the condensing enzyme from P. falciparum is closely 
related to both FabB and FabF proteins, thus hindering a clear classification of the 
protein. However, comparisons of condensing enzyme sequences from different 
organisms should elucidate the evolutionary relationships between these proteins.
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Therefore, phylogenetic analysis of condensing enzyme amino acid sequences was 
performed using the CLUSTALW program (http://www.ebi.ac.uk /clustalw) and 
visualised using the Treeview program (Page, 1996). Sequences of; bacterial FabB 
proteins, bacterial FabF proteins, plant condensing enzymes, human and mouse 
putative mitochondrial Type II KAS and the KAS domains from human and mouse 
Type I FAS were used in the phylogenetic analysis.
The resulting tree (Figure 3.2) places the P. falciparum condensing enzyme within a 
bacterial FabF clade of proteins. The condensing enzymes the two apicomplexan 
parasites (P. falciparum and Toxoplasma gondii) appeared to be most closely related 
to the FabF protein from Bacillus subtilis within a clade that also contains the green 
algae Synechocystis sp.. The theoretical evidence discussed in this section suggests 
that the elongating condensing enzyme in P. falciparum is a FabF type enzyme. 
However, knowledge of enzyme substrate specificity and complementation studies of 
FabF knockouts is essential to classify definitively this enzyme. Until these data 
become available it was decided to designate the P. falciparum condensing enzyme 
pfFabF.
33  Cloning of a Truncated pffabF gene
Amplification of the gene encoding the N-terminal truncated form of pffabF was first 
attempted in a PCR using the cycling parameters and primers shown in Figure 3.3. A 
P. falciparum cDNA library (ring stage; provided by Prof. Steve Walsh, Liverpool 
School of Tropical Medicine) was used as the template. The forward primer, called 
pffabF FI (Figure 3.3B), was designed to anneal to coding strand of the 5’ region of
108
PLANT KAS
At-1Hv-I ENZYMESRc-IPfal-KAS Tgondii KAS Pf-I
Hv-I
At-ll
Bn-I
Rc-
Bs-I Pf-ll
Cw-lla
Ch-IVSyn-
Pa-llAa-
Pp-ll
Yp-I
Ec-I
Yp-llEc-I
BACTERIAL
FabF
ENZYMES
Ag-llRa , ' BACTERIAL 
FabB
ENZYMES
Rp-ll
Hs-mtAg-I Mm-mt At-mt ANIMAL MITOCHONDRIAL 
KAS ENZYMES
Sp-mt
0.1
Figure 3.2 Phylogenetic tree of KAS enzymes based on their amino acid 
sequences.
The amino acid sequence of the mature P. falciparum KAS protein (416 amino acids) was aligned with 
the mature sequences of bacterial and plastid KAS enzymes, and mitochondria KAS proteins, using the 
CLUSTAL W (Thompson el al., 2001) and Treeview programs (Page, et al., 1997). Only the sequences 
of mature proteins were used in the analysis, N-terminal extensions that may encode transit and signal 
peptides were excluded. The full length species names for the abbreviated forms and GenBank 
accession numbers for the sequences are: Agrobacterium tumefaciens, Ag-I (AAL41174) and Ag-II 
(AAK86903); Aquifex aeolicus, Aa-II (AAC07574); Arabadopsis thalania, At-I (AAC49118), At-ll 
(NP_ 178533.2), At-mt (BAB91181); Bacillus subtilis, Bs-II(CAB 12975); Brassica napus, 
Bn-II(AAF61737); Cuphea hookeriana, Ch-IV (AAC68861); Cuphea wrightti, Cw-IIa (AAB37270); 
Escherichia coli, Ec-I (PI4926) and Ec-II(P39435); Homo sapiens, Hs-mt (BAA91286);
Hordeum vulgare, Hv-I (AAA58525) and Hv-IIa (CAA84022); Mus musculus, Ms-mt(BAB30490); 
Pseudomonas aeruginosa, Pa-I (AAC45620) and Pa-II (H83275); Perillafrutescens, Pf-I (AAC04691) 
and Pf-ll (AAC04692); Photbacterium profundum, Pp-II (AAF04118); Ricinus communis, Rc-I 
(AAA33873) and Rc-II (AAA33872); Rickettsia prowazekii, Rp-II (CAA15192);
Schizosaccharomyces pombe, Sp-mt (CAA21898); Synechocystis sp., Syn-11 (S75529);
Toxoplasma gondii, Tgondii KAS (this work and TgTwinScan_0386, www.toxodb.org);
Yersinia pestis, Yp-I (CAC92996) and Yp-II (NP_405182.1); Plasmodium falciparum, PfalKAS -  this 
work and (NP_703921.1; PlasmoDB # MAL6P1.165).
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A pffabF FI
P. falciparum 
cDNA
R1 
B
pjfabF FI 5 ’-GGA TCCAATT AC AA A ATTTG AT AT AACCGG-3 ’
pffabF R1 5 ’-GGA TCCATC ACTTTAC AATTTTTTTG AAAA-3 ’
c
95°C, 5 minutes 
95°C, 1 minute ^
56°C, 1 minute j  ^ 30 cycles
72°C, 1 minute ^
72°C, 5 minutes
10°C, until removed from PCR block
Figure 3J  Primers and cycling parameters used in the initial attempt to amplify 
the pffabf gene
A The position of the oligonucleotide primers in relation to the truncated pjfabF gene 
B Sequences of the oligonucleotide primers. Bam HI sites are shown in italics. 
Nucleotides complementary to the pjfabF gene are underlined.
C Cycling parameters used in the initial attempt to amplify the pjfabF gene
pjfabF
<=p
pjfabF
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the truncated gene (Appendix 1). A reverse primer, called pffabF R1 (Figure 3.3B), 
was complementary to the non-coding strand of the 3’ region and spanned the 
naturally occurring stop codon. The primer oligonucleotides were flanked by Bam HI 
restriction sites to facilitate subsequent subcloning of the PCR generated fragment.
Initial PCRs were performed using a wide range of conditions to amplify the entire 
sequence of the identified pjfabF gene. Alterations in; annealing temperature, MgCl2 
concentrations, different types of DNA polymerase, the number of cycles and the 
length of individual cycle steps were unsuccessful in amplifying the full-length gene. 
This problem may be explained by the exceptionally high (-80%)
A + T richness in the P. falciparum genome. Within the candidate pjfabF gene, the 
overall A + T bias was found to be 70.1%, with some stretches of more than 100 
nucleotides with an A + T bias up to 80%. This may cause the DNA polymerase to 
stall and amplification of the gene may be aborted, leading to insufficient product for 
the subsequent purification and cloning steps.
Amplification of the target sequence was not achieved under the conditions described 
above and it was apparent that a new cloning strategy was required. To improve the 
chances of amplifying sufficient product for cloning, the size of the amplicon was 
reduced. By reducing the size of the amplicon the chance that the DNA polymerase 
will extend to the end of the target sequence is increased. Reducing the amplicon size 
and yet still obtaining the desired protein coding sequence can be achieved by 
producing overlapping fragments of the gene that can be assembled to the full length 
product. This is normally achieved by designing oligonucleotide primers 
complementary to a region part way through the sequence to be amplified. These
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primers are then used in two separate reactions with primers complementary to the 5’ 
and 3’ regions of the target gene. This generates two fragments that can then be 
assembled to yield a full-length gene.
3.4 Adoption of a New Cloning Strategy
To increase the chance of amplifying the truncated pjfabF gene, the target sequence 
was produced in two fragments. To facilitate the joining of the two fragments, the 
primers were designed to flank a naturally occurring Xba I site, approximately 620bp 
into the pjfabF gene (Figure 3.4A). The first of these primers was termed pjfabF R2 
(Figure 3.4B), which complemented the non-coding strand in this region. It was used 
in conjunction with pjfabF FI (Figure 3.4B) to produce a 639bp fragment called 
pjfabF front. The second of these primers, pjfabF F2, complemented the coding 
strand around the Xba I site. It was used in conjunction with pjfabF R 1 to produce a 
548bp fragment called pjfabF back. The two primers flanking the Xba I site are not 
exact complements of each other (Appendix 1 showing the sequence of pfFabF with 
primers highlighted). They were designed so that the 3’ end of the primer terminates 
with two C or G bases, the three hydrogen bonds formed between these bases and the 
template should improve the annealing efficiency. Each pair of primers was used in 
separate PCR reactions using identical cycling parameters. Expand High Fidelity Taq 
(Roche Molecular Biochemicals, Mannheim, Germany) was used as the DNA 
polymerase and P. falciparum cDNA library (as described previously) as the 
template.
Expand High Fidelity Taq does not add an overhang of adenosine residues required 
for the ligation into the pGEM-T vector. Consequently, 5 cycles with generic Taq
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A
pjfabF FI pjfabF F2
r*  CP
Xba I 
pjfabF R2
B
pjfabF  F2 5 ’ -C ATCTT A ATTCTA GA ATC AT ACG -3’
pffabF  R2 5’-TATG AT7CTAGA ATTA AG ATGCC -3’
C
95°C, 5 minutes 
95°C, 1 minute <4------
42°C, 1 minute i 40 cycles
68°C, 2 minutes ►
68°C, 10 minutes 
10°C, until removed from PCR block
Figure 3.4 Primers and cycling parameters used to amplify the pjfabF gene in 
two segments
A The position of the oligonucleotide primers in relation to the truncated pjfabF gene 
B Sequences of the oligonucleotide primers. Xba I sites are shown in italics.
C Cycling parameters used to amplify the truncated pffabF gene in two fragments
P. falciparum 
  cDNA
<50
pjfabF R 1
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polymerase (Sigma Chemicals Ltd., Poole, Dorset, UK) were performed to add 
adenosine overhangs. Following this second PCR, the amplified fragments were 
separated on an agarose gel, purified from the gel and ligated into the pGEM-T vector 
(Sections 2.2.2, 2.2.6 and 2.2.7). The ligation mix was transformed into competent 
E. coli DH5a cells as described in Section 2.2.10 and plated onto LB agar plates 
containing ampicillin. Colonies on the plate were screened using a PCR with either 
pjfabF FI and pjfabF R2 or pjfabF F2 and pjfabF R1 under the conditions described 
in Figure 3.4C. Restriction enzyme digests with Bam HI, Xba I and a double digest 
with both of these restriction enzymes further confirmed the presence of the target 
insert (results not shown).
The orientation of the fragments with the pGEM-T vector was elucidated by 
sequencing using the vector specific M13F and M13R primers (Appendix 2) (results 
not shown). The sequencing results showed that the target sequences had been 
amplified and were flanked by Bam HI and Xba I restriction sites. Upon analysis of 
the sequence chromatograms produced from the pjfabF front clone, it appeared that 
there was a single base mutation compared to the published pjfabF sequence 
(http://plasmodb.org/plasmodb/servlet/sv?page=gene&source_id=MAL6P 1.165&vie 
w=seqs). The adenine nucleotide at position 238 of truncated pffabF had been 
substituted with a cytosine, which resulted in a non-silent mutation of the 114th codon 
(of the entire gene) at the third position from AGA (arginine) to AGC (serine) (Figure
3.1 -  highlighted against a blue background). However, this apparent mutation was 
found to be present in the products of four separate PCRs, which were cloned and 
sequenced independently. This suggested that the mutation has not been introduced by 
the polymerase chain reaction, but arose as a result of a polymorphism within the
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particular P. falciparum cDNA library. No other mutations were observed in the 
clones containing the pjfabF front region. The sequence chromatograms of the pjfabF 
back construct showed no differences from the published pffabF gene and, therefore, 
both fragments were considered suitable for the construction of the gene encoding 
pfFabF.
3.5 Assembly of a Truncated form of the pjfabF gene
Using the strategy illustrated in Figure 3.5, the two fragments were then reconstituted 
to form a truncated version of the pjfabF gene within the pGEM-T vector. Both 
pjfabF front and pjfabF back constructs contain a Xba I restriction site at the region 
where the two fragments overlap. Furthermore, the pGEM-T vector contains several 
restriction enzyme sites on either side of its cloning site. Sequence chromatograms of 
the pjfabF front and back clones elucidated the orientation of the inserts within the 
pGEM-T vector and this knowledge allowed the design of a simple strategy to 
assemble the pjfabF gene.
The pjfabF front construct was used to produce the donor fragment for ligation and 
the pffabF back plasmid acted as the recipient vector (Figure 3.5). Purified plasmid 
DNA from the pjfabF front clone was cut with the restriction enzyme Nco I that 
recognises a single site within the cloning region of pGEM-T upstream of the inserted 
pjfabF fragment. The linearised vector was treated with Klenow enzyme 
(Section 2.2.3) in the presence of dNTPs which filled in the overhangs produced by 
digestion with the restriction enzyme. To limit the probability of the blunt ends 
ligating to themselves in subsequent ligation reactions, the plasmid DNA was then 
treated with shrimp alkaline phosphatase (SAP) (Section 2.2.4). A fragment
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pfFabF FrontBam HI
Nco I
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pfFabF Back Bam HI
Nco I digest 
Klenow treatment 1
Xba I
I Not I digest Klenow treatment Phosphatase treated
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Blunt End ~
Blunt End
Blunt End
pfFabF back -Bam HI
1 Digest with Xba I 1
Blunt End
T
AGATC
\
CTAGA
Blunt End
pfFabF back Bam HI
Ligation with T4 DNA ligase/
BackFront
Truncated pffabf gene 
within pGEM-T
Figure 3.5 Method used for the initial cloning of the pffabf gene
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containing the pffabF front sequence was then excised by cutting with the Xba I 
restriction enzyme (Figure 3.4).
The recipient vector was prepared under similar conditions. First, the plasmid was 
digested with the Not I restriction enzyme that recognised a unique site within the 
cloning region of pGEM-T upstream of the inserted pjfabF fragment. The linearised 
vector was then treated as described above with Klenow enzyme to produce a blunt 
ended fragment. Digestion with the Xba I enzyme resulted in the production of a 
“sticky end”. Both the donor fragment and the recipient vector were then separated by 
submarine gel electrophoresis and visualised under UV light. The two fragments that 
correspond to pjfabF front fragment and the pffabF back linearised plasmid were 
excised and purified from the agarose gel as described in Section 2.2.7.
Following digestion with the Xba I enzyme, both the pjfabF front fragment and the 
pjfabF back vector now contained a “blunt end” and a “sticky end” with a compatible 
Xba 15’ overhang. This configuration forced insertion of the donor fragment in the 
correct orientation. The DNA concentrations of both donor and recipient fragments 
were estimated by visualisation on an agarose gel. The two fragments were added at a 
ratio of 1:1, to a ligation mix containing T4 DNA ligase and buffer. A proportion of 
the resulting ligation mix was then transformed into competent E. coli DH5a cells 
and plated onto LB agar plates containing ampicillin. Positive colonies were identified 
by the production of an amplicon of 1385bp (1166bp from the pjfabF sequence and 
219bp from the pGEM-T vector) in a PCR containing the vector specific M13F and 
M13R primers (Appendix 2) (results not shown). Double digests with Bam HI and 
Xba I excised two fragments 620bp and 530bp in length (results not shown),
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corresponding to the front and back regions of the pjfabF gene, suggesting that the 
pjfabF gene was cloned into the pGEM-T vector. This was confirmed by sequencing. 
The resulting plasmid was named pjfabF N-trunc because not all of the mature pjfabF 
N-terminus had been cloned.
3.6 Identification of a 5’ Extension of the pjfabF gene
The truncated pjfabF gene described and assembled above, encoded a protein that 
showed significant sequence identity with plant and bacterial FabF and FabB proteins 
but had a shorter N-terminus. As mentioned in Section 3.2, a region of the original 
contiguous fragment that encodes for an N-terminal extension of pjfabF was 
identified in an alternative reading frame to the rest of the gene. This region encodes 
35 amino acids that show high sequence identity to E. coli FabF (12/35 -  34% 
identity) and B. subtilis FabF (15/35 -  43%) and also contains 8 completely conserved 
amino acids (Figure 3.1 -  shown as red text). The high sequence identity within the 
N-terminus of FabF proteins suggests that this region is part of the mature protein and 
may significantly contribute to the correct folding and catalytic activity of the 
enzyme.
Therefore, it was essential that the gene encoding the mature P. falciparum FabF 
protein was correctly identified. As described in Section 3.2, a region encoding an 
extension of 35 amino acids, with high sequence homology to both bacterial FabB and 
FabF proteins, was observed in a different reading frame of the contiguous sequence.
118
Confirmation of the frame-shift mutation in the original contiguous sequence was 
observed using the tBlastN program (Altschul et al., 1997) to search databases 
containing P. falciparum contiguous DNA sequences with plant and bacterial FabB 
and FabF sequences. This search identified a single contiguous sequence located on 
chromosome 6 of the P. falciparum genome that had been recently added to the 
database. The newly identified 2637bp contiguous region contained the entire original 
contiguous sequence. However, the 5’ region of the original contiguous fragment had 
been extended by amalgamating the overlapping regions of two contiguous fragments. 
This expanded region was searched for signal and target peptide sequences and an 
initiator methionine for the pjfabF gene but no candidates for either were identified.
In comparison to this new sequence, a sequencing error within the original contiguous 
fragment corresponding to the deletion of an adenosine nucleotide, was revealed 
(Figure 3.6A). The nucleotide in question is positioned within a string of four 
adenosine nucleotides immediately upstream of the cloned pjfabF front region. When 
the adenosine nucleotide was present, the corrected contiguous sequence encoded for 
a mature pjfabF gene, with the exception of a missing methionine initiator codon, 
within the same reading frame.
The expanded region of the pjfabF gene encoded a maximum extension of 35 amino 
acids before an upstream stop codon was reached (Figure 3.6B). High sequence 
identity was observed when these 35 amino acids were aligned with the N-terminal 
region of FabF proteins from other organisms, suggesting that the predicted extension 
is a correct one. The extended pjfabF gene consisted of 1257bp encoding a protein of 
418 amino acids that shows sequence identity along its entire length to other FabF
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enzymes, which indicated that this new version of the gene encoded a mature pfFabF 
protein.
A
I Incorrect reading frame... AAT AGA TAA ATT ACA AAA T IT ....... C-terminus
Asn Arg Stop De Thr Lys Phe
ii
TSRVV region....ATA GAT AAA ATT ACA AAA T IT ..........C-terminus
De Asp Lys De Thr Lys Phe
B
105bp
............. TAG ACT TCT AGA GTG GTG.............
.............. Stop Thr Ser Arg Val V al...........
...........ATT ACA AAA TTT ....
............Be Thr Lys Phe
< ----------------------------------
35 amino acids
Figure 3.6 The corrected nucleotide sequence of pjfabF
A i The original sequence of the contiguous fragment containing the pjfabF gene. An 
erroneous stop codon (shown in bold text) is encoded, as a sequencing error has led to 
the absence of an adenosine residue, ii The corrected sequence of the contiguous 
fragment containing the pjfabF gene. The missing adenosine residue is present 
(underlined) and instead of a stop codon, the CDS of pfFabF continues upstream.
B Nucleotides and amino acids shown in bold text are contained within the pjfabF 
front fragment previously cloned in Section 3.4. Nucleotides and amino acids shown 
in normal text are found in the upstream region of the pjfabF gene. A stop codon is 
observed 105bp upstream of the pjfabF front fragment.
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3.7 Cloning of the 5’ Extension of the pffabF Gene
It was decided to clone the 105 base pairs that encoded the 35 amino acid extension, 
to the 5’ end of the pjfabF N-trunc construct. The pjfabF 5’ extension was designated 
the TSRVV fragment after the first five amino acids within the coding sequence 
(CDS) (Figures 3.1 and 3.6; Appendix 1). The pjfabF gene contained a single Age I 
site, 20 nucleotides downstream of its 5’ terminus that was favourably positioned for 
the addition of a 5* extension (Appendix 1). Primers designed for the PCR 
amplification of the TSR W  fragment are shown in Figure 3.7. The first of these is a 
primer termed TSRW  F, which is complementary to the coding strand of the 5’ 
region of the TSR W  fragment and is flanked by a Bam HI restriction site for cloning 
into an expression vector. This primer was used in conjunction with the primer termed 
TSR W  R, which is complementary to the non-coding strand of the region 
surrounding the Age I restriction site. A 145bp fragment, called TSRW , was 
produced using the same cycling parameters as described in Figure 3.4C. As before, 
Roche High Fidelity Taq was used as the DNA polymerase and the P. falciparum 
cDNA library was used as template DNA. Expand High Fidelity Taq does not add an 
overhang of adenosine residues required for the ligation into the pGEM-T vector. 
Consequently, 5 cycles with generic Taq polymerase (Sigma) were performed to add 
an adenosine overhang.
T S R W  F 5 ’ -GTCGACCGCGGA rCCGACTTCTAGAGTGGTGTGC -3 ’
T S R W R 5’-ACATGACATACCGGTTATATC -3’
Figure 3.7 Sequences of PCR primers used to amplify a 5’ extension of the 
pjfabF gene
A Bam HI site is shown in italics, Age I site is highlighted in bold text and underlined 
nucleotides are complementary to regions of the pjfabF gene.
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Following the second PCR, an amplified fragment of the correct size was visualised 
on an agarose gel under UV light, excised and purified from the gel. The fragment 
was ligated into the pGEM-T vector and transformed into E. coli DH5a competent 
cells. Colonies on the plate were screened using a PCR with the TSR W  F and 
TSR W  R primers under the conditions described above. Restriction enzyme digests 
with Bam HI, Age I and a double digest with both of these restriction enzymes further 
confirmed the presence of the target insert.
The orientation of the fragment within the pGEM-T vector was elucidated by 
sequencing using the vector specific M 13 forward and reverse primers (Appendix 2). 
DNA sequencing also confirmed the absence of mutations compared to the 
contiguous sequence found on the P. falciparum genome database 
(www.plasmodb.org).
3.8 Assembly of a Gene Encoding the Complete Mature pfFabF Protein
The 145bp fragment was ready to be ligated on to the 5’ region of the pjfabF gene 
that was previously cloned into the pGEM-T plasmid (Section 3.5). However, 
sequencing of plasmid DNA from positive clones suggested that the TSRW  
fragment was inserted in different orientations in different clones. Therefore, in order 
to simplify the assembly of the complete pjfabF gene, a clone was chosen that had the 
TSRW  fragment inserted in the pGEM-T cloning site in the same orientation as the 
pjfabF gene. Purified plasmid DNA from this clone was used in further procedures, 
allowing the assembly of the pjfabF gene in two steps, as depicted in Figure 3.8.
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T S R W  Age I 
I
TSRVV pfFabF N-trunc
T S R W  R
Age I
T S R W
PCR with Expand High Fidelity Taq
Clone into pGEM-T vector
I Age I
Bam HI Age I
TSRVV
Sph I
Digest with Age I and Sph I 
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pjfabF trunc
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Sph\
,A  CATGC
GGCC G
CCGGT
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G
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Ligation with T4 ligase
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Figure 3.8 The Cloning of the TSRVV 
fragment and the production of the complete 
pffabF gene within the pGEM-T plasmid
pfFabF
Bam HI
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In this strategy the pGEM-T T SR W  construct acted as the recipient plasmid for an 
excised fragment containing the remainder of the pjfabF gene. First, both the 
pGEM-T TSR W  and pGEM-T pjfabF plasmids were digested with Age I and Sph I, 
a restriction enzyme within the pGEM-T cloning site. The DNA fragments produced 
from each digest were separated in different lanes of an agarose gel (results not 
shown). The only visible fragment observed in the digest of pGEM-T TSR W  
(~3200bp) and the smaller of two visible bands observed in the digested pGEM-T 
pjfabF plasmid (~1200bp) were excised and purified. The vector pGEM-T T SR W  
DNA was then treated with SAP (Section 2.2.4) to prevent the religation of any DNA 
fragments that had not been completely digested. The DNA concentrations of both 
donor and recipient fragments were estimated by visualisation on an agarose gel. 
Equal amounts of the two DNA fragments were added to a ligation mix containing T4 
DNA ligase and buffer. A proportion of the resulting ligation mix was then 
transformed back into competent E. coli DH5a cells and plated onto LB agar plates 
containing ampicillin. Positive colonies were identified by the production of an 
amplicon of 1499bp (1280bp from the pjfabF sequence and 219bp from the pGEM-T 
vector) in a PCR containing the vector specific M13F and M13R primers 
(Appendix 2) (results not shown). Sequencing of the purified plasmid DNA from 
positive clones confirmed that the T SR W  region and pjfabF N-trunc fragment had 
ligated in the correct orientation, to form a gene encoding the mature pfFabF protein. 
Except for the polymorphism described in Section 3.4 and the region encoding a 
predicted bipartite signal sequence of the annotation on the PlasmoDB, the pjfabF 
gene was identical to the sequence found on the P. falciparum genome database 
(PlasmoDB # MAL6P1.165). The pjfabF gene within this construct was flanked by 
Bam HI sites and appeared in a suitable form for the production of pfFabF in a
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recombinant system. The mature pjfabF gene encodes a protein of 416 amino acids 
(followed by a natural stop codon) that shows significant identity throughout its entire 
amino acid sequence to plant and bacterial FabB and FabF proteins.
3.9 Recombinant Expression of pfFabF
3.9.1 Cloning of the pjfabF gene into the pET15b expression vector
In previous studies, recombinant fatty acid synthesis proteins, including FabF from 
E. coli, had been successfully over-expressed in a pET vector system (Abbadi et al., 
2000; Choi et al.t 2000; Schaeffer et al., 2001). This family of vectors utilises a 
promoter derived from the T7 bacteriophage that is not, therefore, recognised by the 
E. coli RNA polymerase. For the production of the recombinant protein, the 
expression vector must be transformed into an E. coli strain engineered to produce the 
T7 RNA polymerase, such as BL21 (DE3) pLysS. The pET vector provides high 
level, tightly regulated expression of the target gene, which is achieved by inducing 
the production of the T7 polymerase by addition of isopropyl 
p-D-thiogalactopyranoside (IPTG).
The pET15b vector encodes a tag of six histidine residues (His-tag) that is expressed 
as a short N-terminal fusion with the recombinant protein. The presence of the 
N-terminal His-tag is advantageous because it allows a convenient detection method 
of the recombinant protein using a nickel-alkaline phosphatase conjugate (Ni-AP). 
This was the method of choice as no anti-serum against pfFabF protein was available. 
Furthermore, the protein could be purified in one step by affinity chromatography on 
a nickel conjugated resin.
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The gene encoding pfFabF was excised from the pGEM-T pffabF plasmid using the 
Bam HI restriction endonuclease. The fragment corresponding to the pjfabF gene was 
purified from an agarose gel and ligated into the pET15b vector, which had been cut 
with Bam HI and treated with shrimp alkaline phosphatase. The ligation reaction was 
then transformed into E. coli DH5a cells and plated onto LB agar plates containing 
ampicillin. The ligation mix that produced the most positive colonies following 
transformation, contained digested pET15b and digested pffabF in a ratio of 2:1. 
Positive colonies were identified by the production of an amplicon of approximately 
1500bp (1271bp from the pjfabF gene and 266bp from pET15b -  see Appendices 1 
and 3. for sequences) in a PCR containing the vector specific primers T7 and SF1 
(Appendix 2). Plasmid DNA was purified from several positive colonies because it is 
possible that the pjfabF fragment could insert into the vector in two directions. The 
orientation of the pjfabF insert within the pET15b vector was then elucidated by DNA 
sequencing using the T7 and SF1 primers, in separate reactions. A single clone that 
contained the pjfabF gene in the correct orientation for expression was chosen and 
termed pET-pjfabF.
3.9.2 Expression of the pfFabF protein in pLysS Cells
The BL21 (DE3) pLysS cells contained a plasmid that expresses lysozyme and can 
increase cell lysis under conditions that are less likely to cause destruction of cellular 
proteins. The pLysS plasmid also confers chloramphenicol resistance to the E. coli. 
The pET -pjfabF plasmid was transformed into competent BL21 (DE3) pLysS cells in 
accordance with Section 2.2.10 and plated out onto LB agar containing ampicillin and
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chloramphenicol. The resultant colonies were screened for their ability to overexpress 
a protein of the correct size after induction with IPTG.
A peptide mass program (Wilkins et al., 1997) predicted the mass of the pfFabF 
protein including the N-terminal His-tag to be 48.8kDa. It was necessary to confirm 
that the pfFabF protein could be produced in a recombinant form in E. coli, so before 
large scale recombinant production of pfFabF could proceed, small scale inductions 
were attempted as described in Section 2.2.12. Samples were removed at 30min, lh, 
2h, 3h and 24h post-induction and analysed for the presence of recombinant protein 
by SDS-PAGE and western blotting, using the Ni-AP conjugate.
SDS-PAGE analysis of a culture grown at 37°C and induced with ImM IPTG 
(Figure 3.9A), appeared to indicate the induction of several proteins of approximately 
the correct size. However, the Western blot showed a single reactive band that 
appeared 30min after the addition of IPTG and accumulated up to 3h post-induction 
(Figure 3.9B). The pfFabF protein appeared to be present solely in the insoluble 
fraction, as no immuno-reactive band was observed in the soluble fraction. This 
small-scale induction proved that the selected pET-pjfabF clone was capable of 
producing recombinant pfFabF within an E. coli system.
However, it was considered preferable to produce pfFabF in a soluble form. Proteins 
that accumulate in the insoluble fraction may be produced too rapidly to be processed 
correctly in the cell and can aggregate together. In an attempt to increase the 
proportion of soluble pfFabF protein, a culture was grown at 42°C, which was 
designed to increase the expression of molecular chaperones as part of a heat shock
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Figure 3.9 Time-course for the induction of pET-pffabF  in BL21 (DE3) pLysS 
cells at 37°C
A= an SDS-PAGE gel, B=Western blot. Samples were removed from the culture at Oh 
(before the addition of IPTG). The other timepoints are at 30min, lh, 2h, 3h and 24h 
post-induction. Samples were prepared as described in Sections 2.2.12 and 2.2.13.
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response. Molecular chaperones such as GroEL, have been shown to aid correct 
protein folding and can increase the amount of soluble recombinant protein (Nollen et 
al., 2001). Furthermore, to curb excessive production of pfFabF this culture was 
induced with l/5th the amount of IPTG (0.2mM) compared to the initial study. A 
small-scale induction of this type suggested that a small proportion (less than 10%) of 
pfFabF was retained in the soluble fraction (Figure 3.10). However, under the same 
conditions, inductions on a larger scale (500ml cultures in 2 litre flasks) yielded no 
soluble pfFabF protein. In addition, compared to the 10ml cultures, the induction of 
pfFabF in larger cultures appeared to be diminished over time (results not shown).
Oh 30min lh 2h 3h 24h Insol. Sol.
200kDa, 
97kDa. 
68kDa. 
43kDa. 
30kDa.
18kDa
14kDa T5St
1  m
Figure 3.10 Time-course for the induction of pET-pffabF in BL21 (DE3) pLysS 
cells at 42°C
Samples were removed from the culture at Oh (before the addtion of IPTG). The other 
timepoints are at 30min, lh, 2h, 3h and 24h post-induction. Samples were prepared as 
described in Sections 2.2.12 and 2.2.13.
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Inductions were also performed at lower temperatures (20°C and 28°C) and with 
lower IPTG concentrations in an attempt to increase soluble pfFabF protein 
production (data not shown). However, for all inductions only low levels of pjfabF 
expression were observed and the results were not reproducible.
3.10 Expression of pfFabF in Codon Plus Cells
Due to the high A + T nucleotide bias in the P. falciparum genome (up to 80% in 
some regions of the pjfabF gene), the codon usage differs substantially from that of 
E. coli (Table 3.1).
Codon (amino acid) E. coli a P. falciparum  a
AGG (Arg)/AGA (Arg) 0.91 b 76.3 c
AUA (De) 0.57 b 53.3 c
GGA (Gly) 1.97 b 43.5 c
CUA (Leu) 0.83 b 15.2 c
Table 3.1 Rare codons found in E. coli mRNA and their corresponding 
frequencies in P. falciparum
a Percentage usage of the codon relative to all other synonymous codons which code 
for the same amino acid. b Medigue et al., 1991. c Nakamura et al.y 1998.
In particular, some commonly used P. falciparum codons for glycine, isoleucine, 
leucine and arginine are rarely observed in E. coli genes. Therefore, the population of 
tRNA molecules that recognise these rare E. coli codons may not be sufficient for the 
efficient production of some heterologous proteins. This tRNA deficiency can cause 
stalling of the ribosome on the mRNA strand, leading to diminished levels of
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expression in E. coli and possibly termination of translation (Kane 1995; Kurland and 
Gallant, 1996). The results obtained in BL21 (DE3) pLysS cells showed that under all 
conditions attempted only small amounts of pfFabF protein were induced, possibly 
due to the presence of rare codons. A search of the pffabF gene detected 47 codons 
rarely used in E. coli, with 8 of the 9 arginine codons (89%) being in this form. 
Furthermore, in two separate regions of the gene, a pair and a triplet of adjacent rare 
codons were observed, thus enhancing the probability of stalling during translation.
To overcome this problem plasmids that overexpress tRNA molecules recognising the 
rare codons of E. coli have been constructed by several groups (Baca and Hoi, 2000; 
Novy et al., 2001). When co-transformed into E. coli cells with the expression 
plasmid, these plasmids have been shown to enhance the expression of proteins from 
P. falciparum and other organisms. The E. coli strain BL21 (DE3) Codon + (RIL) 
contains a plasmid that overexpresses the following tRNAs; argU, ileY and /ewW, 
recognising the arginine codons AGG and AGA, the isoleucine codon AUA and the 
leucine codon CUA. This strain was obtained from Novagen and competent cells 
made in accordance to Section 2.2.9. The pET-pjfabF plasmid was transformed into 
these cells (Section 2.2.10) and colonies used to set-up small scale inductions. 
Unfortunately, no improvement in the proportion of soluble or the total amount of 
pfFabF was observed in these inductions compared to those performed with pLysS 
cells (data not shown).
3.11 Cloning of the pjfabF  Gene into the pMAL Vector System
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The lack of solubility of the pfFabF protein poses questions over the ability of the 
E. coli system to produce active enzyme. An attempt to refold the protein from the 
insoluble fraction (Section 2.2.16; Hill et al., 1996) and subsequent use of a Ni-NTA 
affinity column, failed to purify any substantial protein of the correct size. Western 
blots of the eluted fractions showed no reactive bands against the N-terminal His-tag 
suggesting that either the tag was not accessible to the Ni-AP conjugate or that the 
protein was absent. This initial refolding attempt suggested that it would be difficult 
to recover active pfFabF from the insoluble fraction.
A method of improving the solubility of proteins is to express them as fusions with 
other proteins that usually have a high solubility in the expression system. A screen of 
E. coli proteins showed that a maltose binding protein (MBP) had a very high 
solubility (Kapust and Waugh, 1999). This protein also has the advantage of binding 
with high affinity to maltose (Miller et al., 1983), which could then be exploited to 
allow affinity purification of the fused protein. The pMAL vector family was 
designed so that heterologous proteins can be expressed as fusions with MBP at the 
N-terminus (New England Biolabs, Beverly, MA, USA). In an attempt to increase the 
solubility of the pfFabF protein it was decided to clone the pjfabF gene into the 
pMALc2x plasmid (Appendix 4). The plasmid encodes a Factor Xa cleavage site 
between the MBP and the target protein (Figure 3.11) that can facilitate removal of 
the MBP after purification of the fused product.
The pGEM-T plasmid containing the pjfabF gene was used to create a restriction 
endonuclease fragment for insertion into the pMALc2x vector. New primers were 
designed so that the pjfabF product would be flanked by a proximal EcoR I restriction
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endonuclease site and a distal Sal I site. This strategy had been used by Prigge’s 
research group to insert the P. falciparum FabH (KAS HI) gene into the pMALc2x
Xmn I EcoR I Bam HI Xba I Sal I
ma/E...ATC GAG G<jA AGG ATT i t  A (jAATT^ (jGA Tcfc h'CT AG*A (jT C G aJ .........A
De Glu Gly Arg lie Ser Glu Phe 
Factor Xa cleavage site
Figure 3.11 The cloning site of the pMALc2x vector
The position of the upstream malE gene encoding E. coli maltose binding protein is 
shown. Amino acids of the Factor Xa recognition site are shown in bold text and the 
Factor Xa cleavage site highlighted. Unique restriction sites are indicated. The pjfabF 
gene was cloned into the vector using a proximal EcoR I restriction site and a distal 
Sal I restriction site. (Waters e t al., 2002).
The first primer, pjfabF MAL F, complemented exactly the same nucleotides of the 
pjfabF gene as the TSRVV F primer (Figure 3.12). The 5’ terminus of this primer 
contained an EcoR I site so that the restriction endonuclease digestion of the PCR 
product was possible. The second primer, pffabF MAL R was complementary to the 
3’ region of the pjfabF gene and contained a Sal I restriction site. Six nucleotides 
were added to the 5’ terminus of each primer to facilitate, if necessary, the efficient 
endonuclease cleavage of the PCR product.
A PCR was performed using the cycling parameters shown in Figure 3.4. The DNA 
polymerase used in this reaction was Taq (Sigma Chemicals Ltd., Poole, Dorset, UK) 
and the purified plasmid DNA of the pGEM-T vector containing the pffabF gene was
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used as the template. A band of the correct size ( 1287bp) was purified from an 
agarose gel and ligated into an empty pGEM-T plasmid at 16°C overnight.
pfFabF  5*-GGTGGTGAA7TCATGTCCACTTCTAGAGTGGTGTGC -3’
MALF_________________________________________________
pfFabF  5 * -GGTGGTGTCG AC ATC ACTTTAC AATTTTTTTGAAAAG
MAL R 3’
Figure 3.12 The position of the oligonucleotide primers in relation to the 
truncated pfFabF gene.
An EcoR I site is shown in italics, a Sal I site is highlighted in bold text and 
underlined nucleotides are complementary to regions of the pfFabF gene.
The ligation mix was used to transform competent DH5a cells and several of the 
resulting colonies were chosen and used to produce purified plasmid DNA. The 
presence of the pffabF gene was detected using a restriction enzyme digest of this 
plasmid DNA with EcoR I and Sal I (results not shown). Subsequent sequence 
chromatograms confirmed the presence of the pjfabF gene and that no mutations had 
been introduced in the re-amplification of this gene.
A restriction endonuclease digested pjfabF fragment was produced from the pGEM-T 
plasmid in an incubation containing EcoR I and Sal I and the resulting band purified 
from an agarose gel. The pMALc2x was prepared under the same conditions, 
followed by treatment with SAP and inactivation of the SAP enzyme. Both the pjfabF 
fragment and the pMALc2x vector now exhibited complementary 5’-3’ overhangs 
that will only allow the insertion of pjfabF in the correct orientation. A ligation
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reaction containing equimolar plasmid and insert DNA was performed under standard 
conditions.
The ligation mix was used to transform DH5a strain E. coli cells and plasmid DNA 
was purified from several colonies. DNA sequencing results of an individual clone 
suggested that the pffabF gene had inserted into the pMALc2x vector in the correct 
orientation and the open reading frame of the complete pffabF gene was present -  this 
plasmid was termed pMAL-pffabF.
3.12 Expression of an MBP-pfFabF fusion protein
In preparation for the production of the protein in E. coli cells, the pMAL-pffabF 
plasmid was transformed into competent BL21 (DE3) Codon + RIL cells (Stratagene, 
Amsterdam, The Netherlands) and plated onto agar plates containing ampicillin and 
chloramphenicol. The resulting colonies were tested for their ability to produce the 
pfFabF protein in small scale inductions containing a final concentration of 0.4mM 
IPTG at 20°C for 16h. Die expected size of the MBP-pfFabF fusion protein is 
82.2kDa and the selected clone showed the largest induction of the pfFabF (fused to 
MBP) protein observed in any experiments to date (Figure 3.13). In addition, a 
significant proportion of the MBP-pfFabF fusion was retained in the soluble fraction 
(Figure 3.13) suggesting that these conditions were suitable for the production of 
pfFabF in a soluble form.
Since it had been shown that the pMAL-pffabF construct was capable of producing 
high levels of pfFabF in a recombinant form, a large scale induction was performed
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Figure 3.13 Time-course for the induction of pMAL-pfFabF in Codon Plus cells 
at 20°C
Samples were removed from the culture before the addition of 0.4mM IPTG at Oh and 
at the indicated timepoint post-induction. The proteins contained in each sample were 
separated by SDS-PAGE and visualised by staining with Coomassie blue.
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under the following conditions. Two 20ml volumes of LB, supplemented with 
ampicillin and chloramphenicol were inoculated with the BL21 (DE3) Codon + RIL 
containing the pMAL-pffabF plasmid and grown overnight at 37°C in a shaking 
incubator (250rpm). The following morning, 5ml of these cultures was used to 
inoculate each of four 2 litre baffle flasks, containing 500ml of pre-warmed LB 
medium with the aforementioned antibiotics. These cultures were placed at 37°C in a 
shaking incubator (250rpm) until the attenuance at 600nm was between 0.6-0.8. At 
this point, the flasks were placed in a water bath at 15°C for lOmin and the induction 
was initiated by the addition of IPTG to a final concentration of 0.4mM. Flasks were 
then placed at 20°C with shaking (250rpm) and, after 16h, the cells were harvested by 
centrifugation (8000 x g, 20min, 4°C). At this stage, cell pellets could be stored at 
-20°C until required, with no adverse effect on the purification of the pfFabF protein. 
The harvested cells were then resuspended in 40ml of Column Buffer (20mM 
Tris-HCl, pH7.4, 200mM NaCl, ImM EDTA). Lysis of the cells was achieved by 
three rounds of freeze/thawing and the intracellular contents disrupted by sonication 
(60% amplitude, 30s).
The soluble fraction of the lysed cells was collected by centrifugation (20,000 x g, 
20min, 4°C) and filter-sterilised to remove any remaining intact cells. In an attempt to 
reduce the amount of proteolysis, Protease Inhibitor Cocktail (Sigma Chemicals Ltd., 
Poole, Dorset, UK) was added in accordance to the manufacturer’s instructions and 
the sample stored on ice prior to further processing. SDS-PAGE and Western blot 
analysis of this fraction showed the presence of the MBP-pfFabF fusion protein.
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3.13 Purification of the MBP-pfFabF fusion protein
The MBP-pfFabF fusion protein was purified from the myriad of other E. coli 
proteins using affinity chromatography with amylose resin. The MBP binds with high 
affinity to maltose subunits of the amylose chain (Miller et al., 1983) and the protein 
can then be eluted by the addition of maltose to the Column Buffer.
The amylose resin was originally stored in ethanol and was washed several times in 
equal volumes of Column Buffer at 4°C to remove any traces of the alcohol. A 
column containing 4ml of a 50% suspension of the resin was poured and equilibrated 
with at least ten column volumes of Column Buffer. The filtered cell lysate was then 
applied to the column and unbound proteins washed from the resin using Column 
Buffer until the attenuance of the flow through 280nm was <0.01. Proteins that had 
bound to the resin were eluted using 10 column volumes of Column Buffer containing 
lOmM maltose in 1ml fractions. The absorbance of each fraction at 280nm was 
recorded and used as an approximate indication of protein concentration (assuming a 
1 mg/ml solution had an absorbance of about 1.0). Typically, the highest protein 
concentration was observed in the second of these 1ml fractions and a significant 
amount was also observed in fractions 1 and 3-5. Typically, lmg of purified, soluble 
MBP-pfFabF protein suitable for enzymatic studies was produced from each litre of 
culture. When 1ml fractions were collected the majority of the protein was eluted 
across Fractions 2-4, with the highest concentration (generally 1 mg/ml) in Fraction 2. 
The resin was then regenerated and could be used several times for the purification of 
further MBP fusion protein.
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SDS-PAGE analysis of the whole cell lysate, column flow through, washing steps and 
eluted fractions showed that substantial purification of the MBP-pfFabF fusion was 
achieved using affinity chromatography (Figure 3.14). One of the two major 
contaminating bands, corresponded to the expected size of free MBP (42.2kDa), 
whilst the second major contaminating band is slightly smaller than free MBP. 
Western blot analysis performed on these fractions using serum recognising MBP 
(New England BioLabs, Beverly, MA, USA) confirmed the presence of MBP in the 
two major contaminating bands (Figure 3.15). This suggested that the larger band 
corresponds to free MBP and the smaller protein may be a digestion fragment of 
MBP.
3.14 Attempted cleavage of the MBP-pfFabF fusion
The pMALc2x vector encodes a Factor Xa recognition site within the region between 
MBP and the N-terminally fused target protein (Figure 3.11). This protease site 
should facilitate separation of the pfFabF protein, leaving little or no vector encoded 
amino acids attached. Following successful cleavage, it is possible to separate pfFabF 
from free MBP by affinity chromatography on amylose resin, thus removing the 
contaminating band described above (Section 3.13).
A small amount (20pg) of the eluted Fraction 2, which contained the highest 
concentration of the fusion protein, was used in cleavage experiments by incubation 
with 1 pg of Factor Xa. A negative control containing no Factor Xa protease and a 
positive control containing a MBP-paramyosin fusion (New England BioLabs,
Beverly, MA, USA) and Factor Xa were included in all experiments. No apparent
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Figure 3.14 Purification steps for the MBP-FabF fusion protein
The soluble fraction of cells expressing the MBP-pfFabF fusion protein (Lane 1) was 
run through an amylose column and the effluent collected (Lane 2). The column was 
then washed with Column Buffer to remove any unbound protein (Lanes 3-4). 1ml 
fractions were eluted by the addition of lOmM maltose to the Column Buffer (Lanes 
5-7). The proteins contained in each sample were separated by SDS-PAGE and 
visualised by staining with Coomassie blue.
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Figure 3.15 Purification steps of the MBP-FabF fusion protein
The soluble fraction of cells expressing the MBP-pfFabF fusion protein (Lane 1) was 
run through an amylose column and the effluent collected (Lane 2). The column was 
then washed with Column Buffer to remove any unbound protein (Lanes 3-4). 1ml 
fractions were eluted by the addition of lOmM maltose to the Column buffer 
(Lanes 5-7). The proteins contained in each sample were separated by SDS-PAGE 
and transferred onto a nitrocellulose membrane. The western blot was washed and 
developed using anti-MBP serum (New England Biolabs, Beverly, MA) as described 
in Section 2.2.15.
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cleavage of the MBP-pfFabF fusion was observed after an 8h incubation with 
Factor Xa (Figure 3.16, lane 3). However, under the same conditions, approximately 
half of the MBP-paramyosin fusion protein had been separated into its components, 
suggesting that the Factor Xa protease was active.
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1 MBP-pfFabF -  No Factor Xa
2 MBP-paramyosin + Factor Xa
3 MBP-pfFabF + No Factor Xa
Figure 3.16 Incubation of MBP-pfFabF fusion protein with lpg of Factor Xa
MBP-pfFabF (20pg) and MBP-paramyosin (20pg ) were incubated with 1 pig of Factor 
Xa at 25°C for 8 hours. 1 /20th of the proteins contained in each reaction were 
separated by SDS-PAGE and visualised by staining with Coomassie blue.
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Factor Xa requires calcium ions to cleave target proteins efficiently and is supplied 
(New England BioLabs, Beverly, MA, USA) in a buffer containing 2mM CaCL. 
However, the MBP-pfFabF fusion protein was dissolved in elution buffer that 
contains a ImM concentration of the metal chelating agent EDTA. This may lower 
the effective concentration of CaCl2 and, thus, decrease the activity of Factor Xa. 
Therefore, cleavage of the MBP-pfFabF fusion was performed in a buffer 
supplemented with CaCI2 to a final concentration of 3mM, which was thought 
sufficient for complete Factor Xa activity. The amount of Factor Xa was reduced from 
lpg to 200ng, in an attempt to reduce any unspecific cleavage of the fusion protein.
Under these conditions, SDS-PAGE revealed significant cleavage of the MBP-pfFabF 
protein after 4h incubation with Factor Xa (Figure 3.17). However, accumulation of 
proteins of corresponding size to the cleavage products of pfFabF and MBP is not 
observed with time. Bands of a size smaller than those of pfFabF and MBP can be 
seen on the SDS-PAGE gel, suggesting that digestion of pfFabF by Factor Xa may 
occur at non-canonical sites within the protein. Factor Xa recognises specific sites and 
cleaves the natural substrate prothrombin after the protein sequence 
isoleucine-glutamate-glycine-arginine (IEGR) or, in some cases, 
isoleucine-aspartate-glycine-arginine (IDGR). A search of the pfFabF protein showed 
no sequences with obvious homology to these Factor Xa recognition sites. However, 
proteins can be cleaved at other basic residues depending on the context and several 
sequences containing lysine residues showed homology to Factor Xa recognition sites 
within pfFabF.
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Thus, unfortunately, attempts to separate the pfFabF protein from MBP proved 
unsuccessful. However, even with a large N-terminal extension, the structure of the 
pfFabF protein may be unaffected and the formation of a homodimer with 
ketoacyl-ACP synthase activity could still be feasible. Studies of the enzyme activity 
of the MBP-pfFabF fusion protein are described in Chapter 4.
MBP-pfFabF
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Figure 3.17 Incubation of MBP-pfFabF fusion protein with 200ng of Factor Xa 
and 3mM CaCh
MBP-pfFabF was incubated with 200ng of Factor Xa at 25°C with 3mM CaCL added 
to each reaction, at the times indicated above. The proteins contained in each sample 
were separated by SDS-PAGE and visualised by staining with Coomassie blue.
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3.15 Discussion
The work presented in this chapter describes the identification of a gene encoding a 
condensing enzyme (pfFabF) from the malaria parasite, Plasmodium falciparum. In 
addition, it outlines the first reported cloning, expression and purification of soluble 
pfFabF in a recombinant form. In P. falciparum malaria and other organisms, this 
enzyme is believed to be the main target of the natural antibiotic thiolactomycin and, 
thus, it is advantageous to be able to study the purified, soluble protein. Studies of the 
activity of pfFabF and the inhibitory activity towards this enzyme are described in 
Chapter 4.
The pffabF gene, identified in this chapter, encodes a protein the sequence of which 
aligns with the complete amino acid sequences of mature FabF and FabB proteins 
from bacteria and plants (Figure 3.1). This region is sufficient for condensing enzyme 
activity in the FabB and FabF enzymes isolated from many organisms.
The pffabF gene identified in this project does not encode an initiator methionine 
residue or an N-terminal bipartite signal sequence that would target the protein to the 
apicoplast (the expected location of the Type II FAS pathway and pfFabF). Currently, 
the Plasmodium genome database (www.plasmodb.org) suggests two potential 
N-terminal sequences upstream of the region that encodes the mature protein, which 
starts with a TSRVV sequence (shown in bold).
These are;
MNIRCRKEKKKKKKKNINHVNSKRYAFIKRGIPGISKNYFKGFKLYNSREMK 
NLCETSR W . .. .mature protein 
or
MNIKTSRW....mature protein
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Both of these sequences start with an initiator methionine, usually required for 
successful translation of mRNA to produce proteins. The initiator methionine 
(encoded by the same ATG codon in both predictions) is 380 bases upstream of the 
mature protein sequence, on chromosome 6 of P. falciparum. However, neither of 
these N-terminal peptides would lead us to predict that the protein would be targeted 
to the apicoplast. The composition of these upstream regions does not resemble the 
characteristic bipartite signal sequence utilised for apicoplast targeting, that consists 
of a hydrophobic signal peptide followed by a positively charged target peptide. In 
both cases no obvious hydrophobic signal sequence is observed although in the larger 
peptide a positively charged region enriched with lysine and asparagine is present 
following a long stretch of lysine residues. Based on the presence of an N-terminal 
bipartite sequence, the PATS program (Zuegge et al., 2001) is trained to differentiate 
between parasite proteins localised to the apicoplast and those that are localised 
elsewhere. Both of the N-terminal extensions published on PlasmoDB returned very 
low (0.023 and 0.025, respectively) readings, suggesting that neither would be 
sufficient for targeting of pfFabF to the apicoplast. Within this project, searches using 
a range of techniques were unsuccessful in identifying an N-terminal bipartite 
sequence of pfFabF.
The lack of success, by any group, to identify a 5’ region of the pffabF gene is 
surprising. In this work, all of the searches used the ring stage cDNA library. Because 
the cDNA library is derived from mRNA sequences and contains at least one copy of 
the pffabF gene, identification of the 5’ region should have been as simple as using 
the gene specific TSRVV R primer and an upstream vector primer in a PCR. The 
cDNA library used in this project was originally obtained from (Prof. Steve Walsh,
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Liverpool School Tropical Medicine, UK) but had been used extensively and 
successfully in our laboratory for many years. Unfortunately, the supplying laboratory 
was unable to provide information on the plasmid vector used for cloning the library. 
Although, several common vector specific primers were tested in this work it was not 
possible to amplify fragments with these primers in combination with the gene 
specific TSRW  reverse primer to identify the N-terminus of the pffabF gene. I 
believe that there is a strong chance that pfFabF is targeted to the apicoplast, however, 
at the time of submission of this thesis, no apicoplast targeting sequence had been 
correctly identified.
The N-terminal signal sequence is not required for activity of other enzymes in the 
malaria Type II FAS pathway (Surolia and Surolia, 2001; Waters et al., 2002; Prigge 
et al., 2003; Pillai et a l , 2003; Sharma et al., 2003). In fact, Prigge’s laboratory 
showed that expression of the pfFabH (KAS HI), with the bipartite signal attached, 
produced insoluble protein (Waters et al., 2002). Deletion of the region of pffabH that 
encodes the signal sequence, allowed the expression of soluble protein (Waters et al., 
2002).
The finding that the condensing enzyme identified in this chapter was more closely 
related phylogenetically to FabF proteins than to FabB was not surprising. FabB 
enzymes have so far only been found in Gram-negative enterococciae bacteria and all 
of these organisms also contain a FabA-like dehydratase. The dehydratase in 
P. falciparum is more closely related to FabZ proteins (Sharma et al., 2003) and, 
therefore, it is highly unlikely that P. falciparum contains a FabB homologue.
However, the designation of this gene should help to avoid any confusion in the study
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of this gene and its product. Following the completion of the P. falciparum genome 
project in 2002, a search for FabB, FabF and Type I FAS ketoacyl synthase domains 
was undertaken. No new candidate ketoacyl synthases were, or have since been, 
identified during the course of this work.
The pffabF gene encodes a protein that has significant identity (46% to B. subtilis 
FabF, 39% to E. coli FabF and 31 % to E. coli FabB) to the P-ketoacyl-ACP synthase 
family (Figure 3.1). The catalytic triad of Cysl63/His298/His333 (E. coli FabB 
numbering) is present as Cysl65/His306/His343 and a highly conserved lysine 
residue (K328 - E. coli FabB numbering) that is essential for the correct positioning of 
His333 within the active site, is also conserved in pfFabF (K338).
The single base polymorphism in the pffabF gene identified during this work 
introduces a R114S mutation. An alignment of FabB and FabF proteins (Figure 3.1) 
showed that this residue was not conserved with the FabB/FabF family. Comparison 
of the structures of FabB and FabF proteins places the residues corresponding to R114 
within the Na 1.1 alpha helix (nomenclature from Olsen et al., 1999) (Figure 3.18), a 
long loop that is close to the dimer interface. Q 113 {E. coli FabB numbering) is 
conserved in some FabB enzymes and appears to be the single residue of interest in 
this region (Olsen et al., 1999). It is thought that the active site stretches from C l63 to 
Q113, a distant of 16A, which could reasonably hold the acyl substrates used by FabB 
enzymes. Q113 is not conserved in FabF-like enzymes (Figure 3.1) and the 
contribution of the R114 residue (FI 12 in E. coli FabB) has not been determined. 
However, the large number of different amino acids (E, D, K, R, H, L, S, T and G)
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Figure 3.18 Secondary structure elements in E. coli FabF aligned with pfFabF
Active site residues are marked with asterisks. Highly conserved individual residues within 
the whole of the FabB/FabF family are highlighted in black. Groups of similar amino acids 
conserved within the whole of the FabB/FabF family are highlighted in grey 
(DE/HKF/TVLM/AGS/WFYH/ST). a  helixes are shown by horizontal tubes and P sheets are 
shown by block arrows. The R114S alteration caused by a polymorphism is highlighted 
against a background of blue. Based on secondary structure elements first published in Olsen 
etal., 1999.
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found at this position, suggest that this residue has no central role to the condensing 
enzyme activity or substrate specificity of these enzymes.
The alignment of FabB and FabF proteins shows a region of identity close to the 
C-terminus (residues 387-395, E. coli FabB numbering). The structure of 
thiolactomycin (TLM) bound to E. coli FabB showed that the highly conserved F390 
of this region forms a hydrophobic pocket with P272 that is occupied by the CIO 
methyl group of thiolactomycin (Figures 1.17 and 1.18). The pfFabF protein has a 
leucine in the equivalent position to E. coli FabB F390, as does the pfFabF enzyme of 
B. subtil is (Figure 3.1), an enzyme which is highly resistant to TLM 
(Jackowski et al., 2002). However, Jackowski and colleagues (Jackowski et al., 2002) 
showed that the F390V mutants were resistant to TLM due to steric hindrance 
between the valine side chain and the CIO methyl group of TLM. However, this steric 
clash was absent in F390L mutants and was not sufficient for inducing TLM 
resistance. This suggests that whilst the pfFabF enzyme replaces the highly conserved 
F390 with a leucine residue, it should still be sensitive to TLM. This hypothesis will 
be tested in the following chapter.
Even though the pffabF gene was represented in the cDNA library, it was extremely 
difficult to amplify the gene as a single fragment. The most likely reason for this 
problem was the A/T richness of the gene. Despite the gene being identified by 
several groups and the current focus on malaria fatty acid synthesis as a potential drug 
target no other research group has reported the cloning of the gene encoding this 
protein. It is thought that this may be due to the inherent problems in cloning this 
gene.
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To overcome the lack of over-expression and the lack of soluble protein, two practical 
solutions were employed. The first was to transform the expression vector in to BL21 
(DE3) Codon + (RIL) cells, which successfully overcame the lack of overexpression 
observed in other E. coli cells. Secondly, following discussions with Dr Sean Prigge 
(Johns Hopkins School of Public Health, Baltimore, USA) regarding production of 
another P. falciparum KAS enzyme, the pffabF gene was cloned into the pMALc2x 
vector, which, when expressed, added maltose binding protein to the N-terminus of 
mature region of pfFabF. This procedure helped to increase the amount of soluble 
protein, although a majority remained insoluble under various conditions. The maltose 
binding protein (MBP) system also allowed the efficient purification of the pfFabF 
from E. coli cellular proteins, with the only contaminating bands are free MBP or 
fragments produced by the breakdown of MBP.
The lack of success in cleaving the MBP from the N-terminus of pfFabF is 
disappointing. The FabD enzyme of malaria Type II FAS was also expressed as a 
MBP fusion. This enzyme could also not be efficiently cleaved from MBP but 
retained significant malonyl CoA:ACP transacylase activity in vitro (Prigge et al., 
2003). This indicates that it is possible that the MBP-pfFabF fusion may also retain 
enzyme activity. If there was time to repeat the cloning of pfFabF into an expression 
vector it would be advisable to express pfFabF as a fusion with MBP, but it would be 
advantageous to choose a highly specific protease site, such as enterokinase 
(pMALc2e plasmid, New England Biolabs, Beverly, MA, USA) or tobacco etch virus 
protease (Prigge et al., 2003) between the two proteins in the hope of achieving 
complete cleavage of the fusion protein.
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Chapter 4
Substrate Specificity and Characterisation of MBP-pfFabF
4.1 Initial studies of MBP-pfFabF Activity
A candidate gene encoding a putative FabF protein from P. falciparum was identified, 
cloned and expressed in an E. coli expression system as described in Chapter 3. The 
protein was produced with the 42kDa maltose binding protein (MBP) fused at the 
pfFabF N-terminus in an attempt to increase the solubility and as an aid to purify the 
protein. Attempts to remove the MBP by cleavage at an integral Factor Xa site located 
between the MBP and MBP-pfFabF domains were unsuccessful (Section 3.13) and 
the protein remained connected to MBP. For clarity and consistency, the pfFabF 
fusion protein with MBP is referred to as MBP-pfFabF throughout this Chapter.
FabB and/or FabF condensing enzymes of Type II FAS found in bacteria form 
homodimers that are essential for enzyme activity (Garwin et al.y 1980; Edwards et 
al.y 1997; Olsen et al.y 1999; Huang et al.y 1998; Moche et al.y 2001) and it may be 
assumed that the homologous enzyme from P. falciparum will also function as an 
active dimer. However, the presence of a large protein at the N-terminus of 
MBP-pfFabF may interfere with the formation of a homodimer or occlude the active 
site, leading to abrogation of activity. To test whether the enzyme was capable of 
performing the condensation reaction of fatty acid biosynthesis it was important to 
chose substrates that are utilised by a wide range Type II FAS p-ketoacyl-ACP 
synthases. Generally, in bacteria and plant plastids, palmitate (C l6:0) is the primary 
saturated fatty acid produced by de novo synthesis Table 1.2. Palmitate is synthesised 
by the Claisen-condensation of malonyl-ACP with myristoyl-ACP (C14:0), a reaction 
catalysed in E. coli by both FabB and FabF enzymes. Therefore, in initial studies of
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the P. falciparum KAS it seemed sensible to investigate enzyme activity in an assay 
independent of whether the enzyme showed FabB-or FabF-like substrate specificity 
i.e. an assay containing myristoyl-ACP as the acyl-ACP substrate and malonyl-ACP 
as the donor unit.
To determine if the purified MBP-pfFabF retained any KAS activity, an assay 
containing a large amount (lpg) of the MBP-pfFabF fusion was performed as 
described in Section 2.2.24. As a positive control for the substrates and conditions 
used in the assays, E. coli FabB (ecFabB) was kindly provided by the laboratory of 
Charles Rock (St. Jude Children’s Research Hospital, Memphis). A significantly 
smaller amount of ecFabB (6.25ng), compared to MBP-pfFabF (1 pg), was used in the 
assay because of its known activity under identical assay conditions. For the assay,
14C labelled malonyl-ACP (Section 2.2.24) was generated by transacylation of 
[2-14C]-malonyl-CoA to E. coli ACP (ecACP) catalysed by the E. coli FabD protein 
(ecFabD) (purified in Section 2.2.26). The radiolabelled malonyl-ACP is then able to 
donate a two carbon unit to an acyl-ACP substrate (myristoyl-ACP) to form a 
ketoacyl-ACP (Figures 1.12 & 1.13). In the assay, the ketoacyl group is then released 
from the phosphopantetheine arm of ACP by the reduction of the sulphydryl bond by 
sodium borohydride and tetrahydrofuran (Section 2.2.24). The resulting radiolabelled 
fatty acids were extracted in toluene, added to scintillation solution and the 
incorporation quantified by radioactive counting.
The results of the first assay of MBP-pfFabF activity are shown in Figure 4.1. The 
pfFabF enzyme catalysed the condensation of a large amount of [2-14C]-malonyl-ACP 
with the myristoyl-ACP substrate, suggesting that the MBP-pfFabF fusion protein
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exhibited a reasonable p-ketoacyl-ACP synthase activity. It must be noted that, 
although more radioactive products were observed in the MBP-pfFabF assay 
compared to that of ecFabB, there was over 100-fold more MBP-pfFabF protein than 
ecFabB in the assay. These data also suggested that myristoyl-ACP is a suitable 
acyl-ACP substrate of MBP-pfFabF that could be used for further assays.
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Figure 4.1 The ability of pfFabF to extend myristoyl-ACP
The incorporation of radiolabelled malonyl-ACP with ecFabB (■  ) and pfFabF( □ ) 
Each assay was performed in duplicate and errors are shown as the range of results 
from the mean. Assays contained 6.25ng of ecFabB and lpg of pfFabF and the 
activities were measured using a radiochemical assay as described in Section 2.2.24.
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Having established the activity of MBP-pfFabF it was important to store the enzyme 
in such a way as to retain as much activity for as long as possible. A comparison 
between the activity of; an aliquot of purified MBP-pfFabF that had been stored at 
4°C for 30 days, MBP-pfFabF stored as solution in 50% glycerol at -20°C for 30 days 
and a sample of freshly prepared MBP-pfFabF was performed (Figure 4.2). When 
stored at -20°C in 50% glycerol for 30 days, greater than 90% activity was retained. 
However, storage at 4°C with no glycerol led to a loss of almost all of the condensing 
enzyme activity (2.6% remained) after 30 days. Using this knowledge, each time a 
fresh batch of MBP-pfFabF was purified, sterile glycerol was immediately added to a 
final concentration of 50% and the enzyme was stored at -20°C until required for 
further use.
Fresh pfFabF -20°C pfFabF 4°C pfFabF
Figure 4.2 Effects of storage on MBP-pfFabF activity
The percentage remaining activity of freshly prepared MBP-pfFabF (□), 
MBP-pfFabF stored at -20°C for 30 days in 50% glycerol ( V or stored at 4°C for 30 
days (■ ). Assays were performed in duplicate and errors are shown as the range of 
results from the mean. Each assay contained lpg of the different pfFabF preparations 
and the activities were measured using a radiochemical assay as described in Section 
2.2.24.
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4.2 Refining the conditions of the MBP-pfFabF Assay
In Section 4.2 it was ascertained that the MBP-pfFabF fusion protein was capable of 
catalysing the condensing step in fatty acid biosynthesis. In order to perform studies 
of the acyl-ACP substrate specificity for MBP-pfFabF it was important to examine 
some basic assay conditions. The following experiment was to determine the linearity 
of the reaction with protein. This would also determine if the amounts of the 
substrates, malonyl-ACP or acyl-ACP, are limiting the amount of radiolabel 
incorporation. The activity of the MBP-pfFabF protein was tested at concentrations 
ranging from lpg to 4.1ng whilst the concentrations of myristoyl-ACP (50pM), 
[2-14C] malonyl-CoA (50pM), ACP (lOOpM) and ecFabD (lpg) remained constant. A 
500ng/pl stock of MBP-pfFabF in 50% glycerol was mixed with lOOmM 
Na-Phosphate buffer, pH6.8 containing 50% glycerol, to produce 1 in 3 serial 
dilutions of the MBP-pfFabF protein. The radioactivity incorporated into 
myristoyl-ACP was plotted against the protein concentrations of MBP-pfFabF 
(Figure 4.3) and the points were joined to elucidate if the reaction was still in the 
linear phase. The graph shows a straight line, rising at approximately 45° above the x 
axis suggesting that the amount of radiolabel incorporated into the fatty acids is 
dependent solely on the amount of MBP-pfFabF in the assay. Even in assays 
containing lpg of MBP-pfFabF, the substrates were in abundance and did not impose 
any limit on the rate of the reaction. Therefore, there was confidence in using 
MBP-pfFabF within the range (4.1ng-lpg) in further assays. All subsequent assays 
contained 300ng of MBP-pfFabF protein as this amount was well within the linear 
phase of the reaction and was the lowest concentration (to conserve stocks of 
MBP-pfFabF) that incorporated enough radioactivity to produce a signal to 
background ratio adequate for accurate inhibition studies.
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Figure 43  The amount of radiolabel observed in the acyl-ACP product with 
different amounts of pfFabF
Each assay was performed in duplicate and errors bars show the range of results from 
the mean. The activity of pfFabF was measured using the radiochemical assay as 
described in Section 2.2.24.
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43  Acyl-ACP Substrate Specificity of MBP-pfFabF
Studies of the substrate specificity of MBP-pfFabF help to elucidate the biological 
function of the enzyme and improve the understanding of the fatty acid biosynthesis 
pathway in P. falciparum. FabF-like enzymes are able to use saturated acyl-ACP 
substrates C4-C14 in length and show an overlapping acyl-ACP substrate specificity 
with FabB enzymes, which show a lower activity towards C14:0 acyl-ACP (Edwards 
et al., 1997). Acyl-ACPs were produced as described in Section 2.2.21.
Unfortunately, within the time constraints of the project, only C14:0-, C16:0-and 
C l8:0-ACP substrates were synthesised in time to be used in assays with the 
MBP-pfFabF protein (described in Section 2.2.24). The Mycobacterium tuberculosis 
protein (mtKasA -  kindly provided by Charles Rock, St. Jude Children’s Research 
Hospital, Memphis) was chosen as a positive control because it exhibits KAS activity 
across the range of acyl-ACPs tested (Kremer et al,. 2002).
The results (Figure 4.4) indicate that of the three acyl-ACP substrates tested, 
MBP-pfFabF had a much higher activity with myristoyl-ACP (Cl4) compared to the 
palmitoyl-ACP (Cl6 ) and stearoyl-ACP (C l8 ) equivalents. Activity with 
palmitoyl-ACP and stearoyl-ACP was only 6 % and 3% respectively, compared to that 
observed with myristoyl-ACP. This suggested that the longest saturated fatty acid 
produced in significant amounts in P. falciparum in vivo would be palmitate (16:0). 
However, these results also show that the enzyme is capable of elongating C16:0-and 
C l8:0-ACP substrates, if they are available in sufficient quantities to compete with 
C 14:0-ACP.
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Figure 4.4 The acyl-ACP substrate specificity of MBP-pfFabF
The radioactivity of acyl-ACP products using mtKasA and myristoyl-ACP 
(14:0-ACP)(m), palmitoyl-ACP (16:0-ACP) (■) and stearoyl-ACP (18:0-ACP) ( 4) 
or MBP-pfFabF and myristoyl-ACP (14:0-ACP) (□), palmitoyl-ACP (16:0-ACP) (■  
and 18:0-ACP (gj) as the acyl-ACP substrates. The amounts of mtKasA and 
MBP-pfFabF used in each assay were 150ng and 300ng respectively. The activity of 
both mtKasA and pfFabF were measured using the radiochemical assay as described 
in Section 2.2.24.
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4.4 Thiolactomycin Sensitivity of MBP-pfFabF
4.4.1 A general investigation of MBP-pfFabF sensitivity to Thiolactomycin
Thiolactomycin (TLM) is a thiolactone that is a specific inhibitor of Type II 
p-ketoacyl-ACP synthases and was originally isolated from the soil fungus Nocardia 
species 2-200 (Oishi et al., 1982; Sasaki et al., 1982; Noto et al., 1982; Miyakawa et 
al., 1982). In E. coli, all three KAS enzymes are inhibited by TLM with FabF 
exhibiting the highest sensitivity (IC50 6 pM), FabB is less sensitive (IC50 25 pM) and 
FabH minimally so (IC50 1 lOpM) (Price et al., 2001).
Assays that contained 50pM of TLM, a concentration that inhibits over 50% of E. coli 
FabF and FabB activity were prepared to see if the MBP-pfFabF enzyme was highly 
or minimally sensitive to TLM. In these assays, naturally produced TLM (the 
(5R) enantiomer only) purified from cultures of the Nocardia fungus was kindly 
provided by Charles Rock (St. Jude Children’s Research Hospital, Memphis) and 
ecFabB was used as a positive control for the inhibitory activity of TLM. The results 
(Figure 4.5) indicate that MBP-pfFabF is highly sensitive to TLM, as only 6.4% of 
activity remained when the assay was performed in the presence of 50pM TLM 
compared to the control containing no TLM. The MBP-pfFabF enzyme also appeared 
to be slightly more sensitive than ecFabB (9.7% activity remained) considering the 
amounts of enzymes present. The nature of the sensitivity of MBP-pfFabF to TLM is 
similar to bacterial FabF and FabB enzymes and unlike the low sensitivity observed 
with plant and bacterial FabH proteins (Price et al., 2001, Jones et al., 2000 and 2003, 
Prigge et al., 2003).
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Figure 4.5 Inhibition of ecFabB and MBP-pfFabF with 50pM thiolactomycin
The incorporation of radiolabelled malonyl-ACP with no TLM ecFabB ( □ )  and 
MBP-pfFabF(B) and in the presence of 50pM TLM, ecFabB (□) and MBP-pfFabF 
(□). Each assay was performed in duplicate and errors are shown the range of results 
from mean. Assays contained either 6.25ng of ecFabB or lpg of MBP-pfFabF and the 
activity was measured using the radiochemical assay as described in Section 2.2.24.
4.4.2 Determination of the IC50 of TLM against MBP-pfFabF
In order to get a more accurate estimation of the sensitivity of MBP-pfFabF to TLM, 
assays containing variable concentrations of TLM were performed. Briefly, a 2mM 
stock of TLM was serially diluted in 40% DMSO to produce ImM, 500pM, 200pM, 
lOOpM, 50pM and 25pM stock solutions. When 2pl of each solution was added to the 
total assay volume of 40pl, the final TLM concentrations lay between 
100pM-1.25pM. Assays containing no TLM (but with 2% DMSO) were used to
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estimate the uninhibited activity. The final concentration of DMSO in all the assays 
was 2% and this solvent had a negligible effect on the enzyme activity (results not 
shown). The results (Figure 4.6) suggest that the concentration of TLM that caused 
50% inhibition of MBP-pfFabF activity (IC50) is between 3-3.5pM.
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Figure 4.6 IC50 determination of TLM against MBP-pfFabF
Each assay was performed in duplicate and errors are shown as the range of results 
from the mean. Assays contained 300ng of MBP-pfFabF and the activity was 
measured using the radiochemical assay as described in Section 2.2.24.
These data indicate that the P. falciparum long chain P-ketoacyl-ACP synthase is 
inhibited by thiolactomycin and its sensitivity was comparable to that of E. coli FabF 
(IC50 = 6pM) (Price et al., 2001), which indicate that it may be a FabF-like enzyme.
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4.5 Complementation of an E. coli fa b f knockout with MBP-pfFabF
In order to determine if the P. falciparum long chain condensing enzyme was a 
FabF-like enzyme, complementation studies were performed using FabF knockouts of 
the E. coli strain MG 1655. The Blattner laboratory (Wisconsin University) produces 
clones of this E. coli strain containing knockouts of all non-essential genes (Kang 
et al.y 2004). Loss of the FabF gene was successfully achieved by the insertion of a 
kanamycin cassette on the chromosomal DNA of the bacteria (Kang et al.y 2004). The 
wildtype MG 1655 strain and the fabF  knockout were both obtained from the Blattner 
research laboratory.
The wildtype MG 1655 strain contained the complete array of fatty acid biosynthesis 
genes and, therefore, should produce significant amounts of palmitic acid (16:0), 
palmitoleic acid {cis A9 16:1) and c/s-vaccenic acid (cis A ll 18:1). However, due to 
the absence of the FabF protein, the fabF  knockout should contain a smaller ratio of 
cis-vaccenic acid to palmitoleic acid, when compared to the wildtype strain. The aim 
of this study was to determine if the pMAL-pjfabF expression plasmid could increase 
the amount of cis A11 18:1 (c/s-vaccenic acid) incorporated into membrane lipids of 
the fabF knockout strain.
Competent MG 1655 fabF knockout cells were produced as described in Section 2.2.9. 
These cells were transformed with the pMAL-pjfabF plasmid as described in 
Section 2.2.10 and plated onto LB agar containing kanamycin and ampicillin. At the 
same time MG 1655 wildtype and fabF  knockout strains were streaked on to agar 
plates containing no antibiotics and kanamycin, respectively. The three agar plates 
containing the wildtype, fabF  knockout and fabF  knockout containing pMAL-pjfabF,
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were incubated at 37°C overnight. Single colonies from each of the three bacterial 
strains were used to inoculate 10ml each of M9 minimal medium (Section 2.1.3) 
containing the appropriate antibiotics. These cultures were grown overnight at 37°C 
in a shaking incubator and, the following morning, 500pl used to inoculate 10ml of 
freshly prepared M9 minimal medium. All of the cultures were grown at 37°C in a 
shaking incubator until the fabF  knockout cells containing the pMAL-pjfabF plasmid 
reached an D6oo of 0.4 before expression of pMAL-pjfabF was induced by the 
addition of IPTG to a final concentration of 0.4mM. As a control, 0.4mM IPTG was 
also added to the wildtype and fabF  knockout strains. In an attempt to improve the 
expression of the MBP-pfFabF fusion protein, all of the cultures were placed in a 
shaking incubator at 20°C (Section 3.12). After the cultures had been incubated at 
20°C for 24h, the D6oo of each culture was determined. The cells were harvested and 
the membrane lipids extracted and analysed as described in Section 2.2.28. The major 
fatty acids extracted from the membrane lipids of each culture are shown in Table 4.1.
The percentages of cis A9 16:1 and cis A ll 18:1 fatty acids, described in Tables 4.1 
and 4.2, incorporated the proportions of cis-9, 10-methylene hexadecanoic acid and 
cis-11, 12-methylene octadecanoic acid (lactobacillic acid), respectively. These two 
cyclopropane fatty acids are synthesised directly from cis A9 16:1 and cis A11 18:1 
via modification of the cis bond (For a review see Grogan and Cronan, 1997). They 
appear to be essential the survival of some bacteria species if a sudden drop in pH 
occurs and accumulate in bacteria cultures that reach stationary phase (Chang and 
Cronan, 1999).
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Strain Palmitate 
(16:0) (%)
Palmitoleate® 
(16:1) (%)
ds-vaccenateb (18:1) 
(%)
Wildtype 40.9 28.6 26.8
fabF  knockout 42.2 48.9 4.8
fabF knockout 
pMAL-pfFabF
40.0 49.6 7.0*
Table 4.1 The fatty acid composition of MG1655 strains grown in M9 medium 
cell membranes
Percentages are shown as the proportion of the total extracted fatty acids from 
cultures of these cells grown for 24h at 20°C in M9 minimal medium. a The 
percentage for palmitoleate incorporates the proportion of cis-9, 10-methylene 
hexadecanoic acid, the cyclopropane derivative of this unsaturated fatty acid. b The 
percentage of cw-vaccenate incorporates the proportion of cis-11, 12-methylene 
octadecanoic acid, the cyclopropane derivative of this unsaturated fatty acid.
* Statistically significant when using in a two-tailed T-test with a t value = 0.0239. 
Small amounts of myristate (14:0) and stearate (18:0) were also observed in the 
membrane lipids. An example of an annotated GC trace of wildtype E. coli is given in 
Appendix 5.
The proportion of palmitate within the fatty acids extracted from the membrane lipids 
of each strain was relatively constant. However, as expected the proportion of the 
unsaturated fatty acids and their cyclopropane derivatives differed significantly 
between the wildtype and both of the fabF  knockout strains. A large reduction in the 
amount of ds-vaccenate and an increase in the proportion of palmitoleate was 
observed between the wildtype and fabF  knockout strains. It appeared that some 
complementation of the fabF  knockout had been achieved in the cells containing the 
pMAl^pjfabF plasmid. The average amounts of ds-vaccenate observed in these
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different samples (n=3) may appear to be similar. However, when the percentages 
were normalised, a two-tailed T-test suggested that there is a 97% confidence that the 
differences in the data sets did not arise by chance. Complete complementation of the 
fatty acid composition was not achieved, because a large difference between the 
amounts of 16:1 and 18:1 fatty acids in the wildtype and fabF  knockout 
pMAL-pjfabF strains was evident.
The rather modest increase in cis-vaccenic acid may be due to the low level of 
expression of MBP-pfFabF in the MG1655 fabF  knockout strain, which is not 
optimised for protein expression studies. Furthermore, changes in the membrane fatty 
acid composition in E. coli are modulated by incorporation of de novo fatty acids into 
new membrane lipids, rather than alteration of fatty acids already attached to the 
membrane (Cronan, 2002). Between the time that pMAL-pfFabF expression was 
induced and the harvesting of the cultures, the fabF  knockout pMAL-pfFabF cells had 
gone through approximately two cell divisions. This may limit the amount of 
cw-vaccenate introduced into cell membrane lipids.
The experiments described above were then repeated in LB medium instead of M9 
minimal medium. In LB medium, bacteria often display accelerated growth thus 
allowing more cell divisions to occur in shorter space of time. In these experiments 
IPTG was added to a final concentration of ImM when the cultures were at an 
D600 = 0.2. The cultures were placed at 20°C in a shaking incubator for 24h before the 
cells were harvested, the lipids extracted and fatty acid methyl esters (FAMEs)
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analysed as described in Section 2.2.28. The proportions of fatty acids in the bacterial 
lipids are described in Table 4.2.
Strain Palmitate 
(16:0) (%)
Palmitoleate8 
(16:1) (%)
Cw-vaccenateb (18:1) 
(%)
Wildtype 39.4 30.0 25.6
fabF knockout 39.2 52.3 3.0
fabF knockout 
pMAL-pffabF
37.3 50.2 8.3*
Table 4.2 The fatty acid composition of MG1655 strain grown in LB medium cell 
membranes
Percentages are shown as the proportion of the total extracted fatty acids from 
cultures of these cells grown for 24h at 20°C in LB medium.a The percentage for 
palmitoleate incorporates the proportion of cis-9, 10-methylene hexadecanoic acid, 
the cyclopropane derivative of this unsaturated fatty acid. b The percentage of 
cw-vaccenate incorporates the proportion of cis-11, 12-methylene octadecanoic acid, 
the cyclopropane derivative of this unsaturated fatty acid. * Statistically significant 
when using in a two-tailed T-test with a t value = 0.0014. Small amounts of myristate 
(14:0) and stearate (18:0) were also observed in the membrane lipids.
The fatty acid composition of the MG1655 cells shown in Table 4.2 showed that 
cultures of the fab F knockout pMAL-pffabF cells contained approximately two and a
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half times the amount of cw-vaccenic acid compared to that seen in fabF  knockout 
cells without the plasmid. These percentages were normalised by dividing by the 
smallest percentage of ris-vaccenate (2.72%) found in a fabF  knockout culture. This 
gave the data shown below in Table 4.3.
Wildtype FabF knockout FabF knockout 
pMAL-pjfabF
Culture 1 10.14 1.25 3.08
Culture 2 8.97 1.00 3.42
Culture 3 9.10 1.07 2.62
Mean 9.40 1.11 3.04
SD 0.52 0.10 0.33
Table 43  The proportions of cw-vaccenate found in cultures of E. coli grown at 
20°C for 20h
A two-tailed t-test was performed using Microsoft Excel to determine if the values in 
the fabF  knockouts were statistically different from fabF  knockouts containing the 
pMAL-pfFabF plasmid. * The average proportion of cis-vaccenate is statistically 
different from that observed for fabF  knockouts, t value = 0.0014.
The data presented in Table 4.3 suggests that to the 99% confidence level the amount 
of ris-vaccenate in membrane lipids of fab F knockouts containing the pMAL-pffabF 
is significantly higher than the amounts present in fabF  knockouts. The amount of
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cw-vaccenate produced was approximately three times higher in the complemented 
cells compared to the knockouts
SDS-PAGE and Western blot analysis (Sections 2.2.13 and 2.2.15) was performed on 
cultures of the fabF knockout transfected with the pMAL-pffabF plasmid, to assess 
the expression of the MBP-pfFabF fusion protein (Figures 4.7 and 4.8). In the 
SDS-PAGE gel (Figure 4.7) no overexpression of any proteins could be seen. 
However, the Western blot of the same samples (Figure 4.8) using anti-MBP serum 
(New England Biolabs, Beverly, MA, USA) showed two major bands; the first at 
approximately 82kDa, as expected for the MBP-pfFabF protein and the second at 
~ 42kDa corresponding to free MBP.
The Western blot (Figure 4.8, Page 171) showed the presence of other bands, which 
suggested that both the MBP-pfFabF fusion protein and the free MBP had been 
significantly digested in the cell. This is not surprising because, unlike cell lines 
optimised for protein expression, the MG 1655 fabF  knockout cells are not proteinase 
deficient. For instance, ompT, an outer-membrane proteinase cleaves between 
sequential basic amino acids and an analysis of the MBP-pfFabF protein showed that 
it contained four lysine-lysine motifs (Okuno et al., 2002).
The Western blot also showed that only a rather small amount of the MBP-pfFabF 
fusion protein is observed in the soluble fraction. This may be due to the lack of a 
plasmid expressing rare codons (as discussed in Section 3.10) or because the cells 
have not been optimised for protein expression. The expression of the MBP-pfFabF 
protein in a recombinant form in E. coli has proved problematic (Sections 3.9-3.12)
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and the yields of soluble, active protein were low, even when optimised. The 
low-level of MBP-pfFabF expressed in the fabF  knockout cells, is likely to have 
limited the amount of palmitoleate elongated to c/s-vaccenate and this could explain 
why a relatively small rise in c/s-vaccenic acid is seen in these cells. However, the 
rise in cis-\accenate was statistically significant and suggested that, like the FabF 
(KASII) proteins of bacteria and plants, the MBP-pfFabF protein is able to elongate 
palmitoleate to c/s-vaccenate. Combined with the data obtained on the TLM 
sensitivity of this enzyme (Section 4.5), these complementation studies provide the 
first biochemical evidence that the condensing enzyme identified in P. falciparum  is 
most likely to be a FabF enzyme.
M Oh 24h Sol. Insol.
185kD___
83kDa
62kDa 
48kDa
33kDa 
25kDa___
Figure 4.7 SDS-PAGE analysis of E. coli fabF  knockout cells transfected with the 
pMAL-pffabF plasmid
Samples were removed from the culture before the addition of ImM IPTG at Oh and 
at the indicated timepoint post-induction. Samples were prepared as described in 
Section 2.2.12 and 2.2.13. The proteins contained in each sample were separated by 
SDS-PAGE and visualised by staining with Coomassie blue.
■sraS its*  
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M Oh 24h Sol. Insol.
185kDa
83kDa 
62kDa 
48kDa
33kDa 
25kDa
Figure 4.8 Western blot analysis of E. coli fabF  knockout cells transfected with 
the pMAL-pffabF plasmid
M = molecular weight standards. Samples were removed from the culture before the 
addition of ImM IPTG at Oh and at 24h post-induction. Soluble and insoluble 
fractions were prepared from the culture at the 24h post-induction timepoint. Samples 
were prepared as described in Sections 2.2.12-13 and the Western blot performed as 
described previously (Section 2.2.15).
MBP-pfFabF
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4.6 Discussion
The Plasmodium falciparum (3-ketoacyl-ACP synthase, pfFabF, was purified from 
E. coli cells in a recombinant form (Sections 3.11-3.13), as a fusion with maltose 
binding protein at the N-terminus. It was not known if the pfFabF protein would 
retain condensing enzyme activity whilst remaining bound to MBP. Encouragingly, 
Prigge and colleagues had previously reported that the FabD protein of the 
P. falciparum Type II FAS pathway retained activity when it could not be efficiently 
cleaved from MBP (Prigge et al., 2003). In vitro studies presented in this chapter 
show that the MBP-pfFabF protein was capable of performing condensing reactions 
in fatty acid biosynthesis.
FabF proteins have several conserved residues, of which many have an important role 
in forming and maintaining the correct structure. The first of these in the primary 
sequence is a threonine residue, first identified in Synechocystis sp. FabF enzyme 
(Moche et al., 2001), to which Thr7 of the mature pfFabF protein is analogous. This 
residue interacts with the side chain of another highly conserved residue, Glu245 
(Glu247 in the P. falciparum enzyme) and combined, these residues are thought to be 
essential for the structural integrity of the protein (Moche et a l , 2001). Despite the 
closeness of Thr7 to the N-terminus of the mature pfFabF protein, there are 30 amino 
acids between Thr7 and the C-terminus of the maltose binding protein. It appears that 
this distance is sufficient so that MBP does not interfere with the correct folding of 
the pfFabF protein. Furthermore, since the ~42kDa MBP did not appear to affect the 
formation of an assumed pfFabF homodimer. Bacterial KAS enzymes form 
homodimers that are essential for condensing enzyme activity (Garwin et al., 1980; 
Edwards et al., 1997; Olsen et al., 1999; Huang et a l , 1998; Moche et a l , 2001).
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Whether the N-terminally fused MBP affected the specific activity of the enzyme 
cannot be determined. However, the calculated specific activity of the MBP-pfFabF 
protein was 25 +/- 0.48 pmoles/min/pg with C14:0-ACP (myristoyl-ACP) as the 
acyl-ACP substrate. The specific activities of E. coli FabB and FabF enzymes using 
the same C14:0-ACP substrate are reported to be 3pmoles/min/pg and 
7pmoles/min/pg (Edwards et al,. 1997). Therefore, with regards to the C14:0-ACP 
substrate, the MBP-pfFabF protein exhibits a higher specific activity than both of the 
E. coli P-ketoacyl-ACP synthases. Assays of the E. coli FabF enzyme with C6:0, 
C8:0, C10:0, C l2:0 acyl-ACP substrates show that it exhibits a similar specific 
activity towards all of the substrates ranging from 23-26pmoles/min/pg (Edwards et 
al,. 1997). So MBP-pfFabF appears to have a similar specific activity towards 
C14:0-ACP compared to that of ecFabF towards shorter, saturated acyl-ACP 
substrates. The specific activities of the Mycobacterium tuberculosis condensing 
enzymes, KasA and KasB, using C16:0-ACP as the acyl-ACP substrate were 
determined as 96pmol/min/pg and 29pmol/min/pg, respectively (Kremer et al,. 2002; 
Schaeffer et al,. 2001). Therefore, the MBP-pfFabF protein has a specific activity 
when using a C14:0-ACP substrate similar to the reported activities of bacterial Type 
II FAS condensing enzymes with acyl-ACP substrates of varying size.
These results may indicate that the fusion of MBP at the N-terminus of pfFabF does 
not affect the activity, or disrupt correct folding, of the condensing enzyme. 
Re-cloning of the pffabF gene into a vector that encodes an alternative protease site 
between MBP and pfFabF proteins is being considered as further work to this project.
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This may allow separation of the two proteins and allow the determination of the 
specific activity of the purified pfFabF without its N-terminal fused protein.
A limited series of long-chain saturated acyl-ACPs was used to determine the 
substrate specificity of the MBP-pfFabF protein. The protein showed an enzyme 
activity fifteen-fold higher for myristoyl-ACP (C14:0) compared to that for 
palmitoyl-ACP (Cl6:0) and a fifty-fold increase in activity for myristoyl-ACP 
(C14:0) compared to that with the stearoyl-ACP (18:0) substrate. These data may 
indicate that, in vivo, the final product of the saturated fatty acid biosynthesis pathway 
in P. falciparum would be palmitate (C l6:0).
Despite the evidence that palmitate may be the final saturated acyl product of 
Type II FAS, a bimodal distribution of C16 and shorter acyl products cannot be ruled 
out. Recent evidence suggests that the Type II (3-ketoacyl-ACP synthase found in the 
mitochondria of Arabadopsis thalania predominantly produces a bimodal distribution 
of C8 and C14-16 acyl chains (Yasuno et al., 2004). Very little is known about the 
Type II FAS system in mitochondria, although the pathway appears to be conserved 
in a wide range of organisms as homologues of the mitochondrial KAS enzyme of 
Arabadopsis thalania have been found identified in yeast, mammals and plants 
(Figure 3.2) (Yasuno et al., 2004). There is no evidence that the malaria parasite 
contains a second Type II FAS system in its mitochondria. The synthesis of C8 acyl 
chains, a substrate for lipoic acid synthesis, by this enzyme suggests that it plays a 
major role in the synthesis of lipoic acid precursors in the mitochondria of A. thalania. 
Enzymes responsible for lipoic acid synthesis in P. falciparum are targeted to the 
apicoplast (Wrenger and Muller, 2004) and the pyruvate dehydrogenase complex,
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which requires lipoic acid as an essential co-factor, is predicted to be targeted to the 
same organelle (Ralph et al., 2004). Therefore, it seems plausible that the pfFabF 
enzyme may be involved in the synthesis of lipoic acid precursors in the apicoplast. 
To investigate this area further, a collaboration with Charles Rock (St. Jude 
Children’s Hospital, Memphis) has been organised with the aim to synthesise and 
utilise C4-, C6-, C8-, CIO- and C12-ACPs in assays containing MBP-pfFabF. A 
comparison of the relative specific activities of pfFabF with these substrates should 
provide information on the distribution of saturated acyl chains produced by the 
Type II FAS system of P. falciparum.
The ability of the MBP-pfFabF to participate in the synthesis of unsaturated fatty 
acids was also investigated. In Gram-negative enterococciae, the conversion of 
palmitoleic acid (Cl6:1) to cw-vaccenic acid (C l8:1) at low temperatures is catalysed 
by FabF, in contrast the FabB enzyme lacks this activity. Complementation studies of 
an E. coli mutant lacking the fabF  gene showed that at low temperatures the 
MBP-pfFabF protein was also capable of converting palmitoleic acid to cw-vaccenic 
acid, suggesting that the P. falciparum protein has been correctly assigned as a 
FabF-like enzyme. Whilst these experiments were only performed in triplicate a 
two-tailed T-test predicted that there can be over 99% confidence that this increase in 
cw-vaccenate did not arise by chance.
Like plant and bacterial elongating condensing enzymes MBP-pfFabF is sensitive to 
inhibition with the fungal metabolite thiolactomycin. A review of the scientific 
literature suggested that the IC50 of 3-3.5|iM observed with MBP-pfFabF may be the 
lowest reported IC50 value observed for any enzyme inhibited by TLM. This provides
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evidence that pfFabF is a physiologically relevant target of TLM in the malaria 
parasite and reinforces the concept that TLM may be a good lead compound to 
investigate the inhibition of Type II FAS in P. falciparum.
The sensitivity of MBP-pfFabF to TLM can be interpreted in the context of its amino 
acid sequence. The alignment of FabB and FabF proteins shows a region of identity 
close to the C-terminus (residues 387-395, E. coli FabB numbering) (Figure 3.1). The 
structure of thiolactomycin (TLM) bound to E. coli FabB showed that the highly 
conserved F390 of this region forms a hydrophobic pocket with P272 that is occupied 
by the CIO methyl group of thiolactomycin (Figures 1.18 and 1.19) (Price et al., 
2001). Jackowski and colleagues (Jackowski et al., 2002) showed that an ecFabB 
F390V mutant was resistant to TLM due to steric hindrance between the valine side 
chain and the CIO methyl group of TLM. The piFabF protein possesses a F390L 
substitution, as does B. subtilis FabF (Figure 3.1), an enzyme which is highly resistant 
to TLM. These observations may have indicated that pfFabF would be resistant to 
inhibition by TLM. However, this steric clash observed in the F390V mutant is not 
present in F390L proteins and the F390L replacement was not thought to be sufficient 
for inducing TLM resistance (Jackowski et al., 2002). This explains why, despite the 
replacement of the highly conserved F390 with a leucine residue in the pfFabF 
enzyme, it remains sensitive to TLM.
Many of the assays described in this Chapter were only performed in duplicate. These 
assays use quite large quantities of radiolabelled [2-I4C]-malonyl CoA and lowering 
the number of assays reduced the cost and the risk of exposure to the radioactive 
isotope. Furthermore, these assays are very accurate and reproducible in independent
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experiments, with variations from the means consistently less than 5% (Figures 4.1- 
4.6). Therefore, there is confidence that the data obtained from these assays were a 
true reflection of the enzyme activity.
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Chapter 5
The Cloning and Expression of Plasmodium falciparum FabH
5.1 Overview
The P. falciparum FabH protein, also termed (3-ketoacyl-ACP synthase IH (KAS HI), 
is encoded by a 1113 base pair gene located on chromosome 2 of the malaria parasite. 
Chromosome 2 was the first chromosome to be sequenced and annotated from a 
malaria parasite genome and led to the discovery of, FabH and ACP, the first proteins 
indicative of a Type II FAS pathway in P. falciparum (Waller et al., 1998). When 
translated the fabH  gene encodes a protein of 371 amino acids, of which 
approximately the first 49 residues correspond to a bipartite targeting sequence, which 
facilitates transport of FabH to the apicoplast. The FabH enzymes of other organisms 
catalyse the initial condensation reaction of the Type II FAS pathway, but are not 
substantially involved in chain elongation. Isolation of naturally-occurring FabH from 
the parasite apicoplast is not feasible and, like pfFabF (Chapter 3), production of 
pfFabH was attempted using a recombinant system. Cloning of the gene was 
problematic and the strategies undertaken are described in this Chapter. Eventually, 
an N-terminal truncation of pfFabH without the bipartite leader sequence was 
sub-cloned from a full-length version of the gene (kindly provided by Sean Prigge, 
Johns Hopkins School of Public Health, Baltimore, USA). The FabH protein was 
successfully produced in an E. coli expression system identical to that described for 
pfFabF (Chapter 3) and was subsequently purified as a fusion to maltose binding 
protein. pfFabH was shown to catalyse the initial condensation reaction of Type II 
FAS biosynthesis and its sensitivity to thiolactomycin was investigated.
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5.2 Cloning of the P. falciparum fabH  gene
At the start of this project, the sequence of the P. falciparum fabH  gene had 
previously been identified following the annotation of Chromosome 2 (Gardner et al., 
1998, Waller et al., 1998) from the parasite’s genome. The fabH  gene of 
P. falciparum consists of 1116bp intersected by 7 introns and encodes a protein of 
371 amino acids that includes an N-terminal initiator methionine residue and a stop in 
the 3’ region . The predicted protein, termed pfFabH, showed significant sequence 
homology with FabH proteins from bacteria and plants (Figure 5.1). Waller and 
colleagues observed that the pfFabH protein contained a bipartite leader sequence, 
consisting of a signal peptide and transit peptide sequence, both of which are essential 
for successful targeting to the apicoplast (Waller et al., 1998 and 2000). The signal 
and transit peptide sequences are removed by a proteinase targeted to the apicoplast 
(van Dooren et al., 2000; Waller et al., 2000) and the processed protein is sufficient 
for enzyme activity (Waters et al., 2002).
Isolation of naturally occurring pfFabH from the apicoplast organelle was not 
considered a feasible method of yielding a sufficient quantity of protein for kinetic 
characterisation or structural analysis. Therefore, production of pfFabH was attempted 
using a recombinant system in Escherichia coli. In order to express the pfFabH 
protein in a heterologous system, cloning of the pffabH gene was attempted.
Amplification of the pffabH gene was first attempted using the PCR parameters 
described in Figure 5.2. As in the amplification of pffabF, a ring stage P. falciparum 
cDNA library was used as the template. Two forward primers were designed to 
complement regions of the coding strand near the 5’region of the gene.
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A. thalania 
C. wrightii 
P. falciparum 
M. tuberculosis
MANASGFFTH P SIP N L R SR I HVPVRVSGSG FCVSNRFSKR VLCSSVSSVD 50
MANASGFLGS - SVPALRRAT Q PQ H SISSSR GSSSDFVFKR VFCC --SAV Q  4 7
 MFLYFI TYLCIFHNNI YSVELIKNNK YNFINNVHN---------------- IKYR 3 9
        M 1
A. thalania 
C. wrightii 
Synechocystis 
P.falciparum 
E.coli
M. tuberculosis
A.thalania 
C. wrightii 
Synechocystis 
P. falciparum 
E.coli
M. tuberculosis
KDASSSPSQY
GSDRQSLGDS
 M NTLG--
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------------- KTGG
--------------- MYT
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ILKRDENISM LQIDSAT  
IAAPNETVST MGFEgA 
FAADDESAAS MATEBc
lE W P ^ I  WLjVLMCg j P  1 5 0
E T S C L K P S jl | mVIN A S  j p  1 3 1  
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Synechocystis 
P.falciparum 
E.coli
M. tuberculosis
A. thalania 
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Synechocystis 
P.falciparum 
E.coli
M.tuberculosis
A. thalania 
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M.tuberculosis
IFAFV
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GETPFQ
DCHIRG|GFK 1 9 9  
ACHIRGBGFN 1 9 6  
AQFLR1§VYQ 1 3 6  
YNFLN--RYK 1 7 7  
DQYVKSlAVK 1 3 2  
ADMIRG|GAA 1 4 2
DDG-LFSFDV 2 4  8 
EDG-LFAFDL 2 4  5 
QDN-LLAFEM 1 8 3  
EENKIFNYYL 2 2 7  
E P G -IIS T H L  1 7 9  
G IG  PTVA 18  9
NASVKESRNE GESSSNGSVF GDFPPKQSSY SC I  
KAAIKEDEVD KALGSNGSIR -DFPPRRSSY SC I
NLSYQAN- - P  Q PLTA EK TV A-------------QGTY QAI
TINFDHDKYN LDKPN -------------VNKY GKL
TLPNADRVNP E N S IH  ----------------------- •
QADAI RQDIDWITFA QNPSG ----------------- PR 1
KCVPQ SIESALQKAG  
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V R P D Q lS v iy
FPP 3 4 8  
lEVPQ 3 4 4  
G IP S  2 7 5  
IPM 3 1 6  
SM 2 6 2  
LRP 2 7 6
A.thalania ERVISJ -LAN YW
C.wrightii e r i i s B -LAN Y |
Synechocystis e k i i s B -VGE Y |
P.falciparum SKVL’J -LDE YA
E.coli DNVWT -LDR Hg
M. tuberculosis d a w a J d i e h  t|
A.thalania SAIVBW R - -  4 0 4
C.wrightii s a i i B wG - -  4 0 0
Synechocystis A S Iv J w ----- 3 3 0
P. falciparum CVILKY - - -  3 7 1
E.coli s a l v B f ----- 3 1 7
M.tuberculosis a q w J mPKG 3 3 5
DQAVR
TIAT  
AT
K lBEgD LIA L  
KIWTNDIICM
r i h p I q l v l l  EA
•LALL
TWG 3 97  
TWG 3 93  
LTWA 3 2 4  
SYG 3 6 5  
FTWG 3 1 1  
SYA 3 2 6
Figure 5.1 Alignment of P. falciparum  FabH with plant, bacterial and homologues
This alignment was produced using the ClustalW program (Thompson et al., 1994) and formatted using the Chroma program 
(Goodstadt and Ponting, 2001). The GenBank accession numbers were Arabadopsis thalania FabH (P49243); Cuphea wrightii 
(P49244); Synechocystis sp. (P73951); Plasmodium falciparum  (AAC63960); Escherichia coli (P24249);
Mycobacterium tuberculosis (006399). The active site cysteine is marked with a black asterisk. Regulatory site residues are 
shown by red asterisks.
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The first, pffabH FI complements a region of the gene that is immediately 
downstream of the region encoding the signal peptide. The second primer, pffabH F2, 
was complementary to the region of the gene immediately downstream of the 
predicted signal peptide cleavage site. A reverse primer, called pffabH R 1 
(Figure 5.2), was complementary to the non-coding strand of the 3’ region and 
incorporated the naturally occurring stop codon. A PCR containing the pffabH F2 and 
pffabH R 1 primers should amplify a section of the gene that encodes amino acids 
49-371, the mature region of the pfFabH protein (Figure 3.1).
The forward primers contained Bam HI restriction endonuclease sites at the 5’ 
terminus and the reverse primer a Xho I site at the same position. These sites flank 
any full length fragment generated from the PCR and, in subsequent cloning steps, 
should facilitate insertion of the gene in the correct orientation within expression 
vectors. Initial PCRs were performed using a wide range of conditions to amplify 
these sections of the identified pffabH gene. Alterations in annealing temperature, 
MgCl2 concentrations, different types of DNA polymerase, the number of cycles and 
the length of individual cycle steps were unsuccessful in amplifying these regions of 
the gene.
As described previously, in Section 3.3, the P. falciparum genome exhibits a large 
A+T bias (approximately 80%) which may lead to stalling of the DNA polymerase 
and PCR amplification of the gene may be aborted. Within the pffabH gene the 
overall A+T bias was found to be 74.2%, with some regions of the gene comprising 
up to 88% A+T nucleotides. The A+T bias of the pffabH gene, is higher than that of
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A
pffabH FI pffabH F2
r *  r *
pffabH P. falciparum cDNA
t t
Signal peptide End of basic
cleavage site transit peptide
< 2  
pffabH R \
B
pffabH
FI
5 ’ -GGATCCGTAGAATTAATTA AA AATAATAAATATAAT -3’
pffabH
F2
5*-GGATCCGGAGGTAAAATAATAGGAC -3’
pffabH
R1
5*-CTCGAGTTAATATTTAAGTATAACGCATCC -3’
95 °C, 5 minutes
95°C, 1 minute M-
42°C or 56°C, 1 minute 
72°C, 1 minute
30 cycles
72°C, 5 minutes
Figure 5.2. Primers and cycling parameters used in the initial attempt to amplify 
the pffabH gene
A The position of the oligonucleotide primers in relation to the pffabH gene.
B Sequences of the oligonucleotide primers. Bam HI restriction endonuclease sites are 
shown in bold and a Xho I site in italics. Regions complementary to the sequence of 
the pffabH gene are underlined.
C Cycling parameters used in the initial attempt to amplify the pffabH gene.
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the pffabF gene, 70.1% (Section 3.3), which may suggest that the cloning of pffabH 
may be at least as, if not more, problematic than the cloning of pffabF.
53  Adoption of a new cloning strategy
As described in the cloning of the pffabF gene (Sections 3.3 -3.4), in order to improve 
the chances that the DNA polymerase will extend to the end of the target sequence, 
the size of the amplicon was reduced. In the pffabH gene this was achieved by 
designing two primer oligonucleotides that flank a single Pst I site, present at the 
centre of the gene (the cleavage site is after nucleotide 618; Appendix 6). The first of 
these primers, pffabH R2 (Figure 5.3), complemented the non-coding strand in this 
region and was used in conjunction with pffabH F2 (Figure 5.3). The second of these 
primers, pffabH F3, complemented the coding strand around the Pst I site and was 
used in conjunction with pffabH Rl. The two primers surrounding the Pst I site are 
not exact complements of each other (Appendix 6). The pffabH F3 primer was 
designed so that the 3’ end of the primer terminates with a guanine base, to improve 
the annealing efficiency, this meant the pffabH F3 primer one base longer than the 
pffabH R2 primer (Figure 5.3).
These primers were then used in two separate PCRs with the pffabH FI and Rl as 
described above. It was hoped that this technique would generate two fragments that 
can then be assembled to yield a full length gene (Figure 5.3). Unfortunately, 
alterations in annealing temperature, MgCh concentrations, different types of DNA 
polymerase, the number of cycles and the length of individual cycle steps were again 
unsuccessful in amplifying these regions of the gene. The conditions used to
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pffabH FI
t  t
pffabHF2 pffabHF3
r* CP
Pst I
\
Signal peptide End of basic
cleavage site transit peptide
pffabH  R2
P. falciparum 
cDNA
pffabH Rl
B
pffabH F3 5’- GGAGATGCTGCAGGTGCTG -3’
pffabH R2 5’- AGCACCTGCAGCATCTCC -3’
95°C, 5 minutes 
95°C, 1 minute 
42°C or 56°C, 1 minute 
72°C, 1 minute 
72°C, 5 minutes
30 cycles
Figure 5.3. Primers and cycling parameters used in the second attempt to 
amplify the pffabH gene
A The position of the oligonucleotide primers in relation to the pffabH gene. An 
inherent Pst I site at nucleotide 618 is shown. Both the pffabH F3 and pffabH R2 
complement the region around this site on the coding and non-coding strands, 
respectively.
B Sequences of the oligonucleotide primers.
C Cycling parameters used in the initial attempt to amplify the pffabH gene.
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successfully amplify the pffabF gene (Section 3.4 and Figure 3.3) in three overlapping 
fragments were also used but with no success.
5.4 Screening for pffabH by colony hybridisation
As attempts to clone the pffabH gene using PCR amplification were unsuccessful, an 
alternative technique was utilised in an attempt to isolate this gene. Colony screening 
by hybridisation uses the ability of oligonucleotides to anneal and bind to homologous 
sequences to identify individual clones that contain the gene of interest. As described 
in Section 2.2.17, a P. falciparum cDNA library was used to transform competent 
E. coli DH5a cells (Section 2.1.2), which were plated onto eight LB agar plates 
containing ampicillin. This allowed a good distribution of approximately 4000 
colonies across the plates and ensured that each colony retained a plasmid containing 
a cDNA fragment.
Colonies from individual plates were blotted onto nitrocellulose membranes and lysed 
gently. The oligonucleotide primers designed for the PCR amplification of pffabH 
(pffabH FI, F2, F3, Rl and R2) were then labelled with radioactive 32P, using 
[y-32P]-ATP and polynucleotide kinase to phosphoiylate the 3’ termini. The 
radio-labelled oligonucleotide probes were added to the nitrocellulose blots under 
conditions, which allowed them to anneal to the DNA of lysed bacteria colonies 
(Section 2.2.17). Under the correct annealing conditions the probes should only bind 
to DNA sequences that are identical or very similar to themselves. The nitrocellulose 
blots were incubated with radiographic film to allow any colonies that had hybridised 
with the oligonucleotide probes to be identified.
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When the hybridising temperature was at 55°C there were 25 spots across the 8  plates 
where the radiolabel was present. Due to the high number of colonies on each agar 
plate, in some cases several candidate colonies were identified for each radioactive 
spot. All of the identified colonies were used to inoculate 10ml of LB broth 
containing ampicillin. The plasmid DNA from each individual colony was then 
purified (Section 2.2.5) and the DNA sequenced (Section 2.2.9) using M13F and 
M13R primers. Unfortunately, the sequencing reaction with these primers was not 
particularly successful and analysis of the sequence chromatograms that were 
returned, showed that none of the sequences corresponded to the published sequence 
of pffabH mRNA (Genbank™ Accession # AF038929 (Waller et al., 1998); 
PlasmoDB entry PFB0505c). The sequence of all the returned chromatograms was 
determined using a BlastN program (Altschul et a l , 1997) 
(www.ncbi.nlm.nih.gov/BLAST). This identified all of the returned sequences as 
fragments as vector plasmid DNA and suggested that the M13F/R primers were 
present on the plasmid but in an inappropriate position for the sequencing of cDNA 
inserts. Sequencing was performed using the gene specific primers pffabH F2 and 
pffabH Rl. However, the sequence chromatograms showed that all of these 
sequencing reactions were unsuccessful.
The hybridisation step was performed at 60°C, in order to decrease the chance of 
non-specific binding. Fewer colonies were identified at this temperature and these 
colonies were cultured and their plasmid DNA isolated and sequenced, as described 
above. Once more, none of the sequencing chromatograms showed the presence of 
any DNA sequence corresponding to any region of the pffabH gene. Due to the lack
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of success gathered from these sequencing results (and due to the fact that the 
sequence of the vector plasmid remained unknown) it was decided to use a different 
approach to clone the pffabH gene.
5.5 Engineering of pffabH  to include E. coti preferred codons
To overcome the problems in cloning the pffabH gene that have been described 
previously, a new strategy was implemented. This involved the production of the 
pffabH gene using chemically synthesised oligonucleotides that overlap with each 
other along the entire length of the pffabH gene (Prapunwattana et al., 1996; Pan et 
al., 1999). A diagram that showing the strategy of this technique is shown in 
Figure 5.4. Oligonucleotides were designed to alternate between the coding and 
non-coding strand, which would allow them to anneal to each other using homologous 
overlapping regions. The missing regions of the gene could then be filled in by 
priming off the existing oligonucleotides in a PCR (Prapunwattana et al., 1996; Pan et 
al.y 1999).
This technique offers the prospect of engineering novel features into the gene. In 
particular, the expression of pfFabF showed that the differences in codon usage 
between P. falciparum and E. coli can affect overexpression of recombinant proteins 
(Section 3.10). Thus, the pffabH gene was remodelled so that, for each amino acid the 
codon used most commonly (preferred codon) in E. coli was chosen. These changes 
did not alter the translated protein sequence but it was hoped that expression of the 
protein in the E. coli system might be enhanced.
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CODING I 
5 '  - TACAACCACATGAAGTAGTGG
CODING 2 
+GAAGGTGTTGTTGTAGATGA
ATGTTCCTGTACTTCATCACCTACCTGTGCATCTTCCACAACAACATCTACT
TACAAGGACATGAAGTAGTGGATGGACACGTAGAAGGTGTTGTTGTAGATGA
CATCACCTACCTGTGCATCTTC - 5 '  4----------------------------
NON-CODING II
CODING 2 (cont.) 
GAC
CODING 3
—►5'TATGTTGAAGTAGTTGTTGCAAGTGTTG - -  
CTGTTGAACTGATCAAAAAGAAGAATACAACTTCATCAACAACGTTCACAAC 
GACAACTTGACTAGTTTTTCTTCTTATGTTGAAGTAGTTGTTGCAAGTGTTG
CTGGTGAACTGATCAAAAAGAAGAATAC - 5 ' 4----------------------------  CACAAC . . .
NON - CODING 10 NON - CODING 9
B
95°C, 2 minutes
95°C, 2 minutes <<-
60°C, 2 minutes 
70°C, 2 minutes
40 cycles
65°C, 10 minutes
Figure 5.4 The assembly of the pffabH gene with E. coli preferred codons
A. Representation of the recursive PCR used to produced a synthetic version of the 
pfFabH gene. Oligonucleotides are shown in blue text, the black text represents the 
sequence of the pffabH gene with codons replaced for preferred E. coli usage. In the 
PCR reaction only the overlapping oligonucleotides are present. The oligonucleotides 
in this diagram are a representation of those used in the actual synthesis of this gene 
(see Appendix 7). The red arrows represent priming off of the oligonucleotide by 
DNA polymerase.
B. The PCR conditions utilised to produce a full-length version of the pffabH with 
E. coli preferred codons.
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The original codons of the pffabH gene were replaced with E. coli preferred codons 
(Table 5.1) and the new sequence was searched for any restriction endonuclease sites 
generated by this change in sequence. The proposed codon changes would have 
generated a Bam HI site within the gene at position 243. This site was removed 
because Bam HI endonuclease was to be used in the cloning of the pffabH gene into 
expression vectors. This was achieved by altering an ATC codon to ATT, this 
converted the GGATCC sequence of the Bam HI site to GGATTC. Both the original 
ATC and replacement ATT codons encode isoleucine, so the amino acid sequence 
was unaffected. The percentage usage of the ATT codon compared to all isoleucine 
codons is relatively high (33.5%) and should not be detrimental to the effective 
translation of the gene (Table 5.1).
22 overlapping oligonucleotides, with an average length of 72 bases, were designed to 
span the pffabH gene in its entirety (Appendix 7). Overlapping regions of 19-21 
nucleotides were implemented, to ensure that the annealing temperatures (Tm) 
between neighbouring oligonucleotides was within the range (58-62°C). 11 
nucleotides complemented the coding strand and these were given the prefix 
“Coding” and numbered 1-11 from the 5’-3’. A separate group of 11 nucleotides 
complemented the non-coding strand and were given the prefix “Non-coding” and 
numbered 1-11 from the 5’-3’ of this strand. Therefore, the two oligonucleotides that 
complemented the 5’ terminus on both strands are termed “Coding 1” and 
“Non-coding 1”. These oligonucleotides could be used to amplify the complete gene 
once it was fully assembled. In order, to anneal the oligonucleotides and produce a 
double-stranded DNA copy of the gene, a PCR reaction was performed. The PCR was
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Amino
Acid
Codon % use
27.5get
Ala 16.1gee
24.0
32.3
27.5
16.1ege
Arg 24.0cga
32.3
0.6aga
m .
aat
0.3
Asn 17.2
82.8aac
46.0Asp gat
54.0gac
Cys 38.8
61.2
18.6Gin caa
81.4
Glu 73.4
24.6
50.8
Gly 42.8
2.0
4.4m .
catHis 29.8
70.2cac
33.5att
65.9ate
0.6ata
3.4tta
5.5
Leu 5.6ctt
8.0etc
0.8eta
76.7
Amino
Acid
Codon % usea
Lys aaa 78.6
aag 21.4
Met atg 1 0 0 .0
Phe ttt 29.1
ttc 70.9
Pro cct 1 1 .2
ccc 1 .6
cca 15.3
ccg 71.9
Ser
tct 32.4
tcc 26.6
tea 4.8
teg 7.4
agt 4.5
age 24.3
Thr
act 29.1
acc 53.6
aca 4.7
acg 12.7
Trp tgg 1 0 0 .0
Tyr tat 35.2
tac 64.8
Val
gtt 39.8
gtc 13.5
gta 2 0 .0
gtg 26.8
Table 5.1 The use of each codon for individual amino acids in highly expressed 
E. coli proteins
a Percentage usage of the codon relative to all other synonymous codons which code 
for the same amino acid. Table reproduced from Medigue et al., 1991.
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also capable of amplifying the full length gene so cloning of the pffabH gene in to the 
appropriate expression vector could be achieved. In this PCR, the external 
oligonucleotides (Coding 1 and Non-coding 1) would act as primers for the DNA 
polymerase and were, therefore, added in excess compared to the internal 2 0  
oligonucleotides. The reaction mix contained 300nmoles of the external primers and 
30nmoles of each internal primer. Some of the original conditions were altered 
(annealing temperature, MgCk or MgSC>4 concentrations, different types of DNA 
polymerase, the number of cycles and the length of individual cycle steps) but were 
unsuccessful in amplifying the full-length gene. However, when visualised on an 
agarose gel, a faint band of the expected size (~ 1. lkb) of pffabH was observed in 
reactions that contained final concentrations of either lpM BSA and 0.5% Tween 20 
or 5% DMSO and 0.5% Tween 20 (Figure 5.5). Reactions containing 0.5% Tween 20 
without BSA or DMSO did not produce a band of the expected size (data not shown).
As shown in Figure 5.5 the 1. lkb band is within a smeared region of the gel 
suggesting that DNA fragments of many sizes were present. This may be caused by 
the production of many PCR products of different sizes, in which case, the PCR 
conditions needed to be optimised towards the amplification of the target sequence. 
Subsequently, in an attempt to increase the stringency of the annealing step and to 
prevent mis-priming of the synthetic oligonucleotides, the annealing temperature of 
the PCR was raised to 64°C and then 6 8 °C, and separately, the MgSC>4 concentrations 
lowered from its original 8 mM concentration to 5mM and 2mM. Both of these 
alterations decreased the concentration of the 1.1 kb fragment when visualised on an 
agarose gel. Raising and lowering the concentrations of Tween 20, DMSO and BSA 
also did not improve the production of an individual band of the expected size.
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M 1 3 4 5 6 7 8
&
1373
1078'
I
872 603' 
310“
1.1 kb
Lane Sample
1 No additional reagents
2 lpM BSA
3 5% DMSO
4 0.5% Tween 20
5 BSA + DMSO
6 BSA + Tween 20
7 DMSO + Tween 20
8 BSA + DMSO + Tween 20
Figure 5.5 The effect of additions to the PCR mixture on the assembly and 
amplification of pffabH using synthetic oligonucleotides
The PCRs were performed under standard conditions. The annealing temperature was 
60°C. lOpl of a 50pl reaction were run on a 1.5% agarose gel and visualised under 
UV light.
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To be confident that a single band of the correct size could be excised from the 
agarose gel, a second PCR was performed that used the original PCR as template. The 
conditions of the PCR remained the same as described in Figure 5.4, except that in an 
attempt to reduce the number of spontaneous mutations, the number of cycles was 
decreased from 30 to 12. Reactions were performed at three different annealing 
temperatures using Vent and Expand High Fidelity Taq DNA polymerases. When 
visualised on a 1.5% agarose gel these reactions still showed some smearing but the 
l.lkb band was more prominent (Figure 5.6) than in the earlier reactions (Figure 5.5). 
Two other DNA fragments of ~350bp and ~600bp were amplified but these were 
significantly different in size and caused no interference with the purification of the 
l.lkb band.
The DNA polymerases used in both the first and second rounds of PCR did not add an 
overhang of adenosine residues required for the ligation into the pGEM-T vector. 
Consequently, 2 cycles with generic Taq polymerase (Sigma Chemicals Ltd., Poole, 
Dorset, UK) were performed to add an adenosine overhang. Following this third PCR, 
the amplified fragments were separated on an agarose gel, purified from the gel and 
ligated into the pGEM-T vector (Sections 2.2.2, 2.2.6 and 2.2.7). The ligation mix 
was transformed into competent E. coli DH5a cells as described in Section 2.2.10 and 
plated onto LB agar plates containing ampicillin. Colonies on the plate were screened 
for the presence of the 1. lkb insert using a PCR with the vector specific primers 
M13F and M13R (results not shown). The plasmid DNA from three colonies that 
contained an insert of the correct size was purified (Section 2.2.5) and sent for double 
stranded DNA sequencing using the M13F and M13R primers (Section 2.2.8).
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The sequence chromatograms from each of the colonies revealed the presence of the 
full length pffabH gene and confirmed the presence of the E. coli preferred codons 
throughout the gene. However, the sequence of the gene from each colony contained a
M 1 2 3 4 5 6
Lane Sample
1 Vent polymerase. Annealing temp. 42°C
2 Vent polymerase. Annealing temp. 56°C
3 Vent polymerase. Annealing temp. 60°C
4 Expand Taq. Annealing temp. 42°C
5 Expand Taq. Annealing temp. 56°C
6 Expand Taq. Annealing temp. 60°C
Figure 5.6 A second PCR amplification of pffabH
The PCRs were performed under standard conditions. The annealing temperature was 
60°C. 10pl of a 50pl reaction were run on a 1.5% agarose gel and visualised under 
UV light.
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significant number of mutations in various positions along the gene. A summary of 
the mutations is given in Table 5.2.
Clone No. of mutations Type of mutations Position of mutations
1 9 7 single base deletions 
1 deletion of 4 bases 
1 single base insertion
27, 307, 336, 499, 765, 847, 892 
979-982 
439
3 7 7 single base deletions 300, 351, 372, 517, 747, 892, 1017
4 8 6  single base insertion 
1 double base insertion 
1 single base insertion
97, 124, 273, 492, 892, 1038 
371-372 
380
Table 5.2 Mutations observed in the sequence of pffabH  gene with E. coli 
preferred codon usage
The relatively large number of mutations were distributed evenly through the 
sequence of each gene from the three separate colonies. This decreased the chances of 
piecing together a full length gene from sections of each clone. Interestingly, the 
single base deletion at position 892 was present in the DNA of all three clones. This 
suggests that, when the primers were annealing, one of the initial steps involved the 
Non-Coding 3 oligonucleotide n-1  product that lacked the cytosine base at this 
position. The large number of single base deletions suggest that the synthetic 
oligonucleotides contained many n-1 products at different positions and these 
remained when they became assimilated into the full length gene. If this was the case 
then the problem was inherent in the starting materials and was not a result of 
spontaneous mutations produced by the DNA polymerases. Therefore, reducing the
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number of cycles and altering the PCR conditions would not be expected to have an 
effect. The single base mutations and insertions could be corrected by using site 
directed mutagenesis (SDM). However, the smallest number of corrections needed 
would be seven for Clone 3. This task would not be trivial as SDM depends on PCR 
amplification of the gene, which has proved extremely difficult with the pffabH gene. 
Therefore, it was decided that this technique would be very unlikely to yield a correct 
version the pffabH gene.
5.6 Cloning of a truncated version of pffabH
During the course of this project, other research groups were also attempting to clone, 
express and characterise the pfFabH protein of P. falciparum. The first paper to 
describe the cloning and expression of pfFabH was published by Sean Prigge’s 
laboratory in 2002 (Waters et al., 2002). This paper described the cloning of the full 
length pffabH gene using a cDNA library as template. A truncated form of the pffabH 
gene that encodes amino acids 50-371, i.e. without the bipartite signal peptide, was 
also cloned using an alternative forward primer. The products of these PCRs were 
digested with EcoR I and Sal I and ligated into the pMALc2x expression vector. The 
paper reported that the construct containing the full-length pffabH gene produced 
protein in an insoluble form and that the truncated form was used for all further 
studies (Waters et a l , 2002 and Prigge et al., 2003).
The pMALc2x plasmid containing the full-length construct was obtained from Sean 
Prigge (Johns Hopkins School of Public Health, Baltimore, USA). In an attempt to 
amplify the truncated form of pffabH, described in the previous paragraph, this
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plasmid was used as template in a PCR using two oligonucleotide primers; 
pjfabH-Xmnc F and pffabH-iiunc R (Figure 5.7). Pfu turbo DNA polymerase was used 
(Stratagene, Amsterdam, The Netherlands) and the cycling parameters are shown in 
Figure 5.7.
pffabH
truncF
5»-GGTGGTGAATTCATGTCCGGAGGTAAAATAATAGGAC -3’
pffabH 
trunc R
5*-GGTGGTGTCGACTTAATATTTAAGTATAACGCATCCATATG -3’
B
95°C, 5 minutes
95°C, 45 seconds 
55°C, 45 seconds  ^ 3 q CyC]es
65°C, 2.5 minute 
65 °C, 10 minutes
Figure 5.7 Primers and cycling parameters used in the initial amplification of the 
truncated pffabH gene
A Sequences of the oligonucleotide primers. An EcoR I restriction endonuclease site 
is shown in bold and a Sal I site in italics. Regions complementary to the sequence of 
the pffabH gene are underlined.
B Cycling parameters used to amplify the truncated version of the pffabH gene.
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When the products from this PCR were separated on an agarose gel (Section 2.6), a 
single band of approximately lOOObp was observed. The expected size of the 
truncated form of pffabH, including exterior restriction enzyme sites is 999bp. Pfu 
turbo DNA polymerase does not add an overhang of adenosine residues required for 
the ligation into the pGEM-T vector. Consequently, 2 cycles with generic Taq 
polymerase (Sigma Chemicals Ltd., Poole, Dorset, UK) were performed to add an 
adenosine overhang. This band was excised from the gel, purified and ligated into the 
pGEM-T cloning vector (Sections 2.2 and 2.7). The ligation reaction was transformed 
into competent E. coli DH5a cells and plated onto LB agar plates containing 
ampicillin.
The resultant colonies were screened for the presence of the insert using a PCR 
containing the vector specific primers M13F and M13R (Appendix 2). Positive 
colonies were used to inoculate 10ml of LB medium containing ampicillin and the 
plasmid DNA was subsequently isolated from overnight cultures, as described 
previously (Section 2.2.5). To ensure that no mutations had occurred during the PCR, 
the plasmid DNA was sequenced using M13F and M13R primers. Analysis of the 
sequence chromatograms and subsequent comparison to the published sequence of the 
pffabH gene, showed that the truncated sequence was identical to the corresponding 
region of the gene. A proximal EcoR I site and a distal Sal I site (that were included in 
the oligonucleotide primers), flanked the truncated pffabH gene, which therefore, 
appeared to be in a suitable form for cloning into the pMALc2x vector and for the 
production of pfFabH protein in a recombinant system.
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5.7 Cloning of the pffabH  Gene into the pMAL Vector System
Following the successful production of soluble and active pfFabF protein using the 
pMAL system, it was decided that the truncated pffabH gene should be inserted into 
the pMALc2x plasmid. Furthermore, expression of truncated pfFabH in the pMAL 
system and the production of active protein was reported previously (Waters et a l ,
2002). This suggests that the production of a catalytically active form of pfFabH 
should be a realistic possibility using this system.
The truncated pffabH gene was inserted into the pMALc2x vector using exactly the 
same method as described in Section 3.11. Briefly, both the pGEM-T plasmid 
containing the truncated pffabH gene and the pMALc2x plasmid were digested with 
the restriction endonucleases, EcoR I and Sal I. The digested fragments were 
separated on and purified from an agarose gel. The pMALc2x vector was then treated 
with SAP (Section 2.2.4) to prevent any religation of the plasmid during the ligation 
reaction. A ligation mixture containing equimolar amounts of plasmid and insert DNA 
was performed under standard conditions (Section 2.2.2.).
The ligation mix was used to transform DH5a E. coli and plasmid DNA was purified 
from several of the resulting colonies (Sections 2.2.10 and 2.2.5). DNA sequencing 
results of two separate clones suggested that the truncated pffabH gene was inserted 
into the pMALc2x vector in the correct orientation and the CDS of the truncated 
pffabH gene was present in its entirety -  this plasmid was termed pMAL-pffabH.
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5.8 Expression of an MBP-pfFabH fusion protein
By analogy to the production of the pfFabF protein (Section 3.10), the pMAL-pffabH 
plasmid was transformed into competent E. coli BL21 (DE3) Codon + RIL cells and 
plated out onto agar plates containing ampicillin and chloramphenicol. The resulting 
colonies were used to inoculate 2 litres of LB medium containing the aforementioned 
antibiotics. Expression of the MBP-pfFabH fusion protein was induced by the 
addition of IPTG under the conditions described in Section 3.12. These conditions 
produced a significant amount of MBP-pfFabH fusion protein after 16h (Figure 5.8), 
which was comparable to that observed with MBP-pfFabF (Figure 3.13). A peptide 
mass program (Wilkins et al., 1997) predicted the mass of the MBP-pfFabH fusion 
protein to be 79.3kDa. A reasonable proportion of the fusion protein was retained in 
the soluble fraction, but the majority remained in an insoluble form (Figure 5.8). In 
preparation for the purification of the MBP-pfFabH protein, cells were harvested, 
lysed and the soluble fraction isolated as described in Section 3.12.
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1 2 3 4
175kDa
83kDa
48kDa
33kDa
25kDa
Lane Sample
1 Oh Prior to induction with IPTG
2 I 6 h Post-induction
3 Soluble Fraction
4 Insoluble Fraction
Figure 5.8 Time-course for the induction of pMAL-pfFabH in Codon Plus cells 
at 20°C
Samples were removed from the culture before the addition of 0.4mM IPTG at Oh and 
at 16h post-induction. The proteins contained in each sample were separated by 
SDS-PAGE (12.5% acrylamide) and visualised by staining with Coomassie blue. 
Purified MBP-pfFabF (Chapter 3) and free MBP (supplied as MBP2* from New 
England Biolabs, Beverly, MA, USA) were included on the gel as comparisons of the 
expected size of MBP-pfFabH.
79kDa
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5.9 Purification of MBP-pfFabH in a soluble form
The MBP-pfFabH protein was purified from the soluble fraction using an amylose 
resin column under conditions previously described in Section 3.13. A separate 
column of amylose resin was used from the purification of pfFabF. Separation of the 
MBP-pfFabH protein and free MBP from native E. coli proteins proved successful, 
with only very few contaminating bands present in the eluted fractions (Figure 5.9). 
The major band in the purified fractions was MBP-pfFabH, showing that a relative 
increase in concentration had occurred. A Western blot of the same samples revealed 
that the major contaminating bands were recognised by the anti-MBP serum (New 
England Biolabs, Beverly, MA, USA) (Figure 5.10), which suggested that these 
proteins were produced by the degradation of MBP-pfFabH and free MBP. 
Approximately lmg of soluble MBP-pfFabH was produced from each litre of culture 
and, when 1ml fractions were collected, the majority of the protein was eluted across 
Fractions 2-4.
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175kDa-----
83kDa-----
62kDa-----
48kD a------
33kDa-----
25kDa-----
16kDa-----
Lane Sample
1 Cell supernatant fraction
2 Column flow through
3 Begin of washing steps
4 End of washing steps
5 Eluted fraction 1
6 Eluted fraction 2
7 Eluted fraction 3
Figure 5.9 Affinity purification of MBP-pfFabH protein using an amylose 
column
The soluble fraction from cells that were harvested 16h post-induction with 0.4mM 
IPTG (Figure 5.7) (Lane 1) was run through an amylose column and the flow through 
collected (Lane 2). The column was then washed with Column Buffer to remove any 
unbound protein (Lanes 3-4). 1ml fractions were eluted by the addition of lOmM 
maltose to the Column Buffer (Lanes 5-7). The proteins contained in each sample 
were separated by SDS-PAGE and visualised by staining with Coomassie blue.
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Figure 5.10 A Western blot of the affinity purification of MBP-pfFabH protein 
using an amylose column
The soluble fraction of cells expressing the MBP-pfFabH fusion protein (Lane 1) was 
run through an amylose column and the effluent collected (Lane 2). The column was 
then washed with Column Buffer to remove any unbound protein (Lanes 3-4). 1ml 
fractions were eluted by the addition of lOmM maltose to the Column Buffer (Lanes 
5-7). The proteins contained in each sample were run on a 12.5% acrylamide 
SDS-PAGE gel, transferred to a nitrocellulose membrane and developed using the 
anti-MBP serum (Section 2.2.15).
MBP-
pfFabH
Free MBP
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5.10 Attempted cleavage of the MBP-pfFabH fusion
The pMALc2x vector encodes a Factor Xa recognition site between the regions that 
encode MBP and the N-terminally fused target protein. In the current study, this was 
designed to facilitate separation of the pfFabH protein from the MBP, with only a 
small number of vector encoded amino acids remaining attached at the N-terminus.
Cleavage experiments with a small amount of eluted Fraction 2 were performed as 
described previously (Section 3.14). Samples were incubated with lpg of Factor Xa at 
different timepoints and then separated on an SDS-PAGE gel (Figure 5.11).
Following a 2h incubation with Factor Xa, the amount of MBP-pfFabH in the reaction 
had decreased and the amount of free MBP increased. A band of the expected size for 
free pfFabH was also observed to increase after a 2h incubation. A Western blot of the 
samples showed that this band was not detected by the anti-MBP serum and suggests 
that it was not a digestion product of free MBP (Figure 5.12). As the length of 
incubation was extended, the amount of MBP-pfFabH decreased in proportion to the 
increase in the quantity of free MBP (Figure 5.11, Lanes 3-4). However, at these 
times the band corresponding to pfFabH did not increase in size, suggesting that 
pfFabH had not accumulated. Proteins smaller than the predicted size of pfFabH, were 
observed on the gel and this suggested that digestion of free pfFabH protein had 
occurred. These smaller bands are not observed on the Western blot (Figure 5.12) and 
therefore were not related to MBP.
A search of the pfFabH protein sequence for Factor Xa cleavage sites (IEGR or 
IDGR) located one sequence with low similarity to the Factor Xa cleavage site -  
DELK -  between residues 20-23. Cleavage at this site would produce a protein
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approximately 34kDa in size. The most prominent band that may correspond to a 
cleavage product of pfFabH appears smaller than the 33kDa marker, however, there is 
a faint band at ~ 34kDa. In conclusion, it was clear that the pfFabH protein was being 
degraded in longer incubations and, in order to maximise recovery of the truncated 
form, a 2h incubation was utilised.
M 1 2 3 4
175kDa ~
83kDa —  -  ------  ------  MBP-pfFabH
62kDa
48kDa ____ MBP
<------  pfFabH
33kDa
25kDa
Lane Length of incubation with Factor Xa
1 Oh
2 2h
3 8h
4 24h
Figure 5.11 Timecourse the digestion of the MBP-pfFabH fusion protein with 
lpg of Factor Xa
Each reaction contained lOpg of the MBP-pfFabH protein, which was incubated with 
1 pg of Factor Xa for the times indicated above. The proteins contained in each sample 
were separated by SDS-PAGE and visualised by staining with Coomassie blue.
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Figure 5.12 Timecourse of digestion of the MBP-pfFabH fusion protein with lpg 
of Factor Xa
M = molecular weight markers. Each reaction contained lOpg of the MBP-pfFabH 
protein which was incubated with 1 pg of Factor Xa for the times indicated above.
The proteins contained in each sample were separated by SDS-PAGE and transferred 
onto a nitrocellulose membrane. The western blot was washed and developed using 
the anti-MBP serum (New England Biolabs, Beverly, MA, USA) as described in 
Section 2.2.15.
MBP-pfFabH 
Free MBP
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The relative success of the cleavage of pfFabH from MBP should allow purification 
of the pfFabH protein, by using a second amylose resin column. The cleavage and 
purification steps may prove essential for the analysis of the 3D structure of the 
protein in X-ray crystallography studies. However, due to time constraints of this 
project it was decided not to pursue the purification of free pfFabH. By analogy with 
the enzyme activity of the MBP-pfFabF fusion protein (Chapter 4), the separation of 
MBP from the pfFabH protein may not be necessary for the formation of an active 
homodimer that displays ketoacyl-ACP synthase activity. Some initial explorations of 
the catalytic activity of the MBP-pfFabH fusion are described below.
5.11 Initial studies of MBP-pfFabH activity
Following the start of this PhD project but before preparation of recombinant 
MBP-pfFabH in this study, analyses of the substrate specificity and enzyme activity 
of pfFabH (KASHI) had already been reported in the literature (Waters et al., 2002, 
Prigge et al., 2003). These papers indicated that, like plant and bacterial FabH 
proteins, the pfFabH protein catalyses the initial step of fatty acid synthesis by 
condensing acetyl-CoA and malonyl-ACP to form P-ketobutyryl-ACP and CO2 
(Figure 1.13). Butyryl-CoA is also an acceptable substrate for pfFabH (Prigge et a l,
2003). However, in order to maximise enzyme activity, all inhibitor studies were 
performed using acetyl-CoA. These reactions also contained an excess of 
malonyl-CoA, ecFabD and ecACP in order to generate a sufficient concentration of 
malonyl-ACP for accurate assay (Section 2.2.25).
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To determine if the purified MBP-pfFabH retained any KAS activity, an assay 
containing a large amount (lpg) of the MBP-pfFabH protein was performed as 
described in Section 2.2.25. As a positive control for the substrates and assay 
conditions, E. coli FabH (ecFabH) was kindly provided by the laboratory of Dr. 
Charles Rock (St. Jude Children’s Research Hospital, Memphis). A significantly 
smaller amount of ecFabH (50ng), compared to MBP-pfFabH (lpg), was used in the 
assay because its activity under identical assay conditions had already been 
determined (Dr. Yong-Mei Zhang, St. Jude Children’s Research Hospital, Memphis, 
personal communication). In the assay, 14C labelled acetyl-CoA (Section 2.2.25) is 
condensed with malonyl-ACP to form radiolabelled p-ketobutyryl-ACP.
Radioactivity that was incorporated into the ketoacyl-ACP is precipitated on to filter 
discs and any unreacted 14C acetyl-CoA is separated by washing the discs in 
successive TCA solutions. The radioactivity is then measured by scintillation 
counting (Section 2.2.25). The results of this assay showed that the MBP-pfFabH 
fusion protein contained a significant amount of p-ketoacyl-ACP synthase activity 
(Figure 5.13).
Ideally, a comparison of the activity of the MBP-pfFabH fusion protein and free 
pfFabH - separated by Factor Xa cleavage and removal of the MBP by passing 
through an amylose resin -  should be performed to ascertain if the N-terminal MBP 
affects p-ketoacyl-ACP synthase activity. It was decided that within the time 
constraints of the project and due to the relatively small amounts of purified soluble 
MBP-pfFabH produced, that this comparison would not be performed. However, due 
to the previous studies of pfFabH (Waters et al., 2002 & Prigge et al., 2003) a detailed 
characterisation of the enzyme was not necessary.
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Figure 5.13 The activity of P. falciparum  FabH protein
The incorporation of radiolabelled acetyl-CoA with ecFabH(n) and M BP-pfFabH([J. 
Each assay was performed in duplicate and errors are shown as errors from the mean. 
Assays contained 50ng of ecFabH or lpg of MBP-pfFabH and the activities were 
measured using a radiochemical assay as described in Section 2.2.25.
Having established that the fusion protein had significant KAS activity, it was 
important to store the enzyme in such a way as to retain as much activity for as long 
as possible. An aliquot of purified MBP-pfFabH that had been stored at 4°C for 30
days was compared to MBP-pfFabH stored as solution in 50% glycerol at -20°C for
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30 days and a sample of freshly prepared MBP-pfFabH (Figure 5.14). When stored at 
-20°C in 50% glycerol for 30 days, greater than 90% activity was retained. However, 
storage at 4°C with no glycerol led to a loss of more than half the condensing enzyme 
activity (30.7% remained) after 30 days. Putting this knowledge to effect, each time a 
fresh batch of MBP-pfFabH was purified, glycerol was added immediately to a final 
concentration of 50% and the enzyme was stored at -20°C until required for further 
use. When the protein was stored at -20°C in 50% glycerol for 90 days, only 55% of 
the original activity remained (Figure 5.14), suggesting that a fresh batch of 
MBP-pfFabH should be prepared when required, if the previous batch had been stored 
for over 30 days.
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Figure 5.14 The effects of storage on MBP-pfFabH activity
The percentage remaining activity of freshly prepared MBP-pfFabH ( □), 
MBP-pfFabH stored at -20°C for 30 days in 50% glycerol (*), stored for 90 days in 
50% glycerol (® ) or stored at 4°C for 30 days (® ). Assays were performed in 
duplicate and errors are as the range of results from the mean. Each assay contained 
Ipg of the different MBP-pfFabH preparations and the activities were measured 
using a radiochemical assay as described in Section 2.2.25.
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5.12 Refining the conditions of the MBP-pfFabH Assay
Linearity due to protein concentration was assessed at the normal substrate
concentrations (Section 2.2.25). The activity of the MBP-pfFabH protein was tested at
concentrations ranging from lpg to 25ng whilst the concentrations of
[1-14C] acetyl-CoA, malonyl-CoA, ecACP and ecFabD remained constant.
To produce a gradient of protein concentrations (Figure 5.15), a 500ng/pl stock of 
MBP-pfFabH in 50% glycerol was diluted serially with appropriate amounts of 
lOOmM Na-phosphate buffer, pH6.6 containing 50% glycerol. The incorporation of 
radiolabel in products bound to ACP was plotted against the protein concentrations of 
MBP-pfFabH (Figure 5.15).
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Figure 5.15 The amount of radiolabel observed in the acyl-ACP increases 
linearly with respect to the amount of MBP-pfFabH
Each assay was performed in duplicate and errors are shown as errors from the mean. 
The activity of MBP-pfFabH was measured using the radiochemical assay as 
described in Section 2.2.25.
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The graph shows that the activity of the MBP-pfFabH enzyme increases linearity up 
to 600ng protein. Because the graph indicated that lpg of MBP-pfFabH was outside 
the linear range, this could mean that the original calculation of P-ketoacyl-ACP 
synthase activity of MBP-pfFabH was underestimated.
The enzyme activity was recalculated using lower concentrations of MBP-pfFabH and 
these calculations produced a range of activities from 74-93pmoles min' 1 pg'1, 
suggesting that the original estimation (89.7pmoles min' 1 pg"1 protein) was accurate. 
All subsequent assays were performed using 500ng of MBP-pfFabH protein because, 
at this concentration it was clear that the reaction was directly proportional to the 
amount of protein and not limited by the concentrations of substrates. This amount of 
MBP-pfFabH also incorporated enough radiolabel to produce a signal to background 
ratio adequate for accurate inhibition studies.
5.13 An investigation of MBP-pfFabH sensitivity to thiolactomycin and cerulenin
The bacterial metabolites thiolactomycin and cerulenin are both inhibitors of the 
condensing reactions in fatty acid synthesis. Cerulenin inhibits the reaction in both 
Type I and Type II FAS, whereas TLM is specific for the p-ketoacyl-ACP synthases 
of Type II FAS present in plants, bacteria and protozoan parasites. In E. coli, FabH is 
minimally sensitive to both TLM and cerulenin when compared to the inhibition of 
FabB and FabF enzymes (Price et al., 2001). A very similar result was observed with 
TLM in pea plants (Jones et al., 2000) (no data is available for cerulenin against the 
pea KAS enzymes), suggesting that the closely related pfFabH (Figure 5.1) might also 
be minimally sensitive to both these inhibitors. Prigge and colleagues have already
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reported the inhibition of pfFabH by TLM (R enantiomer -  the purified natural 
product) with an IC50 >330pM (Prigge et al., 2003). However, his study used different 
conditions for the enzyme assay. Furthermore, a different source of TLM was also 
used in this assay and since it is known that different preparations of TLM can have 
quite different activities, it was decided that an evaluation of MBP-pfFabH sensitivity 
to TLM (and cerulenin) under the assay conditions of this study was important. These 
data would be central for comparison of the inhibitory activity of any TLM 
derivatives tested against the MBP-pfFabH enzyme.
Unfortunately, prior to testing the inhibitory effect of TLM on MBP-pfFabH it was 
not possible to gain access to the naturally produced TLM. An alternative source of 
TLM from (Sigma Chemicals, Poole, Dorset, UK) was obtained, as a synthetically 
produced, racemic mix of TLM. A comparison of the inhibitory effect of Sigma TLM 
and naturally produced TLM on the growth of the E. coli strain ANS1 was performed 
as described in Section 2.2.29. The ANSI strain was used because it is deficient in all 
TolC-dependent type I secretion and multidrug efflux systems (Jackowski et al.,
2002). Upregulation of the emrAB efflux pump, a member of the above protein family 
caused TLM resistance in E. coli (Furukawa et al., 1993; Lomovskaya et al., 1995). 
Therefore, it was important to test the inhibitory activity of TLM against a strain, in 
which, the efflux pump activity had been abrogated. The E. coli ANS 1 strain was 
kindly provided by Dr. Charles Rock (St. Jude Children’s Hospital, Memphis, USA).
To achieve the same extent of inhibition as naturally produced thiolactomycin, the 
synthetic compound needed to be present at twice the concentration (Figure 5.16).
This result suggested that the synthetic compound was truly a 50:50 racemic mixture
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and the (5S)-enantiomer did not display an antagonistic effect. Therefore, TLM 
obtained from Sigma will be referred to as racemic TLM throughout the rest of this 
report.
—♦— TLM (5R)- 
enantiomer
—■—racemic
TLM
10 15 20
Compound (pM)
Figure 5.16 Inhibition of the growth of E. coli ANSI strain
The racemic mixture and the (5R)-enantiomer of TLM were tested at 25pM, 12.5pM, 
6.25pM, 3.13pM, 1.56pM, 0.78pM and 0.39pM concentrations formed by 1 in 2 
serial dilutions from the highest concentration. The assay of bacterial growth was 
performed as described in Section 2.2.9. The E. coli ANSI strain was kindly provided 
by Charles Rock (St. Jude Children’s Research Hospital, Memphis, USA).
An assay that contained lOOpM concentration of a synthetically produced, racemic 
TLM (Sigma Chemicals, Poole, Dorset, UK) was prepared. In a separate reaction 
lOOpM of cerulenin was added to see if the MBP-pfFabH enzyme was highly or 
minimally sensitive to cerulenin (Sigma Chemicals, Poole, Dorset, UK) and would
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indicate any differences between TLM and cerulenin sensitivity. The TLM obtained 
from Sigma was used because at the time of these assays there was no access to the 
natural product, (5R)-enantiomer only. The results indicated that the preparation of 
MBP-pfFabH was insensitive to cerulenin and minimally sensitive to TLM 
(Figure 5.17). The lack of inhibition by lOOpM cerulenin is comparable to that of 
bacterial and plant FabH proteins and, therefore, no further studies were performed 
using this compound. Inhibition of 23% of the condensing activity was observed in 
assays containing lOOpM racemic TLM, which suggested that the MBP-pfFabH 
tested in this study is more sensitive to TLM than previously reported (Prigge et al.,
2003).
lOOpM r a c e m ic  TLM 100| iM Ce ru len inControl
Figure 5.17 The inhibition of MBP-pfFabH with thiolactomycin and cerulenin
The incorporation of radiolabelled acetyl-CoA with no inhibitor (□), in the presence 
of lOOpM Sigma TLM ( ■ )  or lOOpM cerulenin ( ■ ). Each assay was performed in 
duplicate and errors are shown as errors from the mean. Assays contained 500ng of 
MBP-pfFabH and the activity was measured using the radiochemical assay as 
described in Section 2.2.25.
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5.14 The determination of the IC50 of TLM against pfFabH
In order to get a more accurate estimation of the sensitivity of MBP-pfFabH to TLM, 
the IC50 of this compound against the enzyme was determined. Briefly, a lOmM stock 
of TLM was serially diluted in 40% DMSO to produce 8mM, 6mM, 4mM, 2mM, 
ImM and 500pM stock solutions. The final DMSO concentrations were kept constant 
and up to 2% had no effect on the enzyme activity. When 2pl of each inhibitor 
solution was added to the total assay volume of 40pl, the final TLM concentrations 
lay between 25pM-400pM. Assays containing no TLM were used to estimate the 
uninhibited activity. The results (Figure 5.18) suggested that the concentration of 
racemic TLM that caused inhibition of 50% of pfFabF activity (IC50) is approximately 
200pM (the equivalent to lOOpM TLM (R enantiomer only).
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Figure 5.18 IC 50 determination for TLM against MBP-pfFabH
Each assay was performed in duplicate and errors are shown as errors from the mean. 
Assays contained 500ng of MBP-pfFabH and the activity was measured using the 
radiochemical assay as described in Section 2.2.25.
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These data indicated that the P. falciparum  FabH (KASHI) enzyme was much less 
sensitive to thiolactomycin compared to the pfFabF enzyme (Figure 5.19), even after 
noting that the standard amounts of enzymes used in the two assays were slightly 
different.
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Figure 5.19 Comparison of TLM inhibition of the two P. falciparum  KAS 
enzymes
Each assay was performed in duplicate and errors are shown as errors from the mean. 
Assays contained 500ng of MBP-pfFabH or 300ng of MBP-pfFabF and the activity 
was measured using the radiochemical techniques as described in Sections 2.2.24- 
2.2.25. The data points of the inhibition of MBP-pfFabH were converted from 
racemic TLM concentrations to naturally produced concentrations by dividing by two. 
These data are shown in separate graphs in Figure 4.6 and Figure 5.18.
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5.15 Discussion
Amplification, and subsequent cloning, of the pfFabH gene was unsuccessful when a 
cDNA library was used as template. Amplification of the gene was only achieved 
when a copy of a plasmid containing the gene, kindly provided from Dr. Sean Prigge 
(Johns Hopkins, School of Public Health, Baltimore, USA) was used as the DNA 
template. A possible reason why cloning of pfFabH was unsuccessful using a cDNA 
template is described below. The ring stage cDNA library used during this project was 
originally obtained from Prof. Steve Walsh (Liverpool School Tropical Medicine,
UK) and had been used extensively and successfully to clone several P. falciparum 
genes in our laboratory over many years. Recent data on the stage specific expression 
of P. falciparum genes has shown that genes that encode proteins of the Type II FAS 
pathway are not expressed at particularly high levels during ring stages (le Roch et al., 
2003; Waters et al., 2002). In contrast, expression of these genes appears to be highest 
in late trophozoite and schizont stages (Waters et al., 2002).
Assuming that the corresponding level of these proteins correlates with the level of 
mRNA this may explain why trophozoite and schizont stages are less sensitive to 
treatment with TLM, cerulenin and triclosan compared to ring stages (Waller et al.,
2003). If the level of transcription of these genes is low in ring stages it might be 
possible that the pffabH gene was not represented in the cDNA library. The high A+T 
bias of the pffabH gene (74.2%) may also have decreased the chances of obtaining a 
full length clone or any large fragments of the gene.
Following the successful cloning of pffabH, the enzyme was expressed and purified in 
the pMAL vector system, which had produced reasonable amounts of MBP-pfFabF
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(Chapter 3, Section 3.11-13) and pfFabH (Waters et al., 2002). This system produced 
approximately lmg of soluble active MBP-pfFabH protein per litre of culture. 
Unfortunately, whilst cleavage of MBP from the N-terminus of pfFabH was achieved 
by treatment with Factor Xa, the pfFabH protein also appeared to be digested by this 
protease. Subsequently, the removal of MBP from pfFabH was not attempted with the 
consequence that the chances of producing a crystal structure of pfFabH would be 
reduced significantly. However, Prigge and colleagues, who separated MBP from 
pfFabH via an engineered TEV protease site, are endeavouring to obtain a crystal 
structure of pfFabH, (Prigge et al., 2003: Sean Prigge, personal communication).
The MBP-pfFabH fusion protein was able to catalyse the initial condensing reaction 
of the Type II FAS cycle (Section 5.11). Compared to the radioactivity incorporated 
using a lower amount of ecFabH enzyme, the MBP-pfFabH enzyme may appear to 
have a poor p-ketoacyl-ACP synthase activity. However, the previously reported 
specific activity for pfFabH under similar conditions was 250pmoles min' 1 jig"1 
protein (Prigge et al., 2003) and the calculated specific activity of the MBP-pfFabH 
protein in this study is 90pmoles min' 1 pg' 1 protein. These activities are of the same 
order and the discrepancy could be due to the slight differences in the assay 
conditions or to a lower activity of the MBP-pfFabH fusion protein purified in this 
project. There are several reports of the activity of the E. coli FabH enzyme, which 
suggest the specific activity of the bacterial enzyme is 5-7nmoles min' 1 pg' 1 protein 
(Khandekar et al., 2000; Clough et al., 1992). Compared to bacteria FabH enzymes, 
the P. falciparum FabH enzyme appears to have a significantly lower specific activity, 
although a comparison of Km and Kcat values would give a more accurate insight into 
the catalytic abilities of these enzymes.
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This Chapter describes the first study of the inhibitory effect of cerulenin on pfFabH. 
In a similar situation to plant and bacterial FabH enzymes, the P. falciparum enzyme 
appears to be insensitive to cerulenin treatment. The IC50 of 200 pM for TLM against 
MBP-pfFabH was also determined and showed that, in our experiments, the enzyme 
was more sensitive to this antibiotic than in the only previous report (>300 pM) 
(Prigge et al, 2003). An IC50 of 200pM may indicate that there is a large window of 
opportunity in which to improve the binding of TLM to the enzyme, via alterations in 
to the structure of thiolactomycin. Recently, Prigge and colleagues have identified 
TLM-like compound that inhibit the pfFabH enzyme and also exhibit an increase 
inhibitory effect on parasites in culture (Prigge et al., 2003). The inhibitory activities 
of TLM derivatives against the MBP-pfFabH protein are described in Chapter 6 .
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Chapter 6
i
Chapter 6  -  Inhibition of P. falciparum  Fatty Acid Synthesis by Thiolactomycin 
and its derivatives
6 . 1  Introduction
Prior to the start of this project, TLM had been shown to inhibit the growth of 
P. falciparum cultures, showing an LD 50 = 50pM against the multi-drug resistant 
strain W2 mef (Waller et a l, 1998). Furthermore, in vivo TLM exhibited rapid 
absorption and wide distribution in tissues and protected against bacterial 
intraperitoneal and urinary tract infections in mice (Miyakawa et a l, 1982). Unlike 
cerulenin, which is a non-selective inhibitor of Type I and Type II FAS, 
thiolactomycin is a selective inhibitor of Type II FAS (Hayashi et al., 1983 and 1984) 
and has negligible toxicity in mammals (Oishi et al., 1982). These studies and the data 
presented in Chapters 4 and 5, suggested that TLM was a promising lead compound 
for the treatment of P. falciparum malaria. Against cultures of protozoan parasites, 
TLM exhibited LD50 values in the mid to high micromolar range (Table 6 .1).
Organism LD 50 (pM)
P. falciparum 49a
T. brucei -150”
T. gondii 1 0 0 c
Table 6.1 The inhibition of protozoan parasites with TLM
a Waller et a l , 2003 (against the W2 mef strain of the parasite).b Morita et al., 2000. 
c McFadden and Roos, 1999. All values are given as the dose that inhibited 50% 
growth of the parasite in in vitro studies as measured by incorporation of 
3H-hypoxan thine.
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An increase in the inhibitory activity of TLM would be necessary before it could be 
considered for the treatment of parasitic infections. Analogues of TLM were first 
shown to have enhanced activity against Type II FAS in pea chloroplasts (Jones et al., 
1994 and 1995) and these analogues also showed an increase in activity against the 
FabB, FabF and FabH enzymes of pea plants (Jones et al, 2000). These analogues 
contained substitutions of the isoprenoid moiety at position 5 of the thiolactone ring 
with longer hydrocarbon chains.
R3
HO R2
HO c h 3
Figure 6.1 Structure of TLM and variable groups
A. The structure of the fungal metabolite TLM. Members of the thiolactone ring are 
numbered in blue text. B. The variable groups at the C5 and C3 positions as they will 
be referred to during the remainder of this report.
During the course of this project, two groups reported that similar substitutions at the 
5 position showed increased activity against Mycobacterium tuberculosis (Kremer et 
al., 2000; Douglas et al., 2002; Senior et al., 2003, 2004 ) and P. falciparum (Waller 
et al., 2003) in vitro. The 3D-structure of the E. coli FabB-TLM complex showed the 
presence of a hydrophobic crevice, which is distinct from the hydrophobic groove that
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usually accommodates the growing acyl chain (Figure 6.2) (Price et al., 2001). In 
ecFabB this crevice is deeper than the isoprenoid group found on TLM and, therefore, 
may not be optimally filled by TLM. Assuming that the structures of the condensing 
enzymes are similar, this may explain the reason for the increased activity of TLM 
derivatives with longer, hydrophobic chains at the C5 position against malaria and 
trypanosome parasites.
Three compounds with similar structures to TLM have already been reported to have 
an increased activity against cultures of P. falciparum and significantly inhibit the 
pfFabH (KASDI) enzyme activity (Prigge et al., 2003). Encouragingly, these results 
showed that derivatives of TLM can demonstrate a marked increase in the inhibitory 
activity against an individual condensing enzyme of P. falciparum, which in turn may 
increase the sensitivity of the parasite.
224
Figure 6.2 The hydrophobic crevice that incorporates the C5 chain of TLM and 
its derivatives
This diagram depicts compound 925, not TLM, docked in the active site of E. coli 
FabB (Jones et al., 2004). The lFJ4.pdb file (Price et al., 2001) was downloaded from 
the Brookhaven database and was manipulated using FlexX Software and SwissPDB 
viewer (Guex and Peitsch, 1997). C5 decyl group is positioned in the same 
hydrophobic pocket that extends to the surface of the protein. This hydrophobic 
pocket is distinct from the one that incorporates the growing acyl chain (Price et al., 
2001).
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6.2 Synthesis of TLM derivatives and determination of LD50
At the outset of this work, collaborations with Dr. Simon Jones and Dr. Ian Gilbert 
(Welsh School of Pharmacy, Cardiff) and Prof. Reto Bran (Swiss Tropical Institute, 
Basel, Switzerland) were arranged with the aim to synthesise and assay analogues of 
TLM for anti-parasitic activity. All of the TLM analogues described subsequently 
were synthesised by Dr. Simon Jones, using methods or modifications of the methods 
described in Jones et al., 2004. The synthesis of these compounds should produce 
equal ratios of the stereoisomers at position C5 and all of the TLM derivatives 
reported from this study are given as total concentrations of preparations, which 
would contain mixtures of the R and S enantiomers (Wang and Salvino, 1984). Prof. 
Reto Bran performed assays of the effect of TLM analogues on the growth of in vitro 
cultures of P. falciparum, as described previously (Jones et al., 2004). These 
compounds were also assayed against cultures of Trypanosoma brucei and 
Trypanosoma cruzi (the causative agents of sleeping sickness and Chagas’ disease, 
respectively). However, because this project focused on P. falciparum , the latter 
results are presented in Appendix 8 .
6.3 TLM and derivatives of the C5 (R l) position
The first group of compounds that were synthesised were based on the series of TLM 
derivatives that exhibited increased activity against pea plastids (Jones et al., 2000).
At the outset of this work, these were the only TLM analogues that had been reported 
with any activity against a Type II FAS system, although later reports showed that 
these compounds also inhibited the growth of P. falciparum  (Waller et al., 2003) and 
M. tuberculosis (Kremer et al., 2000). Thiolactomycin (compound 781) was
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synthesised as described by Jones et al., 2004). Compounds were also produced in 
which the isoprenoid moiety at position 5 of the thiolactone ring was substituted with 
hydrogen, hexyl, octyl, geranyl, decyl and hexadecyl groups. These inhibitory effect 
of these compounds were tested in in situ cultures of P. falciparum K1 strain (Jones et 
al., 2004) and the results are shown in Table 6.2.
Several of these analogues showed greater activity than that of compound 781 (TLM) 
against the parasite; the best of this series, compound 777, displayed a 6 -fold 
improvement. The findings from these studies suggested that replacement of the 
isoprenoid group with longer hydrocarbon chains led to enhanced activity against the 
parasite. Comparison of compounds 778 and 780 showed that a geranyl substitution 
was more effective against the parasite than a saturated, unbranched octyl group, 
suggesting that an increase in the number of double bonds and branched chains 
produced greater inhibition. This trend was subsequently observed in compounds 
tested against the P. falciparum W 2mef strain (Waller et al., 2003), although with 
different LD50 values compared to our studies using strain K l.
The increase in the inhibitory activity of substituted TLM compounds in cultures of 
P. falciparum does not prove that these derivatives target fatty acid synthesis or are 
better inhibitors of the target enzymes (possibly MBP-pfFabF or MBP-pfFabH). Thus, 
the increase in activity may be caused by more efficient diffusion of the more 
hydrophobic compounds through lipid bilayers (ref?). If the Type II FAS system in 
P. falciparum is located in the apicoplast, these compounds would have to pass 
through at least six membranes: - the erythrocyte membrane, the parasitophorous 
vacuolar membrane and the four membranes surrounding the apicoplast.
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C om pound
No.
D escrip tion S tru c tu re LD 50
(pM )
817 C5 Hydrogen
HO CH3 >347
781 C5 Isoprenoid 
(TLM)
HO CH3
143
779 C5 Hexyl h3c
HO CH3
139
780 C5 Octyl 153
778 C5 Geranyl
HO CH3
40
776 C5 Decyl
0
/ HO CH3
36
111 C5 Hexadecyl
HO CHg
25
Table 6.2 H ydrocarbon substitu tio n s  a t  position  5 o f T L M  exhibit enhanced  
activity against P. falciparum cu ltu res
The inhibition of the chloroquine and pyrimethamine resistant K1 strain of 
P. falciparum was measured using a 3H-hypoxanthine assay (Jones et al., 2004). TLM 
and its derivatives were dissolved in 2% DMSO. The LD50 values are calculated using 
the mean of two independent assays performed in duplicate.
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Therefore, compounds with a significantly better ability to diffuse or be actively 
transported through these membranes would be expected to show a greater efficacy 
against P. falciparum.
6.4 Substitutions of the  m ethyl g ro u p  a t  the  C3 (R2) position
6.4.1 E thyl substitu tions a t  th e  C3 (R2) position
The substitutions described at position 5 showed a modest improvement in 
anti-malarial activity. However, substitutions at other positions in the ring have not 
been fully investigated against any Type II FAS system. The detailed study of the 
crystal structure of E. coli FabB complexed with TLM (Price et al., 2001), found that 
the two methyl substituents at the C3 (R2) and C5 (R3) positions were accommodated 
into two small hydrophobic pockets comprising Phe229 & Phe392 and Pro272 & 
Phe390 respectively (Figure 6.3). It has been proposed that the C3 methyl group 
occupies the position of the carboxylate carbon of the natural substrate malonyl-ACP 
(Price et al., 2001). The two oxygen atoms of the malonyl-ACP carboxyl group 
protrude further into this environment (Price et al., 2001), suggesting that the 
hydrophobic pocket surrounding the C3 methyl group was not optimally filled. Based 
on this information, a series of analogues (818-821 and 823), possessing an ethyl 
substituent at C5, were synthesised and tested against cultures of P. falciparum 
(Table 6.3).
With the exception of compound 818, all of the compounds demonstrated greater 
inhibition of P. falciparum cultures, compared to TLM. In parallel with the C3 methyl 
compounds (Table 6.2), C3 ethyl analogues that contained longer chains at C5 tended
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Phe392
Pro272
Phe229
C3 Methyl
C5 Methvl
Phe390
Figure 6.3 The methyl groups of TLM  are  positioned in small hydrophobic 
pockets
TLM is shown bound to the active site of E. coli FabB enzyme, with its two natural 
methyl groups nestled in two small, hydrophobic pockets formed by Phe390 %
Pro272, and Phe392 & Phe229. The lFJ4.pdb file (Price et al., 2001) was downloaded 
from the Brookhaven database and was manipulated using SwissPDB viewer (Guex 
and Peitsch, 1997).
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C om pound
No.
D escrip tion S tru c tu re L D 50
(pM )
818 C5 Hydrogen 
C3 Ethyl
:?C r
HO
233
820 C5 Hexyl 
C3 Ethyl
— xvh3c y j  
ho \
61
823
C5 Octyl 
C3 Ethyl
,——x'rh3c \ = J
ho y 54
821
C5 Decyl 
C3 Ethyl
H3C U  J
ho y 15
819
C5 Hexadecyl 
C3 Ethyl HO \ 19
Table 6.3 Effect of ethyl su b stitu tio n s  a t  C3 o f T L M  on activity  aga in st 
P. falciparum cultures.
See the Legend of Table 6.2 for further details.
to show greater inhibition. The best analogues, 821 and 819 showed 10-fold and 
8-fold increases in inhibition over TLM respectively. Analogues with C3 ethyl groups 
showed enhanced activity against the parasite when compared to those with C3
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methyl groups (compare those in Table 6.3 to Table 6.2). This trend is highlighted 
when comparing the analogues with C5 octyl groups, 823 (54pM) shows a three-fold 
increase in activity compared to 780 (153pM). However, in analogues with longer C5 
chains, the substitution of the C3 ethyl group caused a much smaller improvement in 
activity (compare 821 (15pM) to 776 (36pM) and 819 (19pM) to 777 (25pM). It is 
clear that the ethyl substituent is having a positive influence on the overall inhibitory 
activity against the parasite.
Compounds 817 and 818 (Table 6.2 and 6.3) possess a C5 (Rl) hydrogen group 
exhibit LD50 values in the high micromolar range. Three other compounds (822, 924 
and 926) that possess a hydrogen group at this position were synthesised an assayed 
against the malaria parasites (Table 6.4). In comparison to analogous compounds that 
contain C5 decyl groups (Table 6.4) these compounds show a significant decrease in 
the inhibition of growth in cultures of P. falciparum. All of the five compounds 
containing a C5 (Rl) hydrogen group (Compounds 817, 818, 822, 924 and 926) 
showed lower inhibition of parasite cultures compared to TLM. Members of this 
series also displayed the lowest LD50 values observed in this project. These data 
provide further evidence that hydrophobic interactions, between the C5 group of TLM 
derivatives and the target protein in P. falciparum, make a significant contribution to 
the inhibitory activity of the compounds.
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Compound
No.
Description Structure LD50
(pM)
924 C5 (Rl) Hydrogen 
C3 Propyl
■XV
H O  ' --------------^
>290
925 C5 (Rl) Decyl 
C3 Propyl
S  0
1 0
926 C5 (Rl) Hydrogen 
C3 Benzyl
X Yv )—( r ===\  
—V j /
195
927 C5 (Rl)Decyl 
C3 Benzyl
50
822 C5 (Rl) Hydrogen 
C5 (R2) Ethyl
CO>d> >316
825 C5 (Rl) Hydrogen 
C5 (R2) Ethyl
HO ' 65
Table 6.4 Hydrogen substitutions at position 5 of TLM exhibit decreased activity
against P. falciparum cultures
See the Legend of Table 6.2 for further details.
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6.4.2 Longer hydrocarbon chains at the C3 (R2) position
The above data prompted the synthesis of a group of compounds with longer or larger 
hydrocarbon moieties at position C3. To achieve a direct comparison of these 
analogues the C5 chain length was kept constant. Since the most effective compound 
contained a C5 decyl chain (821: see above), while investigating the effect of altered 
C3 chain lengths, all of the analogues possessed a C5 decyl substituent. Substitutions 
at the C3 position were achieved with propyl, butyl and benzyl groups (Jones et al.,
2004) and these three new compounds were assayed against P. falciparum 
(Table 6.5). These data show that by extending the ethyl chain to a propyl chain an 
LD50 = lOpM was achieved for the first time in this project, giving a 14-fold increase 
in activity over TLM. Extending the chain further to butyl and benzyl groups resulted 
in a decrease in activity. This suggested that the propyl group of three carbons was the 
optimal chain length at the C3 position, beyond which activity was diminished.
To reinforce this assertion, compound 925 was docked into the active site of the 
E. coli FabB protein using FlexX software (Jones et al., 2004) (Figure 6.4). The 
propyl group appeared to fit into the hydrophobic pocket with the C-terminus of the 
propyl chain in close proximity to the active site Cysl63. This same active site 
cysteine is present in the MBP-pfFabF enzyme (Cysl65- MBP-pfFabF numbering). 
However, one of the two highly-conserved residues (Pro272 and Phe390) that 
constitute the hydrophobic pocket where the C3 group is positioned, is replaced by 
leucine in pfFabF (Pro275 and Leu404 - pfFabF numbering). This suggests that there 
may be a larger hydrophobic pocket or that fewer hydrophobic interactions occur in 
this region. A model of pfFabF based on the E. coli FabB-TLM complex was 
constructed using Swiss PDB viewer and suggested that the active site architecture
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was very similar and that a propyl chain at the C3 position of TLM could be 
accommodated into the active site of pfFabF (Results not shown).
Compound
No.
Description Structure LD50
(pM)
925 C5 Decyl 
C3 Propyl
s
1 0
1199 C5 Hexadecyl 
C3 Propyl
hp w
HD '---\
6
927 C5 Decyl 
C3 Benzyl
50
1200 C5 Hexadecyl 
C3 Benzyl
7
Table 6.5 A comparison of C5-decyI and C5-hexadecyl substitutions
See the Legend of Table 6.2 for further details.
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PK0272
PH IH 90
PHI W r
ms29K / _
<  ^swn
IHS333
UR302
PHI.229
MFT201
7
PHI 201
Figure 6.4 Compound 925 docked in the active site of E. coli FabB
The C3 propyl chain of this compound is positioned close to the active site Cysl63 
residue. Part of the C3 propyl group is obscured.
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6.4.3 Hexadecyl substitutions
All of the compounds reported in the previous section possess C5 decyl groups. In the 
original batch of compounds (Section 6.3 & Table 6.2) a C5 hexadecyl group was 
shown to have enhanced activity compared to the analogue containing a C5 decyl 
group (compare 777 to 776). Therefore, because compound 925 contains a decyl 
chain and is the best inhibitor against P. falciparum cultures to date, it seemed logical 
to synthesise the derivative with a C5 hexadecyl chain combined with a C3 propyl. A 
derivative containing a C3 benzyl group was also synthesised and tested against 
P. falciparum cultures (Table 6.6). Both hexadecyl derivatives showed an increased in 
inhibition compared to the corresponding decyl derivatives. This provides further 
evidence that TLM derivatives with longer hydrocarbon side chains have an enhanced 
inhibitory effect on the growth of the malaria parasite.
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Compound
No.
Description Structure LD50
(UM)
776 C5 Decyl 
C3 Methyl '  HO CH3
36
821 C5 Decyl 
C3 Ethyl
^ / N y s ^ Y Sy °
h3c y j
HO \
15
925 C5 Decyl 
C3 Propyl
HO '---^
1 0
944 C5 Decyl 
C3 Butyl
HO '-- v
71
927 C5 Decyl 
C3 Benzyl
50
Table 6 . 6  Substitutions at C3 of TLM exhibit variable activity against 
P. falciparum cultures
See the Legend of Table 6.2 for further details.
6.5 Substitution of the methyl group at the C5 (R3) position
The increased inhibitory activity shown by substitutions of the methyl group at 
position 3 suggested that an improvement might also be observed when substituting
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the methyl group that is the second substituent (R3) at position 5. Two compounds 
with ethyl groups at C5 (R3) were synthesised (compounds 825 and 863) (Jones et al.,
2004). The removal of the C5 methyl group and its replacement with a hydrogen atom 
(compound 943) was also carried out. A comparison of the inhibition of P. falciparum 
by compounds containing hydrogen, methyl- or ethyl- groups at position R3 is shown 
in Table 6.7.
All of the analogues showed improved inhibition over TLM. However, direct 
comparisons of the analogues containing ethyl substituents and their methyl 
counterparts suggested that the presence of the ethyl group causes a decrease in 
activity (Table 6.7). This also appeared to be case in the analogue where the C5 
methyl group was replaced by hydrogen (LD50 = 15pM for 821 and LD50 = 72pM for 
943). Therefore, unlike the substitution of the methyl group at C3, modification of the 
C5 methyl group does not appear to offer any advantage for activity against 
P. falciparum. The two amino acids of E. coli FabB (Phe229 and Phe392) that 
constitute the hydrophobic pocket that the C5 methyl group rests in, are conserved in 
pfFabF (Phe232 and Phe404) and the areas surrounding these residues are also highly 
conserved.
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Compound
No.
Description Structure LD50
(UM)
776
C5 Rl Decyl 
C5 R2 Methyl '  HO ch3 36
825 C5 Rl Decyl 
C5 R2 Ethyl
HO '
65
777
C5 Rl 
Hexadecyl 
C5 R2 Methyl
HO CH,
25
863
C5R1 
Hexadecyl 
C5 R2 Ethyl
35
821
C5 Rl Decyl 
C3 Ethyl 
C5 R2 Methyl
^ / ^ Y Sy 0
h3c y j
HO >
15
943
C5 Rl Decyl 
C3 Ethyl 
C5R2H
/ HO '--
72
Table 6.7 Substitution of the C5 (R3) methyl group of TLM causes a decrease in 
activity against P. falciparum cultures
See the Legend of Table 6.2 for further details.
6 . 6  Replacement of the sulphur heteroatom
6.6.1 Tetronic acids -  substitution of the sulphur heteroatom with oxygen
The 3D structure of E. coli FabB complexed with TLM showed the thiolactone 
sulphur does not make any obvious specific interactions with the protein but sits
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adjacent to the side chain of the active site Cysl63 (Price et al., 2001). However, the 
side chain of Cysl63 moves 2.1 Angstroms to avoid clashing with the TLM sulphur. 
This suggested that replacing the thiolactone sulphur with a similar but smaller atom 
might cause less disruption of the protein. This could allow tighter binding of the 
TLM derivative and, thus, increased inhibition of the enzyme. Three analogues were 
synthesised where the thiolactone sulphur was replaced by an oxygen atom. This 
substitution would allow the shape and structure of the TLM analogues to remain 
essentially the same, whilst reducing the size of the atom at position 1 of the ring. 
These compounds (922, 923 and 945) were tested against P. falciparum cultures and 
were compared to the results observed with their sulphur containing counterparts 
(779, 821 and 945) (Table 6.8).
These compounds exhibited a reasonable activity against the parasite. Two of the 
three compounds showed a decrease in the activity against the parasite compared to 
the sulphur containing analogues; the third showed a small increase in activity. This 
suggested that the replacement of the sulphur thiolactone with an oxygen atom did not 
confer a significant advantage that would justify the replacement. Yields from the 
synthesis of oxygen-containing compounds were lower than those observed with the 
sulphur-containing compounds and it was decided not to continue to synthesise 
oxygen ring compounds.
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Compound
No.
Description Structure
1
!!
922 Ol 
C5 hexyl H3° \=A
HO '
222
779 SI
C5 Hexyl ^ ^ X Yh 3c  w v
HO CH3
139
923
Ol 
C5 Decyl 
C3 Ethyl
94
821
SI
C5 Decyl 
C3 Ethyl
^ / N y Y Sy °
ho \
15
945 Ol 
C5 Decyl 
C3 Butyl
HO '--- y
57
944
SI
C5 Decyl 
C3 Butyl
h p y J
HO '--- v
71
Table 6.8 A comparison of sulphur and oxygen containing heterocycles
See the Legend of Table 6.2 for further details.
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6.6.2 Replacement of the sulphur heteroatom with a nitrogen
An alternative to replacing the sulphur with an oxygen atom could be the introduction 
of a nitrogen atom. This might improve the activity against the parasite and would 
also provide the opportunity to extend from position 1 of the ring structure 
(Figure 6.5), which has so far been impossible.
H O
R2HO
Figure 6.5 The general structure of nitrogen heterocycles and compound 1084
The synthesis of nitrogen heterocycles proved difficult since the adopted variation of 
the original scheme produced a very low yield (Simon Jones, personal 
communication). A new synthetic route was designed and a single compound, 1084, 
was produced in sufficient quantity and purity for biological testing. Unfortunately, as 
a result of the synthetic pathway the C3 methyl group was replaced by a ketone and 
the C5 methyl group was replaced by a hydrogen atom (Figure 6.5). Thus, with the 
nitrogen heterocycle compound, it is difficult to evaluate the effect of replacing the 
sulphur atom with nitrogen, as no direct comparison could be made with previous 
compounds.
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Compound 1084 showed an LD50 of 63jiM against cultures of P. falciparum, which is 
an improvement on TLM. The only compound tested previously that contained decyl 
and hydrogen moieties at position 5 is 943 (LD50 = 72pM), this compound had an 
ethyl group at the C3 position. Whilst there is a slight increase in inhibition observed 
with 1084 compared to 943, we cannot ascertain whether contributions from the 
heteroatom nitrogen or the ethyl to ketone substitution at C3 are solely or partially 
responsible for this increase.
6.7 Addressing problems in solubility
In preparation for biological assays each compound is dissolved in 20% DMSO 
before diluting to 2% DMSO in the final assay, where the solvent itself had no 
detectable effect. Some analogues with hexadecyl chains were turbid when dissolved 
at 2mM concentrations in 20% DMSO, which suggested that these compounds were 
not completely dissolved at these concentrations in this solvent. Other solvents 
(ethanol, tetrahydrofuran) were used to dissolve these compounds, however, these 
solvents had a significant impact on the assay itself (results not shown). These 
undesirable effects were to the detriment of the accuracy of the assays. Therefore, in 
order to improve the solubility of some of these compounds it was decided to attempt 
the synthesis of long chain C5 hydrocarbon chains containing ether or hydroxyl 
groups.
Three compounds, 1021, 1086 and 1195, all possessed C5 chains containing oxygen 
either as ether linkages or as a terminal hydroxyl group. These groups did not contain 
chain lengths equivalent to the hexadecyl chain observed in previous compounds, due
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to the limited range of commercially available precursor molecules for use in 
synthesis. These compounds all dissolved at high concentrations in 2% DMSO and 
the solubility problem appeared to have been addressed. The three derivatives were all 
tested against in vitro cultures of P. falciparum (Table 6.9). These compounds all 
showed LD50 values in the 50-lOOfiM range and did not appear to exhibit any 
increased inhibition compared to compounds with saturated hexadecyl C5 (Rl) side 
groups.
Compound
No.
Structure LD50
(UM)
1 0 2 1 °^xy°
HO ' -------
61
1086 92
1195
HO
>73
Table 6.9 Attempts to overcome solubility in long chain C5 hydrocarbon chains
See the Legend of Table 6.2 for further details.
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6.8 Extending from the 4-hydroxyl group
The structure of the E. coli FabB-TLM complex shows that the 02 oxygen at position 
4 is involved with hydrogen bonding to the carbonyl oxygen of residue 270 and the 
amide nitrogen of residue 305 through a lattice of water molecules (Figure 6.6). These 
interactions may be central to the binding of TLM to the active site of the enzyme.
The water molecules are positioned at the base of the active site tunnel that would 
incorporate the malonyl-ACP substrate and the phosphopantetheine arm of ACP. The 
synthesis of compounds with modifications of the C4 hydroxyl group would allow 
investigation and exploitation of possible interactions with the active site tunnel. Six 
compounds were synthesised utilising the C4 hydroxyl oxygen to generate an ether 
linkage to short and medium length hydrocarbon tethers. These were tested against 
the parasite as described before (Table 6.10).
All of the compounds showed an improvement in the level of inhibition of parasite 
cultures compared to TIM. Compound 1152 exhibited the best activity against 
P. falciparum cultures within this project, demonstrating the first LD50 ~lpM. The C3 
propyl substitution continues to exert a positive influence on the efficacy of the 
compounds (compare 1023 to 1152). When compared to their hydroxyl containing 
counterparts (compare 776 LD50 = 36pM to 1023 LD50 = 6pM and 925 LD50 = lOpM 
to 1152 LD50 = lpM), these analogues exhibited a six-fold and ten-fold increase in 
inhibitory activity. Compounds 1023 and 1152 had longer-chains that ended in an 
ethene group and this unsaturated bond may improve interactions with the 
hydrophobic tunnel. The replacement of the double bond with a benzyl group 
(compound 1192) slightly decreased the inhibitory activity. Suggesting that this large
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group may cause some steric hindrance in the active site tunnel compared to the 
double bond of compound 1152.
Val 270
Phe 392
TLM
C v s 163
Glv 305
His 298
His 333
Figure 6.6 TLM bound in the active site of E. coli FabB
The inhibitor and key residues of E. coli FabB are shown. Hydrogen bonds are shown 
as green dashed lines. Water molecules are shown in orange. Hydrogen bonding 
between the C4 hydroxyl group of TLM and the backbone of two of the amino acid 
residues is shown. The lFJ4.pdb file (Price et al., 2001) was manipulated using 
SwissPDB viewer (Guex and Peitsch, 1997).
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Compound
No.
Structure LD50
(HM)
1023
63
1140
\
44
1152
H,C \ ------ /
\  \ 1.3
1192 3 4
1193
XT
\  x  
0
/ _
■----S I----
2.7
Table 6.10 (continued overleaf)
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1210 >18
OH
Table 6.10 Derivatives at the C4 position show a significant improvement in 
activity against the P. falciparum parasite in vitro
See the Legend of Table 6.2 for further details.
Compounds 1140,1193 and 1210 all contained a C5 (Rl) hydrogen group and cannot 
be directly compared to compounds 1023,1152 and 1193, which all contain a C5 
decyl side chain. Interestingly, compound 1193 that possessed an ether linked longer 
hydrocarbon chain and terminating in a silicon group showed the second best LD50 
within this project suggesting that this group had favourable interactions between the 
target enzymes.
The presence of five different ether linked groups across the series of six compounds 
that showed improvement of activity compared to their hydroxyl counterparts, may 
indicate that the hydroxyl group contributes minimally to the binding of TLM and its 
derivatives to the physiological relevant target in P. falciparum.
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6.9 Saturated ring structures (Dicarbonyl compounds)
Recently, Minnikin reported the synthesis of S O
thiophenedione compounds (Figure 6.7)
(Minnikin etal., 2002). These compounds
allow the addition of two groups at the C3
position thus permitting the investigation of further 
groups at this position. Such structures also differ
from TLM in two major ways. Firstly, the C2, C3 Figure 6.7 A thiophendione 
and C4 of TLM is planar due to the double bond
between C3 and C4, whilst the new thiolactone ring will form a non-planar structure 
that may significantly alter the position of the side groups. In turn, this may disrupt 
existing interactions between TLM and target proteins but also allows for the 
formation of new interactions. The dicarbonyl compounds should allow a decision to 
be made whether the planar structure of the ring is essential for the inhibitory activity 
of TLM and its derivatives. Secondly, the 4-hydroxyl is replaced with a carbonyl 
moiety, which will almost certainly have some effect on the biological activity of the 
compound. We have already reported that, by placing an alkyl chain on the 
4-hydroxyl position through an ether linkage, there was an increase in the antimalarial 
efficacy of some compounds. It is likely that the carbonyl oxygen atom will be in a 
position very similar to the 4-hydroxyl oxygen, however, whilst the carbonyl oxygen 
retains its ability as a hydrogen bond acceptor, it has lost its ability as a donor to 
hydrogen bonds.
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Five saturated ring, dicarbonyl compounds were synthesised with varying 
substitutions at the C3 and C5 positions. These were tested against cultures of blood 
stage P. falciparum and the results are shown in Table 6 .1 1.
Assays of the five compounds showed that saturated ring structures are capable of 
exhibiting a greater activity against the parasite compared to TLM. The replacement 
of a C5 hydrogen with a C5 decyl group increased the inhibitory activity once more 
(compare 1022 to 1020) and a propyl group. The addition of a propyl group at the C3 
position (comparel041 to 1022) also caused a small increase in inhibition. Minnikin 
and colleagues reported the synthesis of a saturated compound with geranyl and 
methyl groups at position 3 and this compound displayed an increased activity against 
cultures of M. tuberculosis (Minnikin et al., 2002). The latter compound also 
appeared to be inactive against the Type II FAS and mycolic acid biosynthesis 
systems in the bacteria, suggesting that the site of action of such a TLM derivative has 
yet to be elucidated. Compound 1194 differs from the Minnikin group compound by a 
substitution of the C3 methyl group with a C3 propyl group because we had already 
shown that this modification conferred has enhanced activity against P. falciparum 
(comparison of 1141 to 1 0 2 2 ).
251
Compound No. Structure LD50
(pM)
1 0 2 0
i
COI 
x-
J1 ------------ 62
1 0 2 2 26
1141 19
1194
> -
8.5
1209 > 1 1
Table 6.11 Open ring, di-carbonyl compounds show that the thiolactone ring is 
not essential for antimalarial activity
See the Legend of Table 6.2 for further details.
Compound 1194 showed the best inhibitory activity of all the saturated thiolactone 
ring derivatives. This compound contains only a C5 hydrogen group and may be
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expected to have a lower activity than compound 1141. However, compound 1194 
also possessed a geranyl group at the C3 position. Initial studies suggest that the 
conformation of this compound in the active site of pfFabF allows the positioning of 
the geranyl group in the hydrophobic pocket in which the C5 group of TLM is 
positioned (results not shown). This may explain why compound 1209 containing 
both a C5 decyl and C3 geranyl group exhibited decreased inhibition compared to 
1194, as both hydrocarbon chains would not be able to fill the hydrophobic pocket 
simultaneously. These inhibitory activity exhibited by these five compounds suggest 
that the unsaturated ring structure and the 4-hydroxyl, present in TLM, are not 
essential for the inhibition of the target enzymes.
6.10 Activity of TLM derivatives against MBP-pfFabF, a P. falciparum 
condensing enzyme
Of the two P. falciparum condensing enzymes that have been identified (this work; 
Waller et al., 1998; Prigge et al., 2003) MBP-pfFabF appears to be much more 
sensitive to the antibiotic thiolactomycin than MBP-pfFabH. This may indicate that 
MBP-pfFabF is the physiologically relevant target of TLM. Derivatives of TLM have 
been shown to exhibit increased activity against Type II FAS in pea plants, although 
purified individual enzymes were not assayed in this paper (Jones et al., 2000). The 
same derivatives exhibited an increase in inhibitory activity towards cultures of 
P. falciparum in erythrocytes (Waller et al., 2003; work presented in this Chapter). So 
far in this Chapter, many TLM derivatives with alterations in almost all positions of 
the thiolactone ring have been described. In this section, all of TLM derivatives were 
tested against the MBP-pfFabF fusion protein to discover whether any displayed 
enhanced activity against the enzyme.
253
The activity of the MBP-pfFabF protein was tested separately in the presence of 
lOOpM of each of the TLM derivatives. These assays should aid the identification of 
any derivatives that exhibit an inhibitory activity against the enzyme similar to TLM 
(IC50 = 3 pM (Figure 6 .8 )).
Unfortunately, none of the TLM derivatives showed similar or enhanced inhibitory 
activity against the MBP-pfFabF enzyme. To ascertain why there is an apparent lack 
of activity against this enzyme, several lines of inquiry were pursued. Firstly, the 
physical properties of the synthetic compounds i.e. purity, degradation during storage, 
mixtures of enantiomers skewed towards the inactive (5S)-enantiomer, should be 
investigated fully. Secondly, the structures of these compounds should be analysed to 
ascertain if there is any rational postulate that might explain their lack of activity 
against MBP-pfFabF.
The physical attributes of each TLM derivative were analysed immediately after 
synthesis (Jones et al., 2004; Simon Jones personal communication). NMR and mass 
spectroscopy were used to test the purity, and confirm the identity, of each compound. 
In these studies, the synthesis of the thiolactone core was based on a method 
described in the first report of the synthesis of a racemic mixture of TLM (Wang and 
Salvino, 1984). Therefore, it was expected that both the (5S) and (5R) enantiomers 
would be equimolar. Subsequently, a test of the chirality of one of the compounds 
(925) showed that this derivative was a 50:50 racemic mixture. The chirality of other
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Figure 6.8 The inhibitory effect of TLM derivatives on MBP-pfFabF activity
Assays were performed as single point concentrations as described in Section 2.2.24. Compound 1140 was not tested against this enzyme
because the stock was exhausted prior to the assays being performed. Assays were performed in duplicate and errors are shown as errors from 
the mean.
compounds was not determined as there were insufficient quantities of all the other 
TLM derivatives to be used in this test. However, there is no apparent chemical 
reason why a 50:50 racemic mixture would not be created and this is supported by the 
results for compound 925. Antagonistic effects of the (5S)-enantiomer cannot be ruled 
out. However, the 50:50 racemic mixture of TLM obtained from Sigma showed no 
evidence of antagonism from the (5S)-enantiomer as its inhibitory potency was half of 
that of the pure (5R)-enantiomer (Figure 5.16).
Compounds synthesised at a later stage of this project (1020-1210; 16 of the 40 
compounds) were tested against the MBP-pfFabF protein within six months of their 
synthesis. However, some of the derivatives that were produced in early 2001 were 
assayed over two years after their synthesis. Following synthesis, compounds were 
generally stored in the absence of solvents at -80°C. Some compounds were stored in 
ethanol at -80°C for two years. The potential effects of long term storage in ethanol is 
described later in this Chapter (Section 6.12). At least 10 of the TLM derivatives were 
assayed against MBP-pfFabF within two weeks of their synthesis and these 
compounds showed no inhibitory activity towards the enzyme (compounds 
1140-1210). The purity and physical properties of these compounds were tested at the 
time of the MBP-pfFabF assays and there was no evidence of degradation. Therefore, 
it appears unlikely that degradation of these compounds was an important factor in 
their apparent lack of activity against MBP-pfFabF.
The structures of the TLM derivatives tested during this project are diverse compared 
to those published in previous studies, which only showed alterations at the C3 and 
C5 positions (Jones et al., 2000; Waller et al., 2003; Kremer et al., 2000). However,
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despite the majority of these TLM derivatives showing increased inhibitory activity 
against in vitro cultures of P. falciparum, none of the compounds show increased 
activity against MBP-pfFabF. This may suggest that the alterations that have been 
made to the TLM structure decrease the affinity of these compounds for the active site 
of MBP-pfFabF. Of all of the side chains present in the structure of TLM, the 
isoprenoid group at C5 is only present in compound 781, a compound which we 
subsequently believed to have degraded significantly due to storage in ethanol. Recent 
evidence has shown that this group appears to be central for the inhibitory activity of 
TLM derivatives against bacterial FabB enzymes (Price et al., 2001). A double bond 
of the isoprenoid group is positioned between two peptide bonds (391-392) and (271- 
272) the interaction between these three delocalised systems is important to TLM 
specificity in E. coli. This may suggest that the alterations made to the C5 side chains, 
in this project, increased the activity against in situ cultures of P. falciparum (Table 
6.2) but caused a significantly decrease in the activity against MBP-pfFabF due to the 
lack of an isoprenoid group.
6.11 Activity of TLM derivatives against MBP-pfFabH
In an attempt to identify compounds that exhibited enhanced activity against the first 
condensing enzyme identified in P. falciparum, the activity of the MBP-pfFabH 
protein was assayed in separate reactions containing lOOpM of all of the TLM 
derivatives described in this report. Racemic TLM showed an IC50 = 200pM 
(Figure 5.18), however inhibition of 30% of MBP-pfFabH activity was observed in 
the presence of 100pM of the compound. Therefore, any compound that showed 
similar or enhanced inhibitory activity towards MBP-pfFabH should be identified in
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this assay. The results of assays containing IOOjjM of each of the TLM derivatives are 
shown in Figure 6.9.
The first batch of compounds (776-780) that were assayed against MBP-pfFabH 
contain a replacement of the C5 isoprenoid group of TLM with other hydrocarbon 
chains. One of these compounds, 777, showed a significant increase in inhibitory 
activity towards MBP-pfFabH. This compound possesses a hexadecyl (Ci6H33) side 
chain, the longest C5 hydrocarbon group synthesised during this project. Compounds 
containing a decyl or geranyl side chain at the C5 position (776 and 778, respectively) 
exhibited activity against MBP-pfFabH, but were not significant improvements 
compared to racemic TLM provided by Sigma. Shorter chain hydrocarbon groups at 
C5 had negligible activity.
A similar trend in the change of activity with C5 substitutions was seen in a second 
series of derivatives, which possess an ethyl substitution at the C3 position. 
Compounds with C5 hydrocarbon chains eight carbons, or fewer, in length, exhibited 
negligible inhibitory activity against MBP-pfFabH. However, compounds containing 
the ten carbon (decyl, compound 821) group at C5 inhibited approximately 40% of 
MBP-pfFabH activity, whilst the sixteen carbon (hexadecyl, compound 819) group 
inhibited over 60% of the enzyme activity (Figure 6.9). Compound 819 possesses a 
C3 ethyl group and the inhibition by this compound was slightly greater than that of 
compound 777, which possessed a C3 methyl group, however this difference was not 
statistically significant.
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Figure 6.9 The inhibitory effect of TLM derivatives on MBP-pfFabH activity
Assays were performed as single point concentrations as described in Section 2.2.25. Assays were performed in duplicate and errors are shown 
as errors from the mean. The majority of errors were within 5% of the average inhibition.
The two TLM derivatives that exhibited the highest inhibitory effect against 
MBP-pfFabH possessed C5 hexadecyl side chains. Unfortunately, due to the very 
hydrophobic nature of the long hydrocarbon side chain, it was extremely difficult to 
dissolve these compounds, at concentrations utilised in the assays, using DMSO as a 
solvent. Alternative solvents (ethanol, THF) were evaluated for their suitability in the 
assay. Whilst the C5 hexadecyl TLM derivatives were soluble in both solvents, the 
solvents themselves had a detrimental effect on the assay, suggesting that they 
interfered with the enzyme activity. Therefore, in further studies, hexadecyl groups 
were not incorporated into TLM derivatives. Instead, decyl groups that were much 
more soluble in DMSO, compared to hexadecyl derivatives, were synthesised.
A series of derivatives that possessed C5 decyl hydrocarbon chains and different C3 
hydrocarbon groups (Figure 6.10) showed that increasing the size of the C3 group 
increased the inhibitory activity against MBP-pfFabH. This trend was similar, in part, 
to those observed in cultures of P. falciparum in situ (Figure 6.10). However, within 
this series, the derivative that exhibited the best inhibitory activity against the whole 
organisms possessed a C3 propyl group, whilst in assays of MBP-pfFabH the 
derivative possessing the C3 benzyl group exhibited the highest inhibitory effect. 
Within this series of compounds, three (925-C3 propyl, 944-C3 butyl and 927-C3 
benzyl) displayed greater inhibitory activity against MBP-pfFabH compared to TLM. 
Separate assays determined that compound 927 had an IC50 ~ 50pM against 
MBP-pfFabH, compared to an IC50 ~ 2 0 0 pM for TLM.
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Figure 6.10 TLM derivatives with different C3 groups
Compounds with hydrocarbon chains of increasing size exhibit increased inhibitory 
activity against pfFabH. Increasing the side chain size from methyl to propyl also 
improved the LD50 value against the in situ cultures of P. falciparum. However, 
compounds possessing a C3 butyl and C3 benzyl group decreased the inhibitory 
activity of these compounds against the parasite.
Of the many alterations to the structure of thiolactomycin, only one derivative 
exhibited increased activity compared to that of compound 781 (synthetically 
prepared TLM). At a concentration of 1 OOpM compound 1194 exhibited the highest 
inhibitory activity described so far in this Chapter, inhibiting 87.5% activity of 
MBP-pfFabH activity. The IC50 was approximately 18pM against MBP-pfFabH, an 
order of magnitude greater than that observed by with TLM. A lOOpM concentration 
of this compound did not significantly inhibit cultures of P. falciparum and suggests
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that there may be problems in the transport of this compound into or through the 
parasite, which would mean the compound is not reaching MBP-pfFabH localised in 
the apicoplast.
The final compound that exhibited significant inhibitory activity is 781. This 
compound should be structurally identical to thiolactomycin. At lOOpM 
concentrations, compound 781 exhibited the second highest inhibition of 
MBP-pfFabH and an IC50 of approximately 25 pM. When compared to racemic TLM 
(Sigma), compound 781 showed a large and significant increase in inhibitory activity 
towards MBP-pfFabH (Figure 6.9). One explanation of this could be a predominance 
of the active (5R)-enantiomer in compound 781. However, the chirality of compound 
925 suggested that compounds produced using the same chemical route are a 50:50 
racemic mixture. The chirality of compound 781 was not tested itself due to extremely 
low yields. Furthermore, if there was a predominance of the (5R)-enantiomer, the 
inhibitory activity against MBP-pfFabF (Figure 6.8) should be increased compared to 
that of racemic TLM, when in fact, it is much lower. Even if compound 781 was 
synthesised as on the (5R)-enantiomer is should not exhibit more than twice the 
activity of Sigma TLM. In combination, these data suggest that compound 781 is not 
thiolactomycin.
6.12 An investigation of compound 781 structure
Following the synthesis of compound 781 in early 2001, NMR and mass spectrometry 
were performed on the compound. These tests confirmed that compound 781 had an
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identical structure to thiolactomycin. The compound was immediately tested against 
in situ cultures of the P. falciparum K1 strain and an LD50=143|jM was observed. 
When evidence was obtained that suggested compound 781 was not TLM, synthetic 
racemic TLM (Sigma Aldrich, Poole, UK) was also tested in cultures of the parasites. 
This racemic compound exhibited an LD5o >95pM, although a more accurate value 
was not obtained. This may indicate that when sent for testing against the K1 strain, 
compound 781 was a racemic mixture of TLM enantiomers and no significant 
degradation had occurred. The value of these LD50s was lower than the 50pM 
previously reported against the W2mef strain (Waller et al., 1998), however, strains 
may have significantly different susceptibilities to different inhibitors.
Assays of the inhibitory activity of compound 781 against MBP-pfFabF and 
MBP-pfFabH were performed in October 2003 and January 2004, respectively. 
During this long period of time between synthesis and testing, compound 781 had 
been stored at -80°C. However, in contrast to other compounds, compound 781 had 
not been stored dry but was dissolved in ethanol. An explanation behind this 
occurrence is explained herein. In preparation for use in biological and enzymatic 
assays, each compound was dissolved in ethanol because of the need to remove 
accurate jig quantities of the compound. An aliquot of the compound dissolved in 
ethanol was then removed and the ethanol evaporated under nitrogen. The compound 
could then be dissolved in the correct volume of DMSO to obtain the desired 
concentration. It appears that with respect to compound 781 the ethanol had not been 
evaporated from the original vial when an aliquot was removed for testing against 
P. falciparum cultures in early 2001. Had storage in ethanol for over two years altered 
the composition of compound 781?
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6.12.1 The effect of storage in ethanol on compound 781
In an attempt to see if compound 781 had degraded whilst being stored in ethanol for 
a long period of time, the compound was analysed by mass spectrometiy. The results 
(Appendix 9), when compared to the mass spectrometiy data of the newly synthesised 
compound, showed a decrease in the peak at 211.0 that corresponds to the molecular 
weight of thiolactomycin. Several other peaks were observed but could not be easily 
identified because the remaining amount of 781 was insufficient for detailed NMR 
analysis.
The synthesis of a second batch of compound 781 would prove useful because it 
could be stored in ethanol and NMR and mass spectrometry could be performed on it 
at regular intervals alongside enzyme inhibitor studies. Frustratingly, it proved 
impossible to purify a second batch of compound 781 throughout the course of this 
project, despite several alternative synthetic routes being implemented. It appears that 
the isoprenoid group at the C5 position is remarkably difficult to synthesise compared 
to other hydrocarbon chain substitutions at C5 (work in this project and a personal 
communication from Charles Rock, St. Jude Children’s Research Hospital, Memphis, 
USA).
As there were insufficient quantities of 781 for NMR analysis, racemic TLM (Sigma 
Aldrich, Poole, Dorset, UK) was stored in ethanol to determine if this had an effect on 
its inhibitory activity against MBP-pfFabH. Storage in ethanol for six weeks at 25°C 
showed an increase of 16% inhibitory activity compared to that not stored in ethanol 
(Figure 6.11), but this difference was not statistically significant. Analysis of this
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compound in H2 labelled ethanol suggested that some degradation had occurred but 
the main breakdown products have yet to be identified. The identification of the 
breakdown products is being actively pursued within this research project as it may 
yield a novel basis for the inhibition of pfFabH.
racemic TLM EtOH for 6 weeksracemic TLM
Figure 6.11 The effect of storage of TLM in ethanol on its inhibition of pfFabH
The assays were performed as described in Section 2.2.25, in triplicate and error bars 
show standard deviations from the mean.
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6.13 Discussion
In this project, forty TLM derivatives were chemically synthesised and their 
inhibitory effect was evaluated in cultures of P. falciparum parasites and in assays of 
both the parasite’s Type II FAS condensing enzymes, pfFabF and pfFabH. 
Encouragingly, against parasite cultures the majority of the derivatives showed 
enhanced inhibitory effect towards TLM. A comparison of the inhibition of parasite 
cultures and of the two condensing enzymes can be found in Figure 6.12.
6.13.1 A lterations o f th e  C5 (R l)  side ch ain
A comparison of a series of compounds that differed from TLM by substitution of the 
C5 isoprenoid group suggested that longer hydrocarbon chains correlated with 
increased inhibition in cultures of the parasites. Compounds that contained a hydrogen 
atom at this position (817 and 818) exhibited lower inhibitory activity compared to 
TLM whilst derivatives with saturated hydrocarbon chains longer than eight carbons 
(compound 780) show a much higher inhibitory effect (Table 6.2).
Increasing the size of the hydrocarbon group to ten carbon and sixteen carbon groups 
at the C5 (Rl) position had an increased inhibitory effect on the parasites 
(Table 6.2-6.3). However, compounds containing hexadecyl groups were often not 
soluble in 2% DMSO, the solvent used in all biological and enzyme assays.
Therefore, the results obtained with these compounds may not represent the maximal 
inhibitory effect that these compounds possess. Consider that if only 50% of these 
compounds were soluble, testing at IOOjliM concentrations means that only an 
effective concentration of 50jllM would be available. To address this problem 
compounds were synthesised with C5 side chains designed to increase the solubility
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Figure 6.12 Combined chart showing the LD50 values and % inhibition of each TLM derivative synthesised in this project
pfFabF and pfFabH inhibition is shown as percentage remaining activity in assays containing lOOpM of each compound is shown on the primary 
y axis. The inhibition of parasite cultures is shown as the L D 5 0  values with pM concentrations of each derivative. L D 5 0  values over 1 OOpM are 
shown in pM above each bar.
of the derivatives. Whilst these compounds (1021, 1086 and 1195) appeared to be 
more soluble in DMSO, unfortunately, none of them exhibited increased activity 
compared to their hexadecyl analogues. However, direct comparison to hexadecyl 
possessing derivatives should be avoided because none of these more soluble 
compounds contained C5 side chains longer than 12 atoms. The length of the C5 side 
chains synthesised in this series of TLM derivatives was limited by the number of 
commercially available precursor molecules.
The unsaturated and branched chains at the C5 (Rl) position of TLM did not appear 
to be essential for inhibition of parasite growth. However, the geranyl side group of 
compound 778 showed enhanced activity when compared to compound 780 that 
contained a saturated hydrocarbon of the same length. These data reinforce the 
previous observations that compounds with more unsaturated, branched hydrocarbon 
groups have an increased inhibitory effect against P. falciparum in situ (Waller et al., 
2003). The isoprenoid group of thiolactomycin consists of a four carbon backbone 
with a methyl side group on the second carbon from the thiolactone ring and two 
double bonds. Unfortunately, no compounds with a saturated butyl group at the C5 
position were synthesised within this project and analysis of the contribution of the 
branched structure and unsaturation of the isoprenoid group cannot be obtained 
directly from the data detailed in this project. Waller and colleagues showed that TLM 
derivatives that possess a four carbon group with a methyl side group on the third 
carbon from the thiolactone ring and only a single double bond show a decrease in 
activity (Waller et a l, 2003). The removal of the double bond also decreased the 
inhibitory activity towards the malaria parasites.
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The presence of the isoprenoid group at the C5 position of TLM may be essential for 
binding of the compound to the area surrounding the active site of pfFabF. None of 
the TLM derivatives synthesised during this project contained a C5 isoprenoid group, 
and all of these compounds were largely ineffective against the enzyme (Fig 6.9). 
Attempts in Cardiff to synthesise derivatives with C5 isoprenoid groups and other 
modifications were unsuccessful. This appears to be due to the difficulty of joining an 
isoprenoid group at the C5 position, due to the double bond at the secondary carbon of 
the precursor.
Interestingly, compound 1152, which exhibited the highest inhibition in cultures of 
the parasite (LD50 = 1.3pM) contained a modification of the C4 hydroxyl group to an 
ether linked unsaturated hydrocarbon. Structural studies of the E. coli FabB enzyme 
suggest that this group would be orientated towards the hydrophobic pocket that 
accommodates the growing acyl chain (Price et al., 2001). The complex of the 
inhibitor cerulenin in the active site of the E. coli FabB enzyme suggested that the 
long hydrocarbon chain of this inhibitor is positioned in the same pocket (Price et al., 
2001). Therefore, hydrophobic interactions between the extended chain and the 
surrounding amino acids of the hydrophobic pocket might be responsible for the 
increase activity against of malaria parasites. However, when tested against the 
pfFabF enzyme at IOOjiM concentrations only -20% of the total enzyme activity was 
inhibited.
Alterations at the C5 (Rl) position also had some influence on the level of inhibition 
observed in the assays containing the pfFabH protein. Compounds containing C5 (Rl) 
decyl or hexadecyl groups consistently showed increased inhibition of the enzyme
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compared to those with shorter side chains. In some comparisons the hexadecyl 
derivatives appear to have a greater inhibitory effect (Figure 6.9 -  compare 776 
(decyl) to 777(hexadecyl); 821 (decyl) to 819 (hexadecyl)) and in other cases decyl 
analogues had increased effect (compare 925 (decyl) to 1195 (hexadecyl); 927 (decyl) 
to 1200 (hexadecyl). This may suggest that these groups are having an effect outside 
of the active site area.
To date, the structure of TLM or any TLM derivative bound to a FabH enzyme has 
not been solved. Most likely because of the lower affinity of TLM for FabH proteins 
compared to FabB and FabF-like proteins. However, the hydrophobic pocket that 
accommodates the C5 (Rl) isoprenoid group in E. coli FabB does not exist in the 
E. coli FabH protein. This suggests that these longer chain C5 (Rl) derivatives would 
not fit into the active site of pfFabH, which shows high sequence identity to the 
E. coli FabH protein, without causing considerable changes in the protein structure.
There is evidence that bacterial and plant FabH proteins possess a highly conserved 
region of 7 amino acids near the C-terminus (Figure 3.1; E. coli numbering 273-279), 
which are involved in feedback inhibition of the enzyme by long chain acyl-ACPs and 
acyl-CoAs (Heath and Rock, 1996; Abbadi et a l, 2000). A N274D mutant of the 
Cuphea wrightti FabH enzyme abrogated the inhibitory effect of long chain 
acyl-ACPs whilst retaining all condensing enzyme activity. This conserved region is 
also present in the P. falciparum FabH protein and suggests that this enzyme may also 
be inhibited by the binding of long chain acyl groups. It is possible that the CIO and 
Cl6- acyl groups present in lOOfiM concentrations in these assays are interacting with 
this regulatory domain to inhibit enzyme activity. However, these acyl groups are not
bound to acyl carrier protein, which may contribute significantly to the interaction 
between the acyl-ACP group and the FabH protein. As further work to this project, 
the activity pfFabH protein should be tested in assays containing long chain 
acyl-ACPs to see if this feedback recognition exists in P. falciparum. Progress in the 
understanding of ACP docking to Type II FAS enzymes of E. coli (Zhang et al., 2001 
& 2003) may help to understand the interaction between the regulatory site and the 
acyl-ACP, with the aim to synthesise inhibitors of FabH proteins that bind to the 
regulatory site.
6.13.2 Alterations of the C3 (R2) side chain
Increasing the size of the C3 methyl group of TLM also increased the activity of the 
TLM derivatives towards the parasites. By extending the methyl group to a propyl 
group (compound 925) an LD50 of lOfiM was achieved (Table 6.5). Increasing the 
propyl tether to a butyl or benzyl derivative resulted in a decrease in activity (LD50S of 
71pM and 50pM, respectively) (Table 6.5). Docking experiments of compound 925 
in the active site E. coli FabB (the homologue of pfFabF the assumed target of TLM 
inhibition in P. falciparum) performed during this project suggested that the propyl 
group fits snugly into the active site of this enzyme, with the terminus of the propyl 
chain in close proximity to the active site Cysl63. Unfortunately, possibly due to the 
lack of derivatives that possessed a C5 (Rl) isoprenoid group, no increase in 
inhibitory activity was observed in substituted C3 groups towards the pfFabF protein.
Encouragingly, the increase in activity towards whole parasites may, in part, be 
explained by the increase inhibition of pfFabH by compounds containing extended C3 
chains (Figure 3.11). The hydrophobic pocket in this enzyme that incorporates the C3
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group is possibly larger than that of E. coli FabB because butyl and benzyl groups 
exhibited increased activity compared to the propyl derivative (Figure 3.11).
6.13.3 A comparison of TLM derivatives in biological and enzyme assays 
The majority of TLM derivatives synthesised during this project were produced prior 
to the production of purified recombinant pfFabF and pfFabH. These compounds 
were, therefore, tested against cultures of the P. falciparum K1 strain prior to studies 
in assays containing the condensing enzymes. A general increase in the inhibitory 
activity of the TLM derivatives against whole parasites is apparent in Figure 6.12. 
The yellow bars show that derivatives synthesised at later stages in the project had 
considerably lower LD50 values compared to those synthesised at the start of the 
project. Interpretation of early in situ data combined with considerations of the TLM 
bound to condensing enzymes was used to design rationally compounds with 
moderate but increased inhibition of P. falciparum parasites. Encouragingly, this 
strategy appeared to be making advances towards finding a sub micromolar inhibitor 
of parasite cultures.
Previous work in this project suggested that pfFabF is inhibited by TLM with an IC50 
of approximately 3pM. Therefore, it may have been expected that TLM derivatives 
that exhibited increased activity against the parasites would also show increased 
inhibition of the pfFabF enzyme. However, this was not reflected in the assays of the 
protein, possibly due to the lack of a C5 (Rl) isoprenoid group (discussed in Section 
6.13.1). Whilst TLM inhibits the purified pfFabF enzyme in vitro, it is possible that 
the best derivatives against whole parasites were targeting the pfFabH condensing 
enzyme. However, compounds 1152, 1192 and 1193 (LD50 values of 1.3jllM, 2.7fiM
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and 4|iM, respectively) had no inhibitory effect on the pfFabH enzyme at lOOpM 
concentrations (Figure 6.9). This suggested that neither of the Type II FAS 
condensing enzymes were the targets of the best inhibitors of whole parasites and that 
inhibition of whole parasites with these TLM analogues must proceed via an as yet 
unidentified pathway.
Only compound 1194 appears to target effectively whole parasites (LD50 = 8.5jjM) 
and one of the condensing enzymes, (IC50= 18pM towards pfFabH). This compound 
contains no large CIO or C l6 hydrophobic groups at the C5 position and, therefore, 
may be expected to show increased solubility and uptake into the parasite compared 
to some of the other derivatives. It may also exhibit increased absorption and 
bioavailability in the host, which are favourable drug characteristics. With Sigma 
TLM, the large discrepancy between the IC50 of 3JlLM towards pfFabF and the LD50 
value of >95pM (Figure 6.12), suggests that TLM may not be able to reach, or 
accumulate in, the apicoplast of P. falciparum.
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Chapter 7
Chapter 7 General Discussion
7.1 Studies of the P. falciparum FabF protein
Work presented in this project describes the first reported cloning and expression of pfFabF, 
a condensing enzyme of the fatty acid synthase of the malaria parasite 
Plasmodium falciparum. The protein shows significant identity with plant and bacterial FabB 
and FabF enzymes and an alignment of the primary sequences of these proteins identified the 
mature pfFabF protein (Figure 3.1). There is direct evidence that the P. falciparum FabH and 
ACP proteins are targeted to the apicoplast (Waller et al., 1998 and 2000). Furthermore, 
genes of the remaining enzymes of the Type II FAS pathway all encode an N-terminal 
bipartite sequence, which is predicted to be sufficient for targeting of these proteins to the 
apicoplast (Surolia and Surolia, 2001; Waters et a l 2002; Prigge et al., 2003; Pillai et al., 
2003; Sharma et al.y 2003). However, attempts to identify a region of the pffabF gene that 
encoded a bipartite signal sequence were unsuccessful. Despite the inability to find an 
apicoplast targeting sequence associated with pfFabF, it is very likely that this protein is 
targeted to the apicoplast and interacts with the other enzymes of the Type II FAS pathway. 
The production of GFP-bound antibodies that recognise pfFabF is now possible following the 
purification of the protein described in this work (care should be exercised so that the 
antibodies do not recognise MBP). Staining of P. falciparum cells with these antibodies may 
provide the first conclusive evidence that pfFabF is located to the apicoplast.
Purified recombinant pfFabF exhibited significant (3-ketoacyl-ACP synthase activity using 
myristoyl-ACP (C14:0) as the acyl-ACP substrate and malonyl-ACP as the donor substrate.
A significant decrease in activity when using palmitoyl-ACP (C16:0) and stearoyl-ACP 
(C18:0) as acyl-ACP substrates (Figure 4.4) suggests that in vivo the predominant final
product of the Type II FAS pathway in P. falciparum may be palmitoyl-ACP, although small 
amounts of stearoyl-ACP and arachidoyl-ACP could be feasibly produced. Unfortunately, the 
ability of the enzyme to synthesise shorter acyl-ACPs was not investigated due to the lack of 
shorter chain acyl-ACP substrates.
The Type II FAS pathway of Trypanosoma brucei predominantly produces myristate (Morita 
et al., 2000; Paul et al., 2001), which is subsequently incorporated into glycosyl- 
phosphatidylinositol (GPI) anchors of the variant surface glycoprotein (VSG), a protein that 
significantly contributes to the parasite’s ability to evade the host immune response. In 
P. falciparum many important surface proteins including the circumsporozoite protein which 
coats the invading sporozoite and merozoite surface proteins (MSP) 1 and 2 are also attached 
to the membrane by GPI anchors. An analysis of MSP-1 and MSP-2 anchors in P. falciparum 
suggests that myristate makes up a quarter of the sn-1 and sn-2 acyl groups and that palmitate 
is the predominant acyl group at these positions (Gerold et a l , 1996) (Figure 7.1). 
Modification of the inositol group by fatty acids also occurs in GPI anchors (Figure 7.1) and 
at least one report suggests that myristate is the predominant fatty acid attached to the inositol 
group in P. falciparum (Gerold et al., 1996). Myristate comprises ~1% of the fatty acids 
present in serum (Paul et al., 2001), and there is no detectable myristate in the membranes of 
non-infected or infected red blood cells (Omodeo-Sale et al., 2003). Therefore, the parasite 
must either stimulate the host to produce the myristate it requires or synthesise myristate 
de novo. Therefore, the synthesis of myristate as a final product of the P. falciparum Type II 
FAS pathway should be investigated in more detail. This could be achieved by measuring the 
incorporation of radiolabelled precursors into fatty acids, especially in the fatty acids of GPI 
anchors and by testing the ability of pfFabF to elongate lauroyl-ACP to myristoyl-ACP in 
vitro.
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Figure 7.1 The basic structure of a P. falciparum GPI anchor
The structure is based on data described by analysis of the fatty acyl groups present on GPI 
anchors linked to merozoite surface proteins (MSP-1 and MSP-2) (Gerold et al., 1996). 
Abbreviations; Ino (inositol); GlcN (N-acetyl glucosamine; Man (mannose); P (phosphate).
There have been two investigations into the incorporation of radiolabelled precursors into 
fatty acids of P. falciparum. The first report suggested that, in whole parasites, myristate was
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the major product of the Type II FAS pathway with smaller amounts of decanoate (10:0) and 
laurate (12:0) also present (Surolia and Surolia, 2001). A separate investigation, in a cell free 
system, suggested that palmitate was the major product of this pathway with smaller amounts 
of myristate and laurate (Sharma et al., 2003). This may indicate that myristate is the major 
fatty acid synthesised by the parasite in vivo. However, myristoyl-ACP synthesised in the 
cell-free system would not be incorporated into membrane lipids or GPI anchors, and may be 
elongated to palmitoyl-ACP in one final cycle of the pathway. The absence of longer, 
saturated chain fatty acids in the above reports, is in agreement with the huge decrease in the 
activity of pfFabF to elongate palmitoyl and stearoyl-ACPs in vitro (Figure 4.4).
Interestingly, in the cell-free system, whilst no decanoate was synthesised, a large band 
corresponding to the expected size of octanoate was present (Sharma et al., 2003). This may 
indicate that octanoate is synthesised by the Type II FAS system of the malaria parasite but 
does not accumulate in whole parasites as it is converted into lipoic acid. Lipoic acid is an 
essential cofactor of the pyruvate dehydrogenase complex, predicted to be targeted to the 
apicoplast, and of several mitochondrial proteins essential for respiration.
7.1.2 Inhibition of pfFabF activity by TLM
The pfFabF enzyme was highly sensitive to the fungal metabolite thiolactomycin (IC 5o= 3 jiM ;  
Figure 4.6), a compound that also inhibits growth in cultures of malaria parasites (this work; 
Waller et al., 1998 and 2003). Data presented in this report indicate that TLM may inhibit 
growth of whole parasites via inhibition of the pfFabF enzyme. Proof that the pfFabF enzyme 
is inhibited by TLM, provides the further evidence of an in vivo target of TLM inhibition in 
malaria parasites. Identification of pfFabF as a target of TLM inhibition in vivo provides a
solid platform for further investigations into the potential of TLM or related compounds as 
candidates for antimalarial drugs. Information on the mechanism of action of TLM inhibition 
on the physiologically relevant target will be required before any potential drug could be 
licensed and reach the market.
12 The potential of TLM as a novel antimalarial drug
Thiolactomycin has several properties that make it a good lead compound for potential 
antimalarial drugs. This antibiotic is not toxic to mice at therapeutic doses and provides 
significant protection against bacterial infections (Miyakawa, et al., 1982). The potency of 
TLM in infected mice is achieved by rapid absorption and distribution to infective sites 
(Miyakawa, et al., 1982), this suggests favourable pharmacokinetics and suitability for drug 
administration. The discovery that triclosan inhibits pfFabl, a second enzyme of the Type II 
FAS pathway (Surolia and Surolia, 2001) provides the opportunity for a double block on the 
pathway which may decrease the emergence of resistance. The other proteins in this pathway 
are also attractive targets for antimalarial compounds. These enzymes are being characterised 
and a search for inhibitors of these enzymes is being actively pursued (Table 7.1) (Prigge et 
al., 2003; Sharma et al., 2003; Pillai et a l , 2003; Lakshmi Swama Mukhi et al., 2004).
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Enzyme Inhibitor Inhibition details Reference
FabF Thiolactomycin IC50 ~3pM This thesis
FabH
l,2-Dithiole-3-one compounds 
Thiolactomycin
IC50= 0.53-10.4pM 
IC50 >330pM
Prigge et al., 
2003
FabG Possibly epigallocatechin 
gallate (EGCG)*
-
Zhang and 
Rock, 2004
FabZ NAS-21
NAS-91
IC50 lOOpM 
IC50 7.4pM
Sharma et al., 
2003
FabI
Triclosan
2,2-dihydroxyphenyl ether
IC50 700nM 
Ki 18nM
Kapoor et al., 
2001
Table 7.1 Known inhibitors of P. falciparum fatty acid synthesis enzymes
* The first reported inhibition of E. coli FabG by polyphenol extracts of green tea e.g. 
epigallocatechin gallate, was reported recently. The inhibitory effect of these compounds on 
tiie Plasmodium falciparum enzyme is yet to be investigated.
72.1 The inhibitory activity of TLM against malaria parasites
Inhibition of the growth of P. falciparum parasites by TLM (LD50 >95pM against K1 strain 
(this work) and LD50 = 49pM (Waller et al., 2003) against the W2Mef strain) is not as high 
as the observed inhibition against pfFabF (IC50 = 3|iM). This suggests that TLM may have 
significant difficulty in reaching, or accumulating in, the apicoplast, the subcellular location 
of the Type II FAS in P. falciparum. This may be due to poor uptake of the compound into 
infected erythrocytes or due to poor transport across the parasitophorous vacuole into the 
parasites where it must traverse the four membranes that surround the apicoplast.
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Alternatively, the compound may be actively exported, in a similar mechanism thought to be 
responsible for the advent of resistance to chloroquine the mainstay malaria drug for 50 years 
(Sanchez et al., 2003) and to TLM resistance in E. coli (Furukawa et al., 1993), or be 
metabolised by the parasite.
Like thiolactomycin, triclosan is a hydrophobic compound that is poorly soluble in water, a 
property that has limited its clinical utility, although it is extensively used in other situations. 
Triclosan inhibits the enoyl reductase (FabI) enzyme of the Type II FAS system and is 
capable of clearing malaria parasites from mice (Surolia and Surolia, 2001). Like pfFabF, the 
FabI enzymes of P. falciparum and T. gondii are predicted to be targeted to the apicoplast. A 
recent investigation showed that when triclosan was linked to releasable octomers of 
arginine, the inhibitor was able to target the FabI enzyme of tachyzoites and encysted 
bradyzoites, causing a delayed death phenotype (Samuel et a l, 2003). It is extremely difficult 
for any compound to penetrate the encysted bradyzoite stages of T. gondii infection due to the 
large number of boundaries the compound needs to negotiate to reach the apicoplast, and 
there are no medicines that treat this form of the disease. Therefore, linking TLM to 
octoarginine groups may increase the ability of the compound to cross membranes in 
P. falciparum and may also increase its bioavailability in T. gondii parasites. This method 
may also improve the likelihood that TLM, or a derivative, may have better absorption and 
increased bioavailability when administered orally. These pharmacokinetic attributes would 
provide a significant advantage if a potential antimalarial was to be used in rural areas, where 
access to health care facilities is limited.
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7.2.2 Synthesis of TLM or derivatives as potential antimalarial drugs
Several other questions about the suitability of TLM as a lead compound need to be 
addressed and investigated in further detail. These include whether the cost of mass 
production of TLM is commercially viable. Our studies suggest that it may be difficult to 
synthesise TLM and/or derivatives that also possess a C5 isoprenoid group from simple 
building blocks. Furthermore, synthesis of the pure (5R)-enantiomer is also a major 
consideration for the financial and clinical suitability of TLM. Recently, the first report of the 
synthesis of the (5R)-thiolactomycin enantiomer was reported using D-alanine as a chiral 
building block (McFadden, et al., 2002). The route of synthesis used to produce this 
optimally enriched TLM was flexible and allowed for the substitution of groups at the C3 and 
C5 positions. This suggests that it may be possible to produce solely the (5R)-enantiomer of 
TLM derivatives. It must be noted that the removal of the double bond of the thiolactone ring, 
observed in the dicarbonyl TLM derivatives (Table 6.11) introduces a chiral centre at the C4 
and C3 positions. This alteration would increase the number of stereoisomers of these 
derivatives and increase the problem of obtaining an optically pure compound.
An alternative route to the synthesis of TLM may be through the engineering of novel 
polyketide synthases that are able to produce large amounts of TLM or derivatives. In 
Nocardia sp., the fungi that produce natural TLM, there is evidence that a polyketide 
synthase (PKS) is involved in the synthesis of TLM (Brown et al., 2003). An investigation of 
the areas of the Nocardia sp. genome that encode PKS modules should elucidate which PKS 
is responsible for the natural synthesis of TLM. Advances in the manipulation and 
engineering of novel PKS suggest that isolation of enzymes capable of synthesising large 
amounts of TLM from acetate precursors is an achievable goal (Khosla et al., 1993;
Watanabe et a l , 2003a, b). Finally, chemical alteration of naturally synthesised TLM may be
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one method that could produce TLM derivatives containing C5 isoprenoid groups, 
overcoming the problems in chemically synthesising these derivatives. This technique is 
probably not a cost-effective method of producing TLM derivatives on a large scale, due to 
the low yield of TLM from cultures of Nocardia and the subsequent derivitisation. However, 
because of the presence of the natural C5 isoprenoid group, this route may provide many 
potent inhibitors of bacterial and Apicomplexan FabB and/or FabF proteins. The inhibitory 
effect of these compounds could then be determined before large scale production of the most 
promising was investigated through an alternative synthetic route.
7.2.3 Alternative targets of TLM inhibition in the human host
There is increasing evidence of a Type II FAS pathway in the mitochondria of mammals, 
plants and yeast (Wada et al., 1997; Brody et al., 1997; Schneider 1997a and 1997b; Torkko 
et al., 2001 ;Yasuno and Wada, 2002; Miinalainen et al., 2003; Zhang et al., 2003; Yasuno et 
al., 2004). In humans, the ACP and malonyl transferase components of this mitochondrial 
system have been identified. Pure recombinant proteins showed that the acyl transferase was 
capable of catalysing the efficient transfer of a malonyl group from coenzyme A to the 
mitochondrial ACP (Zhang et al., 2003), suggesting that the component proteins are 
functional and interact with each other. To date, the only investigation of a mitochondrial 
condensing enzyme was performed on the Arabadopsis thalania protein (Yasuno et al.,
2004). This enzyme appeared to produce a bimodal distribution of acyl-ACP products with 
peaks at C8 and C14-C16 chain lengths, suggesting that this enzyme may be important in the 
synthesis of lipoic acid. The human genome does contain a gene that is predicted to encode a 
Type II FAS-like condensing enzyme (Figure 3.1) and this protein also contains a putative 
N-terminal mitochondrial target sequence (personal observation). It is possible that the
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human mitochondrial enzymes may also be inhibited by TLM and, if this is the case, the level 
and effects of TLM inhibition in mammals will need to be fully investigated before TLM 
could be considered for clinical use.
There is growing evidence that Type I FAS is overexpressed in mammalian cancer cells that 
cause tumours in breast, prostate, stomach and colon tissue (Kuhajda et a l , 1994 and 2000;
U et a ly 2001; Thupari et al.y 2001; Swinnen et al., 2002; Liu et al., 2002; Kusakabe et al., 
2002; Visca et al., 2003; Baron et al., 2004). Studies have shown that overexpression of 
Type I FAS in prostate tumours is an early and common event in the development of 
cancerous cells and that tumours with higher levels of Type I FAS expression had a higher 
proliferative index (Swinnen et al., 2002; Welsh et a l , 2001; Baron et a l , 2004). Cerulenin, 
an inhibitor of the (J-ketoacyl-synthase activity of both Type I FAS and Type II FAS has been 
shown to inhibit the growth of colon carcinomas in mice in vivo (Huang et a l , 2000a and 
2000b). Furthermore, triclosan, once thought to be a specific inhibitor of the enoyl-ACP 
reductase of Type II FAS, inhibits the enoyl reductase activity of Type I FAS with an IC50 of 
10-20|iM, compared to IC50 = 2pM for the E. coli FabI (Heath et a l , 1998) and IC50 = 66nM 
against P. falciparum FabI (Kapoor et a l , 2004a). Triclosan was also shown to have a 
cytotoxic effect against two breast cancer cell lines (LD50 = 17}iM) and no effect against 
normal cells (Liu et a l , 2002).
12A Elucidating the target of TLM derivatives
ft is clear that none of the TLM derivatives synthesised in this project had a high inhibitory 
effect on the pfFabF enzyme (Figure 6.8). However, some of these derivatives exhibited
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significantly better inhibition of the pfFabH enzyme and this demonstrated the scope that 
exists for the design of novel TLM derivatives that target the fatty acid biosynthesis pathway. 
The production of compounds that inhibit the pfFabH enzyme should be actively pursued, in 
tandem with the inhibitors of the pfFabF enzyme, as pfFabH catalyses the initial 
condensation step of the Type II FAS pathway and is ideally suited to regulate the rate of 
fatty acid synthesis (Heath and Rock, 1996a and 1996b; Choi et a l , 2000a and 2000b).
Clearly, in whole parasites the target of some of the derivatives that did not inhibit either of 
the P. falciparum KAS enzymes, for example 1152 (Figure 6.12), remains to be elucidated. 
One way to identify the target of this compound may be to compare the expression profile of 
P. falciparum parasites in controls and cells grown in the presence of the inhibitor, using 
microarray technology. This approach could identify one or many targets for these inhibitors 
with unknown function. However, even if the identification of a single target and validating 
the mechanism of action was achieved, this process could take several years to complete. It 
was deemed too labour-intensive to attempt to identify the target of these TLM derivatives in 
the present study.
7.2.5 Activity of TLM and its derivatives against other parasites
The inhibitory effect of TLM derivatives against cultures of different protozoa parasites is 
shown in Appendix 8 . Many of the TLM derivatives showed enhanced activity against these 
in situ cultures compared to racemic TLM. The best compounds against Trypanosoma brucei, 
Trypanosoma cruzii and Leishmania donovani showed 90-fold, 14-fold and 120-fold 
improvements in LD50 values compared to TLM. Against L  donovani compound 1199 
exhibited the first and only submicromolar L D 50 (500nM) observed in this project.
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Identification of the in vivo target/s of this TLM derivative should be investigated further. 
Bioinformatic searches have identified putative genes that encode enzymes of the Type II 
FAS pathway in Trypanosoma brucei, Trypanosoma cruzii and Leishmania donovani 
including genes for the condensing enzymes FabH and FabB/F and these may be targets of 
inhibition by TLM and/or its derivatives. Also, there is biochemical evidence that suggests 
Trypanosomes can synthesise their own fatty acids (Morita et al., 2000; Paul et a l, 2001 and 
2004). The increased inhibitory activity of TLM derivatives against these parasitic protozoa 
suggests that there is significant scope to produce derivatives with enhanced activity against a 
range of organisms, not just Plasmodium falciparum. Studies of the inhibitory effect of these 
compounds on the FAS synthesis pathway or individual enzymes of these parasites may 
allow the identification of lead compounds in the treatment of many devastating parasitic 
diseases.
At the outset of this project six aims (outlined on Page 74) were used as a guide for the focus 
of this project. The first four of these aims relating to the identification, expression and 
characterisation of pfFabF and the testing of both the P. falciparum condensing enzymes 
against TLM derivatives were achieved partly or in full and are described in Chapters 3-6. An 
excellent kinetic characterisation of the pfFabH enzyme was achieved by a separate research 
group (Prigge et al., 2003) prior to the production of soluble enzyme during this project. It 
was deemed unnecessary to repeat this work. A more detailed characterisation of the pfFabF 
kinetic parameters is still required and future work is planned. Unfortunately, structural 
studies of these enzymes were not possible due to the inability to cleave the N-terminally 
fused maltose binding protein. Whilst, the ultimate aim of finding a new lead antimalarial 
compound was not realised, these studies contribute significantly to our knowledge of the 
targets and mechanism of action of thiolactomycin against Plasmodium falciparum.
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rATAATAAAGGACAAGAAAATACACGATGTTCATTACGATGTTAAGATTTTTATTTTATTTTGTTTGTATTATCAATTATATACAAAGGGGAAAGTT
Y Y F L F F Y V L Q V M L Q F  K N K T N I  I V N I C F P F Q
side I Nde I Ssp I Mse I
rATGCATGTGCCATATGAATATTAGATGTAGAAAAGAAAAAAAAAAAAAAAAAAAAAAAAACATTAATCATGTCATAATATATACTCCATGTATTTT
• t  ♦ ------- »------- t - ..................... . . . . .  i  ) ------- ^ ------ ( -------- --------- t ~ — ♦ --------♦ ■ . . .  i ■     i ■ , ----- t 700
1TACGT ACACGGT ATACTTATAATCTACATCTTTTCTTTTTTTTTTTTTTTTTTTTTTTTTGT AAT TAG T AC AGT ATT AT ATATGAGGT AC AT AAAA
Y A C A I I L D V E K K K K K K K K K T L  I M S  Y I L H V F
Mse I
: Hinc II Mse
de I I Hpa I Mse I Ora I Rsa
UGTAGGTT AACAGTAAAAGGTATGCCTTCATT AAAAGGGGTATACCTGGAAT ATCCAAGAATTATTTTAAAGGTTTCAAGTTGTACAATTCGAGAG•«--- *---- ♦......»-.............. ♦   . ■ ■ . i   --- 1-----  (----- , .....     f---- t . . , ■ ,----- t 800
FACATCCAATTGTCATTTT CCATACGGAAGTAATTTTCCCCAT ATGGACCTTATAGGTTCTTAATAAAATTTCCAAAGTTCAACATGTT AAGC TCTC 
f V G Q K V C L H  K G Y T W N  I O E L F  R F Q V V Q F E R
Rsa I
IGAAAAATCTTTGTGAAGTACTAAATAAAATATATAATATATATAATATATATATATATATATATATATATTTATATTTATATAGTTTTATAAAATG-4 t ---- ♦-----4-----. 1-------------------------  4-----»-----»---- t ---- ------  . -----«   » 900
SCTTTTTAGAAACACTTCATGATTTATTTTATATATTAIATATATTATATATATATATATATATATATATAAATATAAATATATCAAAATATTTTAC 
E K S L  S T K . N I  Y I Y I Y I Y I Y I F I F !  F Y K M
Mse I Mse I Mse I
'ATATACAAATTGTAAAAAAIGATTAAAGTAATAATATGCTATACATTTATTTTTATATATATTTTAATTTTCTTAATTCTTttattttttatttag 
ATATATGTT TAACAT riTTTACTAATTTCAT TAT TATACGATATGTAAATAAAAAT ATAT ATAAAAT TAAAAGAAT TAACAAAAT AAAAAATAAAT C 
Y I Q ! V K N D . S N N M L Y  I Y F Y  I Y F N F L N S F  I F Y L
Xba I HgiA I Ssp I
TCTAGAGTGGTGTGCACAGGTGTAGGGGTAGTAACTGGATTAGGGATTGGCATAGAACATTTTTGGAATAATATTATAAATGGATATACATCAATAG
- ----- . I . . . .  I < ........ « .......... 4 ........... I ... . .  ..................... I ■ ■ ■ ■ < . . . . .  t  I ------- + . ■ ■ ■ t . . . .     I 1 100
;AGATCTCACCACACGTGTCCACATCCCCATCATTGACCTAATCCCTAACCGTATCTTGTAAAAACCTTATTATAATATTTACCTATATGTAGTTATC
f . s g v h r c r g s n v i r d w h r t f l e  y y k w i y  i n r
aaattacaaaatttgatataaccggtatgtcatgtggtattggtagtgaaataaagaaaagcgattttaatcctagtgattattacacaaataaaaa ----♦         > • — ........--....      t---- I ■ ■ ■ ■ I ------h----+ 1200
TTTAATGTTTTAAACTATATTGGCCATACAGTACACCATAACCATCACTTTATTTCTTTTCGCTAAAATTAGGATCACTAATAATGTGTTTATTTTT 
N Y K I Y N R Y V M V Y W  . N K E K R F . S .  . L L H K . K
Mse I Rsa I Alu I
IGTTAATCGTAATGATGATTGTACTCATTATGCAGTCGCAGCCACACGTTTAGCTTTAGACGATGCAAAACTAAATTTGGAAAAATTAGACAAAGAT
—•--------- t  I . . . .  I . . . .  t . . . .  t—  ----->   ......... t ........... .....................................   < ............................................................1 30 0
ACAATTAGCATTACTACTAACATGAGTAATACGTCAGCGTCGGTGTGCAAATCGAAATCTGCTACGTTTTGATTTAAACCTTTTTAATCTGTTTCTA
C . S .  L Y S L C S R S H T F S F R R C K T K F G K  I R Q R
Rsa I Dde I
ACAGGT ACTATCATAGGTAGTGGCAT AGGTGGACTAAGATTTTTAGAAAAAGAAATGAAAACAATGTATGAAAAAGGACATAAAAGAAT AACACCAT
_ — —-4 —  * —  < ■— — ♦ ■. .  . ♦   . ♦...................... .................................. —      —  t moo
tg t c ca t g at ag t at ccatcaccgtatccacctgatt ctaaaaatctttttctttacttttgttacatacttt ttcctgtat tttctt attgtggta
N R Y Y H R  . W H R W T K  I F R K R N E N N V  K R T K N N T I
Sau3A I
Mse I Ssp I Xho II Mse I
taatacctgcaatgatagcaaatactccatctggatatgtatctatcgaaaacaatattagagggatctctcttggtatgttaagtgcatgtgctac
. ,   t  ,  t   I  ------_      I   - I ....I ------- -------------------------------- I 1500
attatggacgttactatcgtttatgaggtagacctatacatagatagcttttgttataatctccctagagagaaccatacaattcacgtacacgatg
N T C N D S K Y S  I W I C I Y R K Q Y .  R D L S V Y V K C M C Y
Alu I
tggtaacacaataggtgaagcctatagatatataaaatataaagagtatgatgttatgatatgtggtggaactgaagctagtataactcctataagt
H------- 4 . . , — i  .................. .. -------1 . . . .  I - ................- .  >---------------------  ■-. --------< ...........» .........      ■ ■ ■.< ............ ♦    > 1600
accattgtgttatccacttcggatatctatatattttatatttctcatactacaatactatacaccaccttgacttcgatcatattgaggatattca
V . H N R . S L .  I Y K I . R V . C Y D M W W N . S . Y N S Y K
Mse I Rsa
Mse I 
Dra I
gctggattcaattcattaaaggctttatgtacaggttataacgataatccaaaaaaaggttgtagacccttcgatttaaaaagaagtggtttcgtta
. ♦ -------♦ ------- * -------- r ........... ....................................      «■........t ------------- »      ■  ■ ■ I  \  I  4 ■ ■—   t 1700
cgacctaagttaagtaatttccgaaatacatgtccaatattgctattaggtttttttccaacatctgggaagctaaatttttcttcaccaaagcaat  
: w l Q F  I K G F M Y R L  . R  . S K K R L  T L R F K K K W F R Y
Mse I Xba I
jAGAAGGTTCAGGCATCTTAATTCTAGAATCATACGAACATGCAATAAAAAGAAATGCACCAATATATGGAGAAATTATTTCATATTCTTCAGAATG
.............  ♦ -------- > •—  ♦ --------♦ --------------------------  t ...... ...............................................       ♦ ......    ■ • •     1800
:TCTTCCAAGTCCGTAGAATTAAGATCTTAGTATGCTTGTACGTTATTTTTCTTTACGTGGTTATATACCTCTTTAATAAAGTATAAGAAGTCTTAC 
R R F R H L N S R I  I R T C N K K K C T N  I W R N Y F  I F F R M
Mse I Mse I Mse I
IGCATACCATATTACTGCACCAG AACCTAATGGGAAAGGTTTAACAAATTCTATTCATAAAGCATTAAAAAATGCAAAT ATAAACATAAATGACGTT
■ i | , ■ - i . . . | . i , .  . | , i . .  . . | . i . .  . | | ( , , , . | . . . .  t . . . .  | , . . .  | , - , |  ^900
4CGTATGGTATAATGACGTGGTC TTGGATTACCCTTTCC AAATTGTTTAAGATAAGTATTTCGTAATTTTTTACGTTTATATTTGTATTTACTGCAA
C I P Y Y C  T R T  V E R F N K F Y S  S I K K C K Y K H K  R
Mse I Mse I
Mse I Rsa I ; Dra I ; Dra I Sau3A I
1ATATTAATGCACATGGTACTTC AAC AAATTTAAATGATAAAATAGAAACCAAGGTTTTTAAAAATGTTTTCAAAGATCATGCATACAAATTATATA 
-------- f ------ ' ...........   ( . . . .  i . . . .  t  t ■ ■ ■ ■ t  i   .............................     ■  ■-i --- >---------\ ------   « 2000
ma ta at ta cg tgt a c catgaagttgtttaaatttactattttatct ttggttccaaaaatt tttacaaaagtttctagtacgtatgtttaatatat
I Y .  C T W Y F N K F K  N R N Q G F  K C F Q R S C  I Q  I I Y
Alu I Mse I Ssp I
:atcaactaaaagtatgacaggacai i gtataggtgctgctggagctatagaatctattgtatgtcttaaaactatgcaaacaaatattataccacc
> ■ • • • • < ■ •  —•- — ■ t • ■ ■— f . . . . i . . - .  ) ,—,— . . _ — ^ *- — • t- 2  1 0 0
STAGTTGATTTTCATACTGTCCTGTAACATATCCACGACGACCTCGATATCTTAGATAACATACAGAATTTTGATACGTTTGTTTATAATATGGTGG 
I N . K Y U R T L  Y R C C V S Y R  I Y C M S  N Y A N K Y Y  T T
Mse I PpuM I Sau3A I Ssp I
TAT TAATTATGAAT AT AAGGACCCAGAT T GTGA TCT AAATT AT ACACCT AATAAAT ATATTCATGCAAAGGAAAAT ATTGATATATCTCTCAATACA * I ■ • -■-»------>----->••••)---------    • •  •-»---- I...................  . . . . . -i -» t ... ■...........   2200
ataat taat acttatattcctgggtctaacactagatttaatatgtggattatttatataagtacgtttccttttataactatatagagagttatgt
Y . L .  I G P R L . S K L Y T .  i y s c k g k y . y i s q y
tings:_________Linear, Certain & Uncertain Sites, Standard Genetic Code
Mse I Nde I
TTTTTTTTTTTTTTTTTTAATAAAATAAAATGAT TCATATGTAT AATAAAATGT AGGAAAAATATGTTACAAACATAT7GCTGTTTATTCTTGCTTAT■ ■ » t   -« ...................................... ■! i  »■■■•» -i ■+ I  I ———► + - — h- 100
aaaaaaaaaaaaaaaaaattattttattttactaagtatacatattattttacatcctttttatacaatgtttgtataacgacaaataagaacgaata
F F F F F L I K  . N D S Y V .  N V G K I C Y K H 1 A V Y S C L
SnaB I
Mse I Mse I
atacgtattaaataaatgacataattttcactgttatttatacaacaaaatatatataaattaaatttggtgtaagtaataataataatgaaaatatg
• ■ i -------»-------♦ .........■+-------- ■----- - - »          ■ 1 .  I ---»------------f 200
tatgcataatttatt tactgtattaaaagtgacaataaatatgttgttt tatatat atttaatttaaaccacattcattatt attattactttt atac
I R  I K  M T  F S L L F  I Q Q N  I Y K L N L V  V I  I I M K I V
Ssp I Rsa I
aaatatt atatatgtatatttacatacatgatgagattttagtaagatgtaaatttgattattattgtgtatataaatacaagtatgtacaatatgat
. ,  t  + ------ »+.  t . .  . ......................... I . . . .  I . . .  . t   t  + I  t . . . .  I   I 3 0 0
tttataatatatacatataaatgt  atgtactactctaaaatcattctacatttaaactaataataacacatatatttatgttcatacatgttatacta
< I L Y M Y I Y I H D E I L V R C K F D Y Y C V Y K Y K Y V Q Y D
a t a t a t a t a t at at at at at at at atatatatatatatgtatgt gt tt at ttatt tatat t tt at at gatacgcat at tctt at tataat ttcat tac
 »---------1------. -♦ ■ ■ ■ ■ I  « --------4— -* -------- i ------- « -------- I 11 ' ................     i | ■ ..............   4 0 0
tatatatatatatatatatatatatatatatatatatacatacacaaataaataaatataaaatatactatgcgtataagaataatattaaagtaatg
Y I Y 1 Y I Y  I Y I Y I C M C L F  I Y I L Y D T H I L I  I I S L
Hae III Ssp I
rCACTTTACAATTTTTTTGAAAAGTAATGCTGTGTTATGGCCTCCAAATCCCAAATTTGTATTGAGAGATATATCAATATTTTCCTTTGCATGAATAT
■ ■  .......................      — ......  - ...... > --------1 ------- -----------f    l  i ---------) f  5 0 0
^GTGAAATGTTAAAAAAACTTTTCATT ACGACACAATACCGGAGGTTTAGGGTTTAAACATAACTCTCTATATAGTT ATAAAAGGAAACGTACTTATA
S L Y N F F E K  C C V M A S K S Q  1 C  I E R Y I N I F L C M N I
Sau3A I PpuM I Mse I Ssp I Mse I
rTATTAGGTGTATAATTTAGATCACAATCTGGGTCCTTATATTCATAATTAATAGTAGGTGGTATAATATTTGTTTGCATAGTTTTAAGACATACAAT■ ■ * t  ...... .........*■--- +-----»..................... t -— > i . .....................<-----. -----soO
\ATAATCCACATATTAAATCTAGTGTTAGACCCAGGAATATAAGTATTAATTATCATCCACCATATTATAAACAAACGTATCAAAATTCTGTATGTTA
r I R C I I I T I V V L  I F  I I N S R V Y N I C L H S F K T Y N
Alu I Sau3A
Mse I 
Dra I
ttTCTATAGCTCCAGCAGCACCTATACAATGTCCTGTCATACTTTTAGTTGATGATATATATAATTTGTATGCATGATCTTTGAAAACATTTTTAAAA
■ ■» ......... » •  .....................................................       I   ■ -----------4 ■ ■ .  ..............  * -----------1----------» ---------t --------- I --------- I 700
TAAGAT ATCGAGGTCGT CGT GGAT ATGTTACAGGACAGTATGAAAATCAACTAC TAT ATATATTAAACATACGT ACT AGAAACTTTT GTAAAAATTT T
F Y S S S S T Y T M S C H T F S  Y I . F V C M I F E N I F K
Mse I
Dra I Rsa I Mse I Mse I Mse I
:TTGGTTTCTATTTTATCATTTAAATTTGTTGAAGTACCATGTGCATTAATATATTTAACGTCATTTATGTTTATATTTGCATTTTTTAATGCTTTAT
....................    1----------- » ' • • ■ ■ I '— ...............  «---------- I ■ ■ ........................................................ ...... . f 8 0 0
iAACCAAAGATAAAATAGTAAATTTAAACAACTTCATGGTACACGTAATTATATAAATTGCAGTAAATACAAATATAAACGTAAAAAATTACGAAATA
L G F Y F I  I I C . S T M C I N  I F N V I Y V Y I C I F . C F M
Mse I
tTAGAAT TTGTTAAACC TTTCCCATTAGG TTCTGGTGCAGTAATATGGTATGCATCACATTC TGAAGAATATGAAATAAT TTCTCCATATATTGGTGC
 , ----------- . | ----------------------------------------» ------------ » ----------- , --------- 4 -------------     - + . ------------1-----------------------------      . . . .  i . . . .  | 900
ATC TTAAACAATT TGGAAAGGGT AATCCAAGACCACGTCATTATACCATACGTAGTGTAAGAC TTC TTATACTTTATTAAAGAGGTATATAACCACG
I R I C . T F P  I R F V C S N M V C  I T F . R I  . N N F S I Y W C
Xba I Mse I
Mse I 
Dra I
TCTTTTTATIGCATGTTCG7ATGATTCTAGAATTAAGATGCCTGAACCTTCTCCCATAACGAAACCACTTCTTTTTAAATCGAAGGGTCTACAACCT
-+ -------  » ------------------ 1------4— — ! —  - 4  — ----- *-• - - -  ) ■ • - • < - ■ ■ ■ !  . • > • ■ -  * ■• • ■■> ■■■■ I • . . . .  ~  • • »  t ...................1000
iAGAAAAATAACGT ACAAGCATAC T AAGATC TT AAT TC FAC GGAC T T GGAAGAGGGTA T T GC TT TGGTGAAGAAAAAT TT AGCTTCCCAGATGTTGGA
S F Y C M F V  F N . D A . T F  S H N E T T S F  . I E G S T 1
Rsa I Mse I Alu I
TTTGGATTATCGT TA r AACCTGT ACATAAAGCC TTT AAT GAATTGAATCCAGC AAAACTTATAGGAGT TATAC TAGCTTCAGTTCCACCACATATCA
—-  I 1 1  t .........4 - .  ■ • ■ >- •.......4  t  .  .  .   ........................................................................  t . . . .  t - .  ■ •  .  » --------------------------------------   t l 100
lAAACCTAATAGCAATATTGGACATGTATTTCGGAAATTACTTAACTTAGGTCGTTTTGAATATCCTCAATATGATCGAAGTCAAGGTGGTGTATAGT
F W I I V I T C T . S L .  I E S S K T Y R S Y T S F S S T T Y H
Mse I Xho II Ssp I
\CATCATACTCTTT ATATTTTATATATCTATAGGCTTCACCTATTGTGTTACCAGACGTAGCACATGCACTTAACAT ACCAAGAGAGATCCCTCTAAT
■ ■ , ■ —  » -------*--------    * ------- » --------I ............. .......... l • *------- t--------  * ' i ..............................  t- .................  1200
'GTAGTATGAGAAATATAAAATATATAGATATCCGAAGTGGATAACACAATGGTCTGCATCGTGTACGTGAATTGTATGGTTCTCTCTAGGGAGATTA
i i i l f i f y i s i g f t y c v t r r s t c t . h t k r d p s n
Mse I
GTTTTCGATAGATACATATCCAGATGGAGTATTTGCTATCATTGCAGGTATTAAATATGGTGTTATTCTTTTATGTCCTTTTTCATACATTGTTTTC
 ,  t  , --------|     . . .    , i   ,  t    t  ,  i _ +  1 300
^CAAAAGCTATCTATGTATAGGTCTACCTCATAAACGATAGTAACGTCCATAATTTATACCACAATAAGAAAATACAGGAAAAAGTATGTAACAAAAG
V F D R Y  I S R W S I C Y H C R Y  I V C Y S F M S F F I H C F
Dde I Rsa I
TCTTTTTCTAAAAATCTTAGTCCACC TATGCCACTACCTATGATAGTACCTGTTTTATCTTTGTCTAATTTTTCCAAATTTAGTTTTGCATCGTCTA
,   i  ------- — t  f  ---------        I --------I ------------------ »--------     > 1 400
AGAAAAAGATTTTTAGAATCAGGTGGATACGGTGATGGATACTATCATGGACAAAATAGAAACAGATTAAAAAGGTTTAAATC AAAACGTAGCAGAT 
F F F  K S  . S T Y A T T Y D S T C F I F V . F F Q I  . F C I V
Alu I Rsa I Mse I Mse I
CTAAACGTGTGGCTGCGAC TGCATAATGAGTACAATCATCATTACGATT AACATCTTTTTTATTTGTGT AATAATCACT AGGATTAAAATCGCTTTT
■ i     i -------- ---------- ---------- -----------1— ... , .....................  ... ■ ..t ...... .-----------------------  I 1 50 0
GATTTGCACACCGACGCTGACGTATTACTCATGTTAGTAGTAATGCTAATTGTAGAAAAAATAAACACATTATTAGTGATCCTAATTTTAGCGAAAA
T C G C D C I M S T I  I I T I N I F F I C V I I T R I K I A F
Msp I Ssp I
TATTTCACTACCAATACCACATGACATACCGGTTATATCAAATTTTGTAATTTTATCTATTGATGTATATCCATTTATAATATTATTCCAAAAATGT
. . . . . .  I ------- + I - — • < .......... ♦...................................... I  ♦  I —  I .    ■ • ! • • • ■ ............ . 1 6 0 0
ATAAAGTGATGGTTATGGTGTACTGTATGGCCAATATAGTTTAAAACATTAAAATAGATAACTACATATAGGTAAATATTATAATAAGGTTTTTACA
Y F T T N T T . H T G Y I K F C N F I Y . C I S I Y N I I P K M
HgiA I Xba I Mse I Mse I
ATGCCAATCCCTAATCCAGTTACTACCCCTACACCTGTGCACACCACTCTAGAAGTCTAAATAAAAAATAAAAGAATTAAGAAAATTAAAATATATA ■.............   •.- ..................I ..............................................    « ....... .................... .................... ....................  —•        • ■ t .................... .................... .................... t 1 7 00
TACGGTTAGGGATTAGGTCAATGATGGGGATGTGGACACGTGTGGT GAGATCTTCAGATTTATTTTTTATTTTCTT AATTCTTTTAATTTTATATAT
Y A N P . S S Y Y P Y T C A H H S R S L N K K  . K N . E N . N I Y
Mse I
AAATAAATGTATAGCATATTATTACTTTAATCATTTTTTACAATTTGTATATATCACATTTTATAAAACTATATAAATATAAATATATATATATATA
 ------ 1 ............    - •.I .......... » --------+ ---------» ..........I .........................     I .........................I --------»-------- t -------- . ---------- > 1 80 0
TTTATTTACAT AT CGTATAATAATGAAATTAGT AAAAAATGTTAAACAT ATAT AGTGTAAAAT ATTTTGATATATTTATATTT ATATAT ATAT ATAT
N K C I A Y Y Y F N H F L Q F V Y  I T F Y K T  I I I Y I V I
Rsa I Rsa I
Mse I 
Ora I
atatatattafatatattatatattttatttagtac  tt cacaaagattt t t cat t tctc  tcgaattgtacaacttgaaacctt taaaat aattcttg
•  I           I ..............................I    ■ ,.! ....................  I ......................I 1 9 0 0
TAT ATATAATATATAT AAT ATAT AAA ATAAATCATGAAGTGTTTCT AAA AAGTAAAGAGAGCTTAACATGTTGAACTTTGGAA ATT TTATTAAGAAC 
I Y I I Y I I Y F I Y F T K  I F H F S  R I V Q L E T F K I  I L
Mse I 
; Hinc II
Mse I : Hpa I Nde I Mse I
MTCCAGGT ATACCCCTTTTAATGAAGGCATACCTTTTACTGTTAACCTACATATGAAAATACATGGAGTATATATTATGACATGATTAATGTTTTT   ,    k .  . . , . . . . ,     ,  ,     . , .       )   t 2000
rAAGGTCCATATGGGGAAAATTACTTCCGTATGGAAAATGACAATTGGATGTATACTTTTATGTACCTCATATATAATACTGTACTAATTACAAAAA
1 S R Y T P F N E G I P F T V N L H M K  I H G V Y I M T  L M F F
Ssp I Nde I Nde I Mse I
TTTTTTTTTTTTTTTTTCTTTTCTACATCTAATATTCATAIGGCACATGCATATGTTTGAAAGGGGAAACATATATTAACTATTATGTTTGTTTTATM----- 1-----   . -----4------4.---- +................    >...........    I--4--------  2100
MAAAAAAAAAAAAAAAGAAAAGA fGTAGATTArAAGTATACCGTGTACGTAT ACAAAC TTTCCCCTTTGTATATAATTGATAATACAAACAAAAfA 
F I -  F F F  S F t  M L  I F  I W H M H M F E R G N  I Y . L L C L F Y
Mse I 
i Dra I
UTTTTAGAATTGTAGCATTACTTGTAGCACATAAAAGAACAGGAAATAATATATTTTTATAATGTATTTTCTCATTTAAAACTTTTTTTTTTTTTT. . . . . . . . .  i --- ------------— .------ ... ... . t +---- (    — ■->-»--i • •  .........I 2200
rAAAAATCTTAACATCGTAATGAACATCGTGTATTTTCTTGTCCTTTATTATATAAAAATATT ACATAAAAGAGTAAATTTTGAAAAAAAAAAAAAA 
I F R I V A L L V A H K R  T G N N  I F C l  F S F K T F F F F
IYIOC I rviae i
ttttttttttatcaattaaagagaatataaaacaggagcattattttaaggaacaacctttttcacatataaaatagttgaaagatttattaaatgta
  ............ t -------- ---------- \ --------- «* — » » -------   * -------- I ■ • •  .............I ............. ....... " I ...............— ■ I ........................ I 2300
a aaaaaaaaatagttaatttctcttatattttgtcctcgtaataaaattccttgttggaaaaagtgtatattttatcaactttctaaataatttacat
F F F Y Q L K R I  . N R S I  I L R N N L F H I  N S . K I Y . M .
Mse I
atgtaaaaaaaaataaaaaatgaaatatgaaaaatgaaaaatgaaaaataaaaaataattttaagatacaataaaataaaaatataataattataaag
^  ■ . f --------■+------------------- . ------- f . . . .  t . . . .  t .. .................. - ■ i------ - • ---------- \ -  ■      -*■-------- + 2400
t a ca t tt t t tt t ta tt t tt t a c t t t a t a c t t t t t a c t t t t t a c t t t t t a t t t t t t at t a a a a t t c t a tg t t a t t t t a t t t t t a t a t t a tt a a t a tt t c
' J V K K N K K  N M K N E K  K I K N N F K I Q . N K N I  I I I K
Ssp I
&AAT AAAAAAATAC ATACATATAT AC A TAT AT AT A TAT AT ATAT ATATATATATGTATAATACAACATTGTGGC ATATAT CAAATAT TAT AC AC ATT A
» • • • t  » ■■■■>------- --------- t  .  i  .  t . ---------♦  ~ . i . . . . .i ........... > ------- f —  i ■ ■ • - ...............   2500
rTTATTTTTTTATGTATGTATATATGTATATATATATATATATATATATATATACATATTATGTTGTAACACCGTATATAGTTTATAATATGTGTAAT
N K K I H T Y I H I Y I Y I Y I Y M Y N T T L V H I S N I I H I
Mse I
Mse I Dra I Ssp
r A C A A C T G T T T T T A T T T A A T T C G T C C C G A A A T A C A A A A A T A A A T A A T G G A G T G G A A G G T T T T A T A T T A T A A A A A A T G A T A T G C T T A C G T T T A A A A A T A
. . « --------1------- « -------- t --------- , . . . , , , ,-----   . | -------- , -------- 4...........»       . .) .   2600
MGTTGACAAAAATAAATTAAGCAGGGCTTTATGTTTTTATTTATTACCTCACCTTCCAAAATATAATATTTTTTACTATACGAATGCAAATTTTTAT 
Y N C F Y L  I R P E  I Q K I M E V K V I Y Y K K  Y A Y V  K Y
Mse I 
: Ora I
' TAAAAATTTTA
 2614
kATTTTTAAAAT
K N F
ings._________Linear, Certain & Uncertain Sites. Standard Genetic Code
Xba I HgiA I Ssp I
FTC T AGAGTGGTGTGCACAGGTGTAGGG6T AGTAACTGGATTAGGGATTGGCATAGAACATTTTTGGAATAATATTATAAATGGATATACATCAATAG■  ................    i' — •+■ — • ■ .».....................................t |     ■         i ..............4 100
AAGATCTCACCACACGTGTCCACATCCCCATCATTGACCTAATCCCTAACCGTATCTTGTAAAAACCTTATTATAATATTTACCTATATGTAGTTATC
S R V V C T G V G V V T G L G  I G  I E H F W N N I  1 N G Y T S  I 
Msp I Mse I
\ A A A T T A C A A A A T T T G A T A T A A C C G G T A T G T C A T G T G G T A T T G G T A G T G A A A T A A A G a a a a g c g a t t t t a a t c c t a g t g a t t a t t a c a c a a a t a a a a a~ >-------- »-- I ■.—........  • I....... ...... t -----* • ■ ■ ' *-----> I   ... I . ... t   .............. I...... ........f- 200
t t t a a t g t t t t a a a c t a t a t t g g c c a t a c a g t a c a c c a t a a c c a t c a c t t t a t t t c t t t t c g c t a a a a t t a g g a t c a c t a a t a a t g t g t t t a t t t t t  
K I T K F D  I T G M S C G  I G S E  I K K S D F N P S D Y Y T N K K
Mse I Rsa I Alu I
kTGTTAATCGTAAT GAT GATTGTACTCATTAT GCAGTCGCAGCCACACGT TTAGCTTTAGACGATGCAAAACTAAAT TTGGAAAAATTAGACAAAGAT
■ * ------ »--------» ......... « --------* --------«........... .......... ............................ ............»—  - ■     • ■......................... ♦ ................... I ----«■.......... f 300
ACAATTAGCATTACTACTAACATGAGTAATACGTCAGCGTCGGTGTGCAAATCGAAATCTGCTACGTTTTGATTTAAACCTTTTTAATCTGTTTCTA
I V N R N D O C T H Y A V A A T R L A L D D A K L N L E K L D K D
Rsa I
Dde I 
HinO I! 
Alu
l A C A G G T A C T A T C A T A G G T A G T G G C A T A G G T G G A C T A A G C T T T T T A G A A A A A G A A A T G A A A A C A A T G T A T G A A A A A G G A C A T A A A A G A A T A A C A C C A T
■ ' ------< -------♦ --------♦ ..........+         —  ♦ ■ ■ ■ ♦ -------t .......... .............  I ------- *  « 400
t g t c c a t g a t a g t a t c c a t c a c c g t a t c c a c c t g a t t c g a a a a a t c t t t t t c t t t a c t t t t g t t a c a t a c t t t t t c c t g t a t t t t c t t a t t g t g g t a
T G T I  I G S G I G G L S F L E K E M K T M Y E K G H K R  I t  p
Sau3A I
Mse I Ssp I Xho II Mse I
T A A T A C C T G C A A T G A T A G C A A A T A C T C C A T C T G G A T A T G T A T C T A T C G A A A A C A A T A T T A G A G G G A T C T C T C T T G G T A T G T T A A G T G C A T G T G C T A C
- I — ---->-------- -I------ I ■ —  4 -------- 4............  t .......... ♦ ..........» .........................>------- *-------------------------- ------------------ ------------ ■ ■ ■ i 500
A T T A T G G A C G T T A C T A T C G T T T A T G A G G T A G A C C T A T A C A T A G A T A G C T T T T G T T A T A A T C T C C C T A G A G A G A A C C A T A C A A T T C A C G T A C A C G A T G
L I P A M  I A N T P S G Y V S  I E N N I R G I  S L G M L S A C A T
Alu I
T G G T A A C A C A A T A G G T G A A G C C T A T A G A T A T A T A A A A T A T A A A G A G T A T G A T G T T A T G A T A T G T G G T G G A A C T G A A G C T A G T A T A A C T C C T A T A A G T
-h . .   4 . .— — 4 « .   - 4 .........................I I ■ . . .  I . . .  . t ■ t ........... . — 4 ------------ ------ -— -4--------- 1------— 600
A C C A T T G T G T T A T C C A C T T C G G A T A T C T A T A T A T T T T A T A T T T C T C A T A C T A C A A T A C T A T A C A C C A C C T T G A C T T C G A T C A T A T T G A G G A T A T T C A
G N T I G E A Y R Y I K Y K E Y D V M I C G G T E A S I T P I S
Mse I Rsa I
Mse I 
Dra I
GCTGGATTCAATT CATTAAAGGCTTTATGTACAGGTTAT AACGATAATCCAAAAAAAGGTTGTAGACCCTTCGATTTAAAAAGAAGTGGTTTCGTTA
• i  I  ( ( ....................................................            -  ■  |-» -I ................ .4 --,----- ~ +  700
CGACCTAAGTTAAGTAATTTCCGAAATACATGTCCAATATTGCTATTAGGTTTTTTTCCAACATCTGGGAAGCTAAATTTTTCTTCACCAAAGCAAT
A G F N S L K A L C T G Y N D N P K K G C R P F D L K R S G F V
Mse I Xba I
GAGAAGGTTCAGGCATCTTAATTCTAGAATCAT ACGAACATGCAATAAAAAGAAATGCACCAATA7ATGGAGAAATTATTTCATATTCT7CAGAATG
• «  t  ............. .......... *  I ■ ■ •~,~f  t  -*->.......... *..........♦ --------t ........... <-— 4 .....................       i --------4 -------- > » 800
CTC 7TCCAAGTCCGTAGAATTAAGATCTTAGTATGCTTGTACGTTATTTTTCTTTACGTGGTTATATACCTCTTTAATAAAGTATAAGAAGTC TTAC
G E G S G  I L  I L E S  Y E H A I K R N A P  [ Y G E  I I S Y S S E C
Mse I Mse I Mse I
TGC ATACCATATT ACTGCACC AGAACCTAATGGGAAAGG TT TAACAAATTCTAT TCATAAAGCATTAAAAAATGCAAAT ATAAACATAAATGACGT T
--------- ,-----------4 -------------------------------. . . . . . .  t ■..- ................................     . i , . . ,-) ---------- t ............    4 -----------1 ............ t  f  g o o
6CGTAT GGT ATAA TGACGTGGTCTTGGATTACCCTT TCCAAATTGTTT AAGAT AAGTATTTCGTAATTTTTTACGTTTATATTTGTATTTACTGCAA 
A Y H I T A P E P N G K G L T N S  I H K A L K N A N I N I N D V
Mse I Mse I
Mse I Rsa I Dra I Dra I Sau3A I
T A 1 A T T A A T G C A C A T G G 1 A C T T C A A C  A A A T  T T A A A T G A  T A A A A  T A G A A A C C A A G G T 7 T T T  A A A A A T G T T T  T C A A A G A T C  A T G C A T A C A A A T T A T A T A  
A T A T A A T T A C G T G T A C C A T G A A G T T G T T T A A A T T T A C T A T T  T T A T C T T T G G T T C C A A A A A T T T T T A C A A A A G T T T C T A G T A C G T A T G T T T A A T A T A T
y i n a h g t s t n l n d k i e t k v f k n v f k d h a y k l y
: atcaactaaaagtatgacaggacattgtataggtgctgctggagctatagaatctattgtatgtcttaaaactatgcaaacaaatattataccacc■ t ■ — i----- *---- <---- *-----I---- *-----I----»■» — -  .............. I............... I............   I---- *.....    1 100
GTAGTTGATTTTCATACTGTCCTGTAACATATCCACGACGACCTCGATATCTTAGATAACATACAGAATTTTGATACGTTTGTTTATAATATGGTGG
S S T K S M T G H C I G A A G A I E S I V C L K T M Q T N I I P P
Dde I?
Mse I?
Rsa I?
Mse I?Mse I PpuM Sau3A Ssp
TATTAATTATGAATATAAGGACCCAGATTGTGATCTAAATTATACACNTNNTAAATATATTCATGCAAAGGAAAATATTGATATATCTCTCAATACA■+ 1200
ATAATTAATACTTATATTCCTGGGTCTAACACTAGATTTAATATGTGNANNATTTATATAAGTACGTTTCCTTTTATAACTATATAGAGAGTTATGT 
1 N Y E Y K D P D C D L N Y T ^ ^ K Y I H A K E N I D  I S L N T
Hae III
TTGGGATTTGGAGGCCATAACACAGCATTAC T FT TCAAAAAAATTGTAAAGTGA■ ' ----*---- »..................... ........- ..f . ■ ■ ■  ---------    1257
AACCCTAAACCTCCGGTATTGTGTCGTAATGAAAAGTTTTTTTAACATTTCACT
L G F G G H N T  A L L F K K  I V K
Appendix 2
Appendix 2 V ector specific PC R  prim ers used in this project
M13F: 5 ’ -GTAAAACGACGGCCAGT-3 ’
M13R: 5’-CAGGAAACAGCTATGAC-3’
T7: 5’-TAATACGACTCACTATAGGG -3’
SF1: 5’-GCTAGTTATTGCTCAGCGG -3’
Appendix 3
pET-15b Vector ™ 15 5
The pET-l5b vector (Cat. No. 69661-3) carries an N-terminal His-Tag" sequence followed by 
a thrombin site and three cloning sites. Unique sites are shown on the circle map. Note that the 
sequence is numbered by the pBR322 convention, so the T7 expression region is reversed on the 
circular map. The cloning/expression region of the coding strand transcribed by T7 RNA poly­
merase is shown below.
pET-Itt W f i n  landmarks
T7 promoter 463 479
T7 transcription start 452
His-Tag coding sequence 362 380
Multiple cloning sites
(Nde\ - BanAi I) 319-335
T7 terminator 213-259
lacl coding sequence (866-1945)
pBR322 origin 3882
bia coding sequence 4643-5500
T7 promoter pnmer #69348-3
Bgl || TT p r o m o te r  )ac o p e r a to r
AGATC ICGATCrrGCGAAAI T A AT ACGAC IC AC t At AGGGGAAT T GTGASCf.GAT AACAAII CCCC TC T AGAAA 1 AA 111 TGI I t At C TTT AAGAAGGAGA
Nco\ _______ Hii-Tag wde| XhoI BemH I
I A I  ACC AT GGGC AGC AGCC AT C A T C A t  t  A T C ATCAC AGC A G C G GC C  I G G T G C C  G CG CC GC A G CC A T A T G C !  C G ACGAT C C GGC t  G C T  AAC A A A G C C C G A  
Wer t  C I y S e r  S e ^ H  • s H i s H i  s H i s H  t s H  < s S e r S e r  G I / L e  j V o  I P r o A r q G  I y S e r  N i s M e t  L e u G  1 u A s p P r  o A I a A  * a A s r L  y  s A  I o A r q  
Spot 1021 thrombin T7 terminator
A A G G A A G f  T G A G t  T G G C ' G C T G C C A C C G C  T G A5 C A A  T AAC T AGC AT  AAC t C C I T G G G G C C T C T A A A C G C G T C ' T G A G G G G T T I T T ' G  
I. v s G  u A  I o G  I u L t r o A  I a  A I a  A I a  T h r  A I a G  f u G  I n f n d----------------
T7 terminator pnmer #69337-3
pET-15b cloning/expression region
BamH
Sph 1(691) 
EcoN l(75
pET-15b
(5708bp)
Bsm 1(2704)
1(1216) 
Bel 1(1230)
11(1627) 
Hpa 1(1722)
Aat 11(5635) 
Ssp 1(5517)
o~.<102 1(267)
1(319) 
X h o  1(324) 
N d e  1(331)
Nco 1(389)
1(428)
Bgl 11(494) 
SgrA 1(535)
1)
Bsa 1(4774) 
Ahd 1(4713)
AlwN 1(4236)
11(1397)
1(1427)
Sea 1(5193) 
Pvu 1(50831
Pst 1(4958)
BspLU11 1(3820)
Sap 1(3704) 
Bst1107 1(3591) 
Acc 1(3590) 
BsaA 1(3572) 
Tth111 1(3565)
Bpuio 1(2926)
PshA 1(2061)
1(2284) 
Nru 1(2319) 
1(2399)
1(2791)
Novagen * o r d e r in g  800-526-7319 ■ t e c h n ic a l  s u p p o r t  800-207-0144
Appendix 4
pM A L™ -p2X
6.721 base pairs
Sequence file available ai www neb com 
See page 138 for ordering information
Feature Coordinates Source
lad' 81-1163 E. coh
Pm 1406-1433 -
expression ORF 1528-2991 -
malE 1528-2703 £ coh
MCS 2704-2809 -
teZ a 2810-2991 -
M(Ap*) 3493-4353 Tn3
M13 ongm 4395-4908 M13
ongm 5019-5607 pMBI
rop 6228-6037 pMBI
ori = origin of replication 
Ap *  ampiciflin
References
1 Guan.C el at. (1987) Gene67,21-30.
2 Maina. C V et ai (1988) Gene 74.365-373
3 Riggs, P.mAusubel. FM etal (eds). Cur­
rent ProL in Moiecubr Biol. (1992) Greene 
Associates/Wiley Interscience. New York
4 Zagursky. RJ al al (1984) Gene21.183-191
pMAL-p2X is an E coli plasmid cloning vector designed for 
recombinant protein expression and purification using the pMAl 
Protein Fusion and Purification System (NEB FE8000S) (1-3) ft 
contains the pMBI origin ol replication from p6R322 and is main­
tained at a simitar copy number to pBR322; in addition, pMAL-pZX 
also contains an Mt 3 origin of replication (4).
The multiple cloning site (MCS) is positioned to allow translational 
fusion of the £. coli maltose binding protein (MBP. encoded by 
the maff gene) to the N-termmus ol the cloned target protein 
MBPS affmity lor amytose allows easy purification of the tusion 
protein, and the MBP domain can be subsequently removed using 
Factor Xa protease (3) Cloning of the target gene at the MCS 
disrupts expression at lac/a, allowing for insert screening by 
<»-complementation
Transaction of the gene fusion is controlled by the inducible 
"tac" promoter (PJ Basal expression from Pfc is minimized by 
the binding ot the Lac repressor, encoded by the lad' gene, to 
the lac operator immediately downstream of PB. A portion ot the 
rrnB operon containing two terminators, derived trom the vector 
pKK233-2, prevents transcription originating from from 
interfering with plasmid functions
pMAl-p2E and pMAl-p2G are identical to pMAl-p2X except they 
replace the Factor Xa protease cleavage site with Enter ok mase and 
Genenase I" cleavage sites, respectively
pMAL-c2-series vectors are identical to the pMAl -p2 senes vectors 
above except tor a deletion o» the matE signal sequence (nt 1531- 
1606) (1).
Enzymes with unique restriction sites are shown m bold type and 
enzymes with two restriction sites are shown in regular type The 
accompanying table shows restriction sites ol those enzymes ihat cut 
a moderate number ot tunes Restriction site coordinates refer to the 
position of the 5 -most base on the top strand w each recognition 
sequence
Open reading frame (ORF) coordinates are m the form translational 
start -  translational stop"; numbers refer to positions on the top 
(clockwise) sband. regardless of the direction ot transcription and 
include the start and slop codons
pMB1 origin ot replication coordinates include the region horn the - 
35 promoter sequence of the RNAII transcript to the RNA/DNA switch 
point For the M13 origin, the arrow shows the direction ot synthesis 
of the (t) strand, which gets packaged into phage particles Ua (Ap") 
gene coordinates include the signal sequence
Use I 6694 
Btg I 6691 
EcoOlOO I - PpuM I 6657 
BpulOI 6557 
BspE I 6474 
BsaBI 6466 
Ale I 6411 
BsmF I 6378 
BsmBI 6016
EcoO1091 PpuM I 6699
PflFI-TV i 111 I 5918 
BstZ171 - Acc I 5894 
S ap  I 5785 
P d  I - All III 5663
\
PflU I 7
BslAP I 106
I - All III 431 
Bd I 445
BstE V 612
Apa I PspOM 1 638
BssHII 642
AlwN I 5249 S
I
\
BspH I 4943 
Nse I NgoM IV 4778 
Ora IV 4672 
BsaX I 4621 —
Pp I 4547   *
Oral 4450 
Swal  4449
Ahdl  4275
Bgl I 4156
Seal  3797
Oral 3700
BspH I 3440
BsmF I 3079
Bgl I 2951
2680 2700 2720 2740
Sacl  Aval
. ATGAAGCCCTGAAAGACGCGCA6ACrAATTCGAGCTCGAACAACAACAACAATAACAATAACAACAACCTCGGG 
wa/ f  A Q T N S S S N N N N N N N N N N L G
EcoRV 879 
H pal 935 
BsmBI 1040 
K a s l - N a r l - S t o l  1070 
BsaX I 1086
U---------  Nde I 1525
I BspE I 1722
;
> .. BstW I 1893
 Psll 1953
/  Bgl 8 1962
BssHII 2039 
BmgB I Blr I 2143 
Bsml  2217 
BslAP I 2242 
AMV I 2243 
BsaBI 2274 
Btg I 2290 
Blp I 2388 
Ate I 2511 
Bdl  2645
MCS
Saol 2Mb 
Aasl 9 * * l  ?74* 
Xawvf ms*
Eoofti a m
B a m H I  2 7 7 *
* N | |  77*2 
sal -Acct  m t  
SMI 2743 
PM! 2794
xisnl EcoRi BamHI Xbal S a i l  P s l l  HI ndl  11
pMALp2X MCS ATf.GAGGGAAGG ATTTCAGAATTCGGATCCTCTAGAG1CGACCTGCAGGCAAGCTTGGCACT6GCC6TCGTT .
I f  8 te . I S E F G S S R V D L Q A S L A  . . . / a c / a
Factor Xa —*
Kpnl EcoRl BawHI Xbal S a i l  P s t I  HIndl11
pMAL p2E MCS GATGACGATGACAAG GTACCGGAATTCGGATCCTCTAGAGTC&ACCTGCAGGCAAGCTTGGCACTGGCCGTCGTT.
B B 8 0 K  V P E F  G S S B V D I Q A S L A  . . .  lacla
E n t e r o k l n a s e  — *
SnaBI EcoRI BamHI Xbal S a i l  P s t I  H1nd111
pMAL p2G MCS CCGGGTGCGGCACACTAC GTA6AATTCGGATCCTCTAGAGTCGACCTGCAGGCAAGCTT&GCACT6GCCGTCGTT .
P 8 A A H f » V  E F G S S  R V 0 I D A  S L A  . . .  J ac / o
Garwnas^* I -------
Appendix 5
I nje c ti o n Date 
Sample Name 
A c q . O p e r a to r
Acq. M e t h o d  
Last chan g ed  
A n a l y s i s  M e t h o d  
Last chan g ed
3 0/03/2004 17:28:36 PM Seq. Line
Location
IAG Inj
Inj Volume 
C : \ H P C H E M \ 1 \ M E T H O D S \ M O R \ W H E A T .M  
2 0 / 01 / 20 0 4 11:37:40 PM b y  IAG 
C : \ H P C H E M \ l \ M E T H O D S \ M O R \ B L O L I P . M  
31/0 3/ 2 00 4  10:50:18 PM b y  IAG 
(modified after loading)
Vial 5 
1
1 pi
FID1 A, (ECOLI3\EC5.D)
mco
oo <n
in
in
10 12
I14
A r e a  Percent Report
S or t e d  By
M u l t i p l i e r
D il u t i o n
Signal 
1 . 0 0 0 0  
1 . 0 0 0 0
Signal 1: FID1 A,
Peak Ret Ti m e T ype W i d t h  A r e a  Height
# [min] [ m m ]  [pA*s] [pA]
Area
1 1 .763 W
2 2.228 W
0.0273 1.26972 7.1245 2 e- l  0.30392
0.0259 5.01989 3 .06323 1.20157
trument 1 31/03/2004 10:50:53 PM IAG Page 1 of 2
Peak RetT i:ne *T"'  ^ * y-\ —.. yp e W ' ci A rea Height Area
# [min] [ m m  j [pA* s ] [pA] %
I
3 3. 079
i !
BB
1
0.0323
1
170.51694
1
81.81861 40.81539
4 3. 382 PV 0.0366 37.08362 15.38176 8.87643
5 4 . 124 PB 0.0409 81.84461 30.87967 19.59054
6 4 . 632 BB 0.0465 6.59372 2.13839 1.57829
7 5 .183 V B 0.0504 88.79726 2 7.29940 21.25475
8 5 . 797 BB 0.0566 3.64862 9 .33687e-l 0. 87334
9 6. 533 BB 0.0671 23.00 17 3 5.41026 5.50576
Totals : 4 17 . 77611 167.63746
R esults o b t a i n e d  w it h  e n h a n c e d  integrator!
*** En d  of Report ***
3trument 1 31/03/2004 10:50:53 PM IAG Page 2 of 2
Appendix 6
auiiuay,  « u y u s i  *rd. /(UCW f  3b  pm Pagi
pIFabH Map (1 > 1116) Site and Sequence
Enzymes : 47 ot 436 enzymes (Filtered)
Settings:________  Linear, Certain & Uncertain Sites, Standard Genetic Code_______________________________________________________________________________________________
Mse I
Mse I
A T G T T T C T A T A T T T T A T T A C A T A T C T C T G T A T T T I C C A  I A A T A A T A T A I  A t T C T G T A G A A  I T A A T  T A A A A A T A A T  A A A T A  I A A T T T T A T A A A T A A T C . T G C  
T A C A A A G A T A T A A A A T A A T G T A T A G A C A C A T A A A A G G  T A T T A T T A T A T A r A A G A C A T C T T A A T T A A T T T T T A T T A r i T A T  AT  T A A A A  T A T T T A T T A C A C G  
M F L Y F ] I Y L C I F H N N I Y S V E L  I K N N K Y N F I N N V  
A T A A T A T A A A G T A T A G A A C I A A A A  T A C G  T G C  T A T T T A  T G G G A A A A C  T G G A G G T  A A A A T  A A T  A G G  A C  A T G G T C A t  T C T T A T C C T T C A A C T G A A A T T T A T A A  
1 A U A T A T T T C A T A T C T T G A T T T T A T G C A C G A T A A A T A C C C T  T T T G A C C T C C A T T T T A T T A T C C T G T A C C A G T  A A G A A T A G G A A G T  T G A C T  T T A A A T A T  T 
H N  I K Y R  T K I S A !  Y G K  T G G K  I ! G H G H S Y P S T E  I Y N
Mse I Mse I
S S D  I 
Mse
tGAC GAAT T AAAAAAA T A T GIT GA TAC C AA T GA T GAAT GCA T AAGAACAAGAACAGGAATT AAAAAAAGAAGAAT AT T AAAAAGGGA TG AAAAT AT ATCA 
TGC T TAAT T IT M TATACAACT ATGG TtAC.T AC T T ACC TAT TCT TGI TC T T G t CC T T AAT T T I T T TC T TCT TAT AAT 1 T TTCCC T AC TT T T ATATAGT 
D F l K K Y V D T N D E V I R T R T G I K K R R I L K R D E N I S
HinO III Mse I
Alu I : Ora I Ode I
»TGT TACAAATAGA1AGIGCTAC TCAAGC1 t 1 AGAGACTIC T TG T TTAAAACCCTCAGATATAGACATGGTTATCAATGCATCGTCTAC TCCTCAAAATT 
TACAAIGT T TATCt ATCACGATGAGT! CGAAATCTC TGAAGAACAAAT T 1 TGGGAGTCTATATCTGTACCAATAGTTACGTAGCAGATGAGGAGTTTT AA 
M l  O I D S A T  Q A L T S C L K P S D  I D M V  I N A S S T P Q N
Sau3A I
Ssp I Mse I Xho II Rsa I
TAT TTGGTGATGCAAATAATATTACTAACAAAATTGGATGTAAAAATAGTGTTAATATGGATCTAACGGCTGCATGTACAGGTTTTATTTTTGCTTTTGT 
vTAAACCACTACG TT TATTATAATCAT TGTT TTAACCTACATTTTTATCACAATTATACC TAGATTGCCGACGTACATGTCC AAAAT AAAAACGAAAAC A 
l F G D A N N I S N K  I G C K N S  V N M C L T A A C T G F  I F A F V
Mse I Afl II
Alu I : Ora I Mse I ; Mse I Sau3A I
rACAGC TTa TAATTTTTTAAATAGATAT AAAAAC A T T T T AAT TG T TGGT AGTGATGCC T T AAGT AATTT TGTAGACTGGAGAGATCG TAATAC TTGTGTT— »•-----».... ♦----*--- ------1— .   ........... i..... ..............   h.....................        600
ITGTCGAATATTAAAAAATITATCTATATTT TTGTAAAATTAACAACCATCACTACGGAATTCATTAAAACATCTGACCTCTCTAGCATTATGAACACAA
T A Y N F L N R Y K N  1 L I V G S D A l  S N F V D V R D R N T C V
Sau3A I
Pst I Ssp I Xho II
TAT TTGGAGATGCTGCAGGTGCTGT TGTATTACAACGAACTGAAGAGAAAGAAGAAAATAAAATATTCAATTATTATCTTGGATCTGATAGTGAACTAA 
IATAAACCTCTACGACGTCCACGACAACATAATGT TGCTTGACTTCTCTTTCTTCTTT TATTTTATAAG TTAATAATAGAACCTAGACTATCACTTGATT 
L F G D A A G A V V L Q R T E E K E E N K I F N Y Y L G S D S E L  
Bd I
Mse I Sau3A l Mse I
TGACC TCTTAACCAT AAAT TT TGATCATGACAAATATAATTTAGATAAGCCTAATGTAAATAAGTATGGGAAATTATATATGAATGGGAAGGAAGTATT 
ACTGGAGAATTGGTATTTAAAACTAGTACTGT TTATATTAAATCTATTCGGATTACATTTATTCATACCCTTTAATATATACTTACCCTTCCTTCATAA 
. D  L L  T I N F D H D K  Y N L D K P N V N K Y G K L  Y M N G K E  V F
Mse I
Ora I : Dra I Alu I Ssp I Alu I
HAATATACTATAAGCAATATACCCAAAAT rTJAAAAAAAGCTATACAACATTCAAATAT AAAT ATTGAAGATAT AAA TTATTTTATATTTCATCAAGCT 
TTTATATGATAT TCGTT A T AT GGG TT T TAAAAT T TT TITCGATATGTTGTAAGTTTATATTTATAACTTCTATATTTAATAAAATATAAAGTAGTTCGA 
K Y T  1 S N  | P K  I L K K A I Q H S N I  N I E D I N Y F  I F H Q A
Mse I
Ora I Xba I Alu I
ICA TC AGAA T T A TAGAAACAG 1AGCCAAAAAT T( AAATATACCTATGTCAAAGGTATTAGTAAATCTAGACGAGTATGCAAATACTTCAGCAGCTTCAA 
rGTAG TC T T AA f AT C I T f  GTC A T CGG f i  T fT AAA T T t a  I ATG G A TAC AGT I T CC A T AAT C A T TTAGATC T GC TC ATACGTT TA TGAAGTCGTCGAAGTT 
t 1 R I I t t V A K N l  N I P M S K V L V N L D E Y A N T S A A S
S S D  I
Mse I Alu I Nde I
ICC T T I A TGC T TC TC I (.AAAA I A I T AAAAA ICG I AAAA 1 AAAAACGAA TGA I A I AA ( A T G T ATCTGTGGAT T TOG AGC T GGAA TGTCA TA I GGA'T GCGT
 * .........................   *............ » ---------- ----------- t  i I .........................................     *--  i---------------------------------------- --------------------- I-------------------- - * ----------------- F 1 1 0 0
GGaaa  t a; ( .aagagag m  i at aa i n  t  i acca  i t t  t  a m  i i gg t t  a g  t  at a i i at a c a i  a c a c a c c  i aaacc  t  cgac c  t  t  acagt  at acc  i acgca
P l  C F S F N I K N V I K  T N D i I C, M C G F G A C M S Y G C V
Sso I 
Mse I ; Mse I
'TACT TAAATAI TAA— • •-+ *► 1116
ATGAATT TATAA1 T
I L K Y
Appendix 7
pfFabH Ecoii preferred codo Map (1 > 1116) Srte and Sequence
Enzymes 47 of 436 enzymes (Filtered)
Settings:___________ Linear, Certain Sites Only. Standard Genetic Code_________
Bd I
Rsa I Sau3A I
ATGTTCCTGTACTTCATCACCTACCTGTGCATCTTCCACAACAACATCTACTCTGTTGAACTGATCAAAAACAACAAATACAACTTCATCAACAACGTTC, -----------(,-----  t -----»------| ----- «■■■■>■--- -4-~ —».......>.......       I- 100
rACAAGGACATGAAGTAGTGGATGGACACGTAGAAGGTGTTGTTGTAGATGAGAC AACTTGAC TAGTTTTTGTTGTTTATGTTGAAGTAGTTGTTGCAAG 
M F L Y F  I T Y L C  I F H N N I Y S V E L  I K N N K Y N F I N N V
Rsa I Sau3A I Msp I
ACAACATCAAATACCGTACCAAAATCCGTGCGATCTACGGTAAAACCGGTGGTAAAATCATCGGTCACGGTCACTCTTACCCGTCTACCGAAATCTACAA
200
TGTTGTAGTTTATGGCATGGTTTTAGGCACGCTAGATGCCATTTTGGCCACCATTTTAGTAGCCAGTGCCAGTGAGAATGGGCAGATGGCTTTAGATGTT
h n i k y r t k i r a i y g k t g g k i i g h g h s y p s t e i y n
Rs a I
Hinc II Rsa I Msp I
tGACGAACTGAAAAAATACGTTGACACCAACGACGAATGGATTCGTACCCGTACCGGTATCAAAAAACGTCGTATCCTGAAACGTGACGAAAACATCTCT 
...................   « . ■-f ------ , ---------)-------- ,........■ + -.......       I ........ ..............................       . ,-| -  ) 300
.LTGCTTGACTTTTTTATGCAACTGTGGTTGCTGCTTACCTAAGCATGGGCATGGCCATAGTTTTTTGCAGCATAGGACTTTGCACTGCTTTTGTAGAGA
D E L K K Y V D T N D E W I R T R T G I K K R R I L K R D E N I S
Pst I 
Sau3A I
>TGC T GC AGA TC GACTCTGCGACCCAGGCGCTGGAAACCTCTTGCCTGAAACCGTCTGACATCGACATGGTTATCAACGCGTCTTCTACCCCGCAGAACC
 —  - I .....................I ...................................      -+-- 4— -1—------   »-  ■— - 4- - -   ............................   » ............4 f 400
ACGACGTCTAGCTGAGACGCTGGGTCCGCGACCTTTGGAGAACGGACTTTGGCAGACTGTAGCTGTACCAATAGTTGCGCAGAAGATGGGGCGTCTTGG
m l q i d s a t q a l e t s c l k p s d i d m v i n a s s t p q n
Mse I
Hinc II HoiA I
Hpa I ; Msp I
TGT fCGGTGACGCGAACAACATC TCTAACAAAATCGGTTGCAAAAAC TCTGTTAACATGGACC TGACCGCGGCGTGCACCGG TTTCATCTTCGCGTTCGT
-  — ------ - - h  *  t    ~  ■ ■ I     ----- . |  . .-------- v------- ---------- t ----------- -------> t ........... ♦ ......... i --------   • I -------------------t 500
W.AAGCCACTGCGCTTGTTGTAGAGATTGTTTTAGCCAACGT7TTTGAGACAATTGTACCTGGACTGGCGCCGCACGTGGCCAAAGTAGAAGCGCAAGCA
c F G D A N N  I S N K  I G C K N S V N M O L  T A A C T G F  I F A F V
Rsa I Sau3A I Hinc II
TACCGCGTACAACTTCCTGAACCGTTACAAAAACATCCTGATCGTTGGTTCTGACGCGCTGTCTAACTTCGTTGACTGGCGTGACCGTAACACCTGCGTT
........... ~  ♦ ...................... - I........... '....................................        1-  t . ■ ■ -4-    I ..... I----------------4--------   h 600
ATGGCGC ATGTTGAAGGACTTGGCAATGTTTTTGTAGGACTAGCAACCAAGACTGCGCGACAGATTGAAGC AACTGACCGCACTGGCATTGTGGACGC AA
T A Y N F L N R Y K N l l I V G S D A L S N F V D V R D R N T C V
Pst I Rsa I
TGT TCGGTGACGCGGCGGGTGCGGTTGTTC TGC AGCGTACCGAAGAAAAAG AAG AAAACAAAATCTTC AAC TACT ACC TGGGTTCTGACTCTGAACTGA
 -------- 1------------   4--4-.-. . ■ (-------4 -------- 1------------   ( -  ♦ ■ ... »--------4--------( ------------   t 4 --------4 700
iACAAGCCACTGCGCCGCCCACGCCAAC AAGACGTCGCATGGCTTCTTTTTCTTCTTTTGTTTTAGAAGTTGATGATGGACCCAAGACTGAGACTTGACT
L F G D A A G A V V I Q R T E E K E E N K I F N Y Y L G S D S E L
Mse I 
Hinc II
Hpa I Rsa I
CGACCTGCTGACCATCAACTTCGACCACGACAAATACAACCTGGACAAACCGAACGTTAACAAATACGGTAAACTGTACATGAACGGTAAAGAAGTTTT
  ------ 4— 4 . .-( ----------------------      4 —  4 -t • , - .4  ■ ■ . ■ I ■  -  t .   t .................... | ............   -4 800
'6CTGGACGACTGGTAGTTGAAGCTGGTGCTGTTTATGTTGGACCTGTTTGGCTTGCAATTGTTTATGCCATTTGACATGTACTTGCCATTTCTTCAAAA
t O L L  T I N F D H D K Y N L O K P N V N K Y G K l  Y M N G K E V F
Sau3A I
iAATACACCATCTCTAACATCCCGAAAATCCTGAAAAAAGCGATCCAGCACTCTAACATCAACATCGAAGACATCAACTACTTCATCTTCCACCAGGCG
— .......... * -------------  <...- 4 I ..................................    h----------------------- -| ■■■ , « . . .  -4 -  ■ •-i ---.----------<    h 900
rTTATGTGGTAGAGATTGTAGGGCTTTTAGGACTTTTTTCGCTAGGTCGTGAGATTGTAGTTGTAGCTTCTGTAGTTGATGAAGTAGAAGGTGGTCCGC
K Y T  I S N I P K  I L K K A I Q H S N I N  I E D I N Y F I F H Q A
Mse I 
Hinc II 
Hpa I
ACATCCGTATC ATCGAAACCGTTGCGAAAAACCTGAACAtCCf. GAT GTCTAAAGTTCTGGTT AAC CTGGACGAATACGCGAAC ACC TCTGCGGCGTCT A -----«----- 4 ---- .......... ............... .. ~ .......... t— — >------ 1----- <---------------- t ------- <.......» « 100 0
tGTAGGCATAGTAGCTTTGGCAACGCTTTTTGGACTTGTAGGGCTACAGATTTCAAGACCAATTG6ACCTGCT t a t g c g c t t g t g g a g a c g c c g c a g a t  
1 1 R 1 I E  T V A K N L  N I P M S K V L  V N L  D E Y A N T S A A S
tCCGCTGTGCT TCTCTGAAAACATCAAAAACGGTAAAATCAAAACCAACGACATCATCTGCATGTGCGGTTTCGGTGCGGGTATGTCTTACGGTTGCGT
 ...................   4.......... 4— ---------  4    ) • • • -  --------4-------------   > —.........   H--— ............4 1100
IGGCGACACGAAGAGAC TT TTG TAGTT T TTGCCATTTTAGTT7TGG T TGC TGTAGT AGACGT ACACGCC.AAAGCC ACGCCCAT ACAGAATGCCAACGCA
P i  C F S E N I  K N G K  I K T N O  I I C M C G F G A G M S Y G C V
ITCCTGAAATACTAA
• I ■ ■ ■ ■- 11 16 
TAGGACTTTATGATT
I L K Y
Overlapping oligonucleotides for E. coli preferred codotta of pfFabH
CODING 1
/va* i
5'CTCG AGG ATCCC AT ATGTTCCTGT ACTTC ATC ACCTACCTGTGC ATCTTCC AC AAC AAC A
T G 3  \  l  l U
V £ « .c ^ u L s > ta  u>
CODING 2
5'C AACTTC ATC AAC AACGTTC AC AAC ATC AAAT ACCGT ACC AAAATCCGTGCG ATCT ACG 
GTAAAACCGGT3’
CODING 3
5'CGTCTACCGAAATCTACAACGACGAACTGAAAAAATACGTTGACACCAACGACGAATGG 
ATTCGTACCCGT ACCGG3'
CODING 4
5’CATCTCTATGCTGCAGATCGACTCTGCGACCCAGGCGCTGGAAACCTCTTGCCTGAAACC
GTCTGACATCGACATGG3’
CODING 5
5’CGGTGACGCGAACAACATCTCTAACAAAATCGGTTGCAAAAACTCTGTTAACATGGACC
TGAC3'
CODING 6
5’CCGCGTACAACTTCCTGAACCGTTACAAAAACATCCTGATCGTTGGTTCTGACGCGCTGT
CTAACTTCGTTGACTGG3'
CODING 7
5’CGGTGACGCGGCGGGTGCGGTTGTTCTGCAGCGTACCGAAGAAAAAGAAGAAAACAAA
ATCTTC3*
CODING 8
5’ACTGAACGACCTGCTGACCATCAACTTCGACCACGACAAATACAACCTGGACAAACCGA
ACGTTAACAAATACGG3*
CODING 9
5'C AAAT AC ACC ATCTCTAAC ATCCCG AAAATCCTG AAAAAAGCG ATCC AGC ACTCTAAC A 
TCAACATCGAAGAC3'
CODING 10
5'CATCCGTATCATCGAAACCGTTGCGAAAAACCTGAACATCCCGATGTCTAAAGTTCTGGT
TAACCTGG3’
CODING 11
5TATCCCGCTGTGCTTCTCTGAAAACATCAAAAACGGTAAAATCAAAACCAACGACATCA
TCTGCATGTGCGG3'
NON-CODING 11
5TGAACGTTGTTGATGAAGTTGTATTTGTTGTTTTTGATCAGTTCAACAGAGTAGATGTTGT
TGTGGAAGATGC3*
NON-CODING 10
5’CGTTGT AG ATTTCGGT AG ACGGGT AAG AGTG ACCGTG ACCG ATG ATTTT ACC ACCGGTTT 
T ACCGT AG ATCG3'
NON-CODING 9
5CGATCTGCAGCATAGAGATGTTTTCGTCACGTTTCAGGATACGACGTTTTTTGATACCGG 
TACGGGTACG AATCC3'
NON-CODING 8
5’GAGATGTTGTTCGCGTCACCGAACAGGTTCTGCGGGGTAGAAGACGCGTTGATAACCAT 
GTCG ATGTC AG ACGG3'
NON-CODING 7
5’GGTTCAGGAAGTTGTACGCGGTAACGAACGCGAAGATGAAACCGGTGCACGCCGCGGTC 
AGGTCC ATGTTAAC AG AG3'
NON-CODING 6
5CCGCACCCGCCGCGTCACCGAACAGAACGCAGGTGTTACGGTCACGCCAGTCAACGAAG
TTAGACAGCT
NON-CODING 5
5'GGTCAGCAGGTCGTTCAGTTCAGAGTCAGAACCCAGGTAGTAGTTGAAGATTTTGTTTTC
TTCTTTTTC3'
NON-CODING 4
5’GGATGTTAGAGATGGTGTATTTGAAAACTTCTTTACCGTTCATGTACAGTTTACCGTATTT
GTTAACGTTCGGT3’
NON-CODING 3
5’CGGTTrCGATGATACGGATGTTCGCCTGGTGGAAGATGAAGTAGTTGATGTCTTCGATGT
TGATGTTAGAG3'
NON-CODING 2
5’CAGAGAAGCACAGCGGGATAGACGCCGCAGAGGTGTTCGCGTATTCGTCCAGGTTAACC
AGAACTTTAG3’
NON-CODING 1 sV'-vt of co^ f
,  T o >
5’C AT ATtjGATCCftTCG AGTT AGT ATTTC AGG AT AACGCAACCGT AAG ACATACCCGC ACC 
GAAACCGCACATGCAGATGATGTC3’
nzymes
settings:
47 ot 436 enzymes (Filtered)
Linear, Certain Sites Only, Standard Genetic Code
Bci I
Rsa I Sau3A I
• n G T T C C T G T A C T  T C A T C A C C T A C C I G T G C A T C T T C C A C A A C A A C A T C T A C T C T G T T G A A C T G A T C A A A A A C A A C A A A T A C A A C T T C A T C A A C A A C G T T C  
1 A C A A G G A C A T G A A G T A G T G G A T G G A C A C G T A G A A G G T G T T G T T G T A G A T G A G A C A A C T T G A C T A G T T T T T G T T G T T T A T G T T G A A G T A G T T G T T G C A A G
m f  l  y f  I T Y L C I F H N N I  y s v e l  i k  n  n  k  y n  f  i n n v
Rsa I Sau3A I Msp I
i C A A C A T C A A A T A C C G T A C C A A A A T C C G T G C G A T C T A C G G T A A A A C C G G T G G T A A A A T C A T C G G T C A C G G T C A C T C T T A C C C G T C T A C C G A A A T C T A C A A
 . „ 4 -  , . , , ---------4     , 4   ■------ +-■-------------------~ I - . - ........ ............ I  *  I   ------------1---------   T --------- ------------- 1 2 0 0
r G T T G T A G T T T A T G G C A T G G T T T T A G G C A C G C T A G A T G C C A T T T T G G C C A C C A T T T T A G T A G C C A G T G C C A G T G A G A A T G G G C A G A T G G C T T T A G A T G T T
- ■ n i k y r t k i r a i  y g k t g g k i  i g h g h s y p s t e  i y n
vgam H u
Hinc II Xho II Rsa I ^ M sp  I C  rw*XA*J W T
3AACTGAAAAAATACGTTGACACCAACGACGAATGGATCCGTACCCGTACCGGTATCAAAAAACGTCGTATCCTGAAACGTGACGAAAACATCTCT
— — -i  ------ <— — ---------   — ---------. r . 4 . . —  t   ------- , —  ------------ 1 — >—  f — >------------300
GC TTGACT TT TT TATGCAACTGTGG TTGC TGC TT ACC TAGGCATGGGCATGGCCATAGTTT T TTGCAGCATAGGAC T TTGCACTGC TT TTGTAGAGA
E l K K Y V D T N O E V I R T R T G I K K R R I L K R D E N I S
Pst I 
Si*o3A I
TTGCAGATCGACTCTGCGACCCAGGCGCTGGAAACCTCTTGCCTGAAACCGTCTGACATCGACATGGT TATCAACGCGTCTTCTACCCCGCAGAACC
  .........................................    - t -♦ > — 4 -----— <----------I 1 ■ • ■  h............................ I— ...................    I ................... -  - •  I 1100
GACGTCTA6C TGAGACGCTGGGT CCGCGACCT T TGGAGAACGGACT TT GGCAGAC TGT AGC TGTACCAAT AG T TGCGCAGAAGATGGGGCGTC TTGG
l o i d s a t o a l e  t s c l k p s d  i o m v i n a s s t p q n
Ueo I
: Hinc II HaiA I
: Hpa I ; Msp I
( tcggtgacgcgaacaacatctctaacaaaatcggttgcaaaaactctgttaacatggacctgaccgcggcgtgcaccggtttcatcttcgcgttcgt
1——  ■ * ...............................* I   I  --------»........   I -------*-------I ......................♦------ »-------I ------ » -------I 500
AAGCCACTGCGCTTGTTGTAGAGATTGTTTTAGCC AACGTTTTTGAGACAATTGTACCTGGACTGGCGCCGCACGTGGCCAAAGTAGAAGCGCAAGCA
F G D A N N I S N K  I G C K N S V N M O L  T A A C T G F  I F A F V
Rsa I Sau3A I Hinc II
CCGCGTACAAC TTCCTGAACCGTTACAAAAACATCCTGATCGTTGGT TCTGACGCGCTGTCTAACTTCGTTGACTGGCGTGACCGTAACACCTGCGTT
— — I----------------- F~  -------- .^.........  I.................................................................          - •.I ................... .................... .1 600
GGCGCATGTTGAAGGACTTGGCAATGTTTTTGTAGGACTAGCAACCAAGACTGCGCGACAGATTGAAGCAACTGACCGCACTGGCATTGTGGACGCAA
T A Y N F L N R Y K N  I L  I V G S D A L  S N F  V D V R D R N  T C V
Pst I Rsa I
GTTCGGTGACGCGGCGGGTGCGGTTGTTCTGCAGCGTACCGAAGAAAAAGAAGAAAACAAAATCTTCAACTACTACCTGGGTTCTGACTCTGAACTGA
• •  -------+     —  *------ ♦ ■ y   -------1....................................................................                ♦ --------- i 700
CAAGCCACTGCGCCGCCCACGCCAACAAGACGTCGCATGGCTTCTTTTTCTTCTTTTGTTTTAGAAGTTGATGATGGACCCAAGACTGAGACTTGACT
f g o a a g a v v l o r t e e k e e n k i f n y y l g s d s e l
Mse I
; Hinc II
; Hpa I Rsa I
GACC TGCTGACCATCAAC TTCGACCACGACAAAT ACAACC TGGACAAACCGAACGT TAACAAAT ACGGT AAAC TG TACATGAACGGT AAAGAAGTT T T
............................   +------- •— I----►-------♦------- ►-------1-   I - ■ ■ ■ .  I • • —     • •.I ............... I 800
CTGGACGAC TGGT AGTTGAAGC TGGTGCTGTTTATGTTGGACCTGTT TGGC TTGCAATTGTTTATGCCATT TGACATGTACT TGCCATTTC TTCAAAA
D L L T I N F D H D K Y N L O K P N V N K Y G K L Y M N G K E V F
Sau3A I
AATACACCATCTCTAACATCCCGAAAATCCTGAAAAAAGCGATCCAGCACTCTAACATCAACATCGAAGACATCAACTACTTCATCTTCCACCAGGCG
— ....................I ------ »—■— I ...........................................     —i . . . .  i ----- >•   .900
TTATGTGGTAGAGATTGTAGGGCT TTTAGGACT TTTTTCGCTAGGTCGTGAGATTGTAGTTGTAGCTTCTGTAGTTGATGAAGTAGAAGGTGGTCCGC
K Y T I S N I P K  I L  K K  A ] Q H S N  I N I E D  I N Y F  I F H Q A
Mse I 
: Hinc II 
i Hpa I
CA TCCG T AT CATCGAAmCCG T T GCGAAAAACC1GAACATCCCGATGTCT AAAGT TC TGGT T AACC TGGACGAA T ACGCGAAC ACC TC TGCGGCGTC T A 
&TAGGCATAGTAGCTTTGGCAACGCTTTTTGGACTTGTAGGGCTACAGATTTCAAGACCAATTGGACCTGC TTATGCGCTTGTGGAGACGCCGCAGAT 
I R I I E  I V A K N L N I P M S K V L V N l  O T  Y A N T S A A S  
r.CGC TGTGC T T C TC T GAAAAC A TC AAAAACGGT AAAAT C AAA ACC AACGAC ATCATC TGC AT G TGCGG T I T CGGTGCGGG T A TG TC T TACGGTT GCGT 
it'G ArC. ACGAAGAGAC T T I TGT AG T T T T TGCC A T T T T AGT I T TGGT I GC TGT AG T AGACG T AC ACGCCAAAGCCACGCCC AT AC AGAAT GCCAACGCA 
I’ I C F S F N 1 K N G K I K T N D I I C M C G F G A G M S Y G C V  
iCCTGAAATACT AA 
\GGAC I T 1ATGA1 1 
I I K Y
Appendix 8
Compound No. P. falciparum 
LD5 0G1M)
T. brucei 
LD50 (pM)
T. cruzi 
LD50 (nM)
L. donovani
LD50 (nM)
Sigma TLM >95 182 >142 56
776 36 171 68 >105
111 25 62 28 >83
778 40 190 68 >106.9
779 139 112 127 >131.3
780 153 194 >350 >116.9
781 143 256 >427 >142.6
817 347 >624 >624 Not tested
818 233 357 568 Not tested
819 19 47 43 Not tested
820 61 71 195 >123.7
821 15 97 54 >100.5
822 316 >568 >568 >189.6
823 54 157 165 >110.9
825 65.2 153 72 >100.5
863 34.4 130 49 >78.3
922 222.1 246 >423 >141.3
924 290.2 288 >522 >174.1
925 10.7 21 56 65.9
926 195.3 408 >408 >136.1
927 50.7 132 64 >83.2
943 17.57 6 164 97.0
944 15.3 8 77 77.4
945 16.1 13 70 >96.6
1020 62.4 79.2 >488.4 29.9
1021 60.5 119.8 195.4 9.3
1022 26.1 157 56 17.5
1023 6.3 167 31 10.5
1084 63 6.7 153 3.3
1086 37 2.0 150 1.1
1140 44 9 359 100
1141 19 9 47 82
1152 1.3 14 80 66
1192 4 >223 13 >74
1193 2.7 149 14 7
1194 8.5 55 21 12
1195 73 246 >110 88
1199 6 29 13 0.5
1200 7 32 14 2
1209 11 >200 >66 >66
1210 19 64 36 36
Appendix 8 Biological activity of TLM derivatives against parasitic protozoa
This table details all of the data obtained from assays against cultures of different 
parasites. The three best LD50 values against each organism are shown in bold. Assays 
were performed as described in Jones et al., 2004.
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11  Generation of anti-complement prodrugs for specific delivery 
of active regulator to disease sites
C.L. Harris. C.E. Hughes, I.G. Goodfellow, B. Caterson, 
B.P. Morgan
Department o f Medical Biochemistry, UW CM , Heath Park, 
Cardiff, CF14 4XN; Connective Tissue Biology Labs, Cardiff 
School o f Biasciences, Cardiff University, CF10 3 US; Division 
of Virology, Institute of Biomedical and Life Sciences, 
University o f Glasgow, Glasgow, G i l  JJR, UK.
We have developed a novel strategy for specific delivery of anti­
complement prodrugs to sites of complement-mediated 
inflammatory disease. Fusion of the regulatory domains of 
complement inhibitors (CD55 and CD59) to the Fc domains of 
antibody extends plasma half life but can also substantially reduce 
biological activity when compared to native regulator or regulator 
released from the Fc following papain cleavage. By incorporating 
cleavage sites for MMPs and/or aggrecanases between CD55 and the 
Fc, we have engineered model prodrugs that would be cleaved at 
inflammatory sites, such as an inflamed joint, to release active 
inhibitor. Exposure of these prodrugs to relevant enzymes, either as 
pure enzyme or as supernatants from cytokine-stimulated chondro­
cytes, efficiently cleaved the reagents, releasing active CD55. 
Optimisation by modification of the enzyme cleavage site and 
antibody Fc are continuing to create a prodrug with essentially no 
systemic anti-complement activity that is efficiently cleaved at 
inflammatory sites to release the active inhibitor. Such agents 
represent a paradigm for the next generation of anti-complement 
therapeutics.
13 Fatty acid synthesis as a target for novel anti-malarials 
J.E. Urch. C. Berry, J.L. Harwood
School o f Biomedical Sciences, Cardiff University, P.O. Box 
911, Museum Avenue, Cardiff, CF10 JUS, UK
Malaria is a parasitic disease that kills over 1 million people every 
year. Increasing resistance to current anti-malarial agents is responsi­
ble for the resurgence of malaria and necessitates the development of 
new drugs to combat this disease.
Fatty acid synthesis is crucial for all living cells. Plants and bacteria 
utilise a dissociable (Type II) multi-enzyme fatty acid synthase 
(FAS) complex, which differs from the multi-functional FAS dimer 
found in mammals. The malaria parasite, Plasmodium falciparum, 
contains a Type II FAS system, which represents a new target for 
the development of antimalarial agents that would not compromise 
the host’s lipid metabolism.
(3-Ketoacyl-ACP synthases (KAS) catalyse the condensation 
reactions of FASs and are obvious potential targets. The antibiotic, 
thiolactomycin is an inhibitor of Type II KAS enzymes. A gene for 
one KAS isozyme from P. falciparum has been identified previously. 
We have identified a second P. falciparum KAS gene and have used it 
for expression studies in E. coli. The expressed KAS enzymes will 
then be used in further studies with thiolactomycin and derivatives 
in order to try and find better chemicals for malaria therapy. 
Supported by; the Cardiff Partnership Fund, the Morgan E.
Williams PhD Fellowship and WHO.
1 2  Study of wheat transformed with sense and anti-sense 
lipase genes
D A .N . Edlin. P. Killc, C.M. Saunders, H .D . Jones* and 
J.L. Harwood
School o f Biosciences, Cardiff University, Cardiff, CF10 JUS, 
UK and *Crop Performance and Improvement, IACR- 
Rolhamsted, Harpenden, Herts, ALJ 2JQ, UK
Wheat is a member of the family Gramineae, which includes some 
of the world’s most important crops. It is primarily used in the 
production of flour for bread, pasta and cakes. Milled wholemeal 
flours are susceptible to the action of bran lipases that lead to the 
production of rancid off-flavours, a loss in nutritional value and a 
reduced baking performance. Deterioration of wholemeal flours is 
initiated by bran lipases on triacylglycerols in the aleurone layer. 
Rapid-acting germ lipoxygenases then produce oxidative products 
from the non-esterified fatty acids released by the lipases when the 
flour is mixed with water. Wastage, due to lipase action, accounts for 
5% of total wholemeal flour in the UK, which equates to an annual 
loss of approximately 6 million pounds sterling. We have identified a 
gene encoding lipase activity from wheat. This gene has been used to 
transform varieties of wheat, using the technique of particle bom­
bardment, with sense and anti-sense copies of the wheat lipase gene 
under the control of the maize ubiquitin promoter.
We acknowledge the financial assistance of the BBSRC.
1 4  Signalling pathways in chondrocyte metabolism and the effects 
of n-3 fatty acid supplementation 
S. H urst. C.L. Curtis, S.G. Rees, B. Caterson,
J.L. Harwood
School of Biosciences, Cardiff University, Cardiff CF10 JUS, 
U K
Previous work has demonstrated that n-J polyunsaturated fatty 
acids (PUFAs) inhibit degradative and inflammatory aspects of 
arthritis. This study was aimed at elucidating signalling pathways 
involved in the observed inhibition of mRNA expression of 
degradative enzymes and inflammatory mediators by n-3 PuFAs. 
Human RNA from arthritic cartilage (with or without fatty acid 
supplementation, and in the absence or presence of IL-ip) was 
extracted and compared using microarray technology. Genes from 
the MAPKinase pathway (egr-1, c-fos), NFkB pathway (iNOS, 
NFkB, IkB-cx, c-myc), TGF-(3 pathway/anti-proliferation pathway 
(p 19, p21, p57) and IL-2 were seen to increase in the presence of IL- 
1. Supplementing with n-3 PUFA reduced the levels of mRNA for 
the above genes.
n-J PUFA have previously been shown to affect the MAPK and 
NFkB pathways. Our results suggest that pathological signalling 
pathways associated with arthritic disease can be inhibited by such 
fatty acids. Studies are on going to elucidate further the relationship 
between these pathways and the effect of n-J PUFAs in alleviating 
arthritic symptoms.
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Abstract—A series of analogues of the naturally occurring antibiotic thiolactomycin (TLM) have been synthesised and evaluated 
for their ability to inhibit the growth of the malaria parasite, Plasmodium falciparum. Thiolactomycin is an inhibitor of Type II fatty 
acid synthase which is found in plants and most prokaryotes, but not an inhibitor of Type I fatty acid synthase in mammals. A 
number of the analogues showed inhibition equal to or greater than TLM. The introduction of hydrophobic alkyl groups at the C3 
and C5 positions of the thiolactone ring lead to increased inhibition, the best showing a fourteenfold increase in activity over TLM. 
In addition, some of the analogues showed activity when assayed against the parasitic protozoa, Trypanosoma cruzi and Trypano­
soma brucei.
©  2003 Elsevier Ltd. All rights reserved.
1. Introduction
Malaria is by far the world’s most important tropical 
disease. In many developing countries and in Africa 
especially, malaria exacts an enormous toll in lives, in 
medical costs, and in days of labour lost. At present, at 
least 300 million people are affected by malaria globally, 
and there are between 1 and 1.5 million malaria deaths 
annually.1,2 Over the last several decades, the rapid 
development of drug-resistant strains has compounded 
the already serious health problems. Of the four known 
human malaria parasites, Plasmodium falciparum is the 
predominant cause of mortality, with 120 million new 
cases and 1 million deaths per year globally. It is this 
particular species, which has given rise to formidable 
drug-resistant strains, resulting in the urgent need for 
new chemotherapeutic agents. The search for new 
agents has recently been aided with the completion of 
the P. falciparum genome.3 Detailed studies4 of this 
genome have identified new potential drug and vaccine 
targets. One such target appears to be fatty acid bio­
synthesis of P. falciparum.
’Corresponding author, fax +44-29-2087-4149; e-mail: gilbertih(a. 
cf ac.uk
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Fatty acid synthesis is a crucial function of living cells. 
The main steps in this process in animals are carried out 
by a single, multifunctional polypeptide fatty acid syn­
thase (Type I FAS). In contrast, plants and bacteria 
utilise a dissociable multienzyme system (Type II FAS).5 
The structural differences between these systems are 
sufficient for the development of selective antibiotics 
targeted against the P-ketoacyl-acyl carrier protein syn­
thase (KAS) and other individual enzymes of the Type 
II FAS.6 7
In plants and bacteria, there appear to be three KAS 
enzymes, denoted KAS I, KAS II and KAS III. The 
initial C2-C4 step is catalysed by KAS III; thereafter 
KAS I and KAS II are involved in chain elongation.8 In 
most organisms with a Type II fatty acid synthase, KAS 
I and KAS II show very high similarity at the protein 
level. Recent discoveries acknowledge that Plasmodium 
synthesises fatty acids in the apicoplast which is a vestigial 
organelle thought to be derived from a chloroplast.9-12 
Not surprisingly, Plasmodium fatty acid synthase (FAS) 
is a Type II enzyme complex and, thus, differs markedly 
from human Type I FAS. Analysis of the recently pub­
lished P. falciparum genome3 reveals just two different 
KAS enzymes, with the KAS I and KAS II of typical 
Type II systems replaced by a single enzyme, that we and 
others, have denoted KAS 1/2, and a separate KAS III.8
684 S. M . Jones et al. / Bioorg. M ed. Chem. 12 (2004) 683-692
HO
1
Figure 1. Structure of thiolactomycin.
A known inhibitor of the dissociable Type II FAS 
enzymes is the naturally occurring thiolactone anti­
biotic, thiolactomycin (TLM) l 1314 (Fig. 1). Originally 
reported in 1982,15 TLM has since become the most 
well-studied of the naturally occurring thiotetronic 
acids. The thiolactone has shown moderate in vitro 
activity against a broad spectrum of pathogens, includ­
ing Gram-positive and Gram-negative16 bacteria and 
Mycobacterium tuberculosis,[1 Furthermore, TLM ana­
logues showed enhanced inhibition of pea (Pisum sativum) 
FAS,18 and effective activity against Staphylococcus 
aureus and Pasteurella multocida.19 Because of its negli­
gible toxicity towards mammals,15 TLM or its analo­
gues are obvious candidates as new drugs for problem 
diseases such as malaria. In fact, recently Waller et al. 
have reported encouraging anti-malarial activity for 
TLM and various analogues.20 Furthermore, because 
there are KAS isoforms in target organisms and each 
KAS isoform of Type II FAS complexes has been 
shown to be sensitive to TLM, then use of such inhibi­
tors offers therapies with less chance o f target-site resis­
tance due to point mutations occurring readily. In this 
paper we present synthetic studies and findings in our 
attempts to improve the overall activity of TLM against 
P. falciparum cultured in red blood cells. Also studies 
against Trypanosoma brucei rhodesiense trypomastigotes 
and intracellular Trypanosoma cruzi amastigotes are 
reported.
2. Chemistry
The first racemic total synthesis of TLM 1 was reported 
by Salvino et al. and involved the alkylation of a thio­
tetronic acid dianion with an isoprene cation equiv­
alent.21 A subsequent Wittig condensation with the 
resulting aldehyde afforded TLM 1. The intermediate 
thiotetronic acid was prepared according to methodol­
ogy developed by Benary.22 Using a modification of this 
methodology we were able to synthesise TLM and a 
range of TLM analogues with varying chain length and 
saturation at the C5 and C3 positions of the ring 
(Scheme 1). Methyl propionylacetate 2 was treated with 
alkyl and benzyl halides in the presence of potassium 
carbonate as base to provide the alkylated products 3. 
Treatment of the resulting P-ketoesters 3 with pyri- 
dinium tribromide in acetic acid afforded the bromides 4 
as a mixture of diastereoisomers. Displacement of the 
bromides 4 proceeded smoothly using thiolacetic acid 
under basic conditions forming the thioacetates 5. 
Cyclisation to the desired thiolactones 6 was accom­
plished upon treatment with aqueous potassium 
hydroxide solution. Isolated yields following flash chro­
matography were varied (30-93%). These derivatives 
were converted into the final compounds 7 after expo­
sure to sodium hydride, butyllithium and the appro­
priate alkyl halides in dry THF at — 78 °C. The 
alkylations tended to be generally low yielding; these 
findings are in agreement with previous publications in 
this area.19 Attempts to protect the hydroxy function­
ality, in the hope that tying up of the free hydroxy 
group may improve the yields for the alkylation step, 
proved unsuccessful.
Derivatisation of the methyl substituent at the C5 posi­
tion was accomplished as shown in Scheme 2. Following 
a literature procedure,23 the P-ketoesters 9 were
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(72-85%)
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7a-e R ‘ = Me, 7a R2= Hex (10%), 7b R 2= O ct (12% ), 
7c R 2= Geranyl (16%). 7d R2= D ec (10%),
7e R 2= Hcxadec (7%), 7f-i r '=  Et, 7 f R 2-  Hex (16% ), 
7g R2-  Oct ( 18%), 7b, R2= Dec (22% ),
7i R2-  llexadec (22%), 7j r '=  Pr, R 2= Dec (12%),
7k R ‘ = Bn, R2= Dec (4%).
6a R ' = Me (90% ), 
6b R '= E t (89%), 
6 c R '- P r  (42%), 
6d R ' = Bn (29%)
5a R ,=  Me, 5 b R '= E t  
5 c R '= P r ,  5d r '=  Bu 
5e R l = Bn
Scheme 1. Reagents and conditions: (a) R'X, K2C 0 3 (4 equiv), THF, reflux; (b) PyBr3, AcOH, rt; (c) AcSH, Et3N, EtOAc, rt; (d) KOH (2 equiv), 
HzO/EtOH (1:1), 4 5 °C; (e) NaH (1.2 equiv), BuLi (1.1 equiv), R2X, THF/DM PU (1:1), rt to -78°C ; (f) NaH, BuLi, C2H5OCHC(CH3)CHO (2 
equiv), THF/Pyrimidnne (1:1), rt to -78°C ; (g) BuLi (2 equiv), Ph3P *-C H 3Br,~ THF, -7 8 °C  to rt.
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12a R '=  Et, R2= M e, R 3= D ec (14%),
12b R ’= Et, R2= M e, RJ= H exadec (12%).
Scheme 2. Reagents and conditions: (a) NaH (1.2 equiv), BuLi (1.1 equiv), R 'l, 0°C  to rt; (b) KOH (2 equiv), H20/EtO H  (1:1), 45°C; (c) NaH (1.2 
equiv), BuLi (1.1 equiv), R3X, rt to -7 8  °C.
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Scheme 3. Reagents and conditions: (a) NaH (1 .2 equiv), BuLi (I.I equiv), iododecane, 0°C  to rt; (b) iodobutane, K2C 0 3 (4 equiv), THF, reflux; 
(c) PyBrj, AcOH, rt; (d) AcSH, Et3N, EtOAc, rt; (e) KOH (2 equiv), H2Q/EtOH (1:1), 45 °C.
prepared in excellent yields by treatment of methyl 
acetoacetate 8 with sodium hydride, butyllithium and 
the relevant alkyl iodides. The corresponding P-keto­
esters 10 were synthesised using the same methodology 
described in Scheme 1, and once formed were duly con­
verted into the desired thiolactones 11 and 12.
Using the same methodology described in Scheme 2, we 
were able to avoid the low yielding alkylation reaction 
at the C5 position with the construction of the desired 
carbon skeleton prior to cyclisation (Scheme 3). Sub­
sequent alkylations of methyl propionylacetate 2 at the 
C4 and C2 positions respectively yielded the P-ketoester
13. Bromination at the tertiary C4 position proceeded in 
reasonable yield (53%) forming the bromide 14, which 
was duly converted to the thioacetate 15 in 48% yield. 
Treatment of the thioacetate 15 with potassium 
hydroxide delivered the derivitised thiolactone 16 
(20%).
3. Results and discussion
All compounds were assayed in vitro for their activity
against the malarial parasite, P. falciparum (Table 1).
Furthermore, the compounds were also assayed against
T. brucei and T. cruzi (Table 1). The screening proce­
dures are briefly described in the Experimental (Section 5).
The basic structure of the thiolactomycin ring was 
retained with the analogues represented mainly by vari­
ations in the isoprenoid moiety and the methyl sub­
stituents at the C3 and C5 positions of the ring. 
Recently, thiolactomycin analogues have been tested in 
assays for fatty acid synthesis*8 20 and activities of the 
individual condensing enzymes.*7 The findings from 
these studies suggest that replacement of the isoprenoid 
side chain with longer tethers leads to an overall 
increase in inhibition of fatty acid synthesis. This nota­
ble trend is also evident in our own findings (Table 1). 
The analogues 7a and 7b showed inhibition comparable 
to that of thiolactomycin 1. In comparison to 1, the 
geranyl analogue 7c showed almost a fourfold increase 
in activity, perhaps indicating that unsaturation in the 
hydrophobic chain enhances inhibition. Waller et al.20 
have reported a sixfold increase in efficacy for the ger­
anyl analogue over TLM against the P. falciparum 
multidrug-resistant strain W2mef. The longer side-chain 
analogues 7d (decyl) and 7e (hexadecyl) also showed 
much improved activity over 1, with 7e registering a 
6-fold (25 pM) increase in inhibition. The influence of 
the longer hydrophobic chain on activity is further
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Table 1. Activities of compounds against P. falciparum cultured in red blood cells; T. brucei trypomastigotes; and T. cruzi amastigotes cultured in 
rat skeletal myoblasts
HO
Compd R' R2 R3 P. falciparum
IC50 (pM)
T. cruzi
IC50 (pM)
T. brucei 
ICso (pM)
1 Me Me Isoprenoid 143 >427 256
6a Me Me H >347 >624 >624
6b Me Et H 233 568 357
6c Me Pr H >290 >522 288
6d Me Bn H 195 >408 408
7a Me Me Hexyl 139 127 112
7b Me Me Octyl 153 >350 194
7c Me Me Geranyl 40 68 190
7d Me Me Decyl 36 68 171
7e Me Me Hexadecyl 25 28 62
7f Me Et Hexyl 61 195 71
7* Me Et Octyl 54 165 157
7h Me Et Decyl 15 54 97
7i Me Et Hexadecyl 19 43 47
7j Me Pr Decyl 10 56 21
7k Me Bn Decyl 50 64 132
l la Et Me H >316 >568 >568
11b Decyl Et H 72 164 6
12a Et Me Decyl 65 72 153
12b Et Me Hexadecyl 35 49 130
16 Me Bu Decyl 71 77 8
Standards: For P . falciparum, chloroquine, IC50 = 0.126 pM; artemisinin, ICso = 0.005 pM ; For T. brucei, melarsoprol, ICso = 0.005 pM ; For T. 
cruzi, benznidazoie, ICjo= 1 -68 pM. The ICjq values are the means of four values o f two independent assays done in duplicate. They were deter­
mined by linear interpolation between the two adjacent drug concentrations above and below the 50% incorporation line.
emphasised by considering the intermediate compounds 
6a-nl and 11a, all of which showed a marked decrease in 
inhibition (195 to >347) in comparison to 1.
Recently, Price et al. have solved the crystal structure of 
TLM bound to Escherichia coli KAS I.24 25 From this 
study a number of key interactions have been identified 
involving the thiolactone ring with the protein’s active 
site. Specifically, the carbonyl oxygen at the C2 position 
binds with two histidines (His 298 and His 333). The 
isoprenoid moiety appears to occupy a hydrophobic 
crevice and is sandwiched between two pairs of amino 
acids (Gly 391 and Phe 392; Ala 271 and Pro 272). 
Interestingly, alignment of P. fa lciparum  KAS 1/2 with 
the E. coli KAS I indicates that these four amino acids 
are retained in the P. fa lciparum  sequence (Gly 403 and 
Phe 404; Ala 274 and Pro 275).25 Price et al.,25 further 
observed that this crevice was not optimally filled by the 
isoprenoid side chain. Our findings lend support to this 
observation, and would suggest that alkyl chains of ten 
carbons and above better occupy this cleft, therefore 
increasing inhibition.
Price ct al.25 made a detailed study of the crystal struc­
ture of E. coli KAS I, and found that the two ring 
methyl substituents, at the C3 and C5 positions, are 
accommodated in hydrophobic pockets (the C3 methyl 
in a pocket bounded by Phe 229, Phe 392 and Thr 300; 
the C5 pocket by Pro 272 and Gly 305). The analogues 
7f-i, all possessing an ethyl substituent at the C3 posi­
tion of the ring, all showed greater inhibition than TLM 
against P. falciparum. Once again, the longer chained
analogues 7h and 7i gave the best inhibition, showing 10 
and 8-fold increases in inhibition over TLM respec­
tively. A further trend was also observed, analogues 7f-i 
all displayed enhanced inhibition towards the parasite in 
comparison to analogues 7a-e bearing a methyl sub­
stituent at C3 of the ring. This trend is highlighted when 
comparing the activities of analogues 7b (153 pM) and 
7g (54 pM). Compound 7g shows a 3-fold improve­
ment in inhibition over 7b. However with the more 
active compounds, there is a much smaller improvement 
in activity on addition of an ethyl group at the C3 
position [compare 7h (15 pM) with 7d (36 pM); and 7i 
(19 pM) with 7e (25 pM)]. Clearly, the ethyl substituent 
is having a positive influence on the overall activity of 
the inhibitors. This led us to probe the C3 position fur­
ther. Indeed, by extending the ethyl chain to a propyl 
group, and placing a decyl side chain at the C5 position 
(analogue 7j) an IC50 of 10 pM was achieved, thus giv­
ing a 14-fold increase in activity over TLM. Increasing 
the propyl tether to a butyl derivative 16 resulted in a 
decrease in activity. A similar result was also obtained 
with the benzyl analogue 7k, which showed an IC50 of 
50 pM. Seemingly, it is plausible that we have reached 
an optimal chain length of three carbons at the C3 
position, beyond which activity is diminished. To lend 
support to this assertion we were able to dock analogue 
7j into the E. coli KAS I using FlexX software (Figs 2 
and 3). The propyl group appears to fit snugly into the 
hydrophobic pocket with the terminus of the propyl 
chain in close proximity to the Cys 163. This same 
amino acid is also present in the P. falciparum  KAS1 /
2.25
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Figure 2. Compound 7j docked into the E. coli KAS I. Part of the 
3-propyl group is obscured.
Figure 3. Inhibitor 7j in relation to the surface of E. coli KAS I.
In an attempt to improve the hydrophobic interactions 
o f  the methyl substituent at the C5 position, an ethyl 
substituent was introduced in place o f  the methyl group. 
Both analogues 12a (65 pM) and 12b (35 pM ) showed  
improved inhibition over TLM (Table 1). However, a 
direct comparison o f these analogues with there methyl 
counterparts [compare 12a (65 pM ) with 7d (36 pM); 
and 12b (35 pM ) with 7e (25 pM)] suggests that the 
presence o f  the ethyl substituent at C5 serves only to 
reduce the activity o f the inhibitors. Likewise, removal 
o f  the C5 methyl substituent (analogue l ib )  also  
appears to reduce the inhibitory effects o f  the analogue. 
This is highlighted with a direct com parison o f  the
activities for analogues 11b (72 pM ) and 7h (15 pM). 
Clearly, modification o f  the methyl substituent at the C5 
position does not appear as influential to the overall 
activity o f  the analogues as modification at the C3 
position.
All our com pounds were also assayed in vitro against 
the T. brucei parasite, which is the cause o f  human 
sleeping sickness and livestock disease in Africa. 
Recently, Englund26 identified thiolactomycin as a pro­
mising lead for antitrypanosomal drug development. T. 
brucei requires large am ounts o f  myristate for synthesis 
o f glycosyl phosphatidylinositol anchored variable sur­
face glycoprotein. Thiolactom ycin was shown to effec­
tively inhibit trypanosomal myristate synthesis in vitro 
with a reported IC50 o f  ~ 1 5 0  p M .26 A number o f our 
com pounds showed inhibition greater than thiolacto­
mycin 1 (IC50 256 pM in our assays), with the best two 
[analogues 1 lb  (6 pM) and 16 (8 pM)] showing a 42-fold 
improvement in activity (Table 1). The most active 
analogue (7j) against the malaria parasite also showed 
improved inhibition against T. brucei, registering an 
IC50 o f  21 pM.
In vitro assays against T. cruzi, the causative organism  
o f  Chagas disease, showed that thiolactomycin 1 was 
inactive with an IC50 o f  > 4 2 7  pM (Table 1). Several o f 
the analogues tended to show enhanced activity towards 
the T. cruzi parasite over thiolactomycin. Analogue 7e 
showed the greatest inhibition with an IC50 o f 28 pM.
Finally, none o f the com pounds showed any appreci­
able activity against the Leishmania donovani parasite. 
The lack o f  activity against Leishmania may be due to 
the parasite being an intracellular parasite dwelling 
within a parasitophorous vacuole within the host cell, 
significantly reducing accessibility o f  com pounds.
4. Conclusion
We have reported the design and synthesis o f  a number 
o f thiolactomycin analogues as agents against P. falci­
parum, a causative organism o f  malaria. The com ­
pounds were designed with the intention o f  targeting the 
Type II FAS utilised for fatty acid biosynthesis. Several 
analogues showed inhibitory effects greater than thio­
lactomycin 1, with the best com pound (7j) showing a 
14-fold increase in activity (10 pM). Furthermore, all 
com pounds were assayed against three other parasitic 
protozoa, T. cruzi, T. brucei and L. donovani. Varied 
activities were found against the T. brucei and T. cruzi 
parasites. However, the analogues showed no appreci­
able activity against L. donovani. Although the inhibi­
tory effects o f  these analogues are only in the 
micromolar range, these show significantly better activ­
ity than thiolactomycin. This study has demonstrated 
the scope that exists for the design o f  new fatty acid 
biosynthesis inhibitors with enhanced activity against 
the parasites which cause malaria, African trypanoso­
miasis and Chagas disease. Significantly improved inhi­
bitors could offer a valuable new way o f controlling  
these important diseases.
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5. Experimental
Melting points were determined using a Gallenkamp 
melting point apparatus and are uncorrected. Infrared 
spectra were recorded as thin films for liquid samples, or 
as Nujol mulls for solid samples, on a Perkin-Elmer 
1600 series FTIR spectrophotometer using sodium 
chloride plates. lH and l3C NMR spectra were recorded 
on a Bruker Advance DPX300 spectrometer operating 
at 300 and 75 M Hz, respectively, with tetramethylsilane 
as internal standard, using deuterated chloroform pur­
chased from Goss unless stated otherwise. Low-resolution 
mass spectra, that is, electrospray [ES], were recorded 
using a fisons VG Platform II spectrometer. High-reso- 
lution spectra were obtained on a VG ZAB spectro­
meter from the EPSRC Mass Spectrometry Service at 
Swansea University, UK. Microanalyses were obtained 
from the analytical and chemical consultancy services 
MEDAC LTD. All reactions were performed in pre­
dried apparatus under an atmosphere of nitrogen unless 
otherwise stated. Solvents and reagents were purchased 
from chemical companies and used without further 
purification. Dry solvents were generally purchased in 
sure sealed bottles stored over molecular sieves. Thin- 
layer chromatography (tic) was performed on Merck 
silica gel 6 OF254 plates. Column chromatography was 
carried out using Fisons matrix silica 60 (35-70 micron).
5.1. Cyclisation, general procedure A
Potassium hydroxide (2.0 equiv) in water (10 mL) was 
added dropwise to a stirred solution of the thioacetate 
(1.0 equiv) in ethanol (20 mL) at ambient temperature. 
The resulting solution was warmed to 40 °C and stirred 
for 3 h. The ethanol was then evaporated and water (~  10 
mL) added. The aqueous layer was washed with diethyl 
ether (2x10 mL) and acidified to ph 1 with the addition 
of 2 M HC1 (~  10 mL). The aqueous layer was extracted 
with diethyl ether. The organic layers were washed with 
brine, dried over anhydrous magnesium sulfate and the 
solvent removed in vacuo. The crude residue was pur­
ified by flash column chromatography (5-20% ethyl 
acetate in hexanes). The coupling constants (7) are in Hz.
5.2. 4-Hydroxy-3,5-dimethyl-2(5H)-thiophenone (6a)
As described in procedure A, starting from 5a (1.0 g,
4.58 mmol) and potassium hydroxide (0.5 g, 9.16 mmol), 
6 a was obtained as a white solid (0.60 g, 90%); mp 131- 
132°C, vMAX/cm“ ' 3197, 2923, 2878, 1555, 1291 and 
1186; 5h (acctone-4) 1 . 6 6  (3H, d, 7 -7 .0 , 5-CH3), 1.74 
(3H, s, 3 -CH3), 4.32 (IH, q, 7=  7.0, 5-H) and 10.22 (1H, 
br s, OH); 5C (acetone-4) 12.6 (3-CH3), 24.5 (5-CH3),
47.9 (4-CH), 115.5 (3-C), 183.6 (4-C) and 199.3 (CO); 
MS (ES) m/z 142.6 (M -H , 100%); HRMS (ES + )
(M +H K  C6H90 2S requires 145.0323, found 145.0321. 
Anal, ealed for C6H8O2S.0.1 H20: C, 49.4; H, 5.7. 
Found: C, 49.3; H, 5.4%.
5.3. 3-Ethyl-4-hydroxy-5-methyl-2(5H)-thiophenone (6b)
As described in procedure A, starting from 5b 
(3.52 g, 7.58 mmol) and potassium hydroxide (1.70 g,
15.17 mmol), 6b was obtained as a white solid 
(1.07 g, 89%); mp 75-76°C, vMAX/cm~' 3188, 2923, 
2869, 1563, 1291 and 1184; 5H (acetone-4) 1.94 (3H, t, 
7=7.2, 2'-CH3), 1.53 (3H, d, 7=7.0, CH3), 2.18 (2H, q, 
7=7.2, T-CH2), 4.21 (1H, q, 7=7.0, 5-CH) and 
10.11 (1H, br s, OH); 5C (acetone-4) 13.4 (2'-CH3),
17.1 (l'-C H 2), 20.2 (5-CH3), 43.4 (5-C), 117.1 (3-C),
179.2 (4-C) and 194.8 (CO); MS (ES~) m/z 156.7 
(M -H ,-  100%); HRMS (ES~) (M -H )~  C7H90 2S 
requires 157.0324, found 157.0323. Anal, ealed for 
C7H 10O2S.0.1H2O: C, 52.5; H, 6.4. Found: C, 52.6; H, 
6.4%.
5.4. 4-Hydroxy-5-methyl-3-propyl-2,5-dihydro-2-thiophene 
(6c)
As described in procedure A, starting from 5c (3.50 g, 
14.22 mmol) and potassium hydroxide (1.59 g, 28.44 
mmol), 6c was obtained as a colourless solid (1.04 g, 
42%); mp 49-50 °C, 5H (acetone-4) 0.91 (3H, t, 7=  7.4, 
3'-CH3), 1.41-1.54 (2H, m, 2'-CH2), 1.65 (3H, d ,7= 7 .0 , 
CH3), 2.22 (2H, t, 7=7.5, l'-CH2) and 4.29 (IH, q, 
7=7.0, 5-CH); 5C (acetone-4) 18.5 (3'-CH3), 24.5 
(CH3), 26.6 (2'-CH2), 29.8 (l'-CH 2), 47.6 (5-CH), 119.8 
(3-C), 183.9 (4-C) and 199.1 (2-CO); MS (ES") m/z 
170.9 (M -H ,-  100%); HRMS (ES + ) (M + NH 4) + 
C8H 120 2S requires 190.0896, found 190.0895. Anal, 
ealed for C8H l20 2S: C, 55.8; H, 7.0. Found: C, 55.4; H, 
7.1%.
5.5. 3-Benzyl-4-hydroxy-5-methyl-2,5-dihydro-2-thiophene 
(6d)
As described in procedure A, starting from 5d (6.00 g, 
20.40 mmol) and potassium hydroxide (2.69 g, 40.80 
mmol), 6d was obtained as a white powder (1.32 g, 
29%); mp 139-141 °C, 5H (acetone-4) 1.59 (3H, d, 
7=6.9, CH3), 3.50 (2H, s, CH2Ph), 4.28 (IH, q, 7=6.9, 
5-CH), 7.08-7.21 (5H, m, ArH) and 10.33 (IH, br s, 
OH); 5C (acetone-^) 20.2 (CH3), 29.3 (CH2Ph), 43.6 (5- 
CH), 115.0 (3-C), 127.1 (ArCH), 129.4 (ArCH), 129.5 
(ArCH), 140.9 (ArC), 180.2 (4-C) and 194.6 (CO); MS 
(ES-) m/z 219.5 (M -H,~ 100%); HRMS (ES~) 
(M -H )- C[2H m0 2S requires 219.0480, found 219.0484. 
Anal, ealed for C |2H |2O2S.0.1H2O: C, 64.9; H, 5.5. 
Found: C, 64.7; H, 5.5%.
5.6. 5-Ethyl-4-hydroxy-3-methyI-2,5-dihydro-2-thiophene 
(11a)
As described in procedure A, starting from 10a (5.36 g,
23.10 mmol) and potassium hydroxide (2.59 g, 46.20 
mmol), 11a was obtained as a pale yellow solid (1.15 g, 
32%); mp 95-96°C, SH (acetone-4) 0.89 (3H, t, 7=7.4, 
2"-CH3), 1.58 (3H, s, l'-CH3), 1.61-1.68 (IH, m, 1"- 
CHaHb), 2.07-2.17 (IH, m, 1"-CHaHr) and 4.14 (IH, 
dd, 7=6.2 and 1.1, 5-CH); 5C (acetone-4) 8.1 (7-CH3),
11.4 (3-CH3), 27.0 (6-CH2), 50.8 (5-CH), 112.0 (3-C),
178.0 (4-C) and 195.2 (2-CO); MS (ES~) m/z 156.8 
(M -H ,-  100%); HRMS (E S 1) (M + NH4) f
C7H l4N 0 2S requires 176.0740; found 176.0740. Anal, 
ealed for C7H 10O2S: C, 53.1; H, 6.4. Found: C, 52.7; H, 
6.4%.
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5.7. 5-Decyl-3-ethyl-4~hydroxy-2(5H)-thiophenone (lib )
As described in procedure A, starting from 10b (870 mg, 
2.43 mmol) and potassium hydroxide (270 mg, 4.86 
mmol), l ib  was obtained as a pale yellow solid (74 mg, 
11%), mp 35-36 °C, 5H 0.88 (3H, t, 7=6.8, 15-CH3),
1.04 (3H, t, 7=7.4, 2'-CH3), 1.26 (14H, m, 7xCH 2), 
1.67-1.73 (2H, m, CH2), 2.24-2.31 (4H, m, 6-CH2 and 
l'-CH2) and 4.18 (IH , dd, 7 = 9.3 and 2.6, 5-CH); 5C
13.1 (15-CH3), 14.5 (2'-CH3), 16.5, 23.1, 27.9, 29.6, 29.7,
29.8. 30.0, 32.3, 33.3 (all CH2), 50.1 (5-CH), 118.0(3-C),
179.2 (4-C) and 199.9 (2-CO); MS (ES") m/z 283.1 
(M -H ,- 100%); HRMS (ES)+ (M + H )+ C 16H290 2S 
requires 285.1883, found 285.1892. Anal, calcd for 
C,6H28O2S.0.2H2O: C, 66.7; H, 9.9. Found: C, 66.8; H, 
1 0 . 1% .
5.8. 3-Butyl-5-decyl-4-hydroxy-5-methyl-2(5//)-thiophe- 
none (16)
As described in procedure A, starting from 15 (2.84 g, 
7.39 mmol) and potassium hydroxide (0.82 g, 14.79 
mmol), 16 was obtained as a pale yellow oil (0.47 g, 
20%), 5h 0.89-0.93 (6H, m, 15-CH3 and 4'-CH3), 1.23- 
1.37 (20H, m, 10xCH2), 1.72 (3H, s, CH3), 1.93-1.96 
(2H, m, 6-CH2) and 2.29 (2H, t, 7=7.2, l'-CH2); 8C
14.1, 14.3 (both CH3), 22.8, 22.9, 23.1, 24.4, 25.4, 25.5,
26.4, 26.6, 29.7, 29.8, 29.9, 30.0, 32.0, 38.7 (all CH2),
58.4 (5-C), 115.6 (3-C), 181.7 (4-C) and 198.6 (2-CO); 
MS (ES- ) m/z 325.4 (M -H ,~  100%); HRMS (ES~) 
(M -H ) ' C 19H330 2S requires 325.2196, found 325.2199.
5.9. Alkylation, general procedure B
Thiophenone (1.0 equiv) was added portionwise to a 
stirred suspension of sodium hydride (1.2 equiv) in dry 
THF (4 mL) and DMPU (4 mL) at ambient tempera­
ture. The suspension was stirred for 0.5 h, then cooled 
to -78  °C and butyllithium (2.5 M solution in hexanes,
1.1 equiv) added dropwise. After stirring for 10 min, the 
mixture was allowed to warm to ambient temperature 
and stirred for 1 h. Once again the mixture was cooled 
to -78° and the halide (1.0 equiv) added dropwise. 
After stirring for 15 min, the mixture was allowed to 
warm to ambient temperature and stirred overnight. 
The reaction was quenched by the addition of 2 M HC1 
(10 mL) and the organic layer separated. The aqueous 
layer was then extracted with ethyl acetate (3x10 mL). 
The organic layers were washed with brine, dried over 
anhydrous magnesium sulfate and the solvent removed 
in vacuo. The crude residue was purified by flash col­
umn chromatography (0-20% ethyl acetate in hexanes).
5.10. Thiolactomycin 1
Butyllithium (1.6 mL of a 2.5 M solution in hexanes,
4.01 mmol) was added dropwise to a stirred suspension 
of the phosphonium salt (710 mg, 2.00 mmol) in dry 
THF (8 mL) at -78 °C. The resulting dark red solution 
was allowed to warm to ambient temperature and stir­
red for I h. The solution was then cooled to -78 °C and 
the aldehyde (430 mg, 2.00 mmol) added dropwise. A 
light brown suspension formed, which was then allowed
to warm to ambient temperature and stirred overnight. 
2M  HC1 (10 mL) was added and the organic layer 
separated. The aqueous layer was extracted with ethyl 
acetate (3x10 mL). The combined organic solutions 
were washed with water (2x20 mL) and brine (2x20 
mL), then dried and evaporated. Purification by column 
chromatography (20% ethyl acetate in hexanes) pro­
vided thiolactomycin 1 as a pale yellow oil (12 mg, 29% 
yield), VMAx/cm-1 3600, 1700, 1630, 1450, 1380, 1325, 
1280 and 1100; lH NM R 8 1.79 (3H, s, CH3), 1.83 (3H, 
s, CH3), 1.91 (3H, s, CH3), 5.15 (IH, d, 7=  11.1, 4'-Ha), 
5.33 (IH, d, 7=  17.2, 4'-Hb), 5.62 (IH, s, l'-H) and 6.37 
(IH , dd, 7=17.2 and 11.1, 3'-H); 8C 7.6 (3-CH3), 12.1 
(CH3), 29.9 (5-CH3), 58.6 (5-C), 110.8 (3-C), 114.0 
(CH2), 129.8, 140.6, 141.1, 181.3 (4-C) and 198.6 (CO). 
Spectroscopic data was identical to those recorded in 
the literature.21
5.11. 5-Hexyl-4-hydroxy-3,5-dimethyl-2(5H)-thiophenone 
(7a)
As described in procedure B, starting from 6a (500 mg,
3.46 mmol), sodium hydride (160 mg, 4.16 mmol), 
butyllithium (1.52 mL, 3.80 mmol) and bromohexane 
(0.48 mL, 3.46 mmol), 7a was obtained as a colourless 
solid (80 mg, 10%); mp 62-64 °C, vMAx/cm_1 3145, 
2929, 1600, 1454, 1247 and 1010; 8H 0.87 (3H, t, 7=6.5, 
6'-CH3), 1.26-1.34 (8H, m, 4xC H 2), 1.66 (3H, s, CH3), 
1.74 (3H, s, CH3) and 1.85 (2H, t, 7=8.0, l'-CH2); 8C 
7.92 (6'-CH3), 14.4 (3-CH3), 22.9 (CH2), 25.5 (5-CH3),
26.4, 29.6, 32.0, 38.9 (all CH2), 58.0 (5-C), 110.9 (3-C),
183.6 (4-C) and 198.4 (CO); MS (ES") m/z 227.2 
(M -H ,"  100%); HRMS (ES") (M -H )~ C ,2H 190 2S 
requires 227.1106, found 227.1106. Anal, calcd for 
C ,2H20O2S.0.2H2O: C, 62.1; H, 8.9. Found: C, 61.9; H, 
8.9%.
5.12. 4-Hydroxy-3,5-dimethyl-5-octyl-2(5H)-thiophenone 
(7b)
As described in procedure B, starting from 6a (500 mg,
3.46 mmol), sodium hydride (160 mg, 4.16 mmol), 
butyllithium (1.52 mL, 3.80 mmol) and 1-iodooctane 
(1.05 mL, 3.46 mmol), 7b was obtained as a pale yellow 
solid (108 mg, 12%); mp 81-83 °C, VMAx/cm-1 1611 
and 1076; 8H 0.97 (3H, t, 7=6.9, 8'-CH3), 1.31 (1 OH, m, 
5xCH2), 1.75 (3H, s, CH3), 1.83 (3H, s, CH3) and 1.89- 
1.94 (2H, m, l'-CH2); 8C 7.9 (8'-CH3), 14.5 (3-CH3),
23.0 (CH2), 25.6 (5-CH3), 26.3, 29.6, 29.8, 29.9, 32.2, 
38.8 (all CH2), 58.5 (5-C), 110.8 (3-C), 181.2 (4-C) and
198.3 (CO); MS (ES~) m/z 255.2 (M -H ,~  100%); 
HRMS (ES+) (M + H )+ C ,4H250 2S requires 257.1570, 
found 257.1568. Anal, calcd for C ,4H24O2S.0.1H2O: C, 
65.1; H, 9.4. Found: C, 65.1; H, 9.6%. Spectroscopic 
data was identical to those recorded in the literature.17
5.13. 5-{(2£)-3,7-Dimethy 1-2,6-octadieny l|-4-hydroxy-3,5- 
dimethyl-2(5H)-thiophenone (7c)
As described in procedure B, starting from 6a (500 mg,
3.46 mmol), sodium hydride (160 mg, 4.16 mmol), 
butyllithium (1.52 mL, 3.80 mmol) and geranyl bromide 
(0.69 g, 3.46 mmol), 7c was obtained as a thick yellow
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oil (160 mg, 16%); VMAx/cm'1 2972, 2927, 1600, 1450, 
1383, 1280 and 969; 5H 1.61 (3H, s, CH3), 1.64 (3H, s, 
CH3), 1.66 (3H, s, CH3), 1.69 (3H, s, CH3), 1.75 (3H, s, 
CH3), 2.04-2.12 (4H, m, 2xC H 2), 2.52-2.69 (2H, m, 
CH2), 5.08 (IH, m, CH) and 5.18 (IH , m, CH); 8C 7.9 
(CH3), 16.9 (3-CH3), 18.1 (CH3), 25.2 (5-CH3), 26.1 
(CH3), 26.8 (CH2), 37.7, 40.2 (both CH2), 58.2 (5-C),
110.7 (3-C), 119.2, 124.3 (both CH), 132.2, 140.5 (both 
C), 180.2 (4-C) and 203.2 (CO); MS (ES~) m/z 279.1 
(M -H ,' 100%); HRMS (ES~) (M -H )~  C ,6H230 2S 
requires 279.1419, found 279.1416. Spectroscopic data 
was identical to those recorded in the literature.17
5.14. 5-Decyl-4-hydroxy-3,5-dimethyl-2(5H)-thiophenone 
(7d)
As described in procedure B, starting from 6a (500 mg,
3.46 mmol), sodium hydride (160 mg, 4.16 mmol), 
butyllithium (1.52 mL, 3.80 mmol) and 1-iodododecane 
(0.73 mL, 3.46 mmol), 7d was obtained as a white solid 
(110 mg, 10%); mp 74-75°C, vMAX/cm ~l 3130, 2947, 
1592, I486, 1270, 1170 and 989; 5H 0.82 (3H, t, 7=6.6, 
10,-CH3), 1.20 (16H, m, 8xC H 2), 1.62 (3H, s, CH3), 
1.71 (3H, s, CH3) and 1.80-1.85 (2H, m, l'-CH 2); 8C 7.9 
(10'-CH3), 14.5 (3-CH3), 23.1 (CH2), 25.6 (5-CH3), 26.3,
29.7, 29.8, 29.9, 30.0, 32.3, 38.8 (all CH2), 58.5 (5-C),
110.8 (3-C), 181.1 (4-C) and 198.3 (2-CO); MS (ES~) 
m/z 283.0 (M -H ,-  100%); HRMS (ES + ) (M + NH4) + 
C16H32N 0 2S requires 302.2154, found 302.2149. Anal, 
calcd for C ,6H28O2S.0.2H2O: C, 66.7; H, 9.9. Found: C, 
66.7; H, 9.9%.
5.15. 5-Hexadecy 1-4-hy droxy-3,5-dimethyH(5H)-thiophe- 
none (7e)
As described in procedure B, starting from 6a (500 mg,
3.46 mmol), sodium hydride (160 mg, 4.16 mmol), 
butyllithium (1.52 mL, 3.80 mmol) and 1-bromohexa- 
decane (1.05 mL, 3.46 mmol), 7e was obtained as a 
white solid (87 mg, 7%), mp 56-57 °C, vMAx/cm_l 
2917, 2848, 1573, 1284, 1226 and 1145; 8H 0.98 (3H, t, 
7=6.9, 16'-CH3), 1.36 (28H, m, 14xCH2), 1.77 (3H, s, 
CH3), 1.85 (3H, s, CH3) and 1.95 (2H, t, 7=7.9, 1'- 
CH2); 5c 7.9 (16'-CH3), 14.5 (3-CH3), 23.1 (CH2), 25.6 
(5-CH3), 26.3, 29.7, 29.8, 30.0, 30.1, 32.3, 38.9 (all CH2),
58.2 (5-C), 110.9 (3-C), 180.1 (4-C) and 190.3 (2-CO); 
MS (ES-) m/z 367.2 (M -H ,“ 100%); HRMS (ES~) 
(M -H )- C22H390 2S requires 367.2671, found: 
367.2666. Anal, calcd for C22H40O2S: C, 71.7; H, 10.9. 
Found: C, 71.7; H, 11.2%.
5.16. 3-Ethyl-5-hexyI-4-hydroxy-5-methyl-2(5H)-thiophe- 
none(70
As described in procedure B, starting from 6b (400 mg, 
2.53 mmol), sodium hydride (120 mg, 3.03 mmol), 
butyllithium (1.77 mL of a 1.57 M solution in hexanes, 
2.78 mmol) and 1-iodohexaane (0.37 mL, 2.53 mmol), 
7f was obtained as a colourless oil (100 mg, 16%), 8H 
0.82 (3H, t, 7=6.8, CH3), 0.98 (3H, t, 7=7.5, 2'-CH3), 
1.21 (8H, m, 4xC H 2), 1.62 (3H, s, CH3), 1.80-1.83 
(2H, m, CH2) and 2.19 (2H, q, 7=7.5, l'-CH2); 8C
13.3 (CH3), 14.4 (CH3), 16.5 (CH3), 23.0, 25.4, 26.3,
29.5, 31.9 and 38.8 (all CH2), 58.1 (5-C), 116.9 (3-C),
180.4 (4-C) and 197.5 (2-CO); MS (ES~) m/z 240.9 
(M -H ,- 100%). HRMS (ES") (M -H )~ C ,3H2,0 2S 
requires 241.1262, found 241.1259. Anal, calcd for 
C13H22O2S.0.2H2O: C, 63.5; H, 9.2. Found: C, 63.6; H, 
9.3%.
5.17. 3-Ethyl-4-hydroxy-5-methyl-5-octyI-2(5H)-thiophe- 
none (7g)
As described in procedure B, starting from 6b (300 mg,
1.89 mmol), sodium hydride (91 mg, 2.27 mmol), butyl­
lithium (1.31 mL of a 1.57M solution in hexanes, 2.07 
mmol) and 1-iodooctane (0.31 mL, 1.89 mmol), 7g was 
obtained as a pale yellow oil (40 mg, 18%); 6H 0.92 (3H, 
t, 7 = 6.7, 8"-CH3), 1.09 (3H, t, 7=7.5 , 2"-CH3), 1.30 
(12H, m, 6xCH2), 1.72 (3H, s, CH3), 1.83-1.86 (2H, m, 
T-CH2), 2.28 (2H, q, 7 = 7.5, l'-C H 2) and 7.68 (IH, br s, 
OH); 8C 13.3, 14.5 and 16.4 (all (CH3), 23.0, 25.4, 26.4,
29.5, 29.6, 29.9, 32.2 and 38.8 (all CH2), 57.8 (5-C),
116.9 (3-C), 179.9 (4-C) and 196.7 (5-C); MS (ES~) 
m/z 269.1 (M -H ,- 100%); HRMS (ES“) (M -H )- 
CtsH250 2S requires 269.1576, found 269.1578.
5.18. 5-Decyl-3-ethyl-4-hydroxy-5-methyl-2(5H)-tliiophene 
(7h)
As described in procedure B, starting from 6b (300 mg,
1.89 mmol), sodium hydride (91 mg, 2.27 mmol), butyl­
lithium (1.31 mL of a 1.57 M solution in hexanes, 2.07 
mmol) and 1-iododecane (0.40 mL, 1.89 mmol), 7h was 
obtained as a colourless solid (125 mg, 22%), rap 36- 
38 °C, 8h 0.93 (3H, t, 7=6.8 , 10"-CH3), 1.10 (3H, t, 
7=7.5, 2'-CH3), 1.30 (14H, m. 7xC H 2), 1.71 (3H, s, 
OCH3), 1.89 (2H, m, CH2), 2.00 (2H, m, CH2), 2.25 
(2H, q, 7=7.5, l'-CH2) and 6.85 (IH , br s, OH); 5C
13.3, 14.5 and 16.5 (all CH3), 23.1, 25.5, 26.4, 29.6, 29.7,
29.8, 29.9, 30.0, 32.3 and 38.8 (all CH2), 57.9 (5-C),
117.0 (3-C), 179.7 (4-C) and 198.2 (2-C); MS (ES“) 
m/z 297.3 (M -H ,~ 100%); HRMS (ES~) (M-H)~ 
C |7H290 2S requires 297.1889, found 297.1888. Anal, 
calcd for C ,7H30O2S: C, 68.4; H, 10.1. Found: C, 68.1;
H, 10.3%.
5.19. 3-Ethyl-5-hexadecyl-4-hydroxy-5-methyI-2(5H)-thio- 
phenone (7i)
As described in procedure B, starting from 6b (300 mg,
1.89 mmol), sodium hydride (91 mg, 2.27 mmol), butyl­
lithium (1.31 mL of a 1.57 M solution in hexanes, 2.07 
mmol) and 1-bromohexadecane (0.31 mL, 1.89 mmol), 
7i was obtained as a colourless solid (160 mg, 22%), mp 
86-87 °C, vmax/citi- 1 3183, 2916, 2848, 1580, 1471, 
1330, 1251 and 1145; 5H 1.00 (3H, t, 7=6.6, 16"-CH3),
I.16 (3H, t, 7=7.5, 2'-CH3), 1.37 (28H, m, 14xCH2), 
1.80 (3H, s, 5-CH3), 1.97-2.01 (2H, m, 1"-CH2), 2.36 
(IH, q, 7 = 7.5, l'-CH2) and 8.04 (IH, br s, OH); 6C
13.3, 14.5, 16.5, 20.7, 23.1, 25.5, 26.4, 29.8, 29.8, 29.9,
29.9, 30.0, 30.1, 32.3, 38.9, 57.9 (5-C), 117.1 (3-C), 179.5 
(4-C) and 196.9 (2-CO); MS (ES~) m/z 381.2 (M -H,~ 
100%); HRMS (ES- ) (M -H )"  C23H410 2S requires 
381.2828, found 381.2835. Anal, calcd for C23H420 2S: 
C, 72.2; H, 11.1. Found: C, 72.3; H, 11.2%.
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5.20. 5-DecyI-4-hydroxy-5-methyl-3-propyl-2,5-dihydro- 
2-thiophene (7j)
As described in procedure B, starting from 6 c (250 mg, 
1.45 mmol), sodium hydride (69 mg, 1.74 mmol), butyl- 
lithium (0.63 mL of a 2.5 M solution in hexanes, 1.59 
mmol) and 1-iododecane (0.31 mL, 0.38 g, 1.45 mmol), 
7j was obtained as a yellow oil (57 mg, 12%); 5H 0.93 
(6 H, m, 2xCH 3), 1.29 (14H, m, 7xCH 2), 1.44-1.60 (2H, 
m, CH2), 1.70 (3H, s, CH3), 1.92-1.94 (4H, m, 2xC H 2) 
and 2.25 (2H, t, 7=7.3, l'-CH2); 6 C 14.1, 14.5 (both 
CH3), 21.8 (CH2), 23.0, 25.5, 26.0 (all CH2), 26.6 (CH3),
29.7, 29.8, 29.9, 30.0, 30.5, 34.5 and 38.8 (all CH2),
68.4 (5-C), 115.3 (3-C), 180.8 (4-C) and 196.8 (2-CO); 
MS (ES") m/z 311.2 (M -H ,-  100%); HRMS (ES~) 
(M—H)~ Cj8H320 2S requires 313.2196, found 313.2195. 
Anal, calcd for CigH320 2S: C, 69.2; H, 10.3. Found: C, 
69.3; H, 10.7%.
5.21. 3-Benzyl-5-decyl-4-hydroxy-5-methyl-2,5-dihydro- 
2-thiophene (7k)
As described in procedure B, starting from 6 d (250 mg, 
1.13 mmol), sodium hydride (54 mg, 1.36 mmol), butyl- 
lithium (0.49 mL of a 2.5 M solution in hexanes, 1.24 
mmol) and 1-iododecane (0.24 mL, 0.30 g, 1.13 mmol), 
7k was obtained as a yellow oil (16 mg, 4%); 8 H 0.85 
(3H, t, 7=6.8, 10'-CH3), 1.20-1.21 (16H, m, 8 xCH 2),
1.58 (3H, s, CH3), 1.79 (2H, t, 7=7.8, l'-CH2), 3.52 
(2H, s, CH 2Ph) and 7.10-7.21 (5H, m, ArH); 8 C 14.5 
(CH3), 23.1 (CH2), 25.5 (CH2), 26.4 (CH3), 29.3, 29.7,
29.8, 29.9, 30.0, 32.3 and 38.9 (all CH2), 57.9 (5-C),
114.0 (3-C), 127.3, 128.9 and 129.4 (all ArCH), 137.9 
(ArC), 180.5 (4-C) and 196.1 (2-CO); MS (ES~) m/z 359.3 
(M -H ,"  100%); HRMS (ES~) (M -H )-  C22H 310 2S 
requires 359.2045, found 359.2048.
5.22. 5-Decyl-5-ethyI-4-hydroxy-3-methyl-2,5-dihydro-2- 
thiophene (1 2 a)
As described in procedure B, starting from 11a (250 mg,
1.58 mmol), sodium hydride (75 mg, 1.51 mmol), butyl- 
lithium (0.69 mL of a 2.5 M solution in hexanes, 1.89 
mmol) and 1-iododecane (0.33 mL, 0.38 g, 1.58 mmol), 
12a was obtained as a yellow oil (34 mg, 14%); 5h 0.90- 
0.98 (6 H, m, 2xC H 3), 1.29 (14H, m, 7xCH2), 1.78 (3H, 
s, CH3) and 1.89-2.00 (4H, m, 2xC H 2); 8 C 6.3 (CH3),
7.9 (CH3), 13.1 (CH3), 21.6, 23.6, 28.2, 28.3, 28.4, 28.5,
28.6, 29.7, 30.8, 36.6 (all CH2), 61.9 (5-C), 110.9 (3-C),
177.1 (4-C) and 191.2 (2-CO).
5.22.1. 5-EthyI-hexadecyl-4-hydroxy-3-methyl-2,5-dihydro- 
2 -thiophene (1 2 b)
As described in procedure B, starting from 11a (200 mg,
1.26 mmol), sodium hydride (60 mg, 1.51 mmol), butyl- 
lithium (0.70 mL of a 2.0 M solution in hexanes, 1.38 
mmol) and 1-bromohexadecane (0.38 mL, 0.38 g, 1.26 
mmo 1), 1 2 b was obtained as a yellow oil (57 mg, 12%); 
8 h 0.98-1.06 (6 H, m, 2xC H 3), 1.37 (26H, m, 13xCH2),
1.85 (3H, s, CH3), 1,98-2.04 (4H, m, 2xCH2) and 6.80 
(1H, br s, OH). Anal, calcd for C2 3H4 20 2S: C, 72.2; H,
11.1. Found: C, 72.0; H, 11.4%.
5.24. Biological assays
5.24.1. Plasmodium falciparum. In vitro activity against 
erythrocytic stages of P. falciparum was determined 
using a 3H-hypoxanthine incorporation assay,27,28 using 
the chloroquine and pyrimethamine resistant K 1 strain 
and the standard drugs chloroquine (Sigma C6628) and 
artemisinin (Sigma 36,159-3). Compounds were dissolved 
in DMSO at 10 mg/mL and added to parasite cultures 
incubated in RPMI 1640 medium without hypoxanthine, 
supplemented with HEPES (5.94 g/L), NaHC03 (2.1 g/L), 
neomycin (100 U/mL), AlbumaxR (5 g/L) and washed 
human red cells A + at 2.5% haematocrit (0.3% para- 
sitaemia). Serial doubling dilutions of each drug were pre­
pared in 96-well microtiter plates and incubated in a 
humidified atmosphere at 37 °C; 4% C 0 2 , 3% 0 2 , 93% N2.
After 48 h 50 pL of 3 H-hypoxanthine ( = 0.5 pCi) was 
added to each well of the plate. The plates were incu­
bated for a further 24 h under the same conditions. The 
plates were then harvested with a Betaplate™ cell har­
vester (Wallac, Zurich, Switzerland), and the red blood 
cells transferred onto a glass fiber filter then washed 
with distilled water. The dried filters were inserted into a 
plastic foil with 10 mL of scintillation fluid, and counted 
in a Betaplate™ liquid scintillation counter (Wallac, 
Zurich, Switzerland). IC50 values were calculated from 
sigmoidal inhibition curves using Microsoft Excel.
5.24.2. Trypanosoma cruzi. Rat skeletal myoblasts (L- 6  
cells) were seeded in 96-well microtiter plates at 2000 
cells/well/100 pL in RPMI 1640 medium with 10% FBS 
and 2 mM L-glutamine. After 24 h, 5000 trypomasti- 
gotes of T. cruzi [Tulahuen strain C2C4 containing the 
P-galactosidase (Lac Z) gene] were added in 100 pL per 
well with 2x of a serial drug dilution. The plates were 
incubated at 37 °C in 5% C 0 2 for 4 days. Then the 
substrate CPRG/Nonidet was added to the wells. The 
colour reaction, which developed during the following 
2-4 h, was read photometrically at 540 nra. From the 
sigmoidal inhibition curve IC 50 values were calculated.
5.24.3. Trypanosoma brucei rhodesiense. Minimum 
Essential Medium (50 pL) supplemented according to 
Baltz et al. 29 with 2-mercaptoethanol and 15% heat- 
inactivated horse serum was added to each well of a 96- 
well microtiter plate. Serial drug dilutions were added to 
the wells. Then 50 pL of trypanosome suspension (T.b. 
rhodesiense STIB 900) was added to each well and the 
plate incubated at 37 °C under a 5% C 0 2 atmosphere for 
72 h. 10 pL Alamar Blue (Trinova, Giessen, Germany) 
was then added to each well and incubation continued for 
a further 2-4 h . 30 The plates are read in a microplate 
fluorescence scanner (Spectramax Gemini XS by Mole­
cular Devices) using an excitation wavelength of 536 nm 
and an emission wavelength of 588 nm. From the sigmoidal 
inhibition curve IC50 values were calculated.
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